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List of Abbreviations 
 
Å ångström 
Ac acetyl  
acac acetyl acetonate  
[α]D specific rotation at 589 nm 
Ad adamantyl  
Alk alkyl  
Am amyl 
AMLA ambiphilic metal ligand activation  
app apparent 
aq. aqueous 
Ar aryl  
atm atmospheric pressure  
ATR attenuated total reflection  
b branched 
BDE bond dissociation energy (at 298 K) 
BDMAEE bis-(2-dimethylaminoethyl)ether 
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c concentration (in g / 100 mL) 
CAAC cyclic alkyl amino carbene 
calc. calculated  
cat. catalytic  
CMD concerted metalation deprotonation  
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Cp* pentamethylcyclopentadienyl  
CPME cyclopentyl methyl ether 
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Cy cyclohexyl  
Cyp cyclopentyl 
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DCIB 1,2-dichloroisobutane 
VI 
ΔEQ quadrupole splitting 
DFT density functional theory 
DG directing group 
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DMF N,N-dimethylformamide  
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DMSO dimethyl sulfoxide  
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DPEN 1,2-diphenylethane-1,2-diamine 
dppb 1,3-bis(diphenylphosphino)butane  
dppbz 1,2-bis(diphenylphosphino)benzene 
dppe 1,3-bis(diphenylphosphino)ethane  
dppf 1,1'-bis(diphenylphosphino)ferrocene 
dppm 1,3-bis(diphenylphosphino)methane  
dppp 1,3-bis(diphenylphosphino)propane  
d.r. diastereomeric ratio 
ee enantiomeric excess  
EI electron ionization  
equiv equivalents  
e.r. enantiomeric ratio 
ESI  electrospray ionization  
Et  ethyl  
EWG  electron-withdrawing group  
Fc ferrocenyl 
FGI functional group interconversion 
 
VII 
g  gram  
GC  gas chromatography  
gem geminal 
h  hour or hexet  
HASPO  heteroatom-substituted secondary phosphine oxide  
Hept heptyl 
hept  heptet  
Het  heteroaryl or heteroatom 
HFIP  1,1,1,3,3,3-hexafluoro-2-propanol  
HPLC  high-performance liquid chromatography  
HR-MS  high resolution mass spectrometry  
Hz  hertz  
i  iso  
ICy·HCl  1,3-dicyclohexyl-1H-imidazol-3-ium chloride  
Ile isoleucine 





IR  infrared  
J  coupling constant  
K Kelvin 
k reaction rate constant 
kcal kilocalorie 
KIE  kinetic isotope effect  
VIII 
L liter or (pre-)ligand 
l linear 
LED light-emitting diode 
LiHMDS  lithium bis(trimethylsilyl)amide  
LLHT  ligand-to-ligand hydrogen transfer  
M  metal or molar 
m  meta  
m  multiplet  
M. p.  melting point  




Me  methyl  
Mes  mesityl  
mg  milligram  
MHz  megahertz  
min  minutes  
mm millimeter 
mmol  millimole  
MOM methoxymethyl 
MPAA mono-N-protected amino acid 
MS mass spectrometry or molecular sieves 
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Np  naphthyl  
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IX 
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Pent  pentyl  
Ph  phenyl  
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The tremendous development of organic synthesis within the last century has 
allowed for the preparation of life-saving pharmaceuticals, crop-protection agents, 
functional materials such as polymers, and dyes, among others, affecting the life of 
billions of people. Despite its transformative nature, which has resulted in diverse 
applications with countless benefits for the society, chemistry continues to be 
perceived as a polluting science due to resource and energy consumption, waste 
generation, and the use of toxic chemicals. 
In order to obviate or at least reduce these drawbacks, the development of more 
environment-friendly, resource-,[1] step- and atom-economical[2] synthetic 
methodologies is highly desirable. In this perspective, Anastas and Warner proposed 
the “12 Principles of Green Chemistry”,[3] which are meant to guide the synthetic 
chemist towards environmentally-benign chemical processes. Among those, 
catalysis, that is the use of catalytic rather than stoichiometric amounts of reagents, 
and the direct use of readily available chemicals without the need of 
pre-functionalization are particularly attractive approaches to reduce the formation of 
byproducts and thereby chemical waste. Furthermore, the use of less-toxic 
compounds and mild reaction conditions is also expected to enable safer chemical 
processes. 
 
1.1. Transition Metal-Catalyzed C–H Activation 
 
“A dream of organic chemists has been the discovery of coupling reactions with no 
prefunctionalization of the coupling partners.” (V. Snieckus)[4] 
 
Organic synthesis, including catalytic reactions, has long been dominated by the 
transformation of functional groups, hence requiring pre-functionalized starting 
materials. In this context, a major achievement of catalysis in the past five decades 
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has been the development of transition metal-catalyzed cross-couplings, forming 
carbon–carbon (C–C) and carbon–heteroatom (C–Het) bonds.[4] Interestingly, 
pioneering results were obtained as early as in the late 19th century by, inter alia, 
Glaser [5] and Ullmann[6] using stoichiometric or catalytic amounts of copper. 
Nevertheless, transition metal-mediated coupling reactions have only found broad 
applications since the development of palladium-catalyzed cross-couplings between 
organometallic reagents with organic electrophiles.[4]  
Major successes in this field have been realized for the formation of C–C bonds 
using diverse coupling partners, resulting in the development of numerous name 
reactions, such as the Suzuki–Miyaura,[7] Negishi,[8] Mizoroki–Heck,[9] Kumada–
Corriu,[10] Hiyama,[11] Stille[12] and Sonogashira–Hagihara[13] cross-coupling 
reactions. Additionally, while not always C–C bond forming processes, the Tsuji–
Trost reaction[14] as well as the Buchwald–Hartwig amination[15] should be mentioned 
as other significant milestones in palladium coupling catalysis. Palladium-catalyzed 
cross-couplings are nowadays a routine tool in organic synthesis, with applications 
ranging from material sciences to the late-stage diversification of biologically active 
compounds,[16] and their importance was recognized by the Nobel Prize in Chemistry 
awarded collectively to Heck, Negishi and Suzuki in 2010.[4,17] 
However, those processes still suffer from various drawbacks which significantly 
affect their ecological footprint. Indeed, the need for rare noble transition metal 
catalysts, pre-functionalized substrates and sensitive organometallic reagents, as 
well as the generation of stoichiometric amounts of harmful waste, render those 
processes hazardous and harmful to the environment. 
Significant achievements have been made to address those limitations, which 
include the use of sustainable non-noble metal catalysts such as nickel[18] and 
iron,[19] the use of biomass-derived solvents,[20] and the development of reusable[21] 
or highly active catalysts operating at low loadings.[22] However, those approaches 
do not tackle the main issues of cross-coupling chemistry, namely the need for 




Therefore, the direct functionalization of omnipresent C–H bonds would appear as a 
highly desirable alternative to conventional cross-couplings due to the improved 
step- and atom-economy (Scheme 1.1). In this context, catalytic C‒H activation has 
experienced a tremendous development in recent years,[23] and has now surfaced as 
a transformative tool for molecular syntheses, with notable applications in 
pharmaceutical industries,[24] as well as the synthesis of complex bioactive natural 
products[25] and material sciences,[26] among others. Nevertheless, the direct 
functionalization of C–H bonds with organic electrophiles still requires the 
prefunctionalization of one of the coupling partners, generating a stoichiometric 
amount of (pseudo)halogenated byproducts (Scheme 1.1b). In contrast, 
hydroarylations[27] would be perfectly atom-economical, redox-neutral, and more 
step-economical as well since no pre-functionalization is required. Cross-
dehydrogenative C–H activation would also, in theory, be a fully atom-economical 
approach, as only molecular hydrogen is formally generated as a byproduct 
(Scheme 1.1c). However, those reactions usually require a stoichiometric oxidant, 
which results in stoichiometric waste generation, and typically suffer from a rather 
narrow substrate scope. 
 
 




Nevertheless, several challenges which need to be overcome are associated with 
synthetically useful C–H activation. First, the C–H bond is typically significantly more 
stable than the C–X bond of common cross-coupling partners                                         
(e.g. BDE(Ph–H) ≈ 113 kcal mol–1 vs. BDE(Ph–Cl) ≈ 97 kcal mol–1,                      
BDE(Ph–Br) ≈ 84 kcal mol–1, BDE(Ph–I) ≈ 67 kcal mol–1).[28] While early examples of 
C–H activations required harsh reaction conditions which strongly limited their 
applications to the synthesis of complex and sensitive molecules, recent progress 
has focused on the development of milder[29] and more selective processes. The 
mechanism of the key C–H cleavage step has been studied extensively as its 
understanding is particularly important for the design of efficient catalytic processes. 
Excluding outer-sphere mechanisms (e.g. carbene/nitrene insertions[30] or radical 
reactions[31]), five general modes of action have been proposed for the C–H 
metalation step depending on the nature of the substrate, the metal catalyst, its 
ligands and oxidation state (Scheme 1.2).[32] These pathways consist of oxidative 
addition, electrophilic substitution, σ-bond metathesis, 1,2-addition and base-
assisted metalation. The oxidative addition pathway is typical for electron-rich, low-
valent complexes of late transition metals, such as rhenium, ruthenium, osmium, 
iridium, platinum and even iron,[32b] from which higher oxidation states are readily 
accessible (Scheme 1.2a). While this mechanism has also been proposed for early 
transition metals, later findings provided support for σ-bond metathesis, typically 
involving an alkyl- or hydride-metal complex (vide infra). Late transition metals in 
high oxidation states, such as Pd(II), Pt(II), Pt(IV), or Hg(II), tend to undergo C–H 
activation by an electrophilic substitution in which the metal acts as a Lewis acid. In 
those processes, the putative intermediate is formed by electrophilic attack of the 
metal, usually in a strongly polar medium (Scheme 1.2b). For early transition metals, 
as well as lanthanides and actinides, σ-bond metathesis tend to be the preferred 
pathway. A key feature this mechanism is the concerted formation and breaking of 
C–H and C–M bonds in the transition state (Scheme 1.2c).[32b] The 1,2-addition route 
is observed for metals with an unsaturated M=Y bond, typically imido, oxo and 
alkylidene complexes. Those transformations occur via a [2σ+2π]-type reaction 
where the Y group serves as the formal hydrogen acceptor (Scheme 1.2d). Finally, 
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another category of C–H cleavage processes is the base-assisted C–H activation. 
Here, the base, most commonly a carboxylate,[32a] facilitates the proton abstraction 
during the C–H scission step. 
 
 
Scheme 1.2. Different pathways for organometallic C–H activation. 
 
Further investigations on base-assisted C–H activations unravelled several different 
possible pathways (Scheme 1.3). Following the pioneering theoretical studies of 
Sakaki,[33] the synergistic interaction between the metal center, carboxylate-ligand 
and C–H bond was rationalized by Gorelsky and the late Fagnou, leading to the 
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concept of concerted metalation-deprotonation (CMD) occurring via a six-membered 
transition state.[34] Subsequent computational studies by Macgregor suggested the 
relevance of an agostic metal-hydrogen interaction in a mechanism named 
ambiphilic metal-ligand activation (AMLA).[32c,35] Those processes are typically 
characterized by a considerable kinetic isotope effect (KIE) and a preference for 
electron-deficient substrates. In contrast, the term internal electrophilic substitution 
(IES)[36] describes a mechanism occurring through a highly strained four-membered 
ring transition state. This process has been proposed for reactions involving alkoxide 
bases. Recently, the concept of base-assisted internal electrophilic substitution 
(BIES)[37] has emerged in order to explain the preference for electron-rich substrates 
in several catalytic transformations. 
 
 
Scheme 1.3. Proposed transition states for base-assisted C–H metalations. 
 
Another challenge of C–H activation chemistry is the fact that C–H bonds are 
omnipresent in organic compounds and have almost identical bond dissociation 
energies. The control of selectivity in those transformations is therefore a task of key 
importance. Various approaches have been developed to tackle this issue, namely 
the use of substrate’s electronic bias, steric control, or a Lewis-basic group that 
coordinates to the transition metal catalyst and directs the C–H activation at the 
desired position (Scheme 1.4). Since electronic and steric biases depend on the 
substrate itself, those approaches usually result in a rather narrow substrate scope. 
In contrast, the introduction of a directing group[38] (DG) allows for a broad variety of 
substrates to be selectively functionalized. Nevertheless, a major limitation of this 
approach is the need to incorporate the directing group in the substrate. However, 
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the use of weakly coordinating,[39] removable[40] or transient[41] directing groups has 
considerably expanded the possibilities of this approach. 
 
 
Scheme 1.4. Methods to achieve positional selectivity in C–H activation. 
 
Major progress in the field of C–H activation has been achieved with late transition 
metal catalysts. However, due to their high cost,[42] low abundance[43] and high 
toxicity,[44] this approach is rather not sustainable. Therefore, the development of 
catalytic methods for the functionalization of otherwise inert C–H bonds employing 
non-noble 3d metals has attracted considerable interest in the last decade.[45] Inter 
alia, the development of cobalt-,[46] iron-,[47] nickel-,[48] manganese-[49] and copper-
catalyzed[50] C–H activations has been particularly successful. 
Despite those major advances, full selectivity control in enantioselective C–H 
functionalizations continues to heavily rely on precious 4d and 5d transition metals, 
prominently featuring toxic and expensive palladium, rhodium, and iridium 
complexes.[51] Indeed, only a few extremely rare examples of enantioselective C–H 
functionalizations utilizing first-row transition metal catalysts had been published at 
the outset of this thesis. However, several additional contributions to this burgeoning 
field of research would later be disclosed in the course of the present work, by 
Ackermann and Cramer, among others (vide infra).[52] In this context, it should be 
noted that the development of catalytic enantioselective methodologies in organic 
synthesis is a topic of extremely high interest, as best exemplified by the Nobel Prize 
in Chemistry awarded in 2001 to Noyori, Knowles and Sharpless for their seminal 
contributions to asymmetric catalysis.[53] Therefore, given the sustainable nature and 
transformative power of 3d metal-catalyzed C–H activations, further exciting 
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developments are expected in the near future in this rapidly-evolving research 
area.[52] 
 
1.2. Cobalt-Catalyzed C–H Activation 
 
The potential of cobalt complexes in catalysis has long been recognized. Indeed, 
during the course of World War II, Roelen discovered, while studying the Fischer–
Tropsch process, that cobalt was able to promote the hydrocarbonylation of 
ethylene.[54] The reaction was found to occur in solution and, consequently, is 
sometimes considered as the birth of homogeneous catalysis.[54] 
Thereafter, Kharasch reported on the cobalt-catalyzed homo-coupling of aryl 
Grignard reagents.[55] Later notable developments of cobalt chemistry in organic 
synthesis include the well-known Pauson–Khand  [56] and Nicholas[57] reactions, 
cross-couplings,[58] hydrogenations,[59] cycloadditions, annulations, and many 
more.[60] 
 
1.2.1. Early Contributions 
 
In the 1950s, Murahashi disclosed the synthesis of 2-phenylphthalimidine 2 from 
imine 1a and carbon monoxide in the presence of catalytic dicobalt octacarbonyl 
(Scheme 1.5).[61] The scope of the transformation was soon extended to include 
azobenzenes.[62] This work is absolutely remarkable as it not only represents the first 
cobalt-catalyzed organometallic C–H activation, but also one of the first examples of 






Scheme 1.5. Cobalt-catalyzed carbonylative cyclization of imines.[61] 
 
This work remained largely neglected until the early 1990s with Klein’s studies on 
the preparation of cyclometalated cobalt complexes from [Co(CH3)(PMe3)4] (3) and 
various chelating substrates (Scheme 1.6).[63] Experimental evidence suggested the 
reaction to be initiated by the dissociation of a PMe3 ligand, which is replaced by 
azobenzene 4, followed by ortho-metalation with elimination of methane to 
deliver 5.[63f] Interestingly, unlike in Murahashi’s work, no cyclized product was 
obtained upon exposure to carbon monoxide. Remarkably, due to the high reactivity 
of complex 3, even 4-membered metallacycles could be obtained.[63e] 
 
 
Scheme 1.6. Stoichiometric cyclocobaltation of azobenzene 4.[63f] 
 
A major contribution in cobalt catalysis was achieved in 1994 by Kisch, who reported 
on the hydroarylation of tolane 7a with azobenzene 4 using a catalytic amount of 
cobalt-hydride complexes 8 or 9 (Scheme 1.7).[64] This work represents the first 
cobalt-catalyzed C–H hydroarylation of alkynes, where the authors proposed the 
active catalyst to be generated in situ after the loss of N2 or H2, respectively. 
Following the seminal work of Kisch, Petit used a related well-defined, low-valent 
phosphine-cobalt complex Co(PMe3)4 as catalyst for various hydroarylations of 





Scheme 1.7. Cobalt-catalyzed hydroarylation of tolane 7a with azobenzene 4.[64] 
 
Another key finding which would pave the way to future developments was 
subsequently disclosed by Brookhart,[66] who observed H/D scrambling in Cp*Co(I) 
complex 11 upon heating in deuterated benzene (Scheme 1.8). Interestingly, the 
authors proposed the C(sp2)–H bonds to be activated through oxidative addition of a 
16-electron cobalt species. 
 
 
Scheme 1.8. H/D scrambling of complex 11 in C6D6.
[66] 
 
Based on the contributions discussed above, cobalt-catalyzed C–H activation was 
for years dominated by the use of “low-valent” cobalt complexes or reductive 
conditions, with key contributions to the field by Nakamura,[67] Yoshikai [46a,46d,68] and 
Ackermann,[69] among others.[45,46c] It is noteworthy that, in most of these studies, the 
active catalyst is ill-defined, being generated in situ from a cobalt salt, a (pre-)ligand 
and an organometallic species. 
 
1.2.2. Cobalt(III)-Catalyzed C–H Activation 
 
The use of cyclopentadienyl-rhodium(III) catalysts allowed for remarkable 
advancements in the field of transition metal-catalyzed C–H activation.[70] However, 
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due to the low natural abundance and high cost of rhodium, the development of 
alternatives employing earth-abundant metals is highly desirable. In this context, a 
major progress was achieved in 2013 by Yoshino, Matsunaga and Kanai, who 
discovered the previously known cationic Cp*Co(III) complex 14[71] to be a potent 
catalyst for C–H activation (Scheme 1.9).[72] It is noteworthy that, while various 
cyclopentadienyl-cobalt(III) complexes had been described previously,[71,73] their use 
in C–H activation had remained unprecedented until then. Among the various 
cyclopentadienyl derivatives that were investigated, Cp* was identified as the best 
ligand, while other derivatives fell short in the envisioned transformation.[72] 
Furthermore, no conversion was obtained with simple cobalt salts. 
 
 
Scheme 1.9. Cobalt(III)-catalyzed hydroarylation of α,β-unsaturated ketones 13 and 
N-sulfonyl imines 16.[72] 
 
Based on related rhodium(III)-catalyzed transformations,[74] the mechanism of the 
cobalt(III)-catalyzed hydroarylation was proposed to be initiated by the displacement 
of the labile benzene ligand by the phenylpyridine substrate 12 to form 18 
(Scheme 1.10).[72] The authors suggested the subsequent C–H activation step to 
occur via an electrophilic aromatic substitution or a concerted metalation-
deprotonation mechanism to form the cyclometalated intermediate 19, which is 
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assumed to be the active catalyst. After ligand exchange with imine 16 to give 20, 
insertion of the latter to give intermediate 21, and proto-demetalation, the product 17 
is released while the active catalyst is regenerated. In a subsequent report, this 
chemistry was extended to indole substrates by Kanai and Matsunaga using 
carboxylate additives which allowed for high catalytic efficacy.[75] 
 
 
Scheme 1.10. Proposed mechanism of the Cp*Co(III)-catalyzed hydroarylation of imines 
16.[72] 
 
Taking inspiration from this elegant work, numerous reports on Cp*Co(III)-catalyzed 
C–H activation were disclosed in the following years.[45,46,76] Only selected relevant 
1. Introduction 
13 
examples are discussed in this thesis, with a focus on enantioselective 
transformations. 
The insertion reactions were not limited to activated C–C and C–N double bonds. 
Indeed, Matsunaga, Kanai and coworkers developed procedures for the selective 
cobalt-catalyzed hydroarylation of alkynes 7 with N-carbamoyl indoles and pyrroles 
23 (Scheme 1.11).[77] Remarkably, small changes of the directing group or the 
reaction conditions had a profound impact on the selectivity of the reaction. Indeed, 
while a judicious choice of the carbamate directing group and reaction temperature 
allowed for either the formation of the hydroarylated product 24 or the 
thermodynamically more stable cyclized product 25 (Scheme 1.11a–b),[77d] the use 
of the cationic complexes [Cp*Co(MeCN)3]
2+ provided access to tetrasubstituted 
alkenes 27 (Scheme 1.11c).[77a] DFT calculations suggested the C–H cleavage step 
to occur through an acetate-enabled CMD manifold. Interestingly, Cp*Rh(III) 
catalysts were found to be inefficient in the envisioned transformations, giving only 
small amounts of the alkenylated product 24. The findings highlighted the different 
reactivity and complementarity of cobalt as compared to rhodium. Thus, the high 
nucleophilicity of the C–Co bond allowed for a unique reactivity.[46a,46b,77a,77d] This 
difference may, partly, be explained by the higher electronegativity of cobalt 
compared to rhodium.[78] The unique reactivity of cobalt(III) catalysts was also 
exploited by Ackermann in an allylation by C–H/C–C activation, where the less 
stable Z-isomer was selectively obtained, using Cp*Co(III) catalysts, while the 





Scheme 1.11. Selectivity control in Cp*Co(III)-catalyzed C–H activation of indoles 23 with 
alkynes 7.[77a,77d] 
 
The scope of Cp*Co(III)-catalyzed C–H activations by hydroarylation is not limited to 
alkynes. Indeed, unactivated alkenes, and even allenes,[80] have been employed as 
coupling partners in C–H activations. However, in the case of alkenes 29, the control 
of linear vs. branched selectivities represents a challenging issue. Ackermann and 
coworkers disclosed in 2017 a procedure for the selective hydroarylation of 
unactivated alkenes (Scheme 1.12a).[37b] Remarkably, while the anti-Markovnikov 
isomer 30 was obtained in the absence of additives, the introduction of 1.0 
equivalent of 1-AdCO2H was found to promote the selective formation of the 
branched product 31. Detailed experimental and computational mechanistic studies 
revealed the switch of selectivity to be caused by a change of mechanism. Indeed, in 
the absence of the carboxylic acid additive, the C–H cleavage step was found to 
proceed via a ligand-to-ligand hydrogen transfer (LLHT)[32a,37b,81] manifold involving 
two substrates 28 and delivering the linear product 30. In contrast, 1-AdCO2H was 
found to enable a base-assisted internal electrophilic type substitution (BIES) 
delivering the branched product 31. This work also provided a proof-of-concept for 
an asymmetric version of this reaction. Thus, various chiral carboxylic acids were 
1. Introduction 
15 
tested in the transformation, with N-phthaloyl protected isoleucine (32) providing 
product 31aa with 62.5:37.5 e.r. (Scheme 1.12b). 
 
 
Scheme 1.12. Selectivity control in cobalt-catalyzed C–H alkylations.[37b] 
 
Triggered by this seminal report, the Ackermann group disclosed in 2018 the first 
highly enantioselective cyclopentadienyl-cobalt(III)-catalyzed C–H activation 
(Scheme 1.13).[82] Essential to success was the design of the new chiral carboxylic 
acid 34. Under the reaction conditions, various indoles 28b and allylbenzene 
derivatives 33 were smoothly converted to the alkylated products 35 with excellent 
enantioselectivity. Computational studies and H/D-exchange experiments suggested 
the enantio-determining step to be an irreversible proto-demetalation promoted by 





Scheme 1.13. Enantioselective cobalt(III)-catalyzed alkylation of indoles 28b.[82] 
 
Furthermore, Cp*Co(III) catalysis is not restricted to hydroarylations. Other C–C 
bond forming reactions include inter alia alkynylations,[83] allylations,[84] 
aminocarbonylations[85] and various annulations.[45] Besides C–C bond forming 
processes, the formation of C–X and C–N bonds has proven quite successful as 
well. In this context, Matsunaga and Kanai established a protocol for the C–H 
amination of indoles 36 with azides 37 using Cp*Co(CO)I2 as an air-stable 
pre-catalyst (Scheme 1.14).[86] Using Cp*Co(CO)I2 and a silver salt to generate the 
cationic catalyst in situ, rather than using the highly sensitive sandwich complex 14, 
has since been a widely applied approach due to its user-friendly nature. However, 
due to the inherently unsafe handling of usually explosive and toxic[87] azides, 
protocols employing safer aminating reagents would be highly desirable. Other 
Cp*Co(III)-catalyzed C–(pseudo)Het bond-forming reactions include 
halogenations,[84d,88] cyanations[84d,89] and thiolations,[90] among others.[45,46,76] 
 
 




Inspired by this report and the topical interest for C–H aminations,[23e] several 
research groups developed additional cobalt-catalyzed transformations to forge C–N 
bonds. Among other findings, the research groups of Chang,[91] Jiao[92] and 
Ackermann[37e] independently pioneered the use of dioxazolones 40 as safer but 
potent amidating reagents in cobalt catalysis (see Chapter 3.1). Two years later, 
Dixon and Seayad reported a thioamide-assisted amidation of C(sp3)–H bonds.[93] 
This work remains one of the rare examples of C(sp3)–H activation with a cobalt 
catalyst. DFT calculations provided support for the C–H activation step to proceed 
via an external carboxylate-assisted concerted metalation/deprotonation 
mechanism. Subsequently, Matsunaga and coworkers developed an asymmetric 
version of this protocol (Scheme 1.15).[94] Here, the highly enantioselective C(sp3)–H 
amidation of thioamides 39 was achieved by the combination of the chiral carboxylic 
acid 42 with an achiral cobalt(III) complex. A remarkable feature of this work was the 
identification of the novel (tert-butyl-tetramethylcyclopentadienyl)Co(III) complex 41, 
which promoted the reaction with higher enantioselectivity than the standard 
Cp*Co(III) complexes. Interestingly, while the tuning of the cyclopentadienyl ligand 
has been intensively investigated in rhodium catalysis,[70a] variations of the Cp* 
ligand remain underdeveloped in Co(III)-catalyzed C–H activation. It is noteworthy 
that this approach represents the first example of enantioselective inner-sphere 
C(sp3)–H activation with a 3d transition metal catalyst. 
 
 
Scheme 1.15. Enantioselective cobalt(III)-catalyzed C(sp3)–H amidation of thioamides 39.[94] 
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The concept of cooperation between an achiral cobalt(III) catalyst and a chiral 
carboxylic acid was further exploited by Shi and coworkers, who, taking inspiration 
from previous works on the cobalt-catalyzed amidation of ferrocenes by the same 
research group[95] and Ackermann,[96] achieved the enantioselective amidation of 
ferrocenes 44 with dioxazolones 40 (Scheme 1.16).[97] Here, the design of the novel 
chiral monoprotected amino acid (MPAA) ligand 45 allowed for the synthesis of 
amidated ferrocene thioamides 46 with high yield but moderate enantioselectivity. 
Interestingly, the modest optical purity could be improved by a single crystallization 
to afford the amidated products in >99% ee. 
 
 
Scheme 1.16. Enantioselective cobalt(III)-catalyzed C–H amidation of ferrocenes 44.[97] 
 
As discussed above, the pioneering examples of enantioselective cyclopentadienyl-
cobalt(III)-catalyzed C–H transformations relied on the use of a simple achiral 
Cp*Co(III)-catalyst in combination with an external chiral carboxylic acid. Very 
recently, Cramer reported a complementary approach based on the use of the finely 
designed trisubstituted[98] chiral cyclopentadienyl-cobalt complex 49.[99] This catalyst 
proved highly efficient for the asymmetric synthesis of dihydroisoquinolones 50 from 
N-chlorobenzamides 47 and a diverse set of alkenes 48[100] (Scheme 1.17).[99] The 
introduction of a bulky tert-butyl group on the chiral Cp ligand was essential to 
achieve high enantioselectivities, and was found to affect the dihedral angle of the 
binaphthyl backbone. A remarkably diverse set of alkenes was fully tolerated in the 
transformation, including styrenes, unactivated alkenes, acrylates and 
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N-vinylphtalimide, providing the cyclized product as a single regioisomer. In contrast, 




Scheme 1.17. Chiral cyclopentadienyl cobalt(III)-catalyzed C–H functionalizations with 
alkenes.[99] 
 
1.2.3. Enantioselective Cobalt-Catalyzed C–H Functionalizations under 
Reductive Conditions 
 
In addition to the reports discussed above employing high-valent Cp*Co(III) 
complexes (Schemes 1.12–13, 1.15–17), several protocols employing cobalt 
catalysts for asymmetric C–H functionalizations under reductive conditions have 
been recently disclosed as well, but remain rare. Those reports highlight the current 
interest for enantioselective C–H activation with earth-abundant 3d metals,[52] and 
the need to conduct further research in this burgeoning field of research. 
In 2014, the Yoshikai group disclosed an elegant enantioselective intramolecular 
hydroacylation of 2-acylbenzaldehydes 51 and 2-alkenylbenzaldehydes 54 for the 
synthesis of synthetically meaningful chiral phthalide 53 and indanone 56 building 
blocks (Scheme 1.18a–b).[102] Previously, this type of asymmetric transformations 
had only been achieved with costly rhodium catalysts.[103] The combination of CoBr2 
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with (R,R)-Ph-BPE (52) was found to provide optimal results for the intramolecular 
hydroacylation of 2-acylbenzaldehydes 51 (Scheme 1.18a). The protocol could be 
extended to 2-alkenylbenzaldehydes 54 when using CoCl2 and (R,R)-BDPP (55) as 
the optimal catalytic system to deliver indanones 56 (Scheme 1.18b). Mechanistic 
studies provided evidence for a relatively facile C–H activation step and a 
subsequent rate-limiting reductive elimination step. In a later report, Yoshikai and 
Gosmini expanded this approach from disubstituted alkenes 54 to more challenging 
trisubstituted alkenes 57, allowing for the expedient synthesis of highly 
functionalized chiral cyclic ketones 58 (Scheme 1.18c).[104] Here, the combination of 
CoBr2 and (R,R)-BDPP (55) provided optimal results. Interestingly, the authors noted 
that the E/Z ratio of the starting materials 57 only had a minor effect on the 





Scheme 1.18. Enantioselective cobalt-catalyzed intramolecular hydroacylations.[102,104] 
 
Yoshikai had previously disclosed a cobalt-catalyzed C–H alkylation of indoles with 
alkenes.[105] In 2015, the same research group developed an enantioselective 
variation of this reaction (Scheme 1.19).[106] Remarkably, this work represents the 
first asymmetric intermolecular transformation by cobalt-catalyzed C–H activation. 
While simple BINOL-derived phosphoramidites provided the desired alkylated 
product 62 in low yield and enantiomeric excess, variations of the chiral diol 
backbone significantly increased the enantioselectivity of the transformation. 
Thereby, diversely substituted indoles 59a and styrene derivatives 60 furnished the 





Scheme 1.19. Enantioselective cobalt-catalyzed hydroarylation of styrenes 60 with indoles 
59a.[106] 
 
In 2017, the Dong group disclosed a unique desymmetrization strategy for the 
intramolecular enantioselective hydroacylation of alkenes 63 to construct chiral 
cyclobutanone derivatives 64 (Scheme 1.20).[107] A cobalt catalyst with (S,S)-BDPP 
(ent-55) as the chiral ligand enabled the highly selective synthesis of unusual 
strained four-membered rings 64 rather than their five-membered regioisomers. The 
authors tested diversely α-substituted dienyl aldehydes 63 which underwent the 
cyclization with high regio- and enantio-selectivities, with sensitive functionalities 
such as TMS or chloro being fully tolerated in the transformation. Mechanistic 
studies provided support for a cobalt(0)/cobalt(II) catalytic cycle. 
 
 






1.3. Iron-Catalyzed C–H Activation 
 
Iron is by far the most abundant metal on Earth.[43] Applications of iron catalysts in 
molecular syntheses benefit from comparatively low costs and toxicities, as well as a 
broad array of available oxidation states.[108] Furthermore, the considerable increase 
of prices of many late transition metals in recent years created a demand for less 
expensive alternatives.[108b] 
The independent synthesis of pentacarbonyliron in 1891 by Mond [109] and 
Berthelot [110] is usually considered as the birth of organoiron chemistry.[108c] A 
subsequent milestone of iron chemistry was the identification of iron salts as potent 
catalysts in reactions with Grignard reagents, including homocouplings, by Kharasch 
in 1941.[55,111] The serendipitous discovery of ferrocene, reported by Pauson and 
Kealy in 1951[112] and whose transformative applications would change the face of 
chemistry,[113] was another major contribution in organometallic iron chemistry. The 
1950s also marked the first use of well-defined organoiron species in organic 
synthesis with the preparation of hydroquinone by Reppe from acetylene and iron 
carbonyl complexes.[114] 
A breakthrough in organoiron catalysis was the identification of iron salts as 
catalysts in cross-couplings between Grignard reagents and vinyl bromides by Kochi 
in 1971,[115] which, remarkably, predated subsequent works with palladium and 
nickel catalysts.[4] Interestingly, the authors probed various metal halides and 
identified iron as “one of the most effective metal catalysts for the promotion of the 
reactions between Grignard reagents and organic halides.”[115a] Although the use of 
iron catalysts in cross-couplings was first overlooked due to the development of 
palladium catalysis,[4] it has since experienced a renaissance. However, despite 
major progress,[19] good mechanistic understanding is lacking and the design of 
novel ligands is required for further advancements.[47b] 
From a historical point of view, it should be noted that stoichiometric C–H activation 
with iron complexes were reported as early as 1968 by Hata.[116] Irradiation of the 
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iron(0) complex 65 resulted in the loss of ethylene and oxidative addition into a 
C(sp2)–H bond of the phosphine ligand (Scheme 1.21). 
 
 
Scheme 1.21. Synthesis of cyclometalated complex 66 by photoinduced C(sp2)–H 
activation.[116] 
 
Later works further demonstrated the feasibility of stoichiometric C–H activation with 
highly reactive low-valent iron complexes.[117] Among others, Fe(PMe3)4 (67), first 
independently prepared by Muetterties[117b] and Schmidbaur [118] in 1975, has been 
particularly effective in directing group-assisted cyclometalations (Scheme 1.22).[119] 
Interestingly, Fe(PMe3)4 was found to predominantly exist as an iron(II) species due 
to C–H activation of the phosphine ligand.[117b,118] 
 
 
Scheme 1.22. Stoichiometric ortho-C–H metalation of ketimines with Fe(PMe3)4.
[119] 
 
Fe(PMe3)4 would later prove instrumental to the development of catalytic C–H 
activations. Indeed, the first efforts towards a catalytic C–H activation employing an 
iron complex were reported by Jones in 1987.[120] Here, the use of a catalyst 
generated from Fe(PMe3)4 (67) and isocyanide ligands (70) allowed for the synthesis 
of imines 1 from benzene under UV irradiation (Scheme 1.23). A reaction conducted 
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in C6D6 showed the solvent – and not the PMe3 ligand – to be the source of the 
aldimine’s hydrogen. Low concentrations were required due to substrate inhibition, 
and the authors suggested that light was needed to induce the dissociation of an 
isocyanide ligand to generate a reactive species able to insert into a C–H bond. 
Furthermore, in a later report over four decades after its original discovery, 
Fe(PMe3)4 was finally found to be effective in iron-catalyzed C–H activations without 
the need of additional ligands, as elegantly demonstrated by Kakiuchi for the 
carbonyl-assisted hydroarylation of alkenes.[121] On the same line, a carbonyl-
directed C–H methylation had been reported by E. Nakamura shortly before.[122] 
 
 
Scheme 1.23. Aldimine synthesis by iron-catalyzed C–H activation.[120] 
 
In 2008, a breakthrough in the field of iron-catalyzed inner-sphere C–H activation 
was made by E. Nakamura, who disclosed an iron-catalyzed oxidative C–H 
arylation.[123] Interestingly, this discovery was made by serendipity by an 
undergraduate student working on an iron-catalyzed cross-coupling reaction.[124] In 
addition to the expected product 12, a small amount of the ortho-arylated 
phenylpyridine 72 was obtained as well (Scheme 1.24). Oxygen traces, as well as 
2,2’-bipyridine (bpy) – another byproduct of the reaction – were later identified as 






Scheme 1.24. Discovery of iron-catalyzed C–H arylation as a byproduct of cross-
coupling.[123] 
 
After extensive optimization of this iron-catalyzed C–H arylation, 1,2-dichloro-2-
methylpropane (DCIB) was identified as the optimal oxidant and phenanthroline as 
the best ligand (Scheme 1.25).[123] Interestingly, the zinc additive was essential for 
the reaction to occur. While its role has been proposed to be the in situ generation of 
arylzinc species, Mg-free Ph2Zn and PhZnBr fell short in delivering any arylated 
product 72, either in the absence or in the presence of TMEDA.  
 
 
Scheme 1.25. First example of iron-catalyzed C–H arylation.[123] 
 
Subsequent achievements by Nakamura and others in the research area of iron-
catalyzed C(sp2)–H arylation include, inter alia, the use of more synthetically useful 
imines[125] and amides[126] as the directing groups, the use of environmentally benign 
oxygen as oxidant,[127] the arylation of non-aromatic C(sp2)–H bonds,[128] the direct 
use of Grignard reagents in the absence of zinc additives,[129] and the use of metallic 
magnesium to prevent the handling of sensitive and dangerous organometallic 
reagents.[130] 
While the authors did not propose a mechanism in their original reports, a plausible 
catalytic cycle was later suggested by Nakamura and coworkers based on KIE 
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studies and stoichiometric reactions (Scheme 1.26).[129] A possible cycle is initiated 
by the formation of an aryliron species (73) by transmetalation of the aryl Grignard 
reagent to the iron center. Then, after a reversible coordination of the iron center to 
the pyridyl group of 12, an irreversible C–H metalation with concomitant elimination 
of an arene can happen. Subsequently, the cyclometalated intermediate 75 can 
undergo a C–C bond forming reductive elimination upon reaction with DCIB to 
generate the desired arylated product 72, isobutene, and dichloroiron species 76. 
Finally, a transmetalation of 76 with the Grignard reagent regenerates the active 
species and closes the catalytic cycle. 
 
 
Scheme 1.26. Proposed mechanism of the oxidative iron-catalyzed C–H arylation.[129] 
 
Thereafter, theoretical calculations on the mechanism of this reaction were reported 
by Shaik and Chen.[131] Their findings suggest that both Fe(II) and Fe(III) can 
promote the C–H activation by means of an uncommon two-state reactivity[132] (TSR) 
scenario. In this way, the initially excited low-spin singlet and doublet states 
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crossover through the high-spin ground states to promote the C–H scission. 
Furthermore, the authors suggested the C–H cleavage step to occur through a type 
of σ-bond metathesis. The key C–C bond forming step was proposed to occur via 
reductive elimination from an iron(III) species, after which the iron catalyst is re-
oxidized by DCIB via a single electron transfer (SET) mechanism. 
A breakthrough in the field was the introduction of bidentate[133] directing groups, 
which not only allowed for unprecedented iron-catalyzed C(sp3)–H activations, but 
also significantly expanded the scope of possible transformations beyond oxidative 
arylations with organometallic reagents. In this context, E. Nakamura reported on an 
iron-catalyzed C(sp3)–H arylation of carboxamides 77 under the assistance of the 
8-aminoquinoline directing group initially introduced by Daugulis[134] for palladium 
catalysis (Scheme 1.27a).[135] The important KIE and preference for terminal methyl 
groups over internal alkyl substituents provided support for an inner-sphere C–H 
activation process rather than a radical pathway. Shortly afterwards, Ackermann 
designed a modular triazole directing group which proved effective for the iron-
catalyzed arylation of both C(sp2)–H and C(sp3)–H positions (Scheme 1.27b).[136] It 






Scheme 1.27. Iron-catalyzed C–H arylation under bidentate directing group 
assistance.[135-137] 
 
Other significant advances were subsequently achieved under the assistance of 
bidentate directing groups by the research groups of E. Nakamura, Ackermann and 
Cook, among others. Major progresses include, but are not limited to, C–H 
alkylations with Grignard reagents or alkyl halides,[138] C(sp2)–H allylations,[137,139] 
C(sp2)–H benzylations,[137,138d] C(sp2)–H alkynylations with alkynyl bromides,[140] 
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C(sp2)–H aminations with N-chloroamines,[141] C–H alkenylations and arylations with 
organoboron reagents,[142] C(sp2)–H and C(sp3)–H methylations with AlMe3,
[143] 
various annulation reactions with alkynes[144] and allenes,[145] the C(sp2)–H alkylation 
of benzylamine derivatives[146] and the two-fold C–H activation/cross-coupling of 
heteroarenes.[147] 
A rare iron-catalyzed C–H activation by hydroarylation was disclosed by Yoshikai in 
2015.[148] Taking inspiration from their previous work on cobalt catalysis[105,106] 
(Scheme 1.19) and from the similar reactivity of iron and cobalt complexes in 
stoichiometric C–H activations,[63c] the authors devised an iron-NHC catalyst for the 
addition of 3-iminoindoles 59 to styrenes 60 (Scheme 1.28a).[148] Slight modifications 
of the reaction conditions allowed for the use of alkynes 7 as well (Scheme 1.28b). 
 
 
Scheme 1.28. Iron-catalyzed hydroarylations of styrenes and alkynes with indoles 59.[148] 
 
Despite major progress, iron-catalyzed C–H activation is still a recent field of 
research. Among other expected advances, the development of enantioselective     
C–H functionalizations is highly desirable. In this context, it should be noted that 
examples of asymmetric transformations by organometallic iron catalysts remain 
extremely rare. Indeed, only a single example had been reported at the outset of the 
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present work, namely an iron-catalyzed cross-coupling of α-chloroesters 86 with aryl 
Grignard reagents by M. Nakamura (Scheme 1.29).[149] This approach would later be 
extended to arylborates.[150] 
 
 
Scheme 1.29. Iron-catalyzed enantioselective cross-coupling of α-chloroesters 86 with 
Grignard reagents.[149] 
 
While our work[151] represents the very first enantioselective functionalization by iron-
catalyzed inner-sphere C–H activation (see Chapter 3.2), it is noteworthy that 
Butenschön reported shortly afterwards an asymmetric arylation of ferrocene 
derivatives 89, providing the planar-chiral product 91 in moderate enantiomeric 
excess (Scheme 1.30).[152] It should be noted that Ackermann had previously 




Scheme 1.30. Enantioselective iron-catalyzed C–H arylation of ferrocenes 89.[152] 
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1.4. Nickel-Catalyzed C–H Activation 
 
1.4.1. General Information 
 
Nickel catalysts have been recognized as powerful tools in molecular syntheses, 
with numerous applications in C–C bond forming processes.[153] Among others, 
applications to cross-coupling chemistry,[18a,18b,18d,154] and the functionalization of 
otherwise inert C–O,[18c,18e,155] C–F,[156] and C–H bonds[45,48] have gained significant 
momentum in recent years. While nickel has been considered as the “impoverished 
younger sibling of palladium”,[153d] its high reactivity and unique properties, such as 
facile oxidative addition and a number of readily available oxidation states, render it 
particularly attractive in catalysis.[153c,153d] Furthermore, it should be noted that the 
use of nickel in catalysis, notably in cross-couplings, actually pre-dates many noble 
metals.[4] 
The potential of nickel for C–H activation was first demonstrated by Dubeck and 
Kleiman in 1963,[157] who prepared the cyclometalated complex 93 by the reaction of 
nickelocene 92 with azobenzene 4 (Scheme 1.31a). Thereafter, no other 
stoichiometric nickelation of non-activated[158] C–H bonds was reported for several 
decades, until Liang discovered in 2006 that the pincer nickel complex 94 could 






Scheme 1.31. Stoichiometric nickel-mediated C–H activations.[157,159] 
 
In the same year, Nakao and Hiyama discovered by serendipity that nickel(0) 
species could catalyze the functionalization of activated, that is somewhat acidic,    
C–H bond with alkynes 7 (Scheme 1.32).[160] Tsuda and Saegusa had previously 
demonstrated the potential of nickel catalysts in related hydroacylation reactions.[158f] 
The selective activation of a C–H bond over a C–CN bond of N-protected 
3-cyanoindoles 96 could be controlled by the proper choice of the ligand and 
N-protecting group of the indole.[160] Under the optimized reaction conditions, diverse 
azoles 99, including benzimidazoles, electron-poor indoles, caffeine, benzofuran, 
benzothiophene, benzoxazole and thiazole, could be alkenylated selectively at the 
C2 position. Based on preliminary experimental mechanistic studies, the authors 
proposed the C–H cleavage step to occur via oxidative addition. However, a later 
study by Zimmerman and Montgomery suggested the possibility of a ligand-to-ligand 





Scheme 1.32. Nickel-catalyzed hydroheteroarylation of alkynes with azoles.[160] 
 
Afterwards, the scope of the hydroheteroarylation of alkynes was expanded to other 
heterocycles, with major contributions of Nakao/Hiyama, Ong/Yap and Miura. 
Among others, oxadiazoles,[162] pyrazoles,[163] simple imidazoles,[164] pyridine 
oxides,[165] pyridines,[166] pyridones[167] and pentafluorobenzene[168] were identified as 
viable substrates in the nickel-catalyzed hydro(hetero)arylation of alkynes. For 
substrates bearing less acidic C–H bonds, the addition of co-catalytic Lewis acidic 
organoaluminium additives was needed for the reaction to occur. In addition to 
azoles 99, formamides proved to be suitable substrates as well.[169] Taking 
inspiration of the success of nickel catalysts in the hydroarylation of alkynes, this 
chemistry was later expanded to alkenes (vide infra) and even allenes.[170] 
While not directly relevant to the topic of this thesis, it should be mentioned that 
other non-hydroarylation-type nickel-catalyzed C–H activations have been reported 
as well. Among other transformations, the arylation,[171] alkylation with alkyl 
(pseudo)halides,[172] alkynylation with alkynyl bromides[173] or terminal alkynes[174] 
and alkenylation[171a,171d,175] of C–H acidic azoles are nowadays well established 
processes. Furthermore, nickel-catalyzed C–H activations are not limited to C–H 
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acidic heteroarenes. Indeed, truly unactivated C–H bonds have been functionalized 
as well, but this chemistry remains so far mostly restricted to the use of bidentate 
directing groups.[176] In this context, the C(sp2)–H arylation,[177] alkylation,[178] 
alkynylation with alkynyl bromides[179] or terminal alkynes,[180] alkyne annulation,[181] 
allylation,[178d,182] carbonylation[183] and thiolation[184] of benzamide derivatives have 
inter alia been achieved with nickel catalysts. The use of bidentate directing groups 
also allowed the functionalization of C(sp3)–H positions.[45,48c,176] While C–H 
transformations of unactivated arenes were long restricted to the use of bidentate 
directing groups, major progress in the field was reported by Ackermann who 
recently introduced the simple and easily removable 2‐pyrimidyl directing group for 
the ortho-functionalization of aniline derivatives.[185] Similarly, Punji disclosed several 
nickel-catalyzed C–H functionalizations of indoles bearing monodentate directing 
groups.[186] 
 
1.4.2. Nickel-Catalyzed C–H Activation by Alkene Hydroarylation 
 
The use of alkenes has gained considerable attention in transition metal-catalyzed 
C–H activation.[187] Indeed, due to their low cost, availability and sustainability (no 
need for pre-functionalization), alkenes are attractive coupling partners for the 
formation of C–C bonds. In this context, nickel catalysts have proven particularly 
powerful for the hydrofunctionalization of C–C multiple bonds.[48a,188] Furthermore, 
the hydroarylation of alkenes generates C(sp3) positions, offering opportunities for 
the development of asymmetric transformations employing chiral nickel catalysts. 
Taking inspiration from their pioneering works on the hydroarylation of alkynes,[188a] 
Nakao and Hiyama reported in 2008 the unprecedented hydroarylation of 
conjugated alkenes with pentafluorobenzene (101) using reaction conditions nearly 
identical to those used for alkynes (Scheme 1.33a).[168] Interestingly, the branched 
product was selectively obtained. Miura disclosed in 2009 the hydroarylation of 
styrenes 60 with oxadiazoles 104 using Ni(cod)2 and the bidentate phosphine ligand 
Xantphos as the catalytic system (Scheme 1.33b).[162] Similar findings were reported 
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shortly afterwards by Nakao and Hiyama who identified the NHC ligand IMes as 
optimal for the envisioned transformation (Scheme 1.33c).[189] Remarkably, the 
authors were also able to use simple alkyl-substituted alkenes for the first time under 
more forcing conditions. In sharp contrast to conjugated alkenes, the linear product 
was obtained in this case. The nickel/NHC manifold would later prove broadly 
applicable in the hydroarylation of alkenes with (hetero)arenes.[45,48a] 
 
 
Scheme 1.33. Early examples of nickel-catalyzed hydroarylations of alkenes with 
(hetero)arenes.[162,168,189] 
 
Based on deuterium-labeling experiments, the C–H cleavage step was proposed to 
occur via a reversible oxidative addition of a nickel(0) complex into the C–H bond 
(Scheme 1.34).[162,168,189] Then, coordination of the alkene followed by 
hydronickelation of the latter produces intermediate 110. Those steps are proposed 
to be reversible, thus explaining the observed H/D scrambling. Thereafter, an 
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irreversible and rate-determining reductive elimination delivers product 106 and 
regenerates intermediate 107. Furthermore, Nakao/Hiyama and Miura proposed the 
formation of the Markovnikov product to be favored because of the formation of 
π-benzyl or π-allyl nickel intermediates, which would also explain the poor 
performance of alkyl-substituted alkenes and acrylates in these reactions.[162,168,189] 
 
 
Scheme 1.34. Proposed catalytic cycle of the nickel-catalyzed hydroarylation of vinylarenes 
60 with azoles 99.[189] 
 
Subsequently, the origin of the regioselectivity of the reaction was investigated in 
detail by DFT by Shi.[190] This study provided support to the mechanism proposed by 
Nakao, Hiyama and Miura, and revealed a secondary orbital overlap between the 
styrene’s aryl group and the nickel center. This interaction was found to accelerate 
the rate-limiting C–C bond forming reductive elimination and favor the formation of 
the Markovnikov product from conjugated alkenes. In case of simple alkyl-
substituted olefins, this interaction is absent and the sterically less hindered linear 
product is thus formed favorably. 
A major breakthrough in the nickel-catalyzed hydroarylation of alkenes was the 
introduction of Lewis acidic organoaluminium additives, which not only allowed 
1. Introduction 
38 
transformations of unactivated heteroarenes and alkenes, but also proved critical to 
control the selectivity of the reaction. Among other substrates, pyridones[167,191] and 
pyridines[192] could be coupled with alkenes in the presence of AlMe3 or MAD as 
additive, as observed previously for the hydroarylation of alkynes. While non-
conjugated alkenes otherwise remain very challenging in nickel-catalyzed 
hydroarylations, organoaluminium additives were found to facilitate their use in either 
inter- or intramolecular reactions with various heteroarenes.[167,191–193] The 
regioselectivity of those transformations is of particular interest. While the branched 
product 106 is normally obtained from conjugated alkenes, aliphatic olefins usually 
provide the linear product.[190] In this context, Ong was able to reverse the usual 
selectivity of the hydroarylation of styrene 60 with benzimidazoles 99 by the addition 
of co-catalytic AlMe3 (Scheme 1.35).
[194] Unselective mixtures were obtained with 
other Lewis acids. 
 
 
Scheme 1.35. Regioselectivity control in nickel-catalyzed hydroarylations of styrenes 60 




Detailed mechanistic studies were conducted by Ong and coworkers to delineate the 
mechanism of this process and the role of AlMe3.
[194a] Their findings revealed that 
AlMe3 not only controlled the regioselectivity of the transformation, but also 
significantly increased the rate of product formation. In contrast, the aluminium-free 
reaction was found to be much slower, still being in its induction period after 3 h. The 
authors were also able to observe a Ni–H species, which may indicate an oxidative 
addition pathway to be involved in the transformation. Furthermore, the adduct of the 
benzimidazole substrate and AlMe3 was isolated. Based on those findings, the linear 
selectivity was proposed to result from steric control during the insertion of the 
styrene into the Ni–H bond (Scheme 1.36). In contrast, in the absence of the 
organoaluminium additive, hydride insertion at the β-carbon of styrene is 
electronically favored, giving the branched product. 
 
 
Scheme 1.36. Model for selectivity switch in the nickel-catalyzed hydroarylation of 
styrenes.[194] 
 
1.4.3. Enantioselective Nickel-Catalyzed C–H Activation 
 
While nickel-catalyzed inner-sphere C–H activations, especially hydroarylations, are 
nowadays well established, asymmetric transformations remain scarce. Thus far, all 
known examples involve the asymmetric functionalization of alkenes.[52] 
Taking inspiration from previous works by Nakao and Hiyama,[169] Cramer reported 
an enantioselective nickel-catalyzed intramolecular hydrocarbamoylation of 
homoallylic formamides 113 (Scheme 1.37).[195] In this context, it should be 
mentioned that (C=O)–H activations have been accomplished with a broad range of 
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catalysts, with the hydroacylations of alkenes and alkynes being extensively 
documented.[196] A significant fraction of formyl C–H activations has been proposed 
to occur through radical mechanisms,[31a] taking advantage of the low bond 
dissociation energy (BDE) of the formyl C–H bond.[28] The chiral heteroatom-
substituted secondary phosphine oxide[197] (HASPO) 114 preligand developed by 
Cramer enabled the asymmetric synthesis of pyrrolidinones 115, featuring a Ni/Al[198] 
heterobimetallic[23b] activation mode. While a nickel catalyst solely prepared from the 
chiral SPO performed poorly, the addition of a co-catalytic amount of phosphine led 
to an increased efficacy, presumably by assisting the displacement of the cod ligand 
from the precatalyst. This work is truly remarkable as it represents the first 




Scheme 1.37. Enantioselective intramolecular nickel-catalyzed hydrocarbamoylations of 
alkenes.[195] 
 
A reasonable catalytic cycle was proposed to begin with the formation of the Al/SPO 
adduct 116, a bifunctional ligand whose aluminium center retains its Lewis acidity 
while the Lewis basic phosphorous atom can coordinate to the nickel center 
(Scheme 1.38). The aluminium center then activates the carbonyl group of 113, 
providing intermediate 118. Thereafter, oxidative of the C–H bond on nickel 
generates the six-membered hetero-bimetallacycle 119. Migratory insertion then 
leads to complex 120, and reductive elimination releases lactam 115 and 
regenerates the heterobimetallic catalyst 117. This mechanism was further 
supported by the independent synthesis of the Lewis acid/SPO adduct 116, which 
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was found to promote the cyclization with excellent yield and enantioselectivity 
without additional AlMe3 or PPh3. 
 
 
Scheme 1.38. Plausible mechanism of the nickel-catalyzed hydrocarbamoylation.[195] 
 
As previously mentioned, Nakao and Hiyama developed an intramolecular C–H 
alkylation of pyridones with unactivated tethered alkenes using a nickel-P(iPr)3 
catalytic system in the presence of AlMe3.
[167] Inspired by these results, Cramer 
subsequently developed a ligand-controlled regiodivergent annulation of pyridones 
121, with IPr giving selectively the endo-cyclized product, while the exo-product was 
obtained with cod as the ligand.[193] Preliminary efforts towards an asymmetric 
version of this reaction were also disclosed (Scheme 1.39a). The chiral NHC ligand 
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122, based on the design of Hong and coworkers,[199] provided the endo-cyclized 
products 123 in 78.5:21.5 e.r. 
 
 
Scheme 1.39. Enantioselective nickel-catalyzed hydroarylation with pyridones.[193,200] 
 
Further investigations by Cramer on the asymmetric cyclization of pyridones with 
tethered olefins led to the discovery of the novel chiral NHC 125, inspired from a 
previous ligand design by Gawley [201] with a modified acenaphthene backbone 
(Scheme 1.39b).[200] Under the optimized reaction conditions, the endo-cyclized 
annulated pyridones and uracils 126 were obtained from diversely decorated 
alkenes 124 in excellent yields and enantiomeric excesses at mild reaction 
temperatures in the presence of MAD. Based on literature precedents,[202] the 
authors proposed the C–H cleavage step to occur through a LLHT manifold. This 
approach was later extended to pyridines 127 by Shi under similar reaction 
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conditions (Scheme 1.40).[203] Thus, the corresponding tetrahydro(iso)quinolines 129 
were obtained with excellent diastereo- and regio-selectivities. 
 
 
Scheme 1.40. Enantioselective nickel-catalyzed hydroarylation with pyridines 127.[203] 
 
Following the elegant studies of Bergman and Ellman,[204] the undirected cyclization 
of azoles with tethered alkenes has long been dominated by rhodium(I) catalysts, 
with a notable exception by Cavell for the nickel-catalyzed cyclization of highly 
activated (benz)imidazolium salts.[205] In this context, Ye reported on the 
unprecedented nickel-catalyzed enantio- and exo-selective hydroarylation of olefins 
130 with tethered imidazoles (Scheme 1.41).[206] The TADDOL-derived HASPO 
preligand 131 enabled a nickel-aluminum bimetallic catalysis. Such TADDOL-
HASPOs had previously been exploited in asymmetric organocatalysis,[207] but their 
use in enantioselective transition-metal catalysis had remained rare.[208] Thus, 
diverse polycyclic azoles 132 with β-stereocenters were obtained in outstanding 
yields and enantioselectivities. Interestingly, sensitive functional groups, including 







Scheme 1.41. Asymmetric nickel-catalyzed exo-selective hydroarylation of alkenes 130.[206] 
 
In analogy to the hydrocarbamoylation presented above (Schemes 1.37–1.38), a 
plausible catalytic cycle begins with the formation of an Al/SPO adduct, which can 
coordinate the nickel precursor to deliver complex 133 (Scheme 1.42). Then, 
through a heterobimetallic mode of activation, the aluminium center can be 
coordinated by the imidazole’s nitrogen, while the nickel center binds the alkene to 
give intermediate 134. The authors suggested the C–H cleavage step to occur 
through a direct LLHT from the imidazole to the olefin, but an oxidative addition 






Scheme 1.42. Proposed mechanism of the asymmetric nickel-catalyzed exo-selective 
hydroarylation.[206] 
 
While nickel-catalyzed intramolecular asymmetric hydroarylations have been 
recognized as a powerful tool for the synthesis of important polycyclic bioactive 
scaffolds, enantioselective intermolecular versions remain hitherto largely unknown. 
In 2011, Fukuzawa disclosed an elegant nickel/NHC-catalyzed three-component 
reaction between benzaldehydes 138, norbornenes 137, and silanes 139 leading to 
polycyclic indanols 141.[209] Thereafter, Cramer designed the chiral NHC ligand 140 
to achieve this transformation in an enantioselective fashion (Scheme 1.43).[210] 
Interestingly, while the flanking N-aryl substituents of Grubbs-type chiral NHCs[211] 
have been extensively investigated, modifications of the chiral backbone remain 
underexplored. This transformation allowed for the expedient diastereoselective 





Scheme 1.43. Nickel-catalyzed asymmetric reductive three-component coupling.[210] 
 
Despite significant progress in very recent years with non-noble metals,[52] such as 
nickel[193,200,203,206] and cobalt[106] (Schemes 1.13, 1.19, 1.39–1.41), enantioselective 
hydroarylation-type C–H activations[23i] remain vastly dominated by costly noble 4d 
and 5d transition metals, such as iridium[212], rhodium,[213] and others,[214] or rare-
earth complexes.[215] Therefore, the development of new chiral catalysts based on 





Methods for the selective functionalization of otherwise inert C–H bonds have been 
recognized as a transformative tool in synthetic organic chemistry, with applications 
ranging from the synthesis of complex bioactive compounds to material 
sciences.[23k,23n,23p,40a,216] In particular, 3d metal catalysts have emerged in recent 
years as inexpensive, earth-abundant and less toxic alternatives to their heavier 
counterparts.[45] However, full selectivity control in base metal-catalyzed C–H 
activation continues to be challenging.[52] In this context, the development of novel 
3d transition metal catalysts enabling chemo- and stereo-selective C–H 
functionalizations should be investigated. 
As catalytic C–H aminations typically rely on noble metal catalysts or require harsh 
reaction conditions,[23e,217] we became interested in the development of a user-
friendly and broadly applicable protocol for the cobalt-catalyzed C–H amidation of 
synthetically useful 2-aryloxazolines 142 employing dioxazolones 40 as versatile 
amidating reagents (Scheme 2.1).[37e] Mechanistic studies were performed to 
delineate the mode of action of the C–H activation. 
 
 
Scheme 2.1. Cobalt-catalyzed C–H amidation. 
 
The enantioselective functionalization of C–H bonds remains largely dominated by 
noble transition metal catalysts such as palladium, rhodium and iridium.[51] While 
significant progress has been very recently achieved by employing earth-abundant 
non-precious 3d metals,[52] iron-catalyzed asymmetric functionalizations by inner-
sphere C–H activation remained completely unprecedented at the outset of this 
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work,[47] and represent an exceptional challenge in asymmetric catalysis. In this 
context, we initiated the development of the first enantioselective iron-catalyzed C–H 
alkylation by alkene hydroarylation (Scheme 2.2).[151] The design of novel chiral NHC 
ligands proved to be crucial to achieve high enantioselectivities. Furthermore, 
detailed studies by 57Fe Mössbauer spectroscopy and electrospray-ionization mass 




Scheme 2.2. Iron-catalyzed enantioselective C–H secondary alkylation. 
 
Inspired by the success of nickel/NHC complexes as catalysts for alkene 
hydroarylations via undirected heteroaromatic C–H activation,[27,188a] we decided to 
probe the newly designed chiral NHC ligands in the nickel-catalyzed secondary 
alkylation of benzimidazoles 99 with styrenes 60. While nickel-catalyzed 
intermolecular hydroarylations are well-documented, the development of an 
asymmetric protocol remains unprecedented. Promising enantioselectivities were 
observed for the first time in this preliminary work. 
 
 
Scheme 2.3. Nickel-catalyzed enantioselective intermolecular C–H alkylation. 
 
The cyclization of heteroarenes with tethered alkenes has long been dominated by 
rhodium(I) catalysts, following the elegant pioneering studies by Bergman and 
Ellman.[204,213d,219] Recently, nickel-catalyzed hydroarylation-type C–H activation has 
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emerged as a cost-efficient alternative.[27,48a] However, the intramolecular 
hydroarylations of unactivated alkenes remain strongly limited by the requirement of 
pyrophoric organoaluminium additives, significantly compromising their functional 
group tolerance and synthetic utility.[200,203,206] This observation prompted us to 
investigate the asymmetric cyclization of N-homoallylimidazoles 144 under 
aluminium-free conditions (Scheme 2.4).[220] Interestingly, the endo product 145 was 
selectively obtained, which in sharp contrast to previously reported methods.[206] 
Mechanistic studies were then conducted in order to delineate the unique reactivity 
of the developed catalytic system. 
 
 
Scheme 2.4. Nickel-catalyzed enantioselective intramolecular C–H alkylation. 
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3. Results and Discussion 
 
3.1. Cobalt(III)-Catalyzed C–H Amidation by Oxazoline Assistance 
 
Diversely decorated 2-aryloxazolines are key structural motifs in bioactive natural 
products and compounds relevant to the pharmaceutical and agrochemical 
industries, among others (Scheme 3.1).[221] In the context of this work, it is 
noteworthy that several ortho-amidated 2-phenyloxazolines have been patented or 
even commercialized as pesticides or fungicides, with applications to crop 
protection.[222] Furthermore, oxazolines are versatile and readily accessible synthetic 
intermediates which can easily be transformed into a wealth of diverse functional 




Scheme 3.1. Selected examples of bioactive 2-aryloxazolines. 
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Hence, methods to access highly functionalized oxazoline derivatives are highly 
sought after by the synthetic community. The ortho-functionalization of 
2-aryloxazolines through directed ortho-metalation (DoM) is well documented.[225] 
However, such methods require relatively harsh reaction conditions, such as an 
excess of organolithium bases, which strongly limit their functional group tolerance. 
Therefore, catalytic processes operating under mild conditions and avoiding 
cryogenic conditions are highly desirable. 
Thereby, we became interested in the development of an atom- and step-
economical method for the diversification of oxazolines. Despite the significant 
progress of oxidative C–H amination reactions in recent years, most pre-existing 
methodologies either required harsh reaction conditions or are restricted to noble 
transition metal catalysts, such as iridium, rhodium, palladium and ruthenium.[23e,217] 
Also, many of these processes typically employed azides as aminating reagents, 
bearing major safety concerns. We hence decided to explore the feasibility of 
cobalt(III)-catalyzed amidations of 2-aryloxazolines 142 using dioxazolones 40 as 
user-friendly and safer[226] amination reagents. 
 
3.1.1. Optimization Studies 
 
After initial results were obtained by Dr. Ruhuai Mei for the Cp*Co(III)-catalyzed 
amidation of various substrates bearing Lewis-basic directing groups,[227] it was 
decided to focus on 2-aryloxazolines due to their importance as synthetic 
intermediates and key motifs in bioactive compounds. 2-Tolyloxazoline 142a and 
dioxazolone 40a were selected as model substrates for optimization studies towards 
the envisioned C–H transformation (Table 3.1). A preliminary solvent optimization 
performed by Dr. R. Mei identified DCE as the optimal reaction medium            
(entries 1–2). Increasing the amount of silver salts and carboxylate additives to 
20 mol % proved beneficial (entry 3). Additional solvents were probed in the 
transformation, giving the desired amidated arene 143aa in low to moderate yields 
(entries 4–9). The effect of additives on the C–H amidation was then extensively 
3. Results and Discussion 
52 
studied (entries 10–22). Interestingly, several carboxylic acids, carboxylates, 
carbonates, phosphates, and mono-protected amino acids were found to promote 
the desired transformation, albeit with lower efficacy than NaOAc. However, sodium 
mesitylcarboxylate and trichloroacetate gave remarkably poor results, presumably 
due to excessive steric hindrance and lower basicity, respectively. Lower reaction 
temperatures were detrimental to the reaction outcome (entry 23). Other cobalt 
precursors were tested in the oxazoline-assisted C–H amidation (entries 24–27), 
revealing Cp*Co(CO)I2 to be the most potent catalyst. While cationic 
[Cp*Co(MeCN)3](SbF6)2 or dimeric [Cp*CoI2]2 were only slightly less efficient than 
Cp*Co(CO)I2, simple cobalt salts such as CoCl2 or unsubstituted CpCo(III) 
complexes in contrast fell short in the desired catalytic transformation. Finally, 
control experiments confirmed the importance of the Cp*Co(III)-catalyst and the 
NaOAc additive (entries 28–29). 
 
Table 3.1. Optimization of the oxazoline-assisted cobalt(III)-catalyzed amidation.[a] 
 
Entry [Co] Solvent Additive Yield [%][b] 
1[c] Cp*Co(CO)I2 TFE NaOAc n.r. 
2[c] Cp*Co(CO)I2 DCE NaOAc 65 
3[c,d] Cp*Co(CO)I2 DCE NaOAc 68 
4[d] Cp*Co(CO)I2 PhCF3 NaOAc 53 
5[d] Cp*Co(CO)I2 1,4-dioxane NaOAc 24 
6[d] Cp*Co(CO)I2 EtOAc NaOAc <10 
7[d] Cp*Co(CO)I2 nBu2O NaOAc 21 
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8[d] Cp*Co(CO)I2 tAmOH NaOAc 6 
9[d] Cp*Co(CO)I2 PhMe NaOAc 31 
10[c] Cp*Co(CO)I2 DCE KOAc 47 
11[c] Cp*Co(CO)I2 DCE PivOH 58 
12[c] Cp*Co(CO)I2 DCE NaOPiv 63 
13[d] Cp*Co(CO)I2 DCE NaO2CMes 3 
14[d] Cp*Co(CO)I2 DCE NaO2CAd 44 
15[d] Cp*Co(CO)I2 DCE Ac-Ile-CO2Na 17 
16[d] Cp*Co(CO)I2 DCE NaO2CCCl3 4 
17[e] Cp*Co(CO)I2 DCE Zn(OAc)2 29 
18[d] Cp*Co(CO)I2 DCE NaHCO3 40 
19[d] Cp*Co(CO)I2 DCE NaOBz 51 
20[d] Cp*Co(CO)I2 DCE Na2HPO4 40 
21[d] Cp*Co(CO)I2 DCE LiOAc 49 
22[d] Cp*Co(CO)I2 DCE HCO2Na 47 
23[d,f] Cp*Co(CO)I2 DCE NaOAc 39 
24[c,d] [Cp*CoI2]2 DCE NaOAc 61 
25[d] CpCo(CO)I2 DCE NaOAc traces 
26[c] CoCl2 DCE NaOAc n.r. 
27[c] [Cp*Co(MeCN)3](SbF6)2 DCE - 54 
28[c] Cp*Co(CO)I2 DCE - 35 
29[c] - DCE NaOAc n.r. 
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30[g] [Cp*Co(MeCN)3](SbF6)2 DCE NaOAc 3 
[a]
 Reaction conditions: 142a (0.50 mmol), 40a (1.2 equiv), [Co] (5.0 mol %), AgSbF6 (10 mol %), 
additive (10 mol %), solvent (2.0 mL), 100 °C, 16 h. 
[b]
 Isolated yield. 
[c]
 Performed by Dr. R. Mei. 
[d]
 Additive (20 mol %) and AgSbF6 (20 mol %). 
[e]





 Under blue LED irradiation at 23 °C in the presence of RuTPP(CO) (1.0 mol %) as 
co-catalyst. AgSbF6 was omitted. 
 
It should be noted that no 2,6-diamidated product was detected, presumably due to 
intramolecular hydrogen bonds between the directing group’s nitrogen and the 
amide’s N–H group, preventing the functionalization of the second ortho-position. 
Furthermore, it is noteworthy that no aminocarbonylation product was observed in 
any of those reactions either, despite dioxazolones being reported to decompose to 
the corresponding isocyanates via heat- or light-induced Lossen rearrangements.[228] 
These findings are complementary to a previous report by Ackermann on the use of 
acylazides in cobalt(III)-catalyzed C–H aminocarbonylations, where the authors 
proposed isocyanates to be formed in situ via a Curtius rearrangement,[85] and 
highlight the unique reactivity of dioxazolones 40 as aminating reagents. Along the 
same lines, dioxazolones are documented to undergo light-induced N–O cleavage 
with CO2 loss in the presence of ruthenium(II) porphyrin catalysts to form rutheno 
N-acycl nitrene intermediates.[229] We hence decided to investigate whether the 
desired C–H amidation would be feasible at ambient temperature under light 
irradiation in the presence of catalytic [Ru(TPP)CO] (Table 3.1, entry 30). 
Unfortunately, a significant conversion of the starting material was not detected 
under those conditions. 
 
3.1.2. Substrate Scope 
 
With the optimized catalytic system in hand, the versatility and robustness of the 
Cp*Co(III)-catalyzed oxazolinyl-directed C–H amination was then investigated. 
Various 2-phenyloxazolines 142 were efficiently converted to the amide products 
143 with high efficacy (Table 3.2). Among others, a wealth of alkyl, aryl, ether and 
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halogenated substituents were fully tolerated in the transformation, affording 
products 143 in moderate to good yield (entries 1–7). Remarkably, even the 
secondary amide 142h bearing free N–H groups was successfully transformed into 
the desired product 143ha with complete site-selectively (entry 8). meta-Substituted 
2-phenyloxazolines 142i-k were also viable substrates for the cobalt-catalyzed C–H 
nitrogenation, and were functionalized on the less sterically hindered ortho-position 
with complete positional selectivity (entries 9–11). Moreover, the C–H amidation was 
found to be scalable. Indeed, a gram-scale reaction was carried and provided 
product 143aa without any loss of efficacy. 
 
Table 3.2. Substrate scope of 2-aryloxazolines 142 in the cobalt-catalyzed C–H amidation.[a] 
 












































 Reaction conditions: 142 (0.50 mmol), 40 (1.2 equiv), Cp*Co(CO)I2 (5.0 mol %), AgSbF6 
(20 mol %), NaOAc (20 mol %), DCE (2.0 mL), 100 °C, 16 h. 
[b]
 Isolated yields. 
[c]
 Reaction 
carried on 5.6 mmol scale. 
[d]
 Reaction carried on 0.25 mmol scale. 
[e]
 Performed by Dr. R. 
Mei. 
[f]
 Using [Cp*RhCl2]2 (2.5 mol %) instead of Cp*Co(CO)I2. 
 
The versatile Cp*Co(III)-catalyst however encountered also limitations. 
2-Phenyloxazolines bearing ortho-substituents could only be converted to the 
desired amides in low to moderate yield. Also, no conversion of the starting material 
was detected when using nitro-substituted oxazoline 142l (Table 3.2, entry 12). 
Furthermore, [Cp*RhCl2]2 was also tested as catalyst in the transformation of 
2-(meta-chlorophenyl)-oxazoline 142j. No significant difference of chemo- or site-
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selectivity compared to Cp*Co(CO)I2 was observed, providing product 143ja in a 
similar yield (Table 3.2, entry 10). 
Additional substrates 142, including 2-phenyloxazolines bearing sensitive halogen, 
ester and cyano substituents, as well as differently substituted dioxazolones 40, 
were also investigated by Dr. R. Mei in the transformation, and thus were found to 
give the desired amidated products.[37e,227a] 
Thereafter, the effect of the substitution pattern of the oxazoline moiety was studied 
(Table 3.3). Diversely functionalized oxazolines as well as six-membered 
dihydrooxazines were efficiently converted to amides 143 in good to excellent yield 
(entries 1–5). However, additional substituents adjacent to the nitrogen atom of the 
oxazolinyl group were not tolerated, with 4-ethyloxazoline 142r remaining untouched 
when submitted to the reaction conditions (entry 6). This outcome is likely explained 
by an excessive steric hindrance near the catalyst-coordinating nitrogen atom of the 
oxazoline directing group. Indeed, the reactivity of cobalt(III) is greatly affected by 
steric factors due to its small ionic radius.[46a,46b] 
 
Table 3.3. Substrate scope of substituted oxazolines and oxazines 142 in the cobalt-
catalyzed C–H amidation.[a] 
 






















 Reaction conditions: 142 (0.50 mmol), 40 (1.2 equiv), Cp*Co(CO)I2 (5.0 mol %), AgSbF6 
(20 mol %), NaOAc (20 mol %), DCE (2.0 mL), 100 °C, 16 h. 
[b]
 Isolated yields. 
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Gratifyingly, the scope of the Cp*Co(III)-catalyzed C–H amidation was not limited to 
2-phenyloxazolines 142. Indeed, various indoles 28/36 were efficiently and 
selectively functionalized at the C2-position under the assistance of removable 
pyridyl (py) and pyrimidyl (pym) directing groups in the presence of diverse alkyl, 
alkoxy and ester substituents, highlighting the versatility and the robustness of the 
developed methodology (Table 3.4). Remarkably, due to the higher inherent 
reactivity of indoles 28/36 compared to 2-aryloxazolines 142, the synthesis of 
amidated products 146/147 was found to be viable at a low catalyst loading of 
2.5 mol % and a rather mild reaction temperature of 70 °C, after further optimization 
by Dr. R. Mei.[227b] CptCo(CO)I2 (Cp
t = 1,3-di-tert-butylcyclopentadienyl) was also 
tested as the catalyst in the cobalt-catalyzed C–H amidation of indoles due to recent 
reports indicating the superiority of Cpt over Cp* in rhodium(III)-catalyzed 
transformations.[230] However, in the present case, the desired product 147aa was 
only formed in a moderate yield of 27% when using the Cpt catalyst, compared to 
the 86% obtained when the Cp* complex was employed (entry 1). For more 
challenging substrates, such as sterically hindered C3-alkylated indole 36b, 
increasing the reaction temperature as well as the catalyst loading improved the 
reaction outcome to afford the desired product 147ba in synthetically useful yields 
(entry 2). Furthermore, it is noteworthy that, while 2-aryloxazolines 142 absolutely 
required carboxylate additives for the transformation to occur with high catalytic 
efficacy, the more reactive indole substrates 28/36 could be amidated in high yield 
even in the absence of the base additive (entry 2). However, weakly coordinating 
directing groups such as carbamates and ureas fell short in the envisioned cobalt-
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Table 3.4. Substrate scope of substituted indoles 28/36 in the cobalt-catalyzed C–H 
amidation.[a] 
 




























 Reaction conditions: 28/36 (0.50 mmol), 40 (1.2 equiv), Cp*Co(CO)I2 (2.5 mol %), AgSbF6 
(5.0 mol %), NaOAc (5.0 mol %), DCE (2.0 mL), 70 °C, 16 h. 
[b]





Co(CO)I2 instead of Cp*Co(CO)I2. 
[d]
 Using Cp*Co(CO)I2 (5.0 mol %), AgSbF6 (10 mol %) and 
NaOAc (10 mol %) at 100 °C. 
[e]
 NaOAc was omitted. 
 
Moreover, the reactions of additional indole substrates 28 bearing sensitive 
electrophilic functional groups, such as bromo and iodo, as well as differently 
substituted dioxazolones 40, including thiophene moieties, were studied in detail by 
Dr. R. Mei, and showcased the chemo-selectivity and robustness of the developed 
C–H functionalization methodology.[37e,227a] In addition to 2-aryloxazonlines 142 and 
N-pyri(mi)dylindoles 28/36, other substrate classes were smoothly amidated 
employing the developed methodology. Indeed, 2-phenylpyridines, 
N-phenylpyrazoles, N-phenylindazoles and 2-phenylpyrimidines were among other 
efficiently converted to the corresponding amides by the Cp*Co(CO)I2 catalyst, as 
reported by Dr. R. Mei.[227a] 
 
3.1.3. Mechanistic Studies 
 
Given the unique features of the versatile cobalt-catalyzed C–H amidation, we 
became interested in delineating its mode of action. Towards this objective, 
experimental mechanistic studies were conducted. 
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First, the effect on the reaction of various radical scavengers, such as TEMPO and 
BHT, was probed (Scheme 3.2a). Here, only a mild reduction of the yield was 
observed, supporting the catalytic transformation not to occur via a radical-based 
mechanism. This observation contrasts with mechanistic studies performed for 
cobalt-catalyzed C–H alkoxylations, where a SET process has been proposed.[231] A 
mercury poisoning test was conducted to probe the homogeneity of the reaction 
(Scheme 3.2b). Here, no significant reduction of the catalytic activity was observed 
in the presence of a stoichiometric amount of metallic mercury, which supports the 
homogenous nature of the catalytic process. 
 
 
Scheme 3.2. Effect of radical scavengers on the cobalt(III)-catalyzed C–H amidation and 
mercury drop test. 
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Reactions with an isotopically labeled protic co-solvent were performed by Dr. R. 
Mei.[227a] A considerable H/D scrambling was observed in the absence of 
dioxazolones 40. Yet, no deuterium incorporation was detected in the presence of 
the amidation reagent 40. Furthermore, kinetic studies were conducted by Dr. R. 
Mei.[227a] A kinetic isotope effect (KIE) of kH/kD ≈ 2.3 revealed the C–H cleavage step 
to be kinetically relevant. Additionally, competition experiments between differently 
substituted substrates indicated more electron-rich 2-aryloxazolines 142 to react 
preferentially, which supports the C–H activation event to occur through a base-




Scheme 3.3. Plausible catalytic cycle of the Cp*Co(III)-catalyzed C–H amidation. 
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Based on the conducted mechanistic studies and previous reports, the 
transformation is believed to be initiated by the formation of the catalytically active 
cationic complex Cp*Co(OAc)+ through halogen abstraction by the silver salt and 
coordination by the carboxylate additive (Scheme 3.3). Then, a plausible catalytic 
cycle begins with a kinetically relevant, acetate-assisted C–H metalation to generate 
cobaltacycle 149, which is believed to occur via a BIES mechanism.[37] Thereafter, 
coordination of the dioxazolone 40 provides intermediate 150. Finally, CO2 extrusion 
and protodemetalation by the formed acetic acid provide the desired amidated 
product 143 and regenerate the active cobalt(III)-carboxylate catalyst. 
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3.2. Asymmetric Iron-Catalyzed Hydroarylations by C–H Activation 
 
While major achievements in the research area of C–H activation have been 
realized with the aid of precious, rather toxic noble transition metals, recent focus 
has shifted to earth-abundant and inexpensive 3d metals.[45] However, despite 
substantial advances, full selectivity control in enantioselective C–H transformations 
continues to heavily rely on noble 4d and 5d transition metals, mostly palladium, 
rhodium and iridium complexes.[51] In sharp contrast, enantioselective C–H 
functionalizations with sustainable 3d metals remain underdeveloped, but have 
gained significant momentum during the course of this doctoral thesis.[52] 
In this context, enantioselective transformations by inner-sphere iron-catalyzed C–H 
activation remained unprecedented at the outset of this work. Drawing inspiration 
from the work of Yoshikai on the racemic iron-catalyzed hydroarylation of styrenes 
60 and alkynes 7 with indoles 59 (Scheme 1.28),[148] the possibility to develop an 
asymmetric iron-catalyzed C–H alkylation was investigated. The envisioned 
transformation is highly desirable due to its perfect atom-economy[2] and the use of 
readily available, non-prefunctionalized alkenes, making the process 
environmentally benign. 
While our work represents the first enantioselective iron-catalyzed transformation via 
organometallic C–H activation, it should be noted that a few examples of iron-
catalyzed enantioselective C–H functionalizations via outer-sphere mechanisms 
have been previously reported.[232] Atroposelective oxidative couplings of 
2-naphthols[233] and biomimetic C(sp3)–H hydroxylations[234] have indeed been 
achieved with chiral iron catalysts in moderate to excellent enantioselectivities. 
Furthermore, it should be duly noted that, to the best of our knowledge,[232,235] chiral 
NHC ligands had never been used in asymmetric iron catalysis prior to this work. 
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3.2.1. Optimization Studies 
 
The optimization studies began by probing the effect of various (pre-)ligands on the 
envisioned enantioselective C2-alkylation of indole 59b with styrene 60b (Table 3.5). 
It should be emphasized that, in addition to chiral NHC[235d,236] precursors, different 
ligand classes, including achiral ligands, were tested in order to understand the 
requirements of the transformation. Indeed, only a very limited number of ligands 
were reportedly tested by Yoshikai in the racemic transformation,[148] which remains 
the sole example of this kind of reaction under iron catalysis. Yoshikai and 
coworkers investigated a narrow class of bis-aryl substituted NHC precursors, with 
the best reaction outcome being obtained with sIXyl∙HCl while more sterically 
hindered NHC ligands gave poor results. A few simple phosphine and bipyridyl 
ligands were also tested, but fell short in providing the C–H alkylated indole in 
synthetically useful yields. We hence became interested in the performance of 
different ligands or differently substituted NHC precursors in this transformation. 
The desired C–H alkylated product 152bb could be obtained in excellent yield using 
a slight modification of the reported conditions,[148] and a control experiment 
demonstrated the importance of the ligand (entries 1–2). No significant enantio-
induction was observed when TMEDA was replaced with (–)-sparteine (entry 3). The 
simple chiral NHC precursor 153, originally introduced by Grubbs as a chiral sIMes 
analogue for enantioselective alkene metathesis,[211] provided product 152bb in low 
yield but promising enantioselectivity (entry 4). Various additives were tested in 
combination with 153, but did not improve the reaction outcome (entries 5–8). 
Interestingly, the bulkier ligand 154 gave even poorer results, with the opposite 
enantiomer being obtained as the “major” product (entry 9). Intrigued by whether the 
poor results of 153, which closely resembles the capable IXyl∙HCl pre-ligand, were 
due to the chiral diphenyl backbone or to the lacking ortho-methyl substituent, 155 
was tested in the transformation (entry 10). While the alkylated product 152bb was 
formed in good yield, no significant enantioselectivity was observed. Different 
carbene classes, such as Berkessel’s triazolium-based NHC pre-ligand 156[237] and 
CAAC[238] precursor 157, were also tested in the reaction (entries 11–12). While 
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moderate to good conversions were observed, their performance was not superior to 
the common IXyl·HCl or IMes·HCl NHC precursors. Then, chiral alkyl-substituted 
NHC precursors 158–160 were investigated in the enantioselective alkylation, but 
unfortunately gave extremely poor results (entries 13–15). 
To further uncover the required ligand properties, different types of (pre-)ligands 
were tested in the transformation. No significant conversion or enantio-induction was 
observed with phosphine or phosphoramidite ligands (entries 16–18). A rather 
promising enantioselectivity was observed with the prototypical chiral secondary 
phosphine oxide (SPO) 164, despite the poor conversion (entry 19). Other simple, 
non-chiral SPOs were hence investigated, but only provided the alkylated product 
152bb in low yields (entries 20–22). Additional (HA)SPOs were then probed, without 
major success (entries 23–24). Phosphine chlorides[239] 170–171 were tested as 
well, but failed to deliver any desired product (entries 25–26). It should be noted that 
phosphine chloride pre-ligands may react with the Grignard reagent to generate the 
corresponding phosphine in situ, although findings by Ackermann in the context of 
palladium-catalyzed Kumada–Corriu couplings provide support for the formation of 
tertiary phosphines not to occur under similar conditions.[239a] The performance of 
nitrogen-based ligands in the envisioned iron-catalyzed asymmetric hydroarylation 
was then explored. As promising results were obtained with the bidentate ligand 
172, its chiral analogue 173, which had been previously successfully employed in 
iron-catalyzed hydrofunctionalizations of alkenes,[240] was probed in the C–H 
alkylation, but no significant enantio-induction was observed (entries 27–28). 
Furthermore, PyBOX[224g] 174 and diamine 175 were tested, but failed to deliver any 
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Table 3.5. Preliminary ligand optimization for the iron-catalyzed hydroarylation of styrene 
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Entry L Yield [%][b] e.r.[c] 
1 IXyl·HCl 92 50:50 
2 --- <2% - 
3[d] IXyl·HCl 53 <5% ee 
4 153 11 60:40 
5[e] 153 traces - 
6[f] 153 n.r. - 
7[f,g] 153 n.r. - 
8[h] 153 traces - 
9 154 6 45:55 
10 155 61 54:46 
11 156 66 - 
12 157 23 - 
13 158 4 <5% ee 
14 159 5 <5% ee 
15 160 8 <5% ee 
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16 161 12 <5% ee 
17 162 15 <5% ee 
18 163 2 <5% ee 
19 164 8 59:41 
20 165 20 - 
21 166 18 - 
22 167 20 - 
23 168 22 <5% ee 
24 169 5 <5% ee 
25 170 traces - 
26 171 traces - 
27 172 32 - 
28[i] 173 17 <5% ee 
29 174 12 55:45 
30 175 10 <5% ee 
[a]
 Reaction conditions: 59b (0.25 mmol), 60b (1.5 equiv), Fe(acac)3 (10 mol %), L 
(10 mol %), CyMgCl (1.0 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 60 °C, 16 h. 
[b]
 Yield of the isolated product. 
[c]
 Determined by chiral HPLC analysis.                   
[d] 
(–)-Sparteine (2.0 equiv) instead of TMEDA. 
[e]
 THF/NMP (5/1) as solvent. 
[f]
 [ZnBr2·TMEDA] (2.0 equiv) was added. 
[g]
 TMEDA was omitted. 
[h]
 LiCl (1.0 equiv) 
was added. 
[i]
 Fe(acac)3 was omitted. 
 
Based on the results discussed above (Table 3.5), it became apparent that only 
bis-aryl NHCs seem to be suitable ligands in this transformation, as no significant 
enantio-induction and/or conversion was observed with other ligand classes or 
differently decorated NHC precursors. Hence, we attempted to rationalize the effect 
of the substituents of the flanking phenyl groups of the NHC core in order to design 
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more selective and effective ligands for this transformation (Scheme 3.4a). It should 
be noted that the development of chiral analogues of the common monodentate 
NHC ligands IMes and IPr has been described as an extremely challenging task. 
Indeed, the differences of steric and electronic properties of chiral NHC ligands 
compared to IMes or IPr often render them incompetent for the envisioned 
transformations.[241] 
First, the comparison of xylyl-substituted pre-ligands (IXyl·HCl and 155) to NHC 
precursor 153 lacking an ortho-methyl group clearly indicated that both substituents 
in 2- and 6-positions of the N-aryl groups are essential for the reaction to provide the 
desired alkylated product in good yield (Table 3.5, entries 1, 4, 10). However, no 
significant enantioselectivity was ever observed with this design. The introduction of 
bulkier ortho-substituents on the aryl groups of Grubbs-type[211] NHC ligands would 
seem highly desirable, as it has been a successful approach in many previous 
reports.[242] However, additional steric bulk on the ortho-position is not tolerated in 
the present case, as exemplified by the extremely poor performances of 154 
(Table 3.5, entry 9) or IPr in Yoshikai’s racemic C–H alkylation.[148] 
Therefore, it appeared clearly that a novel ligand design was required here. Based 
on the results discussed above, it emerged that two small (i.e. primary) ortho-
substituents at the 2- and 6-positions of the flanking aryl groups are necessary in 
order to achieve high conversions, although no significant enantio-induction was 
observed with this substitution pattern. Hence, the design of a NHC ligand able to 
provide the alkylated product with both high yield and enantioselectivity seemed to 
be an unsolvable problem at first. However, we reasoned that replacing the second 
methyl substituent at the 6-position of the N-aryl group with a bulky substituent at the 
adjacent meta 5-position might just do the trick, providing enough steric bulk on both 
sides of the aryl group, but not too close to the metal center. Interestingly, the 
envisioned design would create a wide and rather flexible (due to free rotation about 
the C–N bond) C2-symmetric chiral pocket (Fig. 3.4b). Indeed, it is expected, based 
on the original design by Grubbs,[211] that the chiral DPEN backbone will repel the 
ortho-methyl substituent of the N-aryl groups. The flanking aryl groups then act as 
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chiral relays to position the large meta-substituents on opposite sides of the NHC 
core, transferring the stereo-information of the chiral backbone to the substrates 
bound to the metal center during the reaction. This assumption was subsequently 
supported by a recent publication by Michon and coworkers in which the X-ray 
crystal structure of a rhodium(I) complex with a NHC ligand following the same 
design was reported.[243] While the introduction of bulky meta-substituents had been 
described previously, it should be noted that the reported 2,5-disubstituted N-aryl 
groups always bore large ortho-substituents.[236,244] 
 
 
Scheme 3.4. Rationale for remote meta-substituted NHC ligands. 
 
Thereby, various NHC precursors bearing N-aryl groups with meta-substituents were 
prepared and probed in the envisioned transformation (Table 3.6). While the 
prototypical chiral NHC precursor 153 only provided poor results (Table 3.5, entry 1 
and Table 3.6, entry 4), the introduction of a simple meta-methyl substituent 
exhibited a huge beneficial effect on the reaction outcome (Table 3.6, entry 2). 
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Extensive variations of the meta-substituent (entries 3–9) revealed an isopropyl 
group to be optimal (entry 3). Variations of the ortho-substituent were probed as 
well, but a methoxy substituent provided inferior results compared to a simple methyl 
group (entry 5). N-9-phenanthryl-NHC precursor 186 was tested as well. Despite the 
promising conversion, no significant enantio-induction was observed (entry 10). 
Variations of the chiral DPEN backbone were then investigated. Remarkably, a NHC 
precursor derived from DACH (187, entry 11) promoted the hydroarylation with an 
isolated yield similar to its DPEN-derived analogue (177, entry 3), but no significant 
enantioselectivity was observed. Changing the ligand-to-metal ratio from 1:1 to 2:1 
improved the reaction outcome considerably, increasing the enantiomeric ratio to 
75:25 (entry 12). Finally, replacing TMEDA with other amine additives had a rather 
limited effect on the outcome of the transformation (entries 13–14). 
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Entry L Yield [%][b] e.r.[c] 
1 153 11 60:40 
2 176 48 67:33 
3 177 67 71:29 
4 178 53 70:30 
5 179 21 58:42 
6 180 58 69:31 
7 182 23 64:36 
8 184 33 66:34 
9 185 36 66:34 
10 186 62 55:45 
11 187 57 <5% ee 
12[d] 177 65 75:25 
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13[d,e] 177 68 72:28 
14[d,f] 177 58 68:32 
[a]
 Reaction conditions: 59b (0.25 mmol), 60b (1.5 equiv), Fe(acac)3 (10 mol %), L 
(10 mol %), CyMgCl (1.0 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 60 °C, 16 h. 
[b]
 Yield of the isolated product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 L (20 mol %) 
and CyMgCl (1.1 equiv). 
[e]
 PMDETA instead of TMEDA. 
[f]
 BDMAEE instead of 
TMEDA. 
 
As asymmetric catalysis can sometimes be very substrate-specific, differently 
decorated indoles and styrenes were probed in the transformation (Table 3.7). First, 
the impact of the indole’s N-protecting group was investigated (entries 1–5). 
Whereas different N-alkyl substituents proved viable in the reaction, Boc and p-tosyl 
protecting groups fell short in delivering any C–H alkylated product, in complete 
agreement with the previous report of Yoshikai.[148] Interestingly, those findings are 
in stark contrast to the cobalt-catalyzed hydroarylation of styrenes with indoles 
developed by the same research group, where electron-withdrawing groups such as 
Boc were not only tolerated, but superior to alkyl or benzyl moieties.[106] 
MOM-protected indole 59g provided nearly identical results compared to 
N-methylindole 59b, while the introduction of a bulkier benzyl group had a critical 
effect. Indeed, both the yield and the enantioselectivity were significantly improved 
(entry 5). Further optimization studies were conducted using this substrate 
(entries 6–9). Different Grignard reagents or lower catalyst loadings did not afford 
satisfactory results. Remarkably, in sharp contrast to the work of Yoshikai,[148] the 
transformation was found to occur even in the absence of TMEDA, albeit in lower 
efficiency and selectivity. With the optimal indole substrate 59c in hand, various 
styrene derivatives 60 were tested in the iron-catalyzed asymmetric hydroarylation. 
2-Vinylnaphthalene 60a showed poor performance in the transformation, while para-
fluorostyrene 60g did not give better results than simple styrene 60b (entries 10–11). 
Gratifyingly, the use of electron-rich 4-methoxystyrene 60c provided a far better yield 
and enantioselectivity compared to other styrene analogues (entry 12). The excellent 
conversion allowed us to lower the reaction temperature to 45 °C, improving the 
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enantioselectivity to 89:11 e.r., while maintaining a synthetically useful yield 
(entry 13). While these conditions were initially used to study the substrate scope 
and limitations of the transformation (vide infra), a subsequent ligand screening 
revealed the superiority of meta-adamantyl ligand 180, which provided the 
hydroarylation product 62cc with an enantiomeric ratio of 92:8 (entries 14–19). 
Interestingly, the importance of the small ortho-methyl group was confirmed, as poor 
results were obtained with either a bulkier or no substituent (entries 15–16). 
Additionally, the introduction of a bulkier substituents in the chiral backbone did not 
improve the enantioselectivity (entry 17), in contrast to a previous work of Cramer 
and coworkers (Scheme 1.43).[210] Outstanding conversions were obtained with     
C2- and C1-symmetrical
[241] precursors bearing meta-aryl substituents, but lower 
enantiomeric excesses were observed (entries 18–19). Finally, FeF3 fell short in 
delivering any hydroarylation product (entry 20), despite its documented superiority 
over other iron precursors in iron/NHC-catalyzed Kumada–Corriu-type cross-
couplings.[245] 
 
Table 3.7. Substrate engineering and final optimization for the enantioselective 
hydroarylation of styrenes.[a] (Ligand structures are given in Table 3.6.) 
 
Entry R Ar L T [°C] Yield [%][b] e.r.[c] 
1[d] Me Ph 177 60 65 75:25 
2[d] Boc Ph 177 60 n.r. - 
3[d] Ts Ph 177 60 n.r. - 
4 MOM Ph 177 60 64 75:25 
5[d] Bn Ph 177 60 73 80:20 
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6[d,e] Bn Ph 177 60 43 78:22 
7[d,f] Bn Ph 177 60 n.r. - 
8[d,g] Bn Ph 177 60 42 68:32 
9[d,h] Bn Ph 177 60 52 76:24 
10 Bn 2-Np 177 60 46 56:44 
11 Bn 4-F-C6H4 177 60 72 81:19 
12 Bn PMP 177 60 93 85:15 
13 Bn PMP 177 45 76 89:11 
14 Bn PMP 180 45 95 92:8 
15 Bn PMP 181 45 78 90:10 
16 Bn PMP 188 45 10 58:42 
17 Bn PMP 189 45 87 11:89 
18 Bn PMP 183 45 98 75:25 
19 Bn PMP 190 45 98 87:13 
20[i] Bn PMP 180 45 traces - 
[a]
 Reaction conditions: 59 (0.25 mmol), 60 (1.5 equiv), Fe(acac)3 (10 mol %), L (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 60 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 No hydrolysis, the product was isolated as 
the imine. 
[e]
 PhMgCl instead of CyMgCl. 
[f]
 TMSCH2MgCl instead of CyMgCl. 
[g]
 Fe(acac)3 
(3.0 mol %) and 177 (6.0 mol %). 
[h]
 TMEDA was omitted. 
[i]
 FeF3 instead of Fe(acac)3. 
 
While studying the substrate scope of the reaction (vide infra), vinylferrocene 191a 
was identified as a suitable coupling partner in this transformation, providing the 
hydroarylation product with unprecedented enantioselectivities. Those findings 
prompted us to re-optimize the reaction for this unique class of substrates. 
Ferrocene derivatives are particularly important in asymmetric catalysis,[246] material 
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sciences,[247] and bioinorganic chemistry,[248] among others.[113] First, a 
representative set of chiral NHC precursors was probed in the asymmetric alkylation 
of N-benzylindole 59c with vinylferrocene 191a (Table 3.8). The simple Grubbs’ 
carbenes 153 and 154 performed poorly in the envisioned reaction, but confirmed 
the importance of the ortho-methyl groups (entries 1–2). An excellent conversion but 
only a moderate enantio-induction were observed with xylyl-substituted NHC 
precursor 155 (entry 3). Once more, the introduction of meta-substituents on the 
flanking aryl group of the NHC had a dramatic effect and allowed for high 
enantioselectivities (entries 4–8). Remarkably, a clear trend was observed 
depending on the size of the meta-alkyl substituent, with 1-adamantyl groups giving 
optimal results (entry 7). Interestingly, meta-phenyl substituents gave the highest 
conversion despite the moderate enantio-induction (entry 8). Kündig’s N,N’-alkyl-
substituted NHCs[249] were probed as well, but performed extremely poorly 
(entries 9–10), in agreement with previous work for the hydroarylation of styrenes 
(Table 3.5). 
 
Table 3.8. Ligand optimization of the enantioselective hydroarylation of vinylferrocene 
191a.[a] 
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Entry L Yield [%][b] e.r.[c] 
1[d] 153 5.5 25:75 
2[d] 154 3.3 54:46 
3 155 81 41:59 
4 176 69 11:89 
5 177 69 7:93 
6 178 53 5:95 
7 180 69 4:96 
8 182 76 12:88 
9 159' n.r. - 
10 193 n.r. - 
[a]
 Reaction conditions: 59c (0.25 mmol), 191a (1.5 equiv), Fe(acac)3 (10 mol %), L (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by HPLC analysis. 
[d]
 At 60 °C. 
 
Additional optimization studies and control experiments were then conducted 
(Table 3.9). A Job plot[250] of the ligand-to-metal ratio confirmed a 2:1 ratio to be 
optimal (entries 1–4). However, the only slightly lower conversion obtained using a 
1:1 ligand-to-metal ratio, along with the previous work of Yoshikai,[148] would rather 
indicate a mono-ligated iron/NHC catalyst to be operative in the transformation. 
Moreover, detailed mechanistic studies provided further support for a mono-NHC 
ligated iron species to be catalytically active (vide infra). Sub-stoichiometric amounts 
of CyMgCl only provided the desired alkylated product 192ca in low yields, 
supporting the Grignard reagent to play a bigger role than just serving as a base to 
generate the free NHC in situ (entries 5–7). Other organomagnesium reagents were 
tested in the transformation, but proved to be inferior to CyMgCl (entries 8–11). 
Interestingly, while the highest conversions were obtained with organometallic 
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species prone to β-hydride elimination after transmetalation to iron[240b,251] (entries 1 
and 9), significant conversion was observed with PhMgCl as well (entry 8). In 
contrast, no conversion was observed using NaOtBu as the base (entry 12), which 
supports an in situ generated organoiron species to be involved in the catalysis. 
Despite the different oxidation states and counter-ions, FeCl2 provided results 
comparable to Fe(acac)3 (entry 13). A reaction conducted at ambient temperature 
furnished the alkylated product 192ca with a slightly higher enantiomeric ratio of 
97:3, but significantly lower yield (entry 14). In contrast, increasing the temperature 
to 60 °C improved the yield but lowered the enantioselectivity (entry 15). Once 
again, in stark contrast to the work of Yoshikai,[148] the transformation was found to 
occur even in the absence of TMEDA, albeit in lower efficiency (entry 16). Finally, 
control experiments confirmed the key role of the iron catalyst, as no product 
formation was detected in the absence of Fe(acac)3 or using other first-row transition 
metal salts (entries 17–20). 
 
Table 3.9. Further optimization studies and control experiments for the enantioselective 
hydroarylation of vinylferrocene 191a.[a] 
 
Entry Deviation from the standard conditions Yield [%][b] e.r.[c] 
1 none 69 4:96 
2[d] 180 (5.0 mol %) 36 8:92 
3[d] 180 (10 mol %) 53 5:95 
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4[e] 180 (30 mol %) 65 4:96 
5 CyMgCl was omitted n.r. - 
6 CyMgCl (0.50 equiv) 18 4:96 
7 CyMgCl (0.60 equiv) 26 4:96 
8 PhMgCl instead of CyMgCl 33 4:96 
9 iPrMgCl instead of CyMgCl 55 5:95 
11 TMSCH2MgCl instead of CyMgCl n.r. - 
12 NaOtBu instead of CyMgCl n.r. - 
13 FeCl2 instead of Fe(acac)3 50 5:95 
14 at 23 °C 40 3:97 
15 at 60 °C 72 6:94 
16 TMEDA was omitted 39 5:95 
17 Fe(acac)3 was omitted - - 
18 Co(acac)2 instead of Fe(acac)3 - - 
19 Mn(acac)2 instead of Fe(acac)3 - - 
20 Ni(acac)2 instead of Fe(acac)3 - - 
[a]
 Reaction conditions: 59c (0.25 mmol), 191a (1.5 equiv), Fe(acac)3 (10 mol %), 180 (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 CyMgCl (1.0 equiv). 
[e]
 CyMgCl (1.2 equiv). 
 
It should be highlighted that such high enantioselectivities are remarkable in 
organometallic iron catalysis and remain unmatched as of today. Indeed, at the 
outset of this work, the only previous example of such an asymmetric transformation 
was an iron-catalyzed Kumada–Corriu cross-coupling employing a complex chiral 
bidentate phosphine, which provided the coupled products in up to 91:9 e.r. 
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(Scheme 1.29).[149] Later works on cross-couplings[150] and C–H activation[152] 
provided the corresponding products with even lower enantioselectivities. Thus, 
enantiomeric excesses over 90%, furthermore obtained with a monodentate chiral 
ligand, are absolutely outstanding in this burgeoning field of catalysis. Indeed, the 
present work not only represents the first enantioselective transformation by inner-
sphere iron-catalyzed C–H activation, but also the first use of chiral NHC ligands in 
asymmetric iron catalysis. 
 
3.2.2. Substrate Scope and Limitations 
 
With the optimized iron catalyst in hands, its performance in the intermolecular 
asymmetric C–H alkylation of indole derivatives 59 with the electron-rich 
4-methoxystyrene (60c) was explored (Table 3.10). The desired carbaldehydes 62 
were obtained with excellent yields and high levels of enantiocontrol from diversely 
substituted indoles 59 (entries 1–12). Indeed, electron-rich as well as electron-poor 
indoles 59 were amenable to the present reaction. Furthermore, the transformation 
was fully compatible with numerous functionalities on the indole nitrogen, including 
alkyl and benzyl substituents bearing synthetically useful functional groups. It is 
noteworthy that NHC precursor 177, bearing meta-iPr substituents, was found to 
furnish products 62fc, 62gc and 62bc with a slightly improved enantioselectivity 
compared to pre-ligand 180 (entries 4, 5, 8). Remarkably, the pharmacologically 
relevant 7-azaindole 59n was also identified as a viable substrate for the first time in 
iron-catalyzed C–H activations, although the alkylated product 62nc was only 
obtained with a moderate enantiomeric ratio of 76:24 (entry 13). A single 
recrystallization however improved the enantiomeric ratio to 90:10. Yet, other 
azaindoles gave unsatisfactory results so far (entries 14–15). Furthermore, no 
significant conversion was observed using pyrrole 59q or benzothiophene 194 
(entries 16–17). 
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Table 3.10. Substrate scope of substituted (aza)indoles 59 in the iron-catalyzed 
enantioselective C–H alkylation with styrene 60c.[a] 
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--- <10%[g] - 
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--- <5%[g] - 




--- n.r. - 
[a]
 Reaction conditions: 59 (0.25 mmol), 60c (1.5 equiv), Fe(acac)3 (10 mol %), 180 (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 Using 177 instead of 180. 
[e]
 No hydrolysis, 
product isolated as the imine. 
[f]
 After recrystallization from iPrOH. 
[g]




Thereafter, a variety of styrenes 60 were tested in the C–H transformation 
(Table 3.11). Diverse vinylarenes 60 with electron-rich and electron-poor 
substituents smoothly underwent the iron-catalyzed hydroarylation with good to 
excellent levels of enantioselectivity, providing exclusively the branched products 62 
(entries 1–8). The high chemoselectivity and broad substrate scope of the 
transformation were however met with some limitations. No significant conversion 
was observed with styrenes bearing perfluorinated groups or additional substituents 
on the alkene (entries 9–11). Additionally, several vinylheteroarenes 60 were probed 
in the intermolecular hydroarylation, but no desired alkylated product could be 
obtained (entries 12–13). Unactivated alkenes such as 1-octene 29a also failed to 
provide any C–H alkylated indole (entry 14). Vinyl ethers, vinyl silanes and dienes 
102 also fell short in the reaction (entries 15–17). 
 
Table 3.11. Substrate scope of vinylarenes 60 in the iron-catalyzed enantioselective C–H 
alkylation.[a] 
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--- <10%[d] - 
10 
 
--- n.r.[d] - 
11 
 
--- <10%[d] - 
12 
 
--- n.r.[d] - 
13 
 
--- <10%[d] - 
14 
 
--- n.r.[d] - 
15 
 
--- n.r.[d] - 




--- n.r.[d] - 
17 
 
--- n.r.[d] - 
[a]
 Reaction conditions: 59c (0.25 mmol), 60 (1.5 equiv), Fe(acac)3 (10 mol %), 180 (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 Using 177 instead of 180. 
 
While various vinylheteroarenes failed to deliver any C–H alkylated product in the 
envisioned iron-catalyzed enantioselective hydroarylation (vide supra), 
vinylferrocene 191a was in contrast identified as a viable substrate in this 
transformation. To our delight, differently substituted indoles 59 bearing electron-
rich, electron-poor and various N-substituents were functionalized in moderate to 
good yields and outstanding levels of enantioselectivity, usually over 90% ee 
(Table 3.12, entries 1–12). Pharmacologically meaningful azaindole 59n participated 
in the reaction as well, providing the alkylated product 192 in moderate yield, but 
excellent positional selectivity (entry 13). 
 
 
Table 3.12. Substrate scope of substituted (aza)indoles 59 in the iron-catalyzed 
enantioselective C–H alkylation with vinylferrocene 191a.[a] 
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 Reaction conditions: 59 (0.25 mmol), 191a (1.5 equiv), Fe(acac)3 (10 mol %), 180 
(20 mol %), CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of 
the isolated product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 Using 177 instead of 180. 
[e]
 Product isolated as the imine. 
 
Differently substituted vinylmetallocenes 191 were then tested in the iron-catalyzed 
C2-alkylation of indoles (Table 3.13). In addition to ferrocenylalkenes, the 
isoelectronic but larger ruthenocenyl-substituted olefin 191b smoothly underwent the 
asymmetric hydroarylation (entry 1). Furthermore, the sterically hindered 
pentamethylferrocene-derived olefin 191c proved to be a viable substrate in the 
transformation as well, providing the highly congested Markovnikov product 192 in 
good yield and excellent enantioselectivity (entry 2). The preparation of highly 
enantiomerically-enriched ferrocenyl- and ruthenocenyl-indoles once more 




Table 3.13. Substrate scope of vinylmetallocenes 191 in the iron-catalyzed enantioselective 
C–H alkylation.[a] 
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 Reaction conditions: 59c (0.25 mmol), 191 (1.5 equiv), Fe(acac)3 (10 mol %), 180 (20 mol %), 
CyMgCl (1.1 equiv), TMEDA (2.0 equiv), THF (0.50 mL), 45 °C, 16 h. 
[b]
 Yield of the isolated 
product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 Using 177 instead of 180. 
 
3.2.3. Determination of the Absolute Configuration 
 
The determination of the absolute configuration is of primordial importance in 
asymmetric catalysis. Since styrene derivatives 60 are amorphous solids and lack 
heavy atoms, the highly crystalline bromo-substituted imine 197 was prepared in one 
step and obtained in 99% ee after a single crystallization (Scheme 3.5). Crystals 
suitable for X-ray diffraction were then grown by slow evaporation, allowing for the 















Scheme 3.5. a) Synthesis and b) ORTEP plot of imine 197. Anisotropic displacement 
parameters are depicted at the 50% probability level. The crystal structure was measured 
and solved by H. Keil and approved by Prof. D. Stalke. 
 
Likewise, ferrocene derivative 192ca could be crystallized directly, providing the 
product in >99% ee (Scheme 3.6). Due to the iron atom of the ferrocene moiety, no 
additional heavy atom had to be installed in the compound, and crystals suitable for 
X-ray diffraction analysis could be grown directly by slow evaporation from benzene. 
The R-enantiomer was found to be selectively formed in the transformation. The 
different R/S configuration observed with vinylmetallocenes compared to styrenes is 
only due to different relative priorities of aryl and metallocenyl groups compared to 
the indole core according to the Cahn–Ingold–Prelog sequence rules.[252] 
Interestingly, C–H···π interactions can be observed between the N-benzyl 
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substituent of the indole and the ferrocenyl group, which might explain the 
importance of the benzyl group in order to obtain high enantioselectivities. 
 
               
Scheme 3.6. Preparation and ORTEP plot of 192ca. Anisotropic displacement parameters 
are depicted at the 50% probability level. The crystal structure was measured and solved by 
H. Keil and approved by Prof. D. Stalke. 
 
3.2.4. Product Diversification 
 
The synthetic utility of the iron-catalyzed C–H alkylation was further illustrated by 
late-stage diversification of the thus-obtained products (Scheme 3.7). The formyl 
group could be removed in a traceless fashion under palladium catalysis without 
significant loss of the enantiomeric excess (Scheme 3.7a). It is noteworthy that 
higher catalyst loadings or reaction temperatures provided the deformylated product 
in higher yields, but substantial racemization was then observed. The weakly 
coordinating[39,253] formyl motif could also be used as directing group to promote C–H 
functionalization at the indole’s C4-position. Using the methodology reported by 
Ramaiah Prabhu,[254] the benzene core could be alkenylated with methyl acrylate 
using a ruthenium catalyst,[255] giving access to highly functionalized indoles through 
position-selective twofold C–H activation (Scheme 3.7b). 
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Scheme 3.7. Product diversification. a) Pd(OAc)2 (8.0 mol %), cyclohexane, 4Å MS, 140 °C. 
b) [RuCl2(p-cymene)]2 (5.0 mol %), AgSbF6 (20 mol %), Cu(OAc)2·H2O, methyl acrylate, 
DCE, 120 °C. c) H2, Pd/C, EtOH, 23 °C. d) Morpholine, NaBH(OAc)3, AcOH, DCE, 23 °C. 
e) Ph3PCHCO2Me, PhMe, 130 °C. f) i. NH4OAc, MeNO2, 90 °C; ii. LiAlH4, THF, 85 °C; 
iii. Boc2O, Et3N, 1,4-dioxane, 23 °C. 
 
Various transformations of the synthetically useful formyl group were also conducted 
(Scheme 3.7c–f). The formyl group could be reduced to a methyl group, or 
converted to other functional groups via reductive amination or Wittig reaction. 
Additionally, the pharmacologically relevant protected tryptamine 203 could also be 
obtained in 3 steps without significant racemization. 
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3.2.5. Mechanistic Studies 
 
Given the unique features of the developed asymmetric iron-catalyzed C–H 
alkylation, we became interested in delineating its mode of action. Hence, 
experimental and computational[256] mechanistic studies were performed in order to 
gain insights into the reaction’s mechanism. 
 
3.2.5.1. Deuterium Labeling Experiments 
 
First, experiments with isotopically labelled indole substrate [D]1-59b were 
conducted (Scheme 3.8). The deuterium atom was found to be selectively 
transferred to the terminal position of the alkene, which provides support for an 
inner-sphere C–H activation. This observation can be rationalized with the C–H 
scission occurring by ligand-to-ligand hydrogen-transfer (LLHT) or C–H oxidative 
addition to a low-valent iron species. Interestingly, no deuterium incorporation was 
observed at the methine position as it was the case in the related work of 
Yoshikai.[148] 
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Scheme 3.8. Reactions with isotopically labeled substrate [D]1-59b. 
 
Thereafter, a crossover experiment was conducted between deuterated and non-
deuterated substrates (Scheme 3.9). [D]1-59b and 59f were selected due to their 
similar efficacy in the transformation and the easy separation of their corresponding 
products by silica gel chromatography. Remarkably, a nearly identical deuterium 
incorporation was observed in both products [D]n-62bc and [D]n-62fc. This finding 
seemingly rules out the oxidative addition/reductive elimination pathway initially 
proposed by Yoshikai for the racemic reaction[148] and provides support for a LLHT-
manifold.[32a,37b,81] 
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Scheme 3.9. Crossover experiment between deuterated and non-deuterated substrates 59. 
 
Furthermore, additional experiments with deuterated substrate [D]1-59b revealed a 
kinetic isotope effect (KIE) of kH/kD ≈ 1.0 (Scheme 3.10). A KIE of this magnitude 
suggests that the C–H cleavage step is not turnover-limiting,[257] and provides 
evidence for a facile and reversible C–H activation event. 
 
 
Scheme 3.10. KIE studies. Experiment b was conducted by Dr. D. Zell. 
 




Subsequently, detailed kinetic studies of the enantioselective C–H alkylation were 
conducted by Dr. D. Zell.[151] A first-order dependence on the concentration of the 
indole substrate 59b was observed, along with a saturation kinetics behavior for the 
styrene 60g (Scheme 3.11). 
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Scheme 3.11. Kinetic analysis. The experiments were conducted by Dr. D. Zell. 
 
3.2.5.3. Mercury Drop Test 
 
A mercury poisoning test was conducted to probe the homogeneity of the catalytic 
process (Scheme 3.12). No significant reduction of the catalytic activity was 
observed in the presence of an excess of metallic mercury, which confirms the 
homogenous nature of the transformation. 
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Scheme 3.12. Mercury drop test for the iron-catalyzed C–H alkylation. 
 
This finding is especially important since iron(0) nanoparticles are known to form 
upon exposure of iron salts to Grignard reagents,[258] and their presence in the 
reaction mixture has been indirectly supported by 57Fe Mössbauer spectroscopic 
studies (vide infra). Nevertheless, iron(0) nanoparticles do not appear to play a role 
in the catalyzed transformation. 
 
3.2.5.4. Non-Linear Effect Studies 
 
The effect of the enantiomeric excess of ligand 180 over the enantiomeric induction 
of the transformation was investigated (Scheme 3.13). The absence of a non-linear 
effect (NLE) renders a multi-ligand containing catalyst or catalytically competent 
oligomers unlikely to be operative in the asymmetric C–H secondary alkylation.[259] 
Hence, the beneficial effect of a ligand-to-metal ratio of 2:1 is apparently not due to 
the formation of bis-NHC-ligated iron species. 
 




Scheme 3.13. Non-linear effect studies. 
 
3.2.5.5. In situ Analysis by Mass Spectrometry and Mössbauer Spectroscopy 
 
While detailed kinetic studies, deuterium labelling experiments and non-linear effect 
studies were performed to delineate the modus operandi of the unique iron-
catalyzed enantioselective C–H alkylation (vide supra), the oxidation state and 
coordination sphere of the active catalyst have remained thus far speculative. 
Indeed, in iron/NHC-catalyzed C–H activations,[148,151,260] as well as in related 















3. Results and Discussion 
104 
“low-valent” cobalt/NHC-catalyzed C–H activations,[46c,46d,69a,69c] the active catalyst is 
usually generated in situ from a metal salt and an imidazol(in)ium NHC precursor in 
the presence of a Grignard reagent. The use of well-defined iron/NHC complexes as 
catalysts is well documented in molecular syntheses in different contexts.[235a–c] In 
contrast, no well-defined iron catalysts or intermediates have so far been isolated or 
characterized in the context of C–H activation, with the notable exception of Tatsumi 
and Ohki employing a half sandwich iron(II)/NHC complex for undirected C–H 
borylations of heteroarenes.[261] In the reactions employing in situ generated iron 
catalysts, the organometallic reagent has been proposed to play a dual role, serving 
both as the base and a potential reductant. The mechanism of the generation of the 
catalytically active species, as well as possible side-reactions occurring during this 
process, have thus far been overlooked.[262] Furthermore, iron species with formal 
oxidation states ranging from –2[263] to +4[264] have been observed in reactions of 
iron precursors with Grignard reagents.[108a,265] It is noteworthy that some of these 
species have been postulated as intermediates in iron-catalyzed Kumada–Corriu-
type cross-couplings[19] operating under reaction conditions similar to iron-catalyzed 
C–H activations. So far, all information on the oxidation state of the in situ generated 
iron catalysts enabling the C–H activation has been gained through DFT calculations 
regarding iron-catalyzed oxidative C–H functionalizations with alkyl halides.[131] 
Hence, the nature of the catalytically active species in the asymmetric iron-catalyzed 
hydroarylation has remained unknown until now. 
Interestingly, Yoshikai originally proposed a “low-valent”[266] Fe/NHC complex 
generated in situ through the reduction of the iron(III) pre-catalyst by the Grignard 
reagent to be operative in the racemic hydroarylation of vinylarenes and alkynes with 
indoles, and the C–H activation step to occur via oxidative addition into the C–H 
bond.[148] Yoshikai attributed the requirement of an excess of the Grignard reagent to 
the possible formation of ferrate species. In the course of the optimization studies for 
the enantioselective secondary alkylation of indoles 59, it was observed that 
Fe(acac)3 and FeCl2 pre-catalysts, despite their different oxidation states and 
counterions, gave comparable conversions and enantioselectivities (Table 3.9). This 
observation suggested that the iron precursors were transformed by the Grignard 
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reagent to the same catalytically competent iron species. Another possibility is the in 
situ formation of organoferrates. Indeed, Koszinowski recently reported that the 
nature of the iron precursor has very little effect on the transmetalation reactions with 
organometallic species to form such complexes.[267] These observations raised the 
question as to the nature of the active iron catalyst and its mode of action, and 
highlight the need for detailed, comprehensive mechanistic studies to unravel 
fundamental aspects of iron-catalyzed C–H activations. Such mechanistic insights 
have recently been gained for iron-catalyzed Kumada–Corriu-type cross-coupling 
reactions via Mössbauer spectroscopy and mass spectrometry, among other 
analytical methods.[265,267,268] These reports highlighted the dynamic nature and 
remarkable complexity of organometallic iron chemistry. 
Therefore, we became interested in the application of electrospray-ionization (ESI) 
mass spectrometry and 57Fe Mössbauer spectroscopy to unravel the key 
intermediates formed in situ in the enantioselective iron-catalyzed C–H alkylation.[218] 
In contrast to ESI-MS, 57Fe Mössbauer spectroscopy has the advantage of probing 
the entire population of iron species, regardless of their individual charge. This 
research work was conducted in collaboration with the research groups of Prof. Dr. 
K. Koszinowski (ESI-MS) and Prof. Dr. F. Meyer (Mössbauer spectroscopy). 
We decided to follow a step-by-step approach and therefore initiated our 
investigations by probing the species formed in a stoichiometric reaction between 
the iron precatalyst, the Grignard reagent and TMEDA in THF, without the NHC 
precursor 180 or the indole substrate 59. Negative-ion mode ESI-MS of a solution of 
Fe(acac)3 treated with 8.0 equiv of CyMgCl in the presence of TMEDA (4.0 equiv) 
showed a mixture of various organoferrate species, among which Cy3Fe(II)
– and 
Cy4Fe(III)
– were dominant (Fig. 3.1a). Previous reports had already demonstrated 
the formation of abundant organoferrates upon transmetalation of iron precursors 
with Grignard reagents under similar reaction conditions.[267] Although ESI-MS 
cannot directly detect any neutral species, the observation of small amounts of 
Cy5Fe2
– and Cy4Fe2Cl
–, both with iron in an average oxidation state of +2, may 
indicate the presence of neutral organoiron complexes, such as Cy2Fe or CyFeCl, 
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which supposedly reacted with Cy3Fe(II)
– to afford the dinuclear aggregates. The low 
abundance of the dinuclear anions can be attributed to TMEDA, which has 
previously been shown to prevent the formation of polynuclear organoferrates.[267,269] 
All the observed organoferrates were found to be highly unstable, presumably due to 
β-hydride elimination, and completely vanished within 2 minutes. Experiments 
conducted with the better-behaved PhMgCl were therefore performed as well. 
PhMgCl has previously been shown to promote the desired C–H alkylation as well, 
albeit with a slightly diminished performance (vide supra, Tables 3.7, 3.9). It should 
also be noted that phenyl Grignard reagents have proven instrumental in other 
iron/NHC-catalyzed C–H activations.[148,260] Likewise, iron(II) and iron(III) 
phenylferrates were detected by ESI-MS in the reaction of Fe(acac)3 with PhMgCl in 
the presence of TMEDA (Fig. 3.1b), being in full agreement with previous 
findings.[267,269b,270] 
 
              
Figure 3.1. (a) Negative-ion mode ESI mass spectrum of a solution of the products formed 
in the reaction of Fe(acac)3 (10 mM) with TMEDA (4.0 equiv) and CyMgCl (8.0 equiv) in 
THF; a = [Cy,Fe,O2]
–, b = [Cy2,Fe,O2]
–, c = [Cy3,Fe,O2]
–, d = Cy4Al
–. Ions a–c resulted from 
reactions with residual traces of oxygen, d from an aluminum contamination. (b) Negative-
ion mode ESI mass spectrum of a solution of the products formed in the reaction of 
Fe(acac)3 (10 mM) with TMEDA (4.0 equiv) and PhMgCl (8.0 equiv) in THF; a = [Ph,Fe,O2]
–. 
Ions a resulted from reactions with residual traces of oxygen. The experiments were 
conducted by Dr. T. Parchomyk. 
 
A frozen solution of 57FeCl2/CyMgCl/TMEDA in THF was next analyzed by 
57Fe 
Mössbauer spectroscopy at 80 K (Fig. 3.2a). The obtained spectrum featured the 
(a)                                                                               (b) 
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signatures of two iron species, which were assigned to a major high-spin iron(III) 
species and a minor low-coordinate iron(II) species, in line with the formation of 
Cy4Fe(III)
– and Cy3Fe(II)
– observed by ESI-MS. Interestingly, we did not detect any 
Cy4Fe(IV), which has been observed by Fürstner in a related setting.
[264] The 
remarkable formation of a dominating iron(III) species from the iron(II) precursor in 
the presence of Grignard reagents and the absence of any external oxidant can be 
attributed to disproportionation with concomitant formation of low-valent iron species, 
as previously reported.[267] Yet, no low-valent iron species could be detected in our 
experiments. Therefore, a Mössbauer spectrum was recorded at 7 K (Fig. 3.2b), but 
was essentially identical to the spectrum recorded at 80 K. No signal for iron(0) 
nanoparticles[258] or other low-valent iron species could be observed by 57Fe 
Mössbauer spectroscopy. However, unfavorable relaxation dynamics[271] may lead to 
pronounced line broadening, which prevents detection of iron nanoparticles. 
 
              
Figure 3.2. (a) Mössbauer spectrum of a frozen solution (T = 80 K) of the products formed 
in the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv) and CyMgCl (8.0 equiv) in THF; 
components of the fit: δ(blue) = 0.48 mm s–1, ΔEQ(blue) = 0.89 mm s
–1, rel. int. = 84%; 
δ(red) = 0.21 mm s–1, ΔEQ(red) = 1.56 mm s
–1, rel. int. = 16%. (b) Mössbauer spectrum and 
components of the fit of a frozen solution (T = 7 K) of the products formed in the reaction of 
57FeCl2 (5.0 mM), TMEDA (4.0 equiv) and CyMgCl (8.0 equiv) in THF; components of the fit: 
δ(blue) = 0.48 mm s–1, ΔEQ(blue) = 0.88 mm s
–1, rel. int. = 85%; δ(red) = 0.24 mm s–1, 
ΔEQ(red) = 1.59 mm s
–1, rel. int. = 15%. The spectra were recorded and interpreted by Dr. S. 
Demeshko. 
 
(a)                                                                               (b) 
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The instability of the cyclohexylferrates was further highlighted by 57Fe Mössbauer 
spectroscopic analysis of the same reaction after it was allowed to warm to 23 °C 
(Fig. 3.3). The spectrum showed the complete disappearance of the iron(II) ate 
complex, a reduced amount of Cy4Fe(III)
– and the emergence of a new dominant 
species, whose unspecific doublet unfortunately does not allow for assignment. 
 
 
Figure 3.3. Mössbauer spectrum and components of the fit of a frozen solution (T = 80 K) of 
the products formed in the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv) and CyMgCl 
(8.0 equiv) in THF at 23 °C; components of the fit: δ(gray) = 0.19 mm s–1, 
ΔEQ(gray) = 0.86 mm s
–1, rel. int. = 68%; δ(blue) = 0.48 mm s–1, ΔEQ(blue) = 0.91 mm s
–1, 
rel. int. = 28%; δ(yellow) = –0.10 mm s–1, ΔEQ(yellow) = 1.10 mm s
–1, rel. int. = 3%. The 
spectrum was recorded and interpreted by Dr. S. Demeshko. 
 
A similar spectrum was obtained from the reaction of 57FeCl2 with PhMgCl in the 
presence of TMEDA (Fig. 3.4), indicating the formation of the phenylferrates 
Ph3Fe(II)
– and Ph4Fe(III)
–, being in line with the ESI-MS results (Fig. 3.1b) and 
previous reports.[267,269b] As the catalyzed C–H activation was found to completely 
shut down in the absence of the NHC ligand (vide supra, Table 3.5), the observed 
NHC ligand-free organoferrates are assumed to be catalytically inactive, but are 
plausible intermediates of the generation of the catalytically competent species. 
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Figure 3.4. Mössbauer spectrum of a frozen solution (T = 80 K) of the products formed in 
the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv) and PhMgCl (8.0 equiv) in THF; 
components of the fit: δ(blue) = 0.54 mm s–1, ΔEQ(blue) = 1.12 mm s
–1, rel. int. = 78%; 
δ(red) = 0.20 mm s–1, ΔEQ(red) = 1.44 mm s
–1, rel. int. = 13%; δ(dark yellow) = 0.46 mm s–1, 
ΔEQ(dark yellow) = 2.61 mm s
–1, rel. int. = 9%. The spectrum was recorded and interpreted 
by Dr. S. Demeshko. 
 
Subsequently, similar experiments were performed in the presence of the chiral 
NHC precursor 180. While the homoleptic ferrates remained present in the solution, 
two newly formed iron(II) species could also be detected by ESI-MS, namely 
Cy3Fe(NHC)
– and Cy2FeH(NHC)
– (Fig. 3.5). The latter, with a significantly higher 
intensity, is believed to result from β-hydride elimination of the former. Interestingly, 
no NHC complexes of iron(III) or low-valent iron were detected, suggesting the 
selective formation of Fe(II)/NHC species in the reaction. It should be noted that the 
peak corresponding to the Cy4Al
– contamination only appears so intense because of 
the relative low intensity of the anionic iron species. 
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Figure 3.5. Negative-ion mode ESI mass spectrum of a solution of the products formed in 
the reaction of Fe(acac)3 (10 mM) with TMEDA (4.0 equiv), CyMgCl (8.0 equiv) and 180 
(1.0 equiv) in THF; a = [Fe(NHC)Cy3]
–. NHC = C49H54N2. The experiment was conducted by 
S. Lülf. 
 
When a similar experiment was performed using PhMgCl, Fe/NHC species could not 
be observed (Fig. 3.6a). Yet, the relative intensity of the iron(II) ate complex was 
noticeably reduced, which indicates its consumption for the formation of neutral 
species not detectable by ESI mass spectrometry. Besides, no magnesium-NHC 
complexes or residual imidazolinium salt could be observed by positive-mode 
ESI-MS in any of the experiments (Fig. 3.6b). In this context, it should be mentioned 
that organomagnesium(II)/NHC complexes are known[272] and relevant in 
asymmetric catalysis.[273] Also, a recent study by Bedford on iron-catalyzed Negishi-
type reactions suggests that the phosphine ligand binds to the zinc rather than the 
iron atom.[274] In contrast, the present findings provide evidence for the NHC to 
coordinate to the iron catalyst, and not to magnesium(II). 
 
3. Results and Discussion 
111 
              
Figure 3.6. (a) Negative-ion mode ESI spectrum of a solution of the products formed in the 
reaction of Fe(acac)3 (10 mM) with TMEDA (4.0 equiv), PhMgCl (8.0 equiv) and 180 
(1.0 equiv) in THF; a = [Ph,Fe,O2]
–. (b) Positive-ion mode ESI spectrum representative of all 
experiments; a = Mg3Cl3(OMe)(OH)(TMEDA)
2+, b = Mg3Cl3(OMe)2(THF)2(TMEDA)
+, 
c = Mg3Cl3(OMe)2(THF)3(TMEDA)
+. The incorporated methoxides originate from traces of 
methanol as reported previously.[267,268c,275] The experiments were conducted by Dr. T. 
Parchomyk. 
 
When a frozen solution of 57FeCl2/180/CyMgCl/TMEDA was analyzed by 
57Fe Mössbauer spectroscopy, a rather intricate spectrum could be observed, which 
has been simulated well assuming five subspectra (Fig. 3.7a).[276] Two subspectra 
(Fig. 3.7a, blue and red) are almost identical to the previously detected ferrates 
(Fig. 3.2a). The most pronounced new signal (Fig. 3.7a, green) can be attributed to a 
low-coordinate iron(II) high-spin complex, most likely trigonal-planar 
Cy2Fe(NHC),
[277] in good agreement with ESI-MS (Fig. 3.5). Another newly formed 
species (Fig. 3.7a, magenta), with a higher isomer shift of 0.54 mm s–1 together with 
a lower quadrupole splitting of 2.04 mm s–1, may indicate a more symmetric iron(II) 
high-spin species with a higher coordination number such as Cy3Fe(NHC)
–, as 
detected by ESI-MS (Fig. 3.5). An additional minor species (Fig. 3.7a, cyan) was 
also observed in the 57Fe Mössbauer spectrum of the reaction with CyMgCl, but its 
non-characteristic doublet does not allow for further assignment. 
 
(a)                                                                                       (b) 
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Figure 3.7. (a) Mössbauer spectrum of a frozen solution (T = 80 K) of the products formed 
in the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv), 180 (1.0 equiv) and CyMgCl 
(8.0 equiv) in THF; components of the fit: δ(red) = 0.18 mm s–1, ΔEQ(red) = 1.59 mm s
–1, 
rel. int. = 36%; δ(green) = 0.39 mm s–1, ΔEQ(green) = 3.19 mm s
–1, rel. int. = 27%; 
δ(blue) = 0.46 mm s–1, ΔEQ(blue) = 0.98 mm s
–1, rel. int. = 19%; δ(magenta) = 0.54 mm s–1, 
ΔEQ(magenta) = 2.04 mm s
–1, rel. int. = 11%; δ(cyan) = 0.24 mm s–1, 
ΔEQ(cyan) = 0.40 mm s
–1, rel. int. = 7%.[276] (b) Mössbauer spectrum and components of the 
fit of a frozen solution (T = 80 K) of the products formed in the reaction of 57FeCl2 (5.0 mM), 
TMEDA (4.0 equiv), CyMgCl (8.0 equiv) and 180 (1.0 equiv) in THF at 23 °C; components of 
the fit: δ(red) = 0.22 mm s–1, ΔEQ(red) = 1.57 mm s
–1, rel. int. = 47%; δ(cyan) = 0.22 mm s–1, 
ΔEQ(cyan) = 0.57 mm s
–1, rel. int. = 34%; δ(purple) = 0.75 mm s–1, ΔEQ(purple) =  
1.57 mm s–1, rel. int. = 10%; δ(green) = 0.37 mm s–1, ΔEQ(green) = 3.20 mm s
–1, 
rel. int. = 9%. The spectra were recorded and interpreted by Dr. S. Demeshko. 
 
Two related iron(II) species were also observed in the corresponding reaction with 
PhMgCl (Fig. 3.8). However, no species related to the minor uncharacteristic signal 
observed before (Fig. 3.7a, cyan) was detected in this experiment. It is hence 
believed that this species was formed via β-hydride elimination from the 
Cy2Fe(NHC) complex. This hypothesis is further corroborated by the observation 
that, when the sample was prepared at higher temperatures (Fig. 3.7b), this species 
(Fig. 3.7a, cyan) became more pronounced, while the intensity of the Cy2Fe(NHC) 
signal was reduced (Fig. 3.7b, green). 
 
(a)                                                                                   (b) 
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Figure 3.8. Mössbauer spectrum and components of the fit of a frozen solution (T = 80 K) of 
the products formed in the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv), PhMgCl 
(8.0 equiv) and 180 (1.0 equiv) in THF; components of the fit: δ(blue) = 0.51 mm s–1, 
ΔEQ(blue) = 1.09 mm s
–1, rel. int. = 40%; δ(green) = 0.22 mm s–1, ΔEQ(green) = 4.25 mm s
–1, 
rel. int. = 39%; δ(light green) = 0.56 mm s–1, ΔEQ(light green) = 2.62 mm s
–1, rel. int. = 14%; 
δ(orange) = 0.32 mm s–1, ΔEQ(orange) = 1.70 mm s
–1, rel. int. = 4%; δ(wine) = 1.10 mm s–1, 
ΔEQ(wine) = 4.30 mm s
–1, rel. int. = 3%. The spectrum was recorded and interpreted by 
Dr. S. Demeshko. 
 
Thereafter, additional experiments in the presence of the indole substrate 59b were 
performed. In addition to the previously observed species, [Cy4Fe(indole)]
– was 
observed by ESI-MS analysis of the reaction of 57FeCl2/CyMgCl/TMEDA/180/59b 
(Fig. 3.9a). Yet, this species is believed to be catalytically irrelevant in the C–H 
activation due to the absence of the NHC ligand. Again, the apparent high intensity 
of the Cy4Al
– peak is due to the relative low intensity of the anionic iron species. 
ESI-MS analysis of the reaction of 57FeCl2/PhMgCl/TMEDA/180/59b did not reveal 
any new species, but showed the almost complete disappearance of the Ph3Fe(II)
– 
ferrate (Fig. 3.9b). Its consumption may suggest a reaction between the iron(II) ate 
complex, or a species in equilibrium with it, and the substrate 59 to form a neutral 
species. Therefore, this observation is suggestive of an organometallic iron(II) 
species to be involved in the catalysis as an intermediate or in the generation of the 
active catalyst. 
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Figure 3.9. (a) Negative-ion mode ESI spectrum of a solution of the products formed in the 
reaction of Fe(acac)3 (10 mM) with TMEDA (4.0 equiv), CyMgCl (8.0 equiv), 180 (1.0 equiv) 
and 59b (1.0 equiv) in THF. (b) Negative-ion mode ESI spectrum of a solution of the 
products formed in the reaction of Fe(acac)3 (10 mM) with TMEDA (4.0 equiv), PhMgCl 
(8.0 equiv), 180 (1.0 equiv) and 59b (1.0 equiv) in THF. The experiments were conducted by 
S. Lülf and Dr. T. Parchomyk, respectively. 
 
Further, no new species or significant changes upon the addition of substrate 59b 
were observed by 57Fe Mössbauer spectroscopy analysis of the analogous reactions 
with either CyMgCl or PhMgCl (Fig. 3.10). Yet, a slight reduction of the intensity of 
the species believed to be R2Fe(NHC) was observed (Fig. 3.10a−b, green), possibly 
indicating its consumption in a reaction with 59b. 
 
              
Figure 3.10. (a) Mössbauer spectrum and components of the fit of a frozen solution 
(T = 80 K) of the products formed in the reaction of 57FeCl2 (5.0 mM), TMEDA (4.0 equiv), 
CyMgCl (8.0 equiv), 180 (1.0 equiv) and 59b (1.0 equiv) in THF; components of the fit: 
δ(red) = 0.20 mm s–1, ΔEQ(red) = 1.71 mm s
–1, rel. int. = 53%; δ(green) = 0.43 mm s–1, 
(a)                                                                                 (b) 
(a)                                                                               (b) 
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ΔEQ(green) = 3.13 mm s
–1, rel. int. = 21%; δ(magenta) = 0.58 mm s–1, 
ΔEQ(magenta) = 2.04 mm s
–1, rel. int. = 18%; δ(blue) = 0.47 mm s–1, ΔEQ(blue) =  
0.84 mm s–1, rel. int. = 8%. (b) Mössbauer spectrum and components of the fit of a frozen 
solution (T = 80 K) of the products formed in the reaction of 57FeCl2 (5.0 mM), TMEDA 
(4.0 equiv), PhMgCl (8.0 equiv), 180 (1.0 equiv) and 59b (1.0 equiv) in THF; components of 
the fit: δ(blue) = 0.51 mm s–1, ΔEQ(blue) = 1.09 mm s
–1, rel. int. = 52%; 
δ(green) = 0.22 mm s–1, ΔEQ(green) = 4.21 mm s
–1, rel. int. = 36%; 
δ(light green) = 0.57 mm s–1, ΔEQ(light green) = 2.64 mm s
–1, rel. int. = 7%; 
δ(orange) = 0.32 mm s–1, ΔEQ(orange) = 1.70 mm s
–1, rel. int. = 4%; δ(wine) = 1.10 mm s–1, 
ΔEQ(wine) = 4.30 mm s
–1, rel. int. = 2%. The spectra were recorded and interpreted by Dr. S. 
Demeshko. 
 
In summary, our experimental findings suggest the formation of organometallic 
iron(II)/NHC complexes as intermediates in the iron-catalyzed enantioselective C–H 
alkylation of indoles 59 with vinylarenes 60/191. No interaction between iron and 
TMEDA was observed in any of the experiments, which suggests that TMEDA 
coordinates to the magnesium(II) ions and does not interact with the iron catalyst. 
Additionally, our observations provide support to the long-proposed role of Grignard 
reagents to serve as both reductant and base in iron-catalyzed C–H activations. 
The major limitation of mass spectrometry is, obviously, the difficulty to observe 
neutral species. As a consequence, we reasoned that the use of a charge-tagged 
NHC ligand would allow for the detection of otherwise neutral R2Fe(II)NHC species. 
For example, phosphonium-tags have previously been employed by Koszinowski to 
detect species formed in iron-catalyzed cross-couplings.[269a] We hence became 
interested in the synthesis of a positively charged NHC precursor resembling 
pre-ligand 180. Starting from the amino-tagged NHC precursor 206 reported by 
Grela and coworkers,[278] the ammonium-tagged imidazolinium 207 was prepared 
readily in two steps via salt metathesis and a Menshutkin reaction with methyl iodide 
(Scheme 3.14). A test reaction revealed 207 to be a potent pre-ligand for the iron-
catalyzed hydroarylation, giving the alkylated product with an efficacy comparable to 
IMes∙HCl (Scheme 3.15).[148] However, ESI-MS measurements performed by Dr. T. 
Parchomyk and F. Kraft of the Koszinowski research group have so far remained 
unsuccessful. Indeed, problems of very poor solubility and loss of MeI in solution 
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have so far prevented us from observing the expected NHC-ligated iron species by 
ESI-MS.[279] Interestingly, Grela and coworkers prepared the ammonium-tagged 
NHC/ruthenium complex by a late-stage methylation of the corresponding neutral 
amino-NHC/ruthenium complex.[278] In a later work, it was revealed that the direct 




Scheme 3.14. Synthesis of charge-tagged NHC precursor 207. 
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3.2.6. Proposed Mechanism 
 
Based on the conducted mechanistic studies and literature precedents, the catalytic 
cycle is proposed to begin with the formation of an active organometallic iron 
catalyst through the reduction of the iron(III) precursor by the action of the Grignard 
reagent (Scheme 3.16). While β-hydride elimination certainly plays a role in the 
reduction of the iron precursor when CyMgCl is employed, this process does not 
seem to be essential since significant conversions were observed when using 
PhMgCl (Tables 3.7, 3.9). In the latter case, the reduction process likely occurs via 
reductive elimination from a Ph2[Fe] species, as alternative processes through 
radical expulsion are disfavored.[267] Nevertheless, 57Fe Mössbauer spectroscopy 
strongly supports a facile β-hydride elimination to occur even at ambient temperature 
(Fig. 3.8b). Additionally, iron(II)–hydride species were detected by ESI-MS as well 
(Fig. 3.5, 3.9a). Hence, the Cy2Fe(NHC) species observed by 
57Fe Mössbauer 
spectroscopy (Fig. 3.7) is most likely only an intermediate of the catalyst generation 
process. Furthermore, in consideration of our mechanistic studies and previous 
reports,[267,269b,281] the TMEDA additive is believed to induce deaggregation and 
coordinate to the organomagnesium reagent rather than the active NHC-ligated iron 
catalyst. 
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Scheme 3.16. Proposed mechanism of the asymmetric iron-catalyzed alkylation. 
 
After the in situ formation of an organometallic mono-NHC-iron catalyst, the latter 
can be coordinated by the alkene 60 in a reversible fashion leading to its zeroth-
order dependence (Scheme 3.11). The subsequent kinetically relevant migratory 
insertion is assisted by coordination of the substrate 59,[282] explaining its first-order 
rate law. Given the facile inner-sphere C–H cleavage, the selective deuterium 
transfer to the methyl group in product [D]1-62 (Schemes 3.8) and the crossover 
experiment (Scheme 3.9), the C–H metalation step is proposed to occur via a ligand-
to-ligand hydrogen transfer (LLHT) manifold, by the action of the coordinated 
substrate 59. It should be noted that a turnover-limiting initial coordination of 
substrate 59, followed by C–H activation by oxidative addition, would also be in 
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agreement with our kinetic findings. However, the crossover experiment, along with 
preliminary computational studies by DFT,[256] seem to favor a LLHT regime. 
 
3.2.7. Iron-Catalyzed Alkyne Hydroarylations 
 
In the original report by Yoshikai and coworkers, the substrate scope of the racemic 
iron-catalyzed hydroarylations was not limited to vinylarenes. Indeed, internal 
alkynes proved viable as well.[148] While the alkenylated products do not possess 
any chiral center, we speculated that axial chirality might exist across the C–C bond 
generated in the transformation. This hypothesis was confirmed by the synthesis of 
compound 85ca and the separation of its atropisomers by chiral HPLC (Figure 3.11). 
Methods for the synthesis of axially chiral compounds are of high interest for 
synthetic chemists due to the importance of axially chiral natural products[283] and 
chiral ligands,[70c,284] among others. Interestingly, while several examples of 
atroposelective C–H activations employing noble transition metal catalysts are 
reported in the literature,[213h,285] the selective synthesis of axially chiral compounds 
via 3d transition metal-catalyzed C–H activation remains thus far unprecedented.[52] 
 
 
Figure 3.11. Chiral HPLC chromatogram of 85ca (Daicel CHIRALPAK® IB-3, 
n-hexane/iPrOH = 80/20, flow rate 1.0 mL/min). 
 
Hence, intrigued by the possibility to develop an enantioselective version, a 
representative set of chiral NHC ligands were tested in the envisioned asymmetric 
transformation employing N-benzylindole 59c and tolane 7a (Table 3.14). Sadly, 
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while low conversion was obtained under a slight modification of Yoshikai’s 
conditions (entry 1), no product was detected with any of the tested chiral 
pre-ligands (entries 2–4). Since the racemic reaction is only reported on 
N-methylindole 59b, we reasoned that the extra steric bulk of the benzyl substituent 
might hinder the catalysis. Therefore, various NHC precursors were tested for the 
alkenylation of N-methylindole 59b. While the expected product 85ba was obtained 
in moderate yield using IXyl (entry 5), no conversion was obtained when employing 
chiral ligands (entries 6–8). Furthermore, the analysis by chiral HPLC of product 
85ba revealed the existence of a plateau between the peaks of the two 
atropisomers, which clearly indicates their interconversion at ambient temperature 
(Figure 3.12).[286] The observed lack of reactivity, as well as the conformational 
instability of the formed atropisomers, prompted us to discontinue this project. 
 
Table 3.14. Iron-catalyzed hydroarylation of alkyne 7a with indoles 59.[a] 
 
 
Entry R L Yield [%][b] e.r. 
1 Bn IXyl·HCl 13 - 
2 Bn 180 n.r. - 
3 Bn 176 n.r. - 
4 Bn 186 n.r. - 
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5 Me IXyl·HCl 49 - 
6 Me 180 traces - 
7 Me 176 n.r. - 
8 Me 159 n.r. - 
[a]
 Reaction conditions: 59 (0.25 mmol), 7a (2.0 equiv), Fe(acac)3 (10 mol %), L 
(20 mol %), PhMgCl (1.1 equiv), THF (0.50 mL), 60 °C, 16 h. 
[b]




Figure 3.12. Chiral HPLC chromatogram of 85ba. The plateau between the two peaks 
indicates on-column interconversion of the two atropisomers[286] (Daicel CHIRALPAK® IC-3, 
n-hexane/iPrOH = 70/30, flow rate 1.0 mL/min). 
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3.3. Asymmetric Nickel-Catalyzed Hydroarylations by C–H Activation 
 
Nickel complexes have been recognized as powerful tools in molecular syntheses, 
with numerous applications to C–C bond forming processes.[153d,153e] Due to its high 
abundance in the Earth’s crust, broad range of accessible oxidation states, and 
comparatively low cost,[287] nickel catalysis has experienced a considerable 
development in recent years. Among others, applications to cross-coupling 
chemistry[18] and the functionalization of otherwise inert C–H bonds[45,48b,48c] have 
attracted significant interest. In particular, nickel catalysts have emerged as an 
especially powerful tool for hydroarylation-type C–H activations.[27,188a] 
However, asymmetric nickel-catalyzed hydroarylations remain rare. While major 
progress has been recently achieved for intramolecular hydroarylations employing 
nickel/aluminium[288] heterobimetallic[23b] catalysis,[193,200,203,206] enantioselective 
intermolecular processes are unprecedented. In a broader context, asymmetric 
intermolecular nickel-catalyzed C–H functionalizations remain unknown, with only 
one single exception by Cramer for the reductive three-component coupling of 
benzaldehydes, norbornenes and silanes (Scheme 1.43).[210] 
In this context, the association of N-heterocyclic carbene (NHC) ligands with nickel is 
remarkably versatile and has been intensively exploited for, inter alia, C–C forming 
processes via hydroarylation reactions or cross-couplings.[289] These literature 
precedents prompted us to investigate the performance of the novel chiral NHC 
precursors that were developed for asymmetric iron-catalyzed hydroarylations 
(Chapter 3.2) in the unprecedented nickel-catalyzed asymmetric secondary 
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3.3.1. Preliminary Studies towards Asymmetric Intermolecular Hydroarylations 
by C–H Activation 
 
Initially, we selected the well-documented branched-selective hydroarylation of 
styrenes 60 with azoles 99[162,189,194b,290] as a model system to probe our novel chiral 
NHC precursors. NaOtBu was used as a base to generate the free NHC in situ, as 
was previously reported.[170,203] A preliminary ligand optimization[291] identified 
N,N’-diaryl NHCs, similar to those used in the enantioselective iron-catalyzed 
hydroarylation (Chapter 3.2), as optimal ligands for the transformation in terms of 
conversion. Other ligand classes, including N,N’-dialkyl NHCs, phosphines, 
phosphine oxides, diamines, BOX ligands, dienes and phosphoramidites, gave all 
conversions lower than 25%. However, enantiomeric excesses were found to be 
highly irreproducible. Intrigued by those issues, we decided to investigate their 
cause. A base-induced racemization was immediately suspected to occur since the 
chiral center, a bis-benzylic position substituted with an electron-withdrawing 
benzimidazole moiety, is rather activated. Furthermore, 2-allylbenzimidazoles are 
reported to isomerize in a similar setting, even at a lower temperature of 100 °C.[170] 
Therefore, the effect of the amount of base and various additives on the 
transformation was studied in order to prevent the suspected racemization 
(Table 3.15). First, an increase of the amount of base led to a decreased 
enantiomeric ratio (entries 1–2). Lowering the amount of base was found to improve 
the enantioselectivity of the transformation, but resulted in low conversions 
(entries 3–4). These findings provide strong support for the suspected base-induced 
racemization. Thereafter, the effect of various additives was probed in the 
asymmetric hydroarylation. As inconsistent enantioselectivities were obtained when 
using toluene from different sources (SPS, distilled over Na, etc.), the trace water 
content was suspected to play a key role in the irreproducibility of the reaction. 
Hence, co-catalytic amounts of water were added into the reaction. Remarkably, 
traces of water were found to strongly improve the enantiomeric excess of product 
106bc (entries 5–8). Other protic or Lewis acidic additives were then tested in the 
reaction (entries 9–12), the best results being obtained in the presence of a 
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co-catalytic amount of BHT (entry 12). While the beneficial effect of protic additives 
is not fully understood yet, it is suspected that they might “neutralize” the excess of 
NaOtBu, thus preventing the racemization of product 106bc. Meanwhile, the linear 
product was obtained selectively in the presence of a co-catalytic amount of AlMe3, 
as expected from literature precedents (entry 13).[194] 
 
Table 3.15. Effect of the base and other additives of the enantioselective nickel-catalyzed 
intermolecular hydroarylation of styrene 60c with benzimidazole 99b.[a] 
 
Entry Additive Yield [%][b] e.r.[c] 
1 - 49–67 58:42–79:21 
2[d] - 62 55:45 
3[e] - 22 78:22 
4[f] - traces - 
5[d] H2O
[g] (2.0 equiv) 30 80:20 
6[d] H2O
[g] (1.0 equiv) 30 80:20 
7[d] H2O
[g] (50 mol %) 57 79:21 
8[d] H2O
[g] (20 mol %) 50 68:32 
9[d] BPh3 (50 mol %) 26 73:27 
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10 tAmOH[h] 60 61:39 
11 BHT (50 mol %) 53 80:20 
12 BHT (20 mol %) 57 80:20 
13 AlMe3 (40 mol %) 0
[i] - 
[a]
 Reaction conditions: 99b (0.50 mmol), 60c (2.0 equiv), Ni(cod)2 (10 mol %), 





 Determined by chiral HPLC. 
[d]
 Using NaOtBu (40 mol %). 
[e]
 Using NaOtBu 
(15 mol %). 
[f]
 Using NaOtBu (10 mol %). 
[g]
 Degassed H2O. 
[h]
 PhMe/tAmOH = 15/1 
was used as the reaction medium. 
[i]
 The linear product 112 was obtained in 91% 
yield. 
 
With the issues of racemization and irreproducibility being solved, a representative 
set of chiral NHC precursors was then tested in the envisioned asymmetric 
hydroarylation (Table 3.16). Somewhat surprisingly, all the pre-ligands probed in the 
reaction provided the alkylated product 106bc with almost identical 
enantioselectivities and similar yields. 
 
Table 3.16. Further ligand optimization in the presence of BHT as additive.[a] 
 
Entry L Yield [%][b] e.r.[c] 
1 176 37 82:18 
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2 177 52 79.5:20.5 
3 178 56 80.5:19.5 
4 180 57 80:20 
[a]
 Reaction conditions: 99b (0.50 mmol), 60c (2.0 equiv), Ni(cod)2 
(10 mol %), L (10 mol %), NaOtBu (20 mol %), BHT (20 mol %), PhMe 
(2.0 mL), 130 °C, 16 h. 
[b]
 Isolated yields. 
[c]
 Determined by chiral HPLC. 
 
Preliminary mechanistic studies were conducted to delineate the mode of action of 
the C–H activation. A reaction with the deuterated substrate [D]1-99b was 
performed. Interestingly, while most of the deuterium was selectively transferred to 
the methyl group, indicating an organometallic C–H bond cleavage, significant 
scrambling was observed. This observation can be rationalized with a facile and 
reversible C–H scission step. 
 
 
Scheme 3.17. Reaction with deuterium-labeled substrate [D]1-99b. 
 
Meanwhile, as asymmetric catalysis is known to be substrate-specific, different types 
of heteroarenes and alkenes were probed in the envisioned asymmetric 
hydroarylation. Notably, promising results were obtained for intramolecular 
transformations. Those findings motivated us to investigate enantioselective nickel-
catalyzed cyclizations by C–H activation (vide infra). 
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3.3.2. Optimization Studies of Enantioselective Intramolecular Nickel-
Catalyzed Hydroarylations via C–H Activation 
 
Chemo-, regio- and enantio-selective cyclizations are of key importance in synthetic 
chemistry, with applications to, inter alia, the synthesis of pharmaceuticals and 
bioactive natural products.[56a,193,292] 
In this context, intramolecular hydroarylations[27] represent a particularly attractive 
cyclization strategy due to its perfect atom economy.[2] While nickel catalysts have 
emerged as powerful tools for the hydroarylations of C–C multiple bonds,[48a,188a] 
intramolecular processes have long been restricted to the functionalization of highly 
activated azolium salts.[205] In recent years, the development of heterobimetallic 
nickel/aluminium catalysis[198] has allowed for the use of unactivated alkenes and 
substrates bearing less acidic C–H bonds. Despite being highly desirable, 
enantioselective methodologies remained extremely scarce at the outset of this 
work.[193,195] However, this research area has attracted significant attention during 
the course of this thesis, as several examples were independently reported by other 
research groups.[200,203,206] It is noteworthy that all those works absolutely require 
pyrophoric Lewis acidic organoaluminium additives, such as AlMe3 or MAD,
[293] for 
the reaction to occur. 
Therefore, we decided to investigate the asymmetric cyclization of 
N-homoallylimidazoles 144 by nickel-catalyzed hydroarylation (Table 3.17). This 
model substrate was selected due to literature precedents with rhodium(I) 
catalysts[219b] and the importance of the benzimidazole scaffold in bioactive 
compounds.[294] Our optimization studies began by testing a wealth of chiral ligands 
for the envisioned asymmetric alkene hydroarylation. First, various representative 
NHC precursors and phosphoramidites were tested in the transformation, but fell 
short in delivering any product (entries 1–5). In agreement with literature precedents 
(vide supra), the addition of AlMe3 was found to enable the desired cyclization 
(entry 6). Interestingly, the endo product was selectively obtained, in sharp contrast 
to another methodology independently reported by Ye around the same time.[206] 
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Table 3.17. Optimization of the ligand for the enantioselective Ni-catalyzed cyclization.[a] 
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1 180 NaOtBu (20 mol %) - 130 n.r. - 
2 176 NaOtBu (20 mol %) - 130 n.r. - 
3 159 NaOtBu (20 mol %) - 130 n.r. - 
4 212 - - 130 n.r. - 
5 161 - - 130 n.r. - 
6 180 NaOtBu (20 mol %) AlMe3 (40 mol %) 130 53 67:33 
7 180 NaOtBu (20 mol %) AlMe3 (40 mol %) 100 n.r. - 
8 180 NaOtBu (20 mol %) AlMe3 (1.0 equiv) 130 43 67:33 
9
[d]
 180 NaOtBu (20 mol %) AlMe3 (40 mol %) 130 n.r. - 
10 213 - AlMe3 (40 mol %) 130 88 32:68 
11 213 - 
AlMe3 (40 mol %) + 
PPh3 (10 mol %) 
130 n.r. - 
12 213 - MAD (40 mol %) 130 n.r. - 
13 213 - BPh3 (40 mol %) 130 n.r. - 
14 213 - AlMe3 (40 mol %) 110 n.r. - 
15 213 - AlMe3 (40 mol %) 95 n.r. - 
16 161 - AlMe3 (40 mol %) 130 22 50:50 
17 164 - AlMe3 (40 mol %) 130 67 53:47 
18 - - AlMe3 (40 mol %) 130 traces - 
19 214 - AlMe3 (40 mol %) 130 70 32:68 
20 214 - AlMe3 (40 mol %) 110 65 33:67 
21 214 - AlMe3 (40 mol %) 95 66 32:68 
22 214 - AlMe3 (40 mol %) 80 traces - 
23 214 - AlMe3 (20 mol %) 95 50 33:67 
24 214 - AlMe3 (60 mol %) 95 47 33:67 
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25 214 - - 95 n.r. - 
26
[d]
 214 - AlMe3 (40 mol %) 95 n.r. - 
27
[e]
 214 - AlMe3 (40 mol %) 95 60 39:61 
28
[f]
 214 - AlMe3 (40 mol %) 95 traces - 
29 215 - AlMe3 (40 mol %) 130 12 50:50 
30 131 - AlMe3 (40 mol %) 95 89 48:52 
31 216 - AlMe3 (40 mol %) 95 56 53:47 
32 217 - AlMe3 (40 mol %) 95 n.r. - 
33 218 - AlMe3 (40 mol %) 95 traces - 
34 218 - AlMe3 (40 mol %) 110 55 54:46 
35 219 - AlMe3 (40 mol %) 130 n.r. - 
36 170 - AlMe3 (40 mol %) 130 n.r. - 
37 170 NaOtBu (10 mol %) AlMe3 (40 mol %) 130 16 56:44 
38 220 - AlMe3 (40 mol %) 95 88 >99:1 
39
[d]
 220 - AlMe3 (40 mol %) 95 n.r. - 
40 168 - AlMe3 (40 mol %) 95 86 23:77 
41
[g]
 220 - AlMe3 (10 mol %) 95 95 >99:1 
42
[g]
 221 - AlMe3 (10 mol %) 95 13 55:45 
43 221 - - 95 n.r. - 
44 222 - AlMe3 (40 mol %) 95 85 80:20 
45
[h]
 220 - AlMe3 (4.0 mol %) 95 97 >99:1 
46 220 - AlMe3 (10 mol %) 85 95 >99:1 
47 220 - AlMe3 (10 mol %) 75 94 >99:1 
48 220 - - 95 91 96:4 
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[a]
 Reaction conditions: 144a (0.50 mmol), Ni(cod)2 (10 mol %), L (10 mol %), additive (40 mol %), 
base (20 mol %), PhMe (2.0 mL), 16 h. 
[b]
 Yield of the isolated product. 
[c]
 Determined by chiral HPLC 
analysis. 
[d]
 Ni(cod)2 was omitted. 
[e]
 214 (15 mol %). 
[f]
 214 (5.0 mol %). 
[g]
 Using Ni(cod)2 (2.5 mol %) 
and L (2.5 mol %) in PhMe (1.0 mL). 
[h]
 Using Ni(cod)2 (1.0 mol %) and 220 (1.0 mol %) in PhMe 
(1.0 mL). 
 
The desired product was obtained in moderate yield and enantiomeric excess when 
using the previously developed NHC precursor 180 (entry 6). Lowering the 
temperature or increasing the amount of AlMe3 did not improve the outcome of the 
reaction (entries 7–8). A control experiment proved the importance of the nickel 
catalyst (entry 9). 
Inspired by the success of (HA)SPO pre-ligands in nickel catalysis,[155a,195,206,208,239b] 
this ligand class was investigated in the envisioned transformation. The novel chiral 
HASPO 213, derived from the same diamine intermediate as 180, gave promising 
results (entry 10). The introduction of additional co-catalytic PPh3 completely 
suppressed the reactivity (entry 11), despite being reported as beneficial in other 
transformations occurring under a Ni/Al/SPO regime (see Scheme 1.37).[195,206,208] 
Interestingly, MAD or BPh3 fell short in delivering any cyclized product              
(entries 12–13). Again, lower reaction temperatures proved detrimental to the 
transformation (entries 14–15). Other ligand types were tested as well. Monodentate 
phosphoramidites, such as ligands 161, provided product 145a in poor yield without 
significant enantio-induction (entry 16). Then, the prototypical P-chiral secondary 
phosphine oxide (SPO) 164 provided the product in good yield, but only poor 
enantioselectivity (entry 17). Furthermore, a control experiment confirmed the 
importance of the ligand (entry 18). As (HA)SPOs seemed to be the most promising 
ligand class at this point, we probed next other HASPO pre-ligands, including 
TADDOL-derived 214 (entry 19). Interestingly, while TADDOL-based phosphine 
oxides had previously been employed in asymmetric organocatalysis,[207] their use in 
transition metal catalysis remains rare.[206,208] Remarkably, 214 proved to be superior 
to previously investigated ligands, as the reaction temperature could be lowered to 
95 °C (entries 20–22). A Job plot of the amount of AlMe3 confirmed 40 mol % to be 
optimal (entries 23–25), and a control experiment confirmed the key role of the 
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nickel catalyst (entry 26). Variations of the ligand-to-metal ratio suggested a 1:1 ratio 
to be optimal under those conditions (entries 27–28). While the ortho-tolyl derivative 
214 gave promising results even at lower temperatures, HASPO derived from 
differently substituted TADDOLs performed poorly in the desired transformation 
(entries 29–34). As phosphine chlorides are reported to exhibit a reactivity similar to 
(HA)SPOs,[239a] 219 and 170 were probed in the desired asymmetric cyclization, but 
no conversion of the alkene 144a was observed (entries 35–36). However, some 
product formation could be observed after the addition of co-catalytic NaOtBu 
(entry 37), presumably due to the in situ formation of the corresponding 
diaminooxophosphine.[239b] 
Thereafter, JoSPOphos-type ligands were tested due to their well-documented 
efficacy in rhodium(I)-catalyzed enantioselective hydrofunctionalization reactions.[295] 
Applications of the JoSPOphos ligand family besides rhodium(I) catalysis remain 
scarce, with notable exceptions in ruthenium-[296] and cobalt-catalyzed[297] 
asymmetric hydrogenations. To our delight, JoSPOphos 220 afforded the desired 
product 145a in excellent yield and perfect enantioselectivity (entry 38). In this 
context, it is noteworthy that this transformation represents the first use of 
JoSPOphos pre-ligand 220 with a transition metal other than rhodium(I). Once 
again, a control experiment confirmed the importance of the nickel catalyst 
(entry 39). The related ligand 168 provided the cyclized product in similar yield but 
only moderate enantioselectivity (entry 40). The catalyst loading could be lowered to 
2.5 mol % without losing any activity (entry 41). Meanwhile, poor results were 
obtained with the corresponding JosiPhos ligand 221, highlighting the superiority of 
the secondary phosphine oxide moiety (entries 42–43). The dimenthyl-substituted 
SPO 222 recently disclosed by Hintermann[298] was probed as well in the asymmetric 
C–H alkylation (entry 44). Remarkably, the obtained enantiomeric excess of 60% is 
the highest observed with a monodentate chiral ligand. Thereafter, 220 was found to 
promote the reaction with catalyst loadings as low as 1.0 mol % (entry 45). 
Moreover, the excellent performance of the JoSPOphos-derived catalyst at lower 
temperature once again showcased its remarkable activity (entries 46–47). 
Extraordinarily, control experiments revealed the JoSPOphos-enabled alkene 
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hydroarylation to occur smoothly even in the absence of pyrophoric AlMe3 as 
additive (entry 48). It should be noted that nickel-catalyzed hydroarylations of non-
activated alkenes in the absence of organoaluminium reagents are extremely 
rare,[189,299] and had never been achieved in an enantioselective fashion previously. 
Given the unique opportunity for improved functional group tolerance, we decided to 
further optimize the AlMe3-free conditions (Table 3.18). Control experiments 
confirmed the importance of the nickel catalyst and of pre-ligand 220 (entry 1–3). 
Lower catalyst loadings did not significantly affect the conversion, but lower 
enantioselectivities were observed here (entries 4–7). Lower temperatures did not 
prove beneficial to the reaction outcome (entries 8–9). Thereafter, variations of the 
ligand-to-metal ratio provided informative results (entries 10–15). A ligand-to-nickel 
ratio of 2:1 was found to significantly reduce the enantioselectivity of the reaction, as 
well as the yield at lower catalyst loadings. Somewhat surprisingly, the use of an 
excess of nickel provided the highest enantioselectivities, the best results being 
obtained with a 220/Ni ratio of 1:2 (entry 13). A larger excess of nickel did not 
considerably alter the enantioselectivity of the reaction, but lower conversions were 
observed. Possibly, an excess of nickel may be required in order to prevent the 
formation of less selective bis-ligated nickel species.[300] 
 
 
Table 3.18. Optimization of the additive-free hydroarylation.[a] 
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Entry Ni(cod)2 [mol %] 220 [mol %] T [°C] Yield [%]
[b] e.r.[c] 
1 10 10 95 91 97:3 
2 0 10 95 n.r. - 
3 10 0 95 traces - 
4 5.0 5.0 95 98 89:11 
5 2.5 2.5 95 88 90:10 
6[d] 2.5 2.5 95 n.r. - 
7 1.0 1.0 95 82 91:9 
8 2.5 2.5 85 73 87:13 
9 2.5 2.5 75 16 80:20 
10 10 20 95 59 76:24 
11 10 5.0 95 89 97:3 
12 5.0 10 95 38 77:23 
13 5.0 2.5 95 96 96:4 
14 5.0 1.25 95 31 94:6 
15 2.5 1.0 95 78 96:4 
[a]
 Reaction conditions: 144a (0.50 mmol), Ni(cod)2, 220, PhMe (1.0 mL), 16 h. 
[b]
 Yield of the 
isolated product. 
[c]
 Determined by chiral HPLC analysis of the isolated product. 
[d]
 Using Ni(acac)2 
instead of Ni(cod)2. 
 
3.3.3. Substrate Scope and Limitations 
 
With the optimized conditions in hand, we next decided to explore the versatility and 
robustness of the nickel-catalyzed asymmetric hydroarylation. The remarkably 
simple catalytic system proved able to cyclize various alkene-tethered heteroarenes 
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144 in outstanding yields and levels of enantioselectivity (Table 3.19). The substrate 
scope of the transformation was not limited to benzannulated azoles. Indeed, even 
the simple ester-substituted imidazole 144b was efficiently converted in a highly 
enantioselective fashion (entry 2). Moreover, a variety of highly functionalized 
tethered prochiral alkenes 144 were fully tolerated in the transformation, providing 
the desired cyclized products 145 in high yields and excellent levels of 
enantiocontrol (entries 3–10). Extended alkyl chains, bulky cycloalkyl and benzyl 
groups, cyclic acetals and silyl ethers were smoothly converted, proving the C–H 
alkylated products 145 with high selectivity control. Remarkably, additional double 
bonds in the tethered alkene were compatible with the transformation, with the distal 
olefins left completely untouched. Indeed, N-γ-geranyl- 144h and N-γ-farnesyl-
benzimidazole 144i were selectively cyclized to the desired products 145, with only 
the proximal exo-double bond reacting. Additionally, even unhindered terminal 
alkenes, such as 144j, proved to be viable substrates for the C–H alkylation, without 
significant formation of polycyclic byproducts. 
 
Table 3.19. Substrate scope of gem-substituted olefins 144 and heterocycles in the nickel-
catalyzed intramolecular hydroarylation.[a] 
 




















































 Reaction conditions: 144 (0.50 mmol), Ni(cod)2 (5.0 mol %), 220 (2.5 mol %), PhMe (1.0 mL), 
95 °C, 16 h. 
[b]
 Isolated yields. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 With Ni(cod)2 (10 mol %) and 
220 (5.0 mol %). 
 
Moreover, numerous additional substrates 144 were tested by V. Müller and Dr. D. 
Ghorai in the nickel-catalyzed intramolecular hydroarylation, with a focus on the 
heteroarene moiety. Various substituted benzimidazoles, including electron-rich, 
electron-poor and polychlorinated derivatives performed well in the reaction, once 
again showcasing the chemo-selectivity and versatility of the developed 
organoaluminium-free C–H functionalization methodology (Scheme 3.18). Beside 
diversely decorated benzimidazoles, a variety of pharmaceutically relevant motifs, 
including aza-benzimidazoles, highly functionalized purines and theophylline 
derivatives, were efficiently converted to the cyclized products 145 with high 
selectivity control. 
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Scheme 3.18. Selected additional examples of the substrate scope. [a] Performed by Dr. D. 
Ghorai. [b] Performed by V. Müller. [c] With Ni(cod)2 (10 mol %) and 220 (5.0 mol %). 
 
Further studies were conducted to understand the effect of the substitution pattern of 
the tethered alkene 144 (Table 3.20). The findings revealed that 1,1-disubstituted 
alkenes were essential to achieve high conversion and stereo-selectivity, as 
substrates lacking the gem-disubstitution pattern, despite high enantioselectivities, 
were found to give the 5-membered exo-cyclized product 145 in low to moderate 
yields (entries 1–2). More sterically encumbered substrates, such as 144s and 144t, 
fell short in delivering any cyclized product (entries 3–4). Aryl-substituted alkenes, or 
alkenes with shorter or longer tethers, gave unsatisfactory results too (entries 5–7). 
Interestingly, in the case of the unsubstituted substrate 144x, the isomerized alkene 
223 was obtained as the major product of the transformation, which could be 
supportive of the formation of a nickel-hydride and/or a π-allyl-nickel intermediate 
(entry 8).[299b,301] This hypothesis was further substantiated by performing the same 
reaction with the deuterated analog [D]1-144x, as H/D scrambling was observed 
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Table 3.10. Effect of the substitution pattern of the olefin.[a] 
 











--- n.r. - 
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--- n.r. - 




--- traces - 
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--- n.r. - 
7[d] 
 









 Reaction conditions: 144 (0.50 mmol), Ni(cod)2 (10 mol %), 220 (5.0 mol %), PhMe (1.0 mL), 
95 °C, 16 h. 
[b]
 Yield of the isolated product. 
[c]
 Determined by chiral HPLC analysis. 
[d]
 Experiment 
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3.3.4. Mechanistic Studies 
 
3.3.4.1. Deuterium Labeling Experiments and Kinetic Studies 
 
Given the unique features of the asymmetric aluminium-free nickel-catalyzed C–H 
alkylation, we became attracted to unravel its mode of action. To this end, 
experiments with deuterated compounds and detailed kinetic studies were 
conducted by V. Müller.[220] First, a reaction performed with deuterated substrate 
[D]1-144a revealed H/D scrambling at the methyl group and positions of the former 
olefin (Scheme 3.20a). This observation can be rationalized with a facile and 
reversible C–H cleavage step, and is strikingly different from Ye’s nickel-catalyzed 
exo-selective cyclization in which no scrambling was observed.[206] Then, C–H 
activation performed with isotopically labeled compound [D]1-144a showed a kinetic 
isotope effect (KIE) of kH/kD ≈ 1.1 (Scheme 3.20b), suggesting the C–H scission step 
not to be turnover limiting.[257] 
 
 
Scheme 3.20. Deuterium labeling experiments. Experiments conducted by V. Müller. 
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Furthermore, detailed kinetic studies conducted by V. Müller revealed a first-order 
rate dependence in the substrate 144, the pre-ligand 220 and the nickel precursor, in 
the latter case with an inhibition at higher nickel concentrations (Scheme 3.21a–c). A 
possible interpretation to this rather unusual finding could be the existence of a 
critical nickel concentration beyond which an autocatalytic deactivation of the 
catalyst occurs, possibly via aggregation of nickel, as was previously proposed for 
palladium catalysis.[302] Another explanation to the detrimental effect of higher 
concentrations of Ni(cod)2 could be the competitive coordination of free cod to the 
nickel center, resulting in off-cycle intermediates decelerating the catalysis, as 
previously reported by Zimmerman/Montgomery.[161,202b] This hypothesis is further 
substantiated by the observation that, in the presence of additional free cod, the 
transformation was found to indeed proceed at a lower rate. This finding provides 
additional support to the hypothesis that inhibition of the active nickel catalyst is 








     
 
     
Scheme 3.21. Kinetic analysis nickel-catalyzed hydroarylation. Experiments conducted by 
V. Müller. 
 
3.3.4.2. Non-Linear Effect Studies 
 
In order to get some insights into the unusual ligand-to-metal ratio of 1:2, the effect 
of the enantiomeric excess of JoSPOphos pre-ligand 220 over the enantiomeric 
induction of the transformation was investigated (Scheme 3.22). Here, the absence 
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of a non-linear effect (NLE) apparently excludes a multi-ligand containing catalyst or 





Scheme 3.22. Non-linear effect studies. 
 
3.3.5. Proposed Mechanism 
 
Based on our detailed mechanistic studies and previous literature 
reports,[81,190,202a,303] the catalytic reaction is proposed to be initiated by the formation 
of the organometallic nickel(II) complex 224 (Scheme 3.23). Complex 224 was 
prepared by Dr. D. Ghorai from a stoichiometric reaction of Ni(cod)2 with pre-ligand 
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220, and found to be active in both stoichiometric and catalytic reactions with 
144a.[220] A plausible pathway for the generation of complex 224 could be the 
oxidative addition of nickel(0) into the P(O)–H bond, as it has been previously 
reported in the literature,[304] followed by hydride migration to the bound cod and 
chain walking.[161] It should also be noted that this coordination mode of bidentate 
ligands containing a phosphine oxide moiety has previously been reported for 
iridium(I) complexes.[305] Interestingly, Pfaltz and coworkers described the ligand as 
a P-coordinating, O-anionic phosphinite rather than a P-anionic deprotonated 
phosphine oxide.[305] 
Complex 224 is then coordinated by substrate 144 to form intermediate 225, which 
after loss of a cyclooctene molecule yields intermediate 226, the proposed active 
catalyst. Intermediate 226 then undergoes the stereo-determining and C–C bond 
forming migratory insertion to deliver the cyclized intermediate 227. After a 
kinetically relevant coordination of a second substrate 144, explaining its first-order 
kinetic dependence, the key C–H activation event occurs. In view of our mechanistic 
studies, we propose the facile C–H cleavage to occur via a ligand-to-ligand 
hydrogen transfer (LLHT) manifold.[81,156a,202c,299b,306] The observed H/D scrambling 
and olefin isomerization are believed to be caused by side-reactions of the catalyst, 
presumably involving a nickel-π-allyl or a nickel-hydride species which may possibly 
result from oxidative addition into the P(O)–H bond during the catalyst generation 
process. 
According to the proposed catalytic cycle, complex 224 is a plausible off-cycle 
intermediate, or a resting state, whose reversible formation is favored by higher 
concentrations of cod, explaining the negative order in Ni(cod)2 above a certain 
concentration (Scheme 3.21c) and rationalizing the detrimental effect of adding an 
excess of free cod to the catalytic reaction (Schemes 3.21d). Indeed, such cod-
incorporating π-allyl complexes are documented to be stable off-cycle intermediates 
whose formation diminishes the catalytic efficiency.[161,202b] 
 
3. Results and Discussion 
146 
 
Scheme 3.23. Proposed catalytic cycle. Complex 224 was prepared and crystallized by Dr. 
D. Ghorai. The crystal structure was measured and solved by Dr. C. Golz. 
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3.3.6. Product Diversification 
 
The synthetic value of the nickel-catalyzed C–H alkylation was further demonstrated 
by late-stage diversification of the thus-obtained products (Scheme 3.24). In an 
attempt to introduce a heavy atom in order to determine the absolute configuration 
via X-ray diffraction crystallography, benzimidazolium iodide 230 was prepared by 
treating the standard product 145a with methyl iodide. The R-configuration of the 
cyclized product was confirmed by X-ray diffraction analysis. 
 
 
Scheme 3.24. Diversification of 145a and molecular structure of products 230 and 232 with 
thermal ellipsoids at 50% probability level. The crystal structures were measured and solved 
by Dr. C. Golz. 
 
Thereafter, further transformations of the activated 2-substituent of the 
benzimidazolium moiety were attempted. The formation of reactive N-heterocyclic 
olefins (NHO) upon treatment of 2-alkylimidazolium with a base is indeed well 
documented.[307] The resulting electron-rich NHO intermediate was successfully 
trapped using phenyl isocyanate as the electrophile to provide amide 231 in good 
yield. Unfortunately, the product was obtained as a racemic mixture, presumably due 
to base-induced racemization of the activated allylic position during the process. 
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Therefore, we aimed to functionalize the same position under milder conditions. To 
our delight, the cyclized product 145a could be directly functionalized under 
racemization-free conditions using a procedure reported by Roush[308] to provide 
α-keto-ester 232, whose structure was unambiguously confirmed by X-ray diffraction 
analysis. Interestingly, such polycyclic α-keto esters are regarded as valuable 
synthetic intermediates for the synthesis of antiviral agents.[308] 
Overall, the synthetic utility of the developed enantioselective nickel-catalyzed 
hydroarylation was further showcased by late-stage diversification of the obtained 
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4. Summary and Outlook 
 
Organic synthesis has long relied on time- and energy-consuming 
prefunctionalization strategies which generate stoichiometric amounts of waste. 
Recently, the direct functionalization of C–H bonds has emerged as an 
environmentally benign alternative that avoids lengthy syntheses, and has attracted 
substantial interest from both academia and the chemical industries. However, the 
selective functionalization of omnipresent C–H bonds remains challenging and 
hence a research topic of high interest. While major progress was initially achieved 
with noble transition metal catalysts, the use of inexpensive and earth-abundant 3d 
metals has gained significant momentum within the last decade. 
In the first project, the first cobalt-catalyzed C–H functionalization by the assistance 
of synthetically useful oxazolines was developed (Scheme 4.1).[37e,227a] Previous 
work on catalytic C–H aminations had relied on noble transition metal catalysts or 
harsh reaction conditions.[23e,217] The versatile, robust and user-friendly Cp*Co(III) 
catalyst allowed for the direct C–H amidation of arenes and indoles using 
dioxazolones 40 as amidating reagents under the assistance of, inter alia, 
oxazolinyl, pyridyl and pyrimidyl directing groups. Mechanistic studies provided 
strong support for a kinetically relevant C–H cobaltation via an acetate-enabled BIES 
manifold, and revealed the transformation to be homogenous in nature. Radical 
intermediates were excluded by reactions conducted in the presence of radical 
scavengers. 
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Scheme 4.1. Cobalt(III)-catalyzed C–H amidation. 
 
While significant progress in the field of first-row transition metal-catalyzed C–H 
activation was achieved within the last decade,[45] enantioselective transformations 
continue to heavily rely on noble 4d and 5d metals.[51] However, the last few years 
have witnessed the emergence of 3d-metal catalyzed asymmetric C–H activations, 
but examples remain scarce as this research area is still in its infancy.[52] In this 
context, the first enantioselective iron-catalyzed C–H functionalization by inner-
sphere C–H activation was developed (Scheme 4.2).[151] In the course of extensive 
optimization studies, the design of the novel meta-substituted NHC precursor 180 
was found to be critical to success. A broad range of indoles and azaindoles 59 
proved viable substrates in the hydroarylation of diversely substituted styrenes 60 
and vinylmetallocenes 191, providing the products 62/192 in up to 96:4 e.r. and 
complete branched-selectivity. Remarkably, this work constitutes the first and, so far, 
only highly enantioselective transformation via inner-sphere iron-catalyzed C–H 
activation. Moreover, this work also represents the unprecedented use of a chiral 
NHC ligand in enantioselective iron catalysis. 
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Scheme 4.2. Enantioselective iron-catalyzed C–H alkylation. 
 
Detailed mechanistic studies were conducted to delineate the mechanism of the 
transformation. Our findings support a facile C–H cleavage occurring through a 
ligand-to-ligand hydrogen transfer manifold, and revealed the reaction to be 
homogenous in nature. Furthermore, kinetic studies unravelled a first-order 
dependence in the indole substrate 59 and a rather uncommon zeroth order in the 
alkene 60. Additionally, an in situ analysis of the transformation by electrospray-
ionization mass spectrometry and 57Fe Mössbauer spectroscopy was performed and 
supports an organometallic mono-NHC-ligated iron(II) species to be involved in the 
catalysis.[218] Remarkably, while “low-valent” iron species have initially been 
proposed to be active in iron-catalyzed C–H activations in the presence of Grignard 
reagents, this work provides the first direct evidence of an iron(II) species in such 
processes. 
Thereafter, we then became interested in the development of new enantioselective 
transformations employing our novel chiral NHC pre-ligands. Among the attempted 
reactions, asymmetric nickel-catalyzed hydroarylations appeared most promising. 
Significant enantioselectivities were observed in preliminary studies on 
intermolecular undirected C–H alkylations of benzimidazoles 99 with styrenes 60 
(Scheme 4.3). While the observed enantioselectivities are only moderate, this 
transformation represents the first example of enantioselective undirected 
intermolecular nickel-catalyzed C–H activations. 
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Scheme 4.3. Enantioselective nickel-catalyzed intermolecular hydroarylations. 
 
Finally, drawing inspiration from those preliminary results, we devised the first 
asymmetric endo-selective cyclization of azoles with alkenes (Scheme 4.4).[220] 
Remarkably, in sharp contrast to other nickel-catalyzed intramolecular 
hydroarylations with unactivated alkenes,[193,195,200,203,206] the developed methodology 
obviates the need for pyrophoric organoaluminium reagents.[309] Various substituted 
benzimidazoles 144, including electron-rich, electron-poor and polychlorinated 
derivatives performed well in the transformation. Moreover, the reaction was not 
limited to benzimidazoles since a broad variety of bioactive heterocyclic motifs, 
including highly functionalized purines and theophylline derivatives, were smoothly 
converted to the cyclized products 145 under the optimized reaction conditions. 
Furthermore, the transformation was found to be highly chemoselective, as for 
substrates bearing several olefinic motifs solely reacted at the proximal alkene, with 
the distal olefins remaining untouched. The detailed mechanistic studies provide 
support to the formation of an organometallic nickel(II) species as the active catalyst 
and a facile C–H cleavage step occurring through a LLHT manifold. Finally, the 
absence of a non-linear effect is indicative of a mono-ligated nickel catalyst to be 
operative in the asymmetric hydroarylation. 
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Scheme 4.4. Enantioselective nickel-catalyzed intramolecular hydroarylations. 
 
Given the topical interest for 3d metal-catalyzed C–H activation, further exciting 
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5. Experimental Part 
 
5.1. General Remarks 
 
All reactions involving air- and/or moisture-sensitive compounds were conducted 
under a dry nitrogen atmosphere using pre-dried glassware and standard Schlenk 
techniques. If not otherwise noted, yields refer to isolated compounds which were 
estimated to be >95% pure based on 1H NMR and/or GC analysis. 
 
Vacuum 
The following average pressure was measured on the used rotary vane pump RD4 
from Vacuubrand®: 0.8∙10–1 mbar (uncorrected value). 
 
Melting Points 
Melting points were measured on a Stuart® Melting Point Apparatus SMP3 from 
Barloworld Scientific. Values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 
aluminium sheets from Merck. Plates were either visualized under irradiation at 
254 nm or 365 nm or developed by treatment with a potassium permanganate 
solution followed by careful warming. Chromatographic purifications were 
accomplished by column chromatography on Merck Geduran® silica gel, grade 60 
(40–63 μm, 70–230 mesh ASTM). 
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Infrared Spectroscopy 
IR spectra were recorded using a Bruker® Alpha-P ATR spectrometer. Liquid 
samples were measured as film and solid samples neat. Spectra were recorded in 
the range from 4000 to 400 cm–1. Analysis of the spectral data was carried out using 
Opus 6. Absorption is given in wave numbers (cm–1). 
 
Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were recorded on Mercury Plus 300, VNMRS 300, Inova 500 and 600 
from Varian®, or Avance 300, Avance III 300 and 400, Avance III HD 400 and 500 
from Bruker®. Chemical shifts are reported in δ-values in ppm relative to the residual 
proton peak or carbon peak of the deuterated solvent. 
 1H NMR 13C NMR 
CDCl3 7.26 77.16 
DMSO-d6 2.50 39.52 
Benzene-d6 7.16 128.06 
MeOH-d4 3.31 49.00 
   
The coupling constants J are reported in hertz (Hz). Analysis of the recorded spectra 
was carried out using MestReNova 10.0 software. 
 
Gas Chromatography 
Monitoring of reaction process via gas chromatography or coupled gas 
chromatography-mass spectrometry was performed using a 7890 GC-system 
with/without mass detector 5975C (Triple-Axis-Detector) or a 7890B GC-system 
coupled with a 5977A mass detector, both from Agilent Technologies®. 
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Mass Spectrometry 
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were 
measured on a time-of-flight mass spectrometer AccuTOF from JEOL. Electrospray 
ionization (ESI) mass spectra were recorded on an Io-Trap mass spectrometer LCQ 
from Finnigan, a quadrupole time-of-flight maXis from Bruker Daltonic or on a time-
of-flight mass spectrometer microTOF from Bruker Daltonic. ESI-HR-MS spectra 
were recorded on a Bruker Apex IV or Bruker Daltonic 7T, Fourier transform ion 
cyclotron resonance (FTICR) mass spectrometer. The ratios of mass to charge (m/z) 




Chiral HPLC chromatograms were recorded on an Agilent 1290 Infinity using 
CHIRALPAK® IA-3, IB-3, IC-3, ID-3, IE-3 and IF-3 columns (3.0 μm particle size; 
ø: 4.6 mm and 250 mm length) at ambient temperature. 
 
Specific Rotations 
Optical rotations were measured on a Jasco P-2000 or an Anton Paar MCP 150 
polarimeter using a 10 cm cell with a Na 589 nm filter. Concentrations are indicated 
in g / 100 mL. 
 
Mössbauer Spectroscopy 
Mössbauer spectra were recorded with a 57Co source in a Rh matrix using an 
alternating constant acceleration Wissel Mössbauer spectrometer operated in the 
transmission mode and equipped with a Janis closed-cycle helium cryostat. Isomer 
shifts are given relative to iron metal at ambient temperature. Simulation of the 
5. Experimental Part 
157 




All solvents for reactions involving air- and/or moisture-sensitive reagents were 
dried, distilled and stored under an inert atmosphere (dry nitrogen) according to the 
following standard procedures. 
1,2-Dichloroethane (DCE), N-methyl-2-pyrrolidone (NMP) and 1,3-dimethyl-3,4,5,6-
tetrahydro-2(1H)-pyrimidinone (DMPU) were dried over CaH2 for 8 h, degassed and 
distilled under reduced pressure. 1,4-Dioxane, di-n-butylether (nBu2O) and tert-amyl 
alcohol (tAmOH) were dried over Na for 8 h, degassed and distilled under reduced 
pressure. 
CH2Cl2, DMF, THF, Et2O and PhMe were obtained from a MBRAUN MB SPS-800 
solvent purification system. 
 
Chemicals 
Chemicals obtained from commercial sources with a purity >95% were used as 
received without further purification. CyMgCl was prepared from chlorocyclohexane 
and magnesium turnings in anhydrous THF under nitrogen atmosphere, and titrated 
before use with I2/LiCl.
[311] Pre-ligands 220 (commercial name: SL-J681-1), ent-220 
(SL-J681-2), and 168 (SL-J688-1) were obtained from Solvias AG. 
 
The following compounds were known from the literature and synthesized according 
to previously known methods: 
Dioxazolone 40a,[229b] 2-aryl oxazines 142,[312] (pyridin-2-yl)-1H-indoles 28 and 
(pyrimidin-2-yl)-1H-indoles 36,[313] Cp*Co(CO)I2,
[86] RuTPP(CO),[314] indoles 59c, 59b 
and [D]1-59b,
[105] indole 59a,[106] chiral NHC precursors 153 and 154,[211] 158,[315] 
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159,[316] 160[241] and 179,[243] phosphoramidites 161[106] and 212,[317] SchmalzPhos 
163,[318] HASPO 169 and phosphine chloride 170,[195] iron complex 173,[319] diamine 
175,[320] styrenes 60f, 60h, 60i and 60j,[321] (Z)-trimethyl(styryl)silane 60n,[322] 
vinylthiophene 60p,[323] vinylferrocene 191a,[324] vinylruthenocene 191b,[325] 1-vinyl-
1’,2’,3’,4’,5’-pentamethylferrocene 191c,[326] benzimidazole 144a,[219b] 
benzimidazoles 144r, 144s, 144x, and [D]1-144x,
[206] and TADDOL-SPOs 131, 216 
and 217.[206,207] 
 
The following compounds were kindly synthesized and provided by the persons 
listed below: 
Karsten Rauch: IMes·HCl, IPr·HCl, (HA)SPOs 164–167, 214 and 215, 
[RuCl2(p-cymene)]2, [Cp*RhCl2]2, dry and/or degassed solvents (DCE, tAmOH, 
1,4-dioxane, NMP, H2O). 
Dr. Ruhuai Mei: oxazolines 142j, 142p and 142r, indole 36a, [Cp*Co(CO)I2]. 
Sven C. Richter: IXyl·HCl. 
Dr. Sebastian Lackner: PyBOX ligand 174. 
Dr. Marc Moselage: CAAC precursor 157, dry DMPU. 
Dr. Gianpiero Cera: ligand 172. 
Dr. Tobias Parchomyk (Koszinowski research group): 57FeCl2. 
Dr. Nicolas Sauermann: [Cp*CoI2]2, dry DMPU. 
Dr. Thomas Müller: N-Bn-benzimidazole 99b. 
Dr. Hui Wang: [Cp*Co(MeCN)3](SbF6)2 (26) and NaO2C-Ile-Ac. 
Dr. Alexander Bechtoldt: dienes 112a and 112b. 
Prof. Dr. E. Peter Kündig and coworkers (Université de Genève): chiral NHC 
precursors 159' and 193. 
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Prof. Dr. Hintermann and coworkers (Technische Universität München): SPO 222. 
Prof. Dr. Albrecht Berkessel and coworkers (Universität zu Köln): NHC precursor 
156. 
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5.2. General Procedures 
 
General Procedure for the Cobalt-Catalyzed C–H Amidation of 
2-Aryloxazolines 142 (GP1) 
2-Aryloxazoline 142 (0.50 mmol, 1.0 equiv), dioxazolone 40 (0.60 mmol, 1.2 equiv), 
Cp*Co(CO)I2 (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 
20 mol %) and NaOAc (8.2 mg, 0.10 mmol, 20 mol %) were placed into an oven-
dried 25 mL Schlenk tube equipped with a septum under N2 atmosphere. DCE 
(2.0 mL) was introduced via cannula. The reaction mixture was stirred at 100 °C for 
16 h. After cooling to ambient temperature, the reaction mixture was dry loaded onto 
silica gel and purified by flash column chromatography (n-hexane/EtOAc) to afford 
the desired product 143. 
 
General Procedure for the Cobalt-Catalyzed C–H Amidation of Indoles 28/36 
(GP2) 
Indole 28/36 (0.50 mmol, 1.0 equiv), dioxazolone 40 (0.60 mmol, 1.2 equiv), 
Cp*Co(CO)I2 (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 
5.0 mol %) and NaOAc (2.1 mg, 0.025 mmol, 5.0 mol %) were placed into an oven-
dried 25 mL Schlenk tube equipped with a septum under N2 atmosphere. DCE 
(2.0 mL) was introduced via cannula. The reaction mixture was stirred at 70 °C for 
16 h. After cooling to ambient temperature, the reaction mixture was dry loaded onto 
silica gel and purified by flash column chromatography (n-hexane/EtOAc) to afford 
the desired product 146/147. 
 
General Procedure for the Synthesis of Indoles 59 (GP3) 
A solution of 3-formylindole (3.44 mmol, 1.0 equiv) in anhydrous DMF (35 mL) was 
cooled to 0 °C. NaH (165 mg, 4.13 mmol, 1.2 equiv, 60% in mineral oil) was then 
added portionwise under ice-cooling. The resulting suspension was stirred at 0 °C 
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for 15 min, then allowed to warm up to ambient temperature and stirred for 1 h. The 
reaction mixture was then cooled to 0 °C, and the corresponding alkyl halide 
(4.13 mmol, 1.2 equiv) was added slowly under ice cooling. The resulting 
suspension was stirred at 0 °C for 15 min, then stirred overnight at the indicated 
temperature (23 °C for benzyl bromides, methoxymethyl chloride and 2-bromo-1,1-
difluoroethane, 60 °C for other alkyl halides). The reaction mixture was cooled to 
0 °C, poured into sat. aqueous NH4Cl (100 mL), and extracted with EtOAc 
(3 × 100 mL). The combined organic phases were washed with H2O (3 × 100 mL) 
and brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The residue was triturated with n-hexane to provide the product 204, which was 
used in the next step without further purification. 
The crude product 204 was suspended in PhMe (15 mL) at ambient temperature. 
p-Anisidine (467 mg, 3.79 mmol, 1.1 equiv) and activated 4Å MS (5.0 g) were then 
added in one portion. The resulting suspension was stirred at 60 °C for 16 h. The 
suspension was allowed to cool to ambient temperature and filtered. The filtrate was 
concentrated under reduced pressure. The residue was recrystallized from 
n-hexane/CH2Cl2/isopropanol. The crystals were collected by filtration, washed with 
cold pentane and dried under vacuum to provide the pure imine 59. 
The analytical data of (aza)indoles 59 have been reported elsewhere[151] and are not 
included in this thesis. 
 
General Procedure for the Synthesis of Chiral Imidazolinium Salts (GP4) 
Following a modified procedure,[211] Pd(OAc)2 (16.0 mg, 71 μmol, 5.0 mol %),       
(+/–)-BINAP (88.0 mg, 0.14 mmol, 10 mol %), and NaOtBu (410 mg, 4.26 mmol, 
3.0 equiv) were added under nitrogen atmosphere to anhydrous PhMe (25 mL) and 
stirred for 30 min at ambient temperature. (R,R)-Diphenylethylenediamine (300 mg, 
1.42 mmol, 1.0 equiv) and the corresponding aryl bromide (2.98 mmol, 2.1 equiv) 
were then added and the solution was stirred at 100 °C for 16 h. The solution was 
cooled to ambient temperature, diluted with n-hexane (75 mL), and filtered through a 
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plug of silica. The silica was washed with n-hexane/CH2Cl2 = 1/1 to elute the 
product. The volatiles were removed in vacuo. The residue was purified by rapid 
flash chromatography (n-hexane/CH2Cl2) to provide the crude N,N′-diarylated 
diamine. The crude N,N′-diarylated diamine (1.0 equiv), ammonium tetrafluoroborate 
(1.2 equiv) were stirred in triethyl orthoformate at 120 °C for 5 h. The solution was 
then allowed to cool to ambient temperature. The reaction mixture was dry loaded 
onto silica gel and purified by column chromatography (CH2Cl2/acetone or 
n-hexane/acetone). 
 
General Procedures for the Iron-catalyzed Enantioselective C–H Alkylation 
with Solid Alkenes (GP5) 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate 59 
(0.25 mmol, 1.0 equiv), Fe(acac)3 (8.8 mg, 0.025 mmol, 10 mol %), 180 (38 mg, 
0.050 mmol, 20 mol %) and vinylarene 60 or 191 (0.38 mmol, 1.5 equiv). The 
Schlenk tube was closed with a rubber septum, then evacuated and backfilled with 
nitrogen 3 times. THF (0.50 mL) and TMEDA (58 mg, 0.50 mmol, 2.0 equiv) were 
added via syringe. CyMgCl (0.28 mmol, 1.1 equiv, typically 1M) was then added 
dropwise at ambient temperature. The resulting mixture was stirred at 45 °C for 16 h. 
The reaction mixture was allowed to cool to ambient temperature and diluted with 
THF (1.5 mL). HCl (3.0 M, 2.0 mL) was added in a single portion, and the resulting 
mixture was stirred at ambient temperature for 2 h. The mixture was poured into sat. 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The combined 
organic layers were washed with brine (10 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (n-hexane/EtOAc) to afford the desired product 62/192. 
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General Procedures for the Iron-catalyzed Enantioselective C–H Alkylation 
with Liquid Alkenes (GP6) 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate 59 
(0.25 mmol, 1.0 equiv), Fe(acac)3 (8.8 mg, 0.025 mmol, 10 mol %) and 180 (38 mg, 
0.050 mmol, 20 mol %). The Schlenk tube was closed with a rubber septum, then 
evacuated and backfilled with nitrogen 3 times. THF (0.50 mL), TMEDA (58 mg, 
0.50 mmol, 2.0 equiv) and vinylarene 60 (0.38 mmol, 1.5 equiv) were added via 
syringe. CyMgCl (0.28 mmol, 1.1 equiv, typically 1M) was then added dropwise at 
ambient temperature. The resulting mixture was stirred at 45 °C for 16 h. The 
reaction mixture was allowed to cool to ambient temperature and diluted with THF 
(1.5 mL). HCl (3.0 M, 2.0 mL) was added in a single portion, and the resulting 
mixture was stirred at ambient temperature for 2 h. The mixture was poured into sat. 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The combined 
organic layers were washed with brine (10 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (n-hexane/EtOAc) to afford the desired product 62. 
 
General Procedure for the Synthesis of Racemic Alkylated Indoles 62/192 
(GP7) 
General procedures GP5 or GP6 were followed using 1,3-bis(2,6-dimethylphenyl)-
1H-imidazol-3-ium chloride (IXyl·HCl) (7.8 mg, 25 μmol, 10 mol %) instead of 180. 
 
General Procedure for the Iron-Catalyzed Hydroarylation of Alkynes 7 (GP8) 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate 59 
(0.25 mmol, 1.0 equiv), Fe(acac)3 (8.8 mg, 0.025 mmol, 10 mol %), L (0.050 mmol, 
20 mol %) and tolane 7 (0.50 mmol, 2.0 equiv). The Schlenk tube was closed with a 
rubber septum, then evacuated and backfilled with nitrogen 3 times. THF (0.50 mL) 
was added via syringe. PhMgCl (0.14 mL, 0.28 mmol, 1.1 equiv, 1.9 M) was then 
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added dropwise at ambient temperature. The resulting mixture was stirred at 60 °C 
for 16 h. The reaction mixture was allowed to cool to ambient temperature and 
diluted with THF (1.5 mL). HCl (3.0 M, 2.0 mL) was added in a single portion, and 
the resulting mixture was stirred at ambient temperature for 2 h. The mixture was 
poured into sat. aqueous NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (n-hexane/EtOAc) to afford the desired product. 
The analytical data are in accordance with those previously reported in the 
literature.[148] 
 
General Procedure for the Enantioselective Nickel-Catalyzed Intermolecular 
Hydroarylation (GP9) 
An oven-dried 25 mL Schlenk tube was charged with N-benzylbenzimidazole 99b 
(104 mg, 0.50 mmol, 1.0 equiv) and L (10 mol %, 50 μmol), and introduced into a 
nitrogen-filled glovebox. Ni(cod)2 (13.8 mg, 50 μmol, 10 mol %), NaOtBu (9.6 mg, 
0.10 mmol, 20 mol %) and PhMe (2.0 mL) were then added. The resulting mixture 
was stirred at ambient temperature for 3 min. BHT (22.0 mg, 0.10 mmol, 20 mol %) 
was then added, followed by 4-methoxystyrene 60c (134 mg, 1.0 mmol, 2.0 equiv). 
The Schlenk tube was closed, taken out of the glovebox, placed in a pre-heated oil 
bath at 130 °C and stirred for 16 h. The reaction mixture was allowed to cool to 
ambient temperature, diluted with EtOAc (5.0 mL), filtered through a short plug of 
SiO2, rinsed with EtOAc (3 × 10 mL) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel (n-hexane/EtOAc = 
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General Procedure for the Synthesis of Alkene-Tethered Azoles 144 (GP10) 
Following a modified procedure,[193] MsCl (1.2 equiv) was added dropwise to a 
solution of the unsaturated alcohol (1.0 equiv), Et3N (1.5 equiv) and DMAP 
(5.0 mol %) in dry CH2Cl2 (0.10 M) at 0 °C. The reaction mixture was allowed to 
warm to 23 °C, stirred for 16 h, and diluted with CH2Cl2 to 4 × the initial volume. The 
obtained solution was washed successively with 2M HCl (twice), sat. aqueous 
NaHCO3, brine and dried (Na2SO4). Concentration under reduced pressure afforded 
the crude mesylate which was used in the next step without further purification. 
A solution of benzimidazole (500 mg, 4.23 mmol, 1.00 equiv) in anhydrous DMF 
(40 mL) was cooled to 0 °C. NaH (203 mg, 5.08 mmol, 1.20 equiv, 60% in mineral 
oil) was then added portionwise under ice-cooling. The resulting suspension was 
stirred at 0 °C for 15 min, then allowed to warm up to ambient temperature and 
stirred for 1 h. The reaction mixture was then cooled to 0 °C, and the corresponding 
mesylate (5.08 mmol, 1.2 equiv) was added slowly under ice cooling. The resulting 
suspension was stirred at 0 °C for 15 min, then stirred at 23 °C for 16 h. The reaction 
mixture was cooled to 0 °C, poured into sat. aqueous NH4Cl (100 mL), and extracted 
with EtOAc (3 × 100 mL). The combined organic phases were washed with H2O 
(4 × 100 mL) and brine (50 mL), dried over Na2SO4, and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc). 
The analytical data of alkene-tethered azoles 144 have been reported elsewhere[220] 
and are not included in this thesis. 
 
General Procedure for the Nickel-Catalyzed Enantioselective Intramolecular 
Hydroarylation (GP11) 
An oven-dried 25 mL Schlenk tube was charged with substrate 144 (0.50 mmol, 
1.0 equiv), Ni(cod)2 (6.9 mg, 25 μmol, 5.0 mol %), 220 (6.3 mg, 12.5 μmol, 
2.5 mol %) and PhMe (1.0 mL) under N2. The Schlenk tube was closed with a rubber 
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septum and placed in a pre-heated oil bath at 95 °C. The reaction mixture was 
stirred at 95 °C for 16 h, then cooled to ambient temperature and diluted with EtOAc 
(5 mL). The mixture was filtered through a short plug of silica gel, rinsed with EtOAc 
(4 × 10 mL) and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel (n-hexane/EtOAc) to provide the product 145. 
 
General Procedure for the Nickel-Catalyzed Racemic Intramolecular 
Hydroarylation (GP12) 
The general procedure GP11 was followed using Ni(cod)2 (13.8 mg, 50 μmol, 
10 mol %), AlMe3 (0.10 mL, 0.20 mmol, 0.40 equiv, 2M in PhMe) and 
rac-Ph(tBu)P(O)H (9.1 mg, 50 μmol, 10 mol %) instead of 220. 
 
  
5. Experimental Part 
167 
5.3. Cobalt(III)-Catalyzed Directed C–H Amidation 
 




The general procedure GP1 was followed using oxazoline 142a (81 mg, 0.25 mmol, 
1.0 equiv), dioxazolone 40a (49 mg, 0.30 mmol, 1.2 equiv), Cp*Co(CO)I2 (6.0 mg, 
0.013 mmol, 5.0 mol %), AgSbF6 (17 mg, 0.050 mmol, 20 mol %) and NaOAc 
(4.1 mg, 0.050 mmol, 20 mol %) in DCE (1.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 5/1) yielded 143aa (39 mg, 56%) 
as a white solid. Reaction carried on 5.6 mmol: 905 mg, 58%. Reaction performed 
by Dr. R. Mei on 0.50 mmol: 95 mg, 68%. M. p. = 149–150 °C. 1H NMR (400 MHz, 
CDCl3): δ = 13.00 (s, 1H), 8.82 (s, 1H), 8.10 (d, J = 8.1 Hz, 2H), 7.77 (d, J = 8.0 Hz, 
1H), 7.58–7.45 (m, 3H), 6.92 (dd, J = 8.0, 1.4 Hz, 1H), 4.41–4.33 (m, 2H), 4.19–4.14 
(m, 2H), 2.43 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 166.0 (Cq), 164.9 (Cq), 143.4 
(Cq), 140.0 (Cq), 135.3 (Cq), 131.5 (CH), 129.1 (CH), 128.5 (CH), 127.7 (CH), 123.3 
(CH), 120.3 (CH), 111.0 (Cq), 66.1 (CH2), 54.6 (CH2), 22.1 (CH3). IR (ATR): 3055, 
2982, 2915, 1677, 1363, 1155, 1103, 1055, 817, 754, cm–1. MS (EI) m/z (relative 
intensity) 281 (20) [M+H+], 280 (55), 263 (25), 203 (100), 160 (50). HR-MS (EI) m/z 
calcd for C17H16N2O2 [M
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The general procedure GP1 was followed using oxazoline 142b (74 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 11/2) yielded 143ba 
(95 mg, 71%) as a white solid. M. p. = 143–145 °C. 1H NMR (400 MHz, CDCl3): 
δ = 13.03 (s, 1H), 8.97 (dd, J = 8.5, 1.2 Hz, 1H), 8.10 (d, J = 8.1 Hz, 2H), 7.91 (dd, 
J = 7.9, 1.7 Hz, 1H), 7.59–7.45 (m, 4H), 7.12 (ddd, J = 7.9, 7.3, 1.2 Hz, 1H), 4.42 (td, 
J = 9.4, 1.1 Hz, 2H), 4.21 (td, J = 9.4, 1.1 Hz, 2H). 13C NMR (100 MHz, CDCl3): 
δ = 166.2 (Cq), 165.1 (Cq), 140.4 (Cq), 135.5 (Cq), 132.8 (CH), 131.8 (CH), 129.4 
(CH), 128.7 (CH), 127.9 (CH), 122.5 (CH), 120.1 (CH), 113.7 (Cq), 66.4 (CH2), 54.9 
(CH2). IR (ATR): 3026, 1614, 1446, 1303, 1058, 943, 748, 703, 674 cm
–1. MS (EI) 
m/z (relative intensity) 266 (56) [M+], 189 (96), 146 (42), 105 (100), 77 (75), 51 (12). 
HR-MS (ESI) m/z calcd for C16H13N2O2 [M–H]
–: 265.0983, found: 265.0991. 





The general procedure GP1 was followed using oxazoline 142c (88 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 7/1) yielded 143ca (95 mg, 
65%) as a white solid. M. p. = 122–124 °C. 1H NMR (300 MHz, CDCl3): δ = 13.02 (s, 
1H), 8.87 (dq, J = 1.8, 0.6 Hz, 1H), 8.17–8.05 (m, 2H), 7.81 (d, J = 8.1 Hz, 1H), 
7.61–7.43 (m, 3H), 6.96 (ddt, J = 8.1, 1.7, 0.6 Hz, 1H), 4.40 (td, J = 9.1, 1.0 Hz, 2H), 
4.19 (td, J = 9.1, 1.0 Hz, 2H), 2.74 (q, J = 7.6 Hz, 2H), 1.30 (t, J = 7.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 166.1 (Cq), 165.0 (Cq), 149.8 (Cq), 140.3 (Cq), 135.5 
(Cq), 131.6 (CH), 129.3 (CH), 128.6 (CH), 127.8 (CH), 122.2 (CH), 119.4 (CH), 111.3 
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(Cq), 66.3 (CH2), 54.8 (CH2), 29.6 (CH2), 15.5 (CH3). IR (ATR): 3065, 2962, 1620, 
1580, 1296, 1242, 1052, 698, 678 cm–1. MS (EI) m/z (relative intensity) 294 (49) 
[M+], 277 (14), 217 (100), 174 (36), 105 (47), 77 (49). HR-MS (EI) m/z calcd for 
C18H18N2O2 [M




The general procedure GP1 was followed using oxazoline 142d (83 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 85/15) yielded 143da 
(101 mg, 71%) as a white solid. M. p. = 163–165 °C. 1H NMR (300 MHz, CDCl3): 
δ = 13.16 (s, 1H), 8.79 (dd, J = 12.2, 2.6 Hz, 1H), 8.08 (d, J = 8.0 Hz, 2H), 7.88 (dd, 
J = 8.9, 6.5 Hz, 1H), 7.62–7.43 (m, 3H), 6.80 (ddd, J = 8.9, 7.6, 2.6 Hz, 1H), 4.41 (td, 
J = 9.2, 1.3 Hz, 2H), 4.19 (td, J = 9.2, 1.3 Hz, 2H). 13C NMR (100 MHz, CDCl3): 
δ = 166.2 (Cq), 165.0 (d, 
1JC–F = 249.0 Hz, Cq), 164.4 (Cq), 142.1 (d, 
3JC–F = 12.8 Hz, 
Cq), 134.9 (Cq), 131.9 (CH), 131.1 (d, 
3JC–F = 10.4 Hz, CH), 128.6 (CH), 127.8 (CH), 
109.8 (d, 4JC–F = 2.9 Hz, Cq), 109.5 (d, 
2JC–F = 22.5 Hz, CH), 107.3 (d,                    
2JC–F = 28.8 Hz, CH), 66.3 (CH2), 54.6 (CH2). 
19F NMR (282 MHz, CDCl3):                   
δ = –104.2 (m). IR (ATR): 3111, 2975, 1614, 1599, 1544, 1430, 1255, 705 cm–1. 
MS (EI) m/z (relative intensity) 284 (33) [M+], 207 (84), 164 (30), 105 (100), 77 (45), 
44 (10). HR-MS (ESI) m/z calcd for C16H14N2O2F [M+H









The general procedure GP1 was followed using oxazoline 142e (108 mg, 0.50 
mmol, 1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 85/15) yielded 143ea 
(106 mg, 63%) as a white solid. M. p. = 191–193 °C. 1H NMR (300 MHz, CDCl3): 
δ = 13.10 (s, 1H), 9.34 (d, J = 1.8 Hz, 1H), 8.08 (d, J = 8.0 Hz, 2H), 8.02–7.93 (m, 
1H), 7.63–7.44 (m, 3H), 7.33 (ddd, J = 8.3, 1.8, 0.7 Hz, 1H), 4.46 (td, J = 9.3, 1.3 Hz, 
2H), 4.24 (td, J = 9.3, 1.3 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 166.2 (Cq), 164.2 
(Cq), 140.6 (Cq), 134.7 (Cq), 134.1 (q, 
2JC–F = 32.7 Hz, Cq), 132.0 (CH), 129.8 (CH), 
128.7 (CH), 127.7 (CH), 123.6 (q, 1JC–F = 273.1 Hz, Cq), 118.7 (q, 
3JC–F = 3.8 Hz, 
CH), 116.9 (q, 3JC–F = 4.2 Hz, CH), 116.0 (Cq), 66.5 (CH2), 54.8 (CH2). 
19F NMR 
(282 MHz, CDCl3): δ = –63.2 (s). IR (ATR): 3016, 1622, 1588, 1426, 1333, 1118, 
1081, 1055, 922, 899, 701 cm–1. MS (EI) m/z (relative intensity) 334 (28) [M+], 257 
(36), 214 (14), 158 (7), 105 (100), 77 (44), 51 (6). HR-MS (ESI) m/z calcd for 
C17H14N2O2F3 [M+H




The general procedure GP1 was followed using oxazoline 142f (112 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 6/1) yielded 143fa 
(127 mg, 74%) as a white solid. M. p. = 170–171 °C. 1H NMR (300 MHz, CDCl3): 
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δ = 13.08 (s, 1H), 9.34 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 8.1 Hz, 2H), 7.95 (d, 
J = 8.2 Hz, 1H), 7.80–7.69 (m, 2H), 7.62–7.32 (m, 7H), 4.41 (td, J = 9.2, 0.9 Hz, 2H), 
4.21 (td, J = 9.2, 0.9 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 166.3 (Cq), 165.0 
(Cq), 145.3 (Cq), 140.7 (Cq), 140.2 (Cq), 135.4 (Cq), 131.8 (CH), 129.8 (CH), 128.9 
(CH), 128.7 (CH), 128.2 (CH), 127.9 (CH), 127.5 (CH), 121.1 (CH), 118.5 (CH), 
112.5 (Cq), 66.4 (CH2), 54.9 (CH2). IR (ATR): 3056, 1618, 1569, 1409, 1249, 1064, 
697, 678 cm–1. MS (EI) m/z (relative intensity) 342 (64) [M+], 265 (100), 222 (35), 






The general procedure GP1 was followed using oxazoline 142g (110 mg, 
0.50 mmol, 1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc = 7.5/1) 
yielded 143ga (84 mg, 50%) as a white solid. M. p. = 120–122 °C. 1H NMR 
(500 MHz, CDCl3): δ = 13.05 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.13–8.07 (d, 
J = 8.1 Hz, 2H), 7.77 (d, J = 8.7 Hz, 1H), 7.57–7.45 (m, 3H), 6.70 (dd, J = 8.7, 
2.4 Hz, 1H), 4.36 (td, J = 9.3, 0.9 Hz, 2H), 4.15 (td, J = 9.3, 0.9 Hz, 2H), 1.49 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 166.3 (Cq), 164.9 (Cq), 159.8 (Cq), 141.2 (Cq), 135.4 
(Cq), 131.7 (CH), 130.0 (CH), 127.8 (CH), 127.8 (CH), 116.8 (CH), 113.1 (CH), 108.0 
(Cq), 79.6 (Cq), 66.2 (CH2), 54.6 (CH2), 29.1 (CH3). IR (ATR): 2978, 2935, 2877, 
1630, 1578, 1362, 1257, 1239, 707 cm–1. MS (EI) m/z (relative intensity) 338 (7) 
[M+], 282 (67), 205 (100), 162 (19), 105 (83), 77 (53), 57 (24). HR-MS (EI) m/z calcd 
for C20H22N2O3 [M
+]: 338.1630, found: 338.1627. 
 




The general procedure GP1 was followed using oxazoline 142h (102 mg, 
0.50 mmol, 1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc = 2/1) yielded 
143ha (94 mg, 58%) as a white solid. M. p. = 189–191 °C. 1H NMR (300 MHz, 
DMSO-d6): δ = 13.07 (s, 1H), 10.28 (s, 1H), 8.96 (d, J = 2.1 Hz, 1H), 8.02 (d, 
J = 7.8 Hz, 2H), 7.80 (d, J = 8.7 Hz, 1H), 7.72–7.53 (m, 4H), 4.42 (td, J = 9.1, 1.1 Hz, 
2H), 4.16 (td, J = 9.1, 1.1 Hz, 2H), 2.09 (s, 3H). 13C NMR (100 MHz, CDCl3): 
δ = 168.8 (Cq), 166.6 (Cq), 164.9 (Cq), 142.0 (CH), 140.7 (Cq), 135.2 (CH), 132.0 
(CH), 130.8 (CH), 128.8 (CH), 127.9 (CH), 113.8 (Cq), 109.8 (Cq), 109.6 (Cq), 66.4 
(CH2), 54.7 (CH2), 24.9 (CH3). IR (ATR): 3312, 3278, 1621, 1518, 1402, 1360, 1286, 
1240, 1061, 704 cm–1. MS (EI) m/z (relative intensity) 323 (23) [M+], 246 (38), 204 
(11), 161 (10), 105 (44), 77 (39), 58 (15), 43 (100). HR-MS (EI) m/z calcd for 
C18H17N3O3 [M




The general procedure GP1 was followed using oxazoline 142i (108 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 7/1) yielded 143ia (108 mg, 
65%) as a white solid. M. p. = 184–187 °C. 1H NMR (300 MHz, CDCl3): δ = 13.17 (s, 
1H), 9.11 (dt, J = 8.9, 0.7 Hz, 1H), 8.19 (dt, J = 2.3, 0.6 Hz, 1H), 8.09 (d, J = 8.1 Hz, 
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2H), 7.75 (ddt, J = 8.9, 2.3, 0.6 1H), 7.64–7.45 (m, 3H), 4.48 (td, J = 9.1, 1.6 Hz, 
2H), 4.26 (td, J = 9.1, 1.6 Hz, 2H). 13C NMR (125 MHz, CDCl3): δ = 166.2 (Cq), 164.0 
(Cq), 142.8 (Cq), 134.7 (Cq), 132.0 (CH), 129.2 (q, 
3JC–F = 3.4 Hz, CH), 128.6 (CH), 
127.7 (CH), 126.5 (q, 3JC–F = 4.0 Hz, CH), 124.9 (q, 
1JC–F = 271.3 Hz, Cq), 124.2 (q, 
2JC–F = 33.4 Hz, Cq), 119.9 (CH), 113.4 (Cq), 66.6 (CH2), 54.8 (CH2). 
19F NMR 
(282 MHz, CDCl3): δ = –62.2 (s). IR (ATR): 3013, 1627, 1308, 1237, 1107, 1082, 
1058, 952, 695 cm–1. MS (EI) m/z (relative intensity) 334 (38) [M+], 257 (57), 214 
(21), 158 (10), 105 (100), 77 (64). HR-MS (EI) m/z calcd for C17H13N2O2F3 [M
+]: 




The general procedure GP1 was followed using oxazoline 142j (91 mg, 0.50 mmol, 
1.0 equiv), dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*RhCl2]2 (7.7 mg, 
0.013 mmol, 2.5 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc 
(8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 5/1) yielded 143ja (111 mg, 74%) as a white solid. (Reaction 
performed by Dr. R. Mei using Cp*Co(CO)I2: 101 mg, 67%.) M. p. = 140–141 °C. 
1H NMR (400 MHz, CDCl3): δ = 12.88 (s, 1H), 8.90 (d, J = 9.0 Hz, 1H), 8.01 (d, 
J = 8.2 Hz, 2H), 7.77 (d, J = 2.6 Hz, 1H), 7.54–7.45 (m, 1H), 7.49–7.40 (m, 2H), 7.39 
(dd, J = 9.0, 2.6 Hz, 1H), 4.34 (td, J = 9.4, 1.0 Hz, 2H), 4.12 (td, J = 9.4, 1.0 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ = 165.8 (Cq), 163.8 (Cq), 138.6 (Cq), 134.8 (Cq), 132.2 
(CH), 131.7 (CH), 128.8 (CH), 128.5 (CH), 127.6 (CH), 127.2 (Cq), 121.0 (CH), 114.7 
(Cq), 66.3 (CH2), 54.6 (CH2). IR (ATR): 3048, 2969, 1666, 1615, 1579, 1474, 1230, 
1057, 950, 693 cm–1. MS (EI) m/z (relative intensity) 300 (30) [M+] (35Cl), 307 (5), 
223 (30), 180 (15), 124 (15), 105 (100). HR-MS (EI) m/z calcd for C16H13
35ClN2O2 
[M+] 300.0666, found 300.0655. 




The general procedure GP1 was followed using oxazoline 142k (98 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 4.5/1) yielded 143ka 
(116 mg, 74%) as a white solid. M. p. = 161–163 °C. 1H NMR (300 MHz, CDCl3): 
δ = 12.93 (s, 1H), 8.86 (d, J = 14.3 Hz, 1H), 8.06 (d, J = 8.0 Hz, 2H), 7.61–7.43 (m, 
4H), 4.43 (td, J = 9.3, 1.4 Hz, 2H), 4.21 (td, J = 9.3, 1.4 Hz, 2H), 3.91 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 165.6 (Cq), 164.1 (Cq), 154.3 (d, 
1JC–F = 250.9 Hz, 
Cq), 142.5 (d, 
2JC–F = 11.6 Hz, Cq), 135.0 (d, 
4JC–F = 10.9 Hz, Cq), 135.0 (Cq), 131.6 
(CH), 128.5 (CH), 127.6 (CH), 113.9 (d, 3JC–F = 3.8 Hz, CH), 109.4 (d, 
3JC–F = 3.4 Hz, 
Cq), 108.8 (d, 
2JC–F = 25.5 Hz, CH), 66.3 (CH2), 56.6 (CH3), 54.7 (CH2). 
19F NMR 
(282 MHz, CDCl3): δ = –125.8 (ddd, J = 14.3, 9.2, 1.5 Hz). IR (ATR): 2968, 1614, 
1544, 1271, 1206, 1020, 944, 877, 702 cm–1. MS (EI) m/z (relative intensity) 314 
(26) [M+], 297 (5), 237 (18), 194 (6), 105 (100), 77 (21). HR-MS (EI) m/z calcd for 
C17H15N2O3F [M




The general procedure GP1 was followed using oxazoline 142m (88 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 8/1) yielded 143ma 
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(125 mg, 85%) as a white solid. M. p. = 126–128 °C. 1H NMR (400 MHz, CDCl3): 
δ = 13.06 (s, 1H), 8.83 (dq, J = 1.1, 0.6 Hz, 1H), 8.16–8.06 (m, 2H), 7.78 (d, 
J = 8.0 Hz, 1H), 7.59–7.45 (m, 3H), 6.97–6.88 (m, 1H), 4.81 (ddq, J = 9.4, 7.4, 
6.2 Hz, 1H), 4.26 (dd, J = 14.2, 9.4 Hz, 1H), 3.73 (dd, J = 14.2, 7.4 Hz, 1H), 2.44 (s, 
3H), 1.44 (d, J = 6.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 166.2 (Cq), 164.5 
(Cq), 143.5 (Cq), 140.2 (Cq), 135.6 (Cq), 131.7 (CH), 129.3 (CH), 128.7 (CH), 127.9 
(CH), 123.4 (CH), 120.5 (CH), 111.4 (Cq), 75.0 (CH), 61.3 (CH2), 22.2 (CH3), 21.1 
(CH3). IR (ATR): 3063, 2974, 1622, 1585, 1295, 1243, 1062, 1049, 696, 677 cm
–1. 
MS (EI) m/z (relative intensity) 294 (22) [M+], 217 (100), 160 (29), 105 (34), 77 (44). 
HR-MS (EI) m/z calcd for C18H18N2O2 [M




The general procedure GP1 was followed using oxazoline 142n (119 mg, 
0.50 mmol, 1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc = 8/1) yielded 
143na (131 mg, 74%) as a white solid. M. p. = 131–133 °C. 1H NMR (400 MHz, 
CDCl3): δ = 12.99 (s, 1H), 8.88 (t, J = 1.1 Hz, 1H), 8.16–8.06 (m, 2H), 7.90 (d, 
J = 8.0 Hz, 1H), 7.61–7.45 (m, 3H), 7.45–7.30 (m, 5H), 6.96 (ddd, J = 8.0, 1.7, 
0.8 Hz, 1H), 5.64 (dd, J = 10.1, 7.7 Hz, 1H), 4.60 (dd, J = 14.5, 10.1 Hz, 1H), 4.13 
(dd, J = 14.5, 7.7 Hz, 1H), 2.46 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 166.2 (Cq), 
164.6 (Cq), 143.8 (Cq), 140.7 (Cq), 140.4 (Cq), 135.5 (Cq), 131.7 (CH), 129.5 (CH), 
129.0 (CH), 128.7 (CH), 128.6 (CH), 127.9 (CH), 125.8 (CH), 123.6 (CH), 120.6 
(CH), 111.0 (Cq), 79.6 (CH), 62.9 (CH2), 22.3 (CH3). IR (ATR): 3066, 2965, 1618, 
1294, 1055, 759, 707, 694, 677 cm–1. MS (EI) m/z (relative intensity) 356 (40) [M+], 
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279 (45), 238 (25), 160 (61), 119 (27), 105 (99), 77 (100). HR-MS (EI) m/z calcd for 
C23H20N2O2 [M




The general procedure GP1 was followed using oxazoline 142o (95 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 8/1) yielded 143oa 
(132 mg, 86%) as a white solid. M. p. = 103–105 °C. 1H NMR (400 MHz, CDCl3): 
δ = 13.13 (s, 1H), 8.87–8.81 (m, 1H), 8.16–8.07 (m, 2H), 7.78 (d, J = 8.0 Hz, 1H), 
7.58–7.45 (m, 3H), 6.93 (ddd, J = 8.0, 1.7, 0.8 Hz, 1H), 3.89 (s, 2H), 2.44 (s, 3H), 
1.50 (s, 6H). 13C NMR (100 MHz, CDCl3): δ = 166.1 (Cq), 163.9 (Cq), 143.3 (Cq), 
140.2 (Cq), 135.6 (Cq), 131.6 (CH), 129.2 (CH), 128.6 (CH), 127.9 (CH), 123.3 (CH), 
120.4 (CH), 111.7 (Cq), 82.9 (Cq), 66.6 (CH2), 27.4 (CH3), 22.2 (CH3). IR (ATR): 
3065, 2974, 2873, 1620, 1583, 1298, 1059, 695, 677 cm–1. MS (EI) m/z (relative 
intensity) 308 (53) [M+], 275 (21), 231 (100), 160 (93), 134 (14), 105 (72), 77 (69), 
51 (9). HR-MS (ESI) m/z calcd for C19H21N2O2 [M+H
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The general procedure GP1 was followed using oxazine 142p (88 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 8/1) yielded 143pa (97 mg, 
66%) as a white solid. M. p. = 127–129 °C. 1H NMR (300 MHz, CDCl3): δ = 13.87 (s, 
1H), 8.81 (d, J = 8.5 Hz, 1H), 8.07–7.97 (m, 2H), 7.72 (d, J = 2.1 Hz, 1H), 7.58–7.41 
(m, 3H), 7.27 (dd, J = 8.5, 2.1 Hz, 1H), 4.42 (t, J = 5.4 Hz, 2H), 3.73 (t, J = 5.9 Hz, 
2H), 2.34 (s, 3H), 2.04 (tt, J = 5.9, 5.4 Hz, 2H). 13C NMR (125 MHz, CDCl3): 
δ = 165.7 (Cq), 157.1 (Cq), 137.9 (Cq), 136.1 (Cq), 132.3 (CH), 131.5 (Cq), 131.4 
(CH), 128.6 (CH), 128.4 (CH), 127.6 (CH), 120.1 (CH), 118.3 (Cq), 65.5 (CH2), 42.1 
(CH2), 21.7 (CH2), 21.0 (CH3). IR (ATR): 2853, 1641, 1595, 1525, 1349, 1237, 822, 
701, 543 cm–1. MS (EI) m/z (relative intensity) 294 (54) [M+], 217 (100), 189 (11), 
160 (61), 105 (52), 77 (61). HR-MS (ESI) m/z calcd for C18H19N2O2 [M+H
+]: 




The general procedure GP1 was followed using oxazine 142q (90 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 85/15) yielded 143qa 
(106 mg, 71%) as a white solid. M. p. = 144–147 °C. 1H NMR (400 MHz, CDCl3): 
δ = 14.19 (s, 1H), 8.75 (dd, J = 12.1, 2.7 Hz, 1H), 8.06–7.96 (m, 2H), 7.89 (dd, 
J = 8.9, 6.6 Hz, 1H), 7.58–7.43 (m, 3H), 6.74 (ddd, J = 8.9, 7.5, 2.7 Hz, 1H), 4.41 (tt, 
J = 5.2, 0.8 Hz, 2H), 3.72 (t, J = 5.9 Hz, 2H), 2.04 (tt, J = 5.9, 5.2 Hz, 2H). 13C NMR 
(100 MHz, CDCl3): δ = 166.0 (Cq), 164.3 (d, 
1JC–F = 249.0 Hz, Cq), 156.6 (Cq), 142.2 
(d, 3JC–F = 12.5 Hz, Cq), 135.5 (Cq), 131.6 (CH), 129.8 (d, 
3JC–F = 10.2 Hz, CH), 
128.5 (CH), 127.6 (CH), 114.4 (d, 4JC–F = 2.9 Hz, Cq), 108.9 (d, 
2JC–F = 22.1 Hz, CH), 
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107.2 (d, 2JC–F = 28.2 Hz, CH), 65.5 (CH2), 41.9 (CH2), 21.6 (CH2). 
19F NMR 
(282 MHz, CDCl3): δ = –(106.36–106.53) (m). IR (ATR): 2894, 2859, 1642, 1533, 
1261, 1134, 703, 676 cm–1. MS (EI) m/z (relative intensity) 298 (34) [M+], 221 (100), 
193 (9), 164 (62), 105 (55), 77 (49), 51 (7). HR-MS (ESI) m/z calcd for C17H16N2O2F 




The general procedure GP2 was followed using indole substrate 36a (98 mg, 
0.50 mmol, 1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc = 2/1) yielded 
147aa (148 mg, 94%) as a pale yellow solid. M. p. = 137–138 °C. 1H NMR 
(300 MHz, CDCl3): δ = 12.99 (s, 1H), 8.63–8.59 (m, 1H), 8.57–8.55 (m, 2H), 7.94–
7.87 (m, 2H), 7.55–7.41 (m, 4H), 7.37 (s, 1H), 7.17 (pd, J = 7.2, 1.5 Hz, 2H), 6.95 (t, 
J = 4.8 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ = 163.5 (Cq), 158.6 (Cq), 157.3 (CH), 
135.5 (Cq), 134.4 (Cq), 132.5 (Cq), 131.7 (CH), 129.9 (Cq), 128.7 (CH), 126.9 (CH), 
123.0 (CH), 122.4 (CH), 119.7 (CH), 116.5 (CH), 115.9 (CH), 95.6 (CH). IR (ATR): 
3015, 1667, 1587, 1492, 1348, 1253, 791, 703, 588, 444 cm–1. MS (EI) m/z (relative 
intensity), 315 (5) [M+H+], 314 (40) [M+], 231 (10), 210 (20), 105 (100). HR-MS (EI) 
m/z calcd for C19H14N4O [M
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The general procedure GP2 was followed using indole 36b (105 mg, 0.50 mmol, 
1.0 equiv), dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (11.9 mg, 
0.025 mmol, 5.0 mol %), AgSbF6 (17 mg, 0.050 mmol, 10 mol %) and NaOAc 
(4.1 mg, 0.050 mmol, 10 mol %) at 100 °C. Purification by column chromatography 
on silica gel (n-hexane/EtOAc = 8:2→6:4) yielded 147ba (106 mg, 65%) as a white 
solid. (Without NaOAc: 101 mg, 61%.) M. p. = 159–160 °C. 1H NMR (300 MHz, 
CDCl3): δ = 10.88 (s, 1H), 8.70 (d, J = 4.8 Hz, 2H), 8.56–8.46 (m, 1H), 7.99 (d, 
J = 6.9 Hz, 2H), 7.61–7.43 (m, 4H), 7.34–7.20 (m, 2H), 7.04 (t, J = 4.8 Hz, 1H), 2.31 
(s, 3H). 13C NMR (125 MHz, CDCl3): δ = 158.1 (Cq), 157.9 (CH), 157.9 (Cq), 134.5 
(Cq), 134.2 (Cq), 132.0 (CH), 130.0 (Cq), 129.1 (Cq), 128.8 (CH), 127.5 (CH), 123.6 
(CH), 122.5 (CH), 118.5 (CH), 116.1 (CH), 114.9 (CH), 110.3 (Cq), 10.2 (CH3). 
IR (ATR): 1673, 1562, 1503, 1429, 1272, 740, 710, 624 cm–1. MS (EI) m/z (relative 
intensity) 328 (58) [M+], 223 (95), 207 (26), 153 (12) 105 (100), 77 (51), 44 (55). 
HR-MS (ESI) m/z calcd for C20H17N4O [M+H
+]: 329.1397, found: 329.1396. 
 
Methyl 2-Benzamido-1-(pyridin-2-yl)-1H-indole-6-carboxylate (146ca) 
 
The general procedure GP2 was followed using indole 28c (126 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 2a (98 mg, 0.60 mmol, 1.2 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 3:1→3:2) yielded 146ca (169 mg, 
91%) as an off-white solid. M. p. = 180–183 °C. 1H NMR (500 MHz, CDCl3): 
δ = 11.95 (s, 1H), 8.67 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 8.32 (dt, J = 1.5, 0.8 Hz, 1H), 
8.02 (ddd, J = 8.3, 7.5, 1.9 Hz, 1H), 7.97–7.87 (m, 3H), 7.82 (dt, J = 8.2, 0.9 Hz, 1H), 
7.63 (dd, J = 8.2, 0.6 Hz, 1H), 7.57 (ddt, J = 8.2, 6.4, 1.3 Hz, 1H), 7.52 (ddt, J = 8.2, 
6.6, 1.4 Hz, 2H), 7.39–7.32 (m, 2H), 3.93 (s, 3H). 13C NMR (125 MHz, CDCl3): 
δ = 168.0 (Cq), 163.9 (Cq), 151.7 (Cq), 148.4 (CH), 140.1 (CH), 137.9 (Cq), 134.1 
(Cq), 133.9 (Cq), 132.3 (CH), 131.5 (Cq), 129.0 (CH), 127.3 (CH), 123.6 (CH), 123.4 
(Cq), 121.5 (CH), 120.1 (CH), 118.5 (CH), 112.6 (CH), 93.9 (CH), 52.1 (CH3). 
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IR (ATR): 3059, 2952, 1703, 1673, 1530, 1436, 1262, 1219, 998, 786 cm–1. 
MS (EI) m/z (relative intensity) 371 (34) [M+], 281 (17), 253 (8), 207 (54), 105 (100), 
77 (30), 44 (18). HR-MS (ESI) m/z calcd for C22H18N3O3 [M+H





The general procedure GP2 was followed using indole 28d (112 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 3/1) yielded 146da 
(165 mg, 96%) as a pale yellow solid. M. p. = 152–154 °C. 1H NMR (500 MHz, 
CDCl3): δ = 11.75 (s, 1H), 8.61 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.97–7.86 (m, 3H), 
7.75 (dt, J = 8.3, 1.0 Hz, 1H), 7.58–7.45 (m, 3H), 7.41 (s, 1H), 7.30–7.18 (m, 2H), 
7.11 (t, J = 8.1 Hz, 1H), 6.66 (dd, J = 7.9, 0.6 Hz, 1H), 3.98 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 163.5 (Cq), 153.4 (Cq), 152.2 (Cq), 148.2 (CH), 139.5 (CH), 
134.5 (Cq), 133.5 (Cq), 133.2 (Cq), 131.9 (CH), 128.8 (CH), 127.1 (CH), 122.7 (CH), 
120.9 (CH), 119.9 (Cq), 118.2 (CH), 104.0 (CH), 102.7 (CH), 91.2 (CH), 55.7 (CH3). 
IR (ATR): 3057, 2954, 1666, 1538, 1470, 1437, 1250, 1090, 764, 686 cm–1. MS (EI) 
m/z (relative intensity) 343 (69) [M+], 281 (6), 238 (27), 207 (20), 169 (7), 105 (100), 
77 (40), 44 (11). HR-MS (ESI) m/z calcd for C21H18N3O2 [M+H










The general procedure GP2 was followed using indole 28e (104 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 5/1) yielded 146ea 
(159 mg, 97%) as an off-white solid. M. p. = 166–169 °C. 1H NMR (500 MHz, 
CDCl3): δ = 11.92 (s, 1H), 8.52–8.46 (m, 1H), 7.97–7.91 (m, 2H), 7.66–7.58 (m, 3H), 
7.58–7.50 (m, 2H), 7.50–7.46 (m, 1H), 7.29 (s, 1H), 7.28–7.16 (m, 2H), 7.11 (ddd, 
J = 5.2, 1.5, 0.8 Hz, 1H), 2.49 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 163.8 (Cq), 
152.2 (Cq), 151.4 (Cq), 147.9 (CH), 135.1 (Cq), 134.4 (Cq), 132.0 (CH), 132.0 (Cq), 
129.8 (Cq), 128.9 (CH), 127.2 (CH), 122.2 (CH), 122.1 (CH), 121.7 (CH), 120.8 (CH), 
118.6 (CH), 110.7 (CH), 93.6 (CH), 21.6 (CH3). IR (ATR): 3228, 3044, 1672, 1523, 
1459, 1259, 805, 685, 636, 447 cm–1. MS (EI) m/z (relative intensity) 327 (60) [M+], 
222 (26), 195 (26), 105 (100), 77 (41), 44 (33). HR-MS (ESI) m/z calcd for 
C21H18N3O [M+H




The general procedure GP2 was followed using indole 28b (104 mg, 0.50 mmol, 
1.0 equiv) and dioxazolone 40a (98 mg, 0.60 mmol, 1.2 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 5/1) yielded 146ba 
(151 mg, 92%) as a pale yellow solid. M. p. = 171–173 °C. 1H NMR (300 MHz, 
CDCl3): δ = 11.80 (s, 1H), 8.45 (dp, J = 2.3, 0.8 Hz, 1H), 8.00–7.86 (m, 2H), 7.75 
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(ddd, J = 8.4, 2.4, 0.7 Hz, 1H), 7.67 (dd, J = 8.4, 0.8 Hz, 1H), 7.65–7.61 (m, 1H), 
7.60–7.47 (m, 4H), 7.28 (t, J = 0.5 Hz, 1H), 7.24–7.13 (m, 2H), 2.44 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 163.6 (Cq), 149.9 (Cq), 148.2 (CH), 140.1 (CH), 
134.9 (Cq), 134.4 (Cq), 132.0 (Cq), 131.9 (CH), 130.7 (Cq), 129.6 (Cq), 128.8 (CH), 
127.2 (CH), 121.9 (CH), 121.7 (CH), 120.7 (CH), 117.6 (CH), 110.5 (CH), 93.5 (CH), 
18.2 (CH3). IR (ATR): 3183, 3049, 1683, 1539, 1477, 1455, 783, 690, 650, 637 cm
–1. 
MS (EI) m/z (relative intensity) 327 (60) [M+], 281 (24), 253 (13), 207 (76), 105 (100), 
77 (35), 44 (22). HR-MS (ESI) m/z calcd for C21H18N3O [M+H
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5.3.2. Mechanistic Studies 
 
Reactions with Radical Scavengers 
142a (81 mg, 0.50 mmol, 1.0 equiv), 40a (98 mg, 0.60 mmol, 1.2 equiv), 
Cp*Co(CO)I2 (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 
20 mol %), NaOAc (8.2 mg, 0.10 mmol, 20 mol %) and the radical scavenger were 
placed into an oven-dried 25 mL Schlenk tube equipped with a septum under N2 
atmosphere. DCE (2.0 mL) was introduced via cannula. The reaction mixture was 
stirred at 100 °C for 16 h. After cooling to ambient temperature, the reaction mixture 
was dry loaded onto silica gel and purified by flash column chromatography 
(n-hexane/EtOAc = 7/1) to yield the product 143aa as an off-white solid. 
 
Table 5.1. Effect of radical scavengers on the cobalt-catalyzed C–H amidation. 
Entry Radical scavenger Yield [%][a] 
1 none 68 
2 TEMPO (1.0 equiv) 46 
3 TEMPO (2.0 equiv) 49 
4 BHT (1.0 equiv) 48 
5 (E)-stilbene (1.0 equiv) 63 
6 Ph2C=CH2 (1.0 equiv) 67 
7 galvinoxyl (1.0 equiv) 14 
 [a]
 Isolated yield. 
 
Mercury Poisoning Test 
142a (81 mg, 0.50 mmol, 1.0 equiv), 40a (98 mg, 0.60 mmol, 1.2 equiv), 
Cp*Co(CO)I2 (12 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 
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20 mol %), and NaOAc (8.2 mg, 0.10 mmol, 20 mol %) were placed into a 25 mL 
Schlenk tube equipped with a septum under N2 atmosphere. DCE (2.0 mL) was 
introduced via cannula. The reaction mixture was stirred at 100 °C for 2.5 min and 
mercury (100 mg, 0.50 mmol, 1.0 equiv) was added via syringe. At this point, no 
detectable formation of 143aa was observed by GC-MS analysis of an aliquot of the 
reaction mixture. The reaction mixture was stirred at 100 °C for 16 h. After cooling to 
ambient temperature, the reaction mixture was dry loaded onto silica gel and purified 
by flash column chromatography (n-hexane/EtOAc = 7/1) to yield the product 143aa 
(92 mg, 66%) as a white solid. 
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5.4. Synthesis of Novel Chiral Ligands 
 




ium Tetrafluoroborate (155) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(200 mg, 0.94 mmol, 1.0 equiv), Pd(OAc)2 (21.1 mg, 94 µmol, 10 mol %),              
(+/–)-BINAP (117 mg, 188 µmol, 20 mol %), NaOtBu (271 mg, 2.82 mmol, 3.0 equiv) 
and 2-bromo-1,3-dimethylbenzene (366 mg, 1.98 mmol, 2.1 equiv) in PhMe (20 mL). 
Short column chromatography (n-hexane/CH2Cl2 = 3/2→1/1) yielded the crude 
diarylated diamine (285 mg, 72%). The crude N,N′-diarylated diamine (280 mg, 
0.67 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate (84 mg, 
0.80 mmol, 1.2 equiv) and triethyl orthoformate (1.0 mL). Purification by column 
chromatography (CH2Cl2/acetone = 9/1→4/1) yielded 155 (277 mg, 80%) as a white 
solid. M. p. = 149–151 °C. 1H NMR (300 MHz, CDCl3): δ = 8.78 (s, 1H), 7.44–7.32 
(m, 10H), 7.18 (d, J = 3.9 Hz, 4H), 6.94 (dd, J = 6.7, 2.7 Hz, 2H), 6.04 (d, J = 0.7 Hz, 
2H), 2.72 (s, 6H), 2.00 (s, 6H). 13C NMR (125 MHz, CDCl3): δ = 158.2 (CH), 136.6 
(Cq), 134.5 (Cq), 131.2 (Cq), 131.1 (CH), 130.8 (CH), 130.3 (CH), 129.5 (CH), 129.5 
(CH), 129.4 (CH), 128.8 (CH), 72.9 (CH), 19.1 (CH3), 18.4 (CH3). 
19F NMR 
(282 MHz, CDCl3): δ = –152.84 (s), –152.90 (dd, J = 2.5, 0.8 Hz). IR (ATR): 3059, 
1613, 1222, 1050, 1031, 699 cm–1. MS (ESI) m/z (relative intensity): 431 (100) 
[M−BF4]
+. HR-MS (ESI) m/z calcd for C31H31N2 [M−BF4]
+ 431.2482, found 431.2479. 
[α]D
20: +303.1 (c = 1.05, CHCl3). 
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ium Tetrafluoroborate (176) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(150 mg, 0.71 mmol, 1.0 equiv), Pd(OAc)2 (7.9 mg, 35 µmol, 5.0 mol %),                     
(+/–)-BINAP (44 mg, 71 µmol, 10 mol %), NaOtBu (204 mg, 2.12 mmol, 3.0 equiv) 
and 2-bromo-1,4-dimethylbenzene (275 mg, 1.48 mmol, 2.1 equiv) in PhMe (15 mL). 
Short column chromatography (n-hexane/CH2Cl2 = 2/1) yielded the crude diarylated 
diamine (300 mg, quantitative). The crude N,N′-diarylated diamine (300 mg, 
0.71 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate (90 mg, 
0.86 mmol, 1.2 equiv) and triethyl orthoformate (1.5 mL). Purification by column 
chromatography (CH2Cl2/acetone = 7/1) yielded 176 (313 mg, 85%) as a white solid. 
M. p. = 125–127 °C. 1H NMR (400 MHz, CDCl3): δ = 8.45 (d, J = 0.7 Hz, 1H), 7.44–
7.32 (m, 10H), 7.28 (t, J = 1.1 Hz, 2H), 7.09–6.98 (m, 4H), 5.78 (d, J = 0.7 Hz, 2H), 
2.39 (s, 6H), 2.24 (s, 6H). 13C NMR (100 MHz, CDCl3): δ = 157.4 (CH), 138.0 (Cq), 
133.7 (Cq), 132.4 (Cq), 131.4 (CH), 130.9 (CH), 130.3 (CH), 129.8 (Cq), 129.7 (CH), 
128.1 (CH), 127.9 (CH), 76.1 (CH), 20.6 (CH3), 17.9 (CH3). 
19F NMR (282 MHz, 
CDCl3): δ = –151.31 (s), –151.36 (d, J = 2.5 Hz). IR (ATR): 3066, 1613, 1049, 1035, 
756, 700 cm–1. MS (ESI) m/z (relative intensity): 431 (100) [M−BF4]
+. HR-MS (ESI) 
m/z calcd for C31H31N2 [M−BF4]
+ 431.2482, found 431.2481. [α]D
20: +412.1 (c = 1.01, 
CHCl3). 
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(4R,5R)-1,3-Bis(5-isopropyl-2-methylphenyl)-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium Tetrafluoroborate (177) 
 
Under inert atmosphere, an oven-dried 100 mL Schlenk flask was charged with 
(R,R)-diphenylethylenediamine (350 mg, 1.65 mmol, 1.0 equiv), Pd(dba)2 (95 mg, 
0.16 mmol, 10 mol %), dppf (183 mg, 0.33 mmol, 20 mol %) and NaOtBu (475 mg, 
4.94 mmol, 3.0 equiv). The flask was evacuated and backfilled with nitrogen 3 times. 
PhMe (20 mL) and freshly prepared 5-isopropyl-2-methylphenyl 
trifluoromethanesulfonate[329] (980 mg, 3.46 mmol, 2.1 equiv) were then added via 
syringe. The flask was then placed in a pre-heated oil bath at 100 °C, and stirred for 
16 h. The solution was then cooled to ambient temperature, diluted with n-hexane 
(60 mL), filtered through a plug of silica and washed with n-hexane/CH2Cl2 = 1/1. 
The filtrate was concentrated under reduced pressure. Short column 
chromatography (n-hexane/CH2Cl2 = 4/1) yielded the crude N,N′-diarylated diamine 
as a pale yellow foam (605 mg, 78%). The crude N,N′-diarylated diamine (600 mg, 
1.28 mmol, 1.0 equiv), ammonium tetrafluoroborate (161 mg, 1.54 mmol, 1.2 equiv), 
and triethyl orthoformate (5.0 mL) were stirred at 120 °C for 5 h. The solution was 
then allowed to cool to ambient temperature. The reaction mixture was dry loaded 
onto silica gel and purified by column chromatography (CH2Cl2/acetone = 
15/1→10/1). The obtained product was washed with Et2O until colorless to yield 177 
(529 mg, 72%) as a colorless powder. M. p. = 133–135 °C. 1H NMR (500 MHz, 
CDCl3): δ = 8.52 (s, 1H), 7.45–7.35 (m, 10H), 7.25 (d, J = 1.7 Hz, 2H), 7.10 (qd, 
J = 8.0, 1.4 Hz, 4H), 5.81 (s, 2H), 2.82 (hept, J = 6.9 Hz, 2H), 2.44 (s, 6H), 1.11 (dd, 
J = 6.9, 6.2 Hz, 12H). 13C NMR (125 MHz, CDCl3): δ = 157.1 (CH), 149.0 (Cq), 133.6 
(Cq), 132.4 (Cq), 131.4 (CH), 130.3 (CH), 130.0 (Cq), 129.6 (CH), 128.3 (CH), 128.2 
(CH), 125.9 (CH), 76.0 (CH), 33.3 (CH), 23.6 (CH3), 23.4 (CH3), 17.9 (CH3). 
19F NMR (282 MHz, CDCl3): δ = –151.20 (s), –151.25 (dd, J = 2.1, 0.9 Hz). 
IR (ATR): 2962, 1624, 1613, 1212, 1049, 701 cm–1. MS (ESI) m/z (relative intensity): 
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487 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C35H39N2 [M−BF4]
+ 487.3108, found 
487.3106. [α]D
20: +379.9 (c = 1.03, CHCl3). 
 
(4R,5R)-1,3-Bis[5-(tert-butyl)-2-methylphenyl]-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium Tetrafluoroborate (178) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(100 mg, 0.47 mmol, 1.0 equiv), Pd(OAc)2 (5.3 mg, 24 µmol, 5.0 mol %),                      
(+/–)-BINAP (29 mg, 47 µmol, 10 mol %), NaOtBu (136 mg, 1.42 mmol, 3.0 equiv) 
and 2-bromo-4-(tert-butyl)-1-methylbenzene[330] (225 mg, 0.99 mmol, 2.1 equiv) in 
PhMe (10 mL). Short column chromatography (n-hexane/CH2Cl2 = 4/1) yielded the 
crude diarylated diamine (240 mg, quantitative). The crude N,N′-diarylated diamine 
(240 mg, 0.47 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate 
(60 mg, 0.56 mmol, 1.2 equiv) and triethyl orthoformate (4.0 mL). Purification by 
column chromatography (CH2Cl2/acetone = 15/1→5/1) yielded 178 (210 mg, 74%) 
as a white solid. M. p. = 125–128 °C. 1H NMR (300 MHz, CDCl3): δ = 8.52 (s, 1H), 
7.47–7.32 (m, 12H), 7.24 (dd, J = 8.0, 2.0 Hz, 2H), 7.13 (dd, J = 8.0, 0.7 Hz, 2H), 
5.81 (s, 2H), 2.46 (s, 6H), 1.18 (s, 18H). 13C NMR (125 MHz, CDCl3): δ = 157.0 
(CH), 151.2 (Cq), 133.5 (Cq), 132.2 (Cq), 131.1 (CH), 130.2 (CH), 129.7 (Cq), 129.5 
(CH), 128.3 (CH), 126.8 (CH), 125.1 (CH), 76.1 (CH), 34.6 (Cq), 31.0 (CH3), 17.8 
(CH3). 
19F NMR (282 MHz, CDCl3): δ = –151.14 (s), –151.19 (d, J = 2.2 Hz). 
IR (ATR): 2962, 1604, 1214, 1050, 1031, 700 cm–1. MS (ESI) m/z (relative intensity): 
515 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C37H43N2 [M−BF4]
+ 515.3421, found 
515.3420. [α]D
20: +326.0 (c = 1.00, CHCl3). 
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Following a modified procedure,[331] a suspension of 1-bromoadamantane (15.0 g, 
69.7 mmol, 1.00 equiv), Pd/C 10 wt. % (3.70 g, 3.50 mmol, 5.00 mol %), K2CO3 
(11.6 g, 83.6 mmol, 1.20 equiv) and PhMe (200 mL) was refluxed for 16 h under a 
slow stream of N2. The mixture was allowed to cool to ambient temperature, diluted 
with n-hexane (200 mL), filtered through a plug of Celite® and concentrated under 
reduced pressure. The residue was recrystallized from n-hexane at −30 °C, 
collected by filtration, washed with cold n-pentane and dried under high vacuum to 
provide 1-(p-tolyl)adamantane 233 (13.8 g, 87%) as a colorless crystalline solid. 





Following a modified procedure,[330] 1-(p-tolyl)adamantane 233 (5.57 g, 24.6 mmol, 
1.0 equiv) was dissolved in chloroform (12.2 mL). The flask was wrapped with 
aluminum foil and placed in an ice bath. Under stirring, bromine (1.27 mL, 
24.6 mmol, 1.0 equiv) was added dropwise via syringe. The mixture was stirred at 
ambient temperature for 16 h. Then, the solution was poured into NaHSO3 (0.1 M, 
100 mL) and extracted with n-hexane (3 × 100 mL). The combined organic layer was 
washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced 
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pressure. The residue was taken into n-hexane and filtered through a short plug of 
silica gel. The silica was washed with n-hexane. The combined filtrate was 
concentrated under reduced pressure and the residue recrystallized from n-hexane 
at −30 °C to yield the product 234 as a white crystalline solid (5.82 g, 77%). 
M. p. = 115–117 °C. 1H NMR (400 MHz, CDCl3): δ = 7.50 (d, J = 1.8 Hz, 1H), 7.20 
(dd, J = 8.0, 1.8 Hz, 1H), 7.17 (dt, J = 8.0, 0.6 Hz, 1H), 2.36 (s, 3H), 2.09 (h, 
J = 2.7 Hz, 3H), 1.94–1.85 (m, 6H), 1.84–1.68 (m, 6H). 13C NMR (100 MHz, CDCl3): 
δ = 151.1 (Cq), 134.7 (Cq), 130.4 (CH), 129.0 (CH), 124.9 (Cq), 123.8 (CH), 43.1 
(CH2), 36.7 (CH2), 36.0 (Cq), 28.9 (CH), 22.3 (CH3). IR (ATR): 2902, 2845, 1493, 
1447, 1031, 801, 675 cm–1. MS (EI) m/z (relative intensity): 306 (65) [M]+ (81Br), 304 
(65) [M]+ (79Br), 249 (34) (81Br), 247 (33) (79Br), 168 (100), 94 (24). HR-MS (EI) m/z 
calcd for C17H21
79Br [M]+ 304.0827, found 304.0834. 
 
(4R,5R)-1,3-Bis[5-(adamantan-1-yl)-2-methylphenyl]-4,5-diphenyl-4,5-dihydro-
1H-imidazol-3-ium Tetrafluoroborate (180) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(200 mg, 0.94 mmol, 1.0 equiv), Pd(OAc)2 (10.6 mg, 47 µmol, 5.0 mol %),                  
(+/–)-BINAP (59 mg, 94 µmol, 10 mol %), NaOtBu (272 mg, 2.83 mmol, 3.0 equiv) 
and 1-(3-bromo-4-methylphenyl)adamantane 234 (604 mg, 1.98 mmol, 2.1 equiv) in 
PhMe (15 mL). Short column chromatography (n-hexane/CH2Cl2 = 6/1) yielded the 
crude diarylated diamine (602 mg, 91%). The crude N,N′-diarylated diamine 
(565 mg, 0.85 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate 
(108 mg, 1.03 mmol, 1.2 equiv) and triethyl orthoformate (4.0 mL). Purification by 
column chromatography (n-hexane/acetone = 3/1→1/1) yielded 180 (522 mg, 81%) 
as an off-white solid. M. p. = 196–198 °C. 1H NMR (300 MHz, CDCl3): δ = 8.59 (s, 
1H), 7.49–7.34 (m, 10H), 7.28 (d, J = 1.9 Hz, 2H), 7.22 (dd, J = 8.0, 2.0 Hz, 2H), 
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7.15 (d, J = 8.1 Hz, 2H), 5.81 (d, J = 0.6 Hz, 2H), 2.47 (s, 6H), 2.10–2.00 (m, 6H), 
1.80–1.68 (m, 24H). 13C NMR (125 MHz, CDCl3): δ = 157.0 (CH), 151.3 (Cq), 133.7 
(Cq), 132.3 (Cq), 131.2 (CH), 130.1 (CH), 129.8 (Cq), 129.5 (CH), 128.3 (CH), 126.5 
(CH), 124.5 (CH), 76.1 (CH), 42.7 (CH2), 36.6 (CH2), 36.1 (Cq), 28.9 (CH), 17.9 
(CH3). 
19F NMR (282 MHz, CDCl3): δ = –151.11 (s), –151.17 (d, J = 2.2 Hz). 
IR (ATR): 2899, 2846, 1604, 1213, 1052, 755, 699 cm–1. MS (ESI) m/z (relative 
intensity): 671 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C49H55N2 [M−BF4]
+ 
671.4360, found 671.4360. [α]D
20: +278.6 (c = 1.02, CHCl3). 
 
(4R,5R)-1,3-Bis[5-(adamantan-1-yl)-2-ethylphenyl]-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium Tetrafluoroborate (181) 
 
1-(3-Bromo-4-ethylphenyl)adamantane was prepared in 2 steps from ethylbenzene 
following the same procedure as for the synthesis of 234.[330,331] The crude product 
was used without purification. 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(202 mg, 0.95 mmol, 1.0 equiv), Pd(OAc)2 (21.4 mg, 95 µmol, 10 mol %),             
(+/–)-BINAP (119 mg, 191 µmol, 20 mol %), NaOtBu (275 mg, 2.86 mmol, 3.0 equiv) 
and crude 1-(3-bromo-4-ethylphenyl)adamantane (638 mg, 2.0 mmol, 2.1 equiv) in 
PhMe (20 mL). Short column chromatography (n-hexane/CH2Cl2 = 7/1→3/1) yielded 
the crude diarylated diamine (470 mg, 72%) as a yellow foam. The crude 
N,N′-diarylated diamine (470 mg, 0.68 mmol, 1.0 equiv) was treated with ammonium 
tetrafluoroborate (86 mg, 0.82 mmol, 1.2 equiv) and triethyl orthoformate (3.0 mL). 
Purification by column chromatography (CH2Cl2/acetone = 35/1→20/1) yielded 181 
(364 mg, 68%) as a pale yellow solid. M. p. = 167–169 °C. 1H NMR (500 MHz, 
CDCl3): δ = 8.41 (s, 1H), 7.46–7.37 (m, 10H), 7.36 (d, J = 2.0 Hz, 2H), 7.27 (dd, 
J = 8.1, 1.8 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 5.81 (s, 2H), 2.81–2.71 (m, 4H), 2.09–
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2.00 (m, 6H), 1.76–1.71 (m, 24H), 1.32 (t, J = 7.4 Hz, 6H). 13C NMR (125 MHz, 
CDCl3): δ = 157.3 (CH), 151.4 (Cq), 136.0 (Cq), 133.6 (Cq), 131.8 (Cq), 130.4 (CH), 
129.7 (CH), 129.1 (CH), 128.7 (CH), 126.9 (CH), 125.3 (CH), 76.6 (CH), 42.7 (CH2), 
36.7 (CH2), 36.2 (Cq), 28.9 (CH), 23.7 (CH2), 15.2 (CH3). 
19F NMR (471 MHz, 
CDCl3): δ = −150.93, −150.99 (d, J = 2.3 Hz). IR (ATR): 2900, 2847, 1603, 1454, 
1268, 1211, 1052, 699 cm–1. MS (ESI) m/z (relative intensity): 699 (100) [M−BF4]
+. 
HR-MS (ESI) m/z calcd for C51H59N2 [M−BF4]
+ 699.4673, found 699.4674. [α]D
20: 
−237.7 (c = 0.97, CHCl3). 
 
(4R,5R)-1,3-Bis(4-methyl-[1,1'-biphenyl]-3-yl)-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium Tetrafluoroborate (182) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(180 mg, 0.85 mmol, 1.0 equiv), Pd(OAc)2 (9.5 mg, 42 µmol, 5.0 mol %),              
(+/–)-BINAP (53 mg, 85 µmol, 10 mol %), NaOtBu (244 mg, 2.54 mmol, 3.0 equiv) 
and 3-bromo-4-methyl-1,1'-biphenyl[332] (440 mg, 1.78 mmol, 2.1 equiv) in PhMe 
(15 mL). Short column chromatography (n-hexane/CH2Cl2 = 4/1→2.5/1) yielded the 
crude diarylated diamine (395 mg, 85%). The crude N,N′-diarylated diamine 
(375 mg, 0.69 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate 
(87 mg, 0.83 mmol, 1.2 equiv) and triethyl orthoformate (2.5 mL). Purification by 
column chromatography (CH2Cl2/acetone = 15/1→5/1) yielded 182 (379 mg, 85%) 
as an off-white solid. M. p. = 162–164 °C. 1H NMR (300 MHz, CDCl3): δ = 8.58 (s, 
1H), 7.64 (d, J = 1.8 Hz, 2H), 7.55–7.48 (m, 4H), 7.47–7.27 (m, 18H), 7.23 (d, 
J = 8.0 Hz, 2H), 5.85 (s, 2H), 2.50 (s, 6H). 13C NMR (125 MHz, CDCl3): δ = 157.7 
(CH), 140.8 (Cq), 138.7 (Cq), 133.3 (Cq), 133.0 (Cq), 132.0 (CH), 131.9 (Cq), 130.3 
(CH), 129.7 (CH), 128.8 (CH), 128.5 (CH), 128.2 (CH), 127.7 (CH), 127.0 (CH), 
125.8 (CH), 76.3 (CH), 18.2 (CH3). 
19F NMR (282 MHz, CDCl3): δ = –150.45 (s),         
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–150.50 (d, J = 2.2 Hz). IR (ATR): 3060, 1600, 1212, 1052, 759, 697 cm–1. MS (ESI) 
m/z (relative intensity): 555 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C41H35N2 
[M−BF4]
+ 555.2795, found 555.2796. [α]D
20: +383.6 (c = 1.10, CHCl3). 
 
(4R,5R)-1,3-Bis(4'-(tert-butyl)-4-methyl-[1,1'-biphenyl]-3-yl)-4,5-diphenyl-4,5-
dihydro-1H-imidazol-3-ium Tetrafluoroborate (183) 
 
3-Bromo-4'-(tert-butyl)-4-methyl-1,1'-biphenyl was prepared following reported 
procedures.[332] 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(300 mg, 1.41 mmol, 1.0 equiv), Pd(OAc)2 (15.9 mg, 71 µmol, 5.0 mol %),             
(+/–)-BINAP (88 mg, 14.1 µmol, 10 mol %), NaOtBu (407 mg, 4.24 mmol, 3.0 equiv) 
and 3-bromo-4'-(tert-butyl)-4-methyl-1,1'-biphenyl (900 mg, 2.97 mmol, 2.1 equiv, 
70% purity) in PhMe (12.0 mL). Short column chromatography (n-hexane/CH2Cl2 = 
10/1→2.5/1) yielded the crude diarylated diamine (853 mg, 92%) as an off-white 
foam. The crude N,N′-diarylated diamine (853 mg, 1.30 mmol, 1.0 equiv) was treated 
with ammonium tetrafluoroborate (170 mg, 1.62 mmol, 1.25 equiv) and triethyl 
orthoformate (5.0 mL). Purification by column chromatography (CH2Cl2/acetone = 
30/1→7/1) followed by recrystallization from iPrOH (8.0 mL) yielded 183 (911 mg, 
93%) as an off-white solid. M. p. = 325–326 °C. 1H NMR (400 MHz, CDCl3): δ = 8.60 
(s, 1H), 7.67 (d, J = 1.9 Hz, 2H), 7.51–7.46 (m, 4H), 7.46–7.42 (m, 10H), 7.42–7.34 
(m, 6H), 7.22 (d, J = 8.0 Hz, 2H), 5.86 (s, 2H), 2.49 (s, 6H), 1.34 (s, 18H). 13C NMR 
(100 MHz, CDCl3): δ = 157.9 (CH), 151.0 (Cq), 140.9 (Cq), 136.0 (Cq), 133.6 (Cq), 
133.2 (Cq), 132.2 (CH), 131.7 (Cq), 130.5 (CH), 129.9 (CH), 128.5 (CH), 128.4 (CH), 
126.8 (CH), 126.0 (CH), 125.8 (CH), 76.5 (CH), 34.7 (Cq), 31.5 (CH3), 18.2 (CH3). 
19F NMR (376 MHz, CDCl3): δ = −150.61, −150.66 (d, J = 2.2 Hz). IR (ATR): 2962, 
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1607, 1495, 1213, 1053, 818, 699, 567 cm–1. MS (ESI) m/z (relative intensity): 667 
(100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C49H51N2 [M−BF4]
+ 667.4047, found 
667.4047. [α]D
20: +333.5 (c = 1.0, acetone). 
 




235 was prepared from methyl p-toluate following reported procedures.[330,333] The 
crude product 235 was used in the next step without further purification. 
 
(4R,5R)-1,3-Bis{5-[bis(4-fluorophenyl)methyl]-2-methylphenyl}-4,5-diphenyl-
4,5-dihydro-1H-imidazol-3-ium Tetrafluoroborate (184) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(120 mg, 0.57 mmol, 1.0 equiv), Pd(dba)2 (36 mg, 63 µmol, 11 mol %),                   
dppf (63 mg, 114 µmol, 20 mol %), NaOtBu (163 mg, 1.70 mmol, 3.0 equiv) and 
crude 4,4'-[(3-bromo-4-methylphenyl)methylene]bis(fluorobenzene) (235) (591 mg, 
1.20 mmol, 2.1 equiv, 70% purity) in PhMe (8.0 mL). Short column chromatography 
(n-hexane/CH2Cl2 = 9/1→4/1) yielded the crude diarylated diamine (402 mg, 90%) 
as an off-white foam. The crude N,N′-diarylated diamine (380 mg, 0.48 mmol, 
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1.0 equiv) was treated with ammonium tetrafluoroborate (60 mg, 0.57 mmol, 
1.2 equiv) and triethyl orthoformate (4.0 mL). Purification by column chromatography 
(CH2Cl2/acetone = 13/1) yielded 184 (394 mg, 92%) as an off-white solid. 
M. p. = 132–133 °C. 1H NMR (500 MHz, CDCl3): δ = 8.78 (s, 1H), 7.38–7.31 (m, 
2H), 7.30–7.25 (m, 4H), 7.20–7.15 (m, 4H), 7.14 (d, J = 7.9 Hz, 2H), 6.91 (m, 20H), 
5.56 (s, 2H), 5.44 (s, 2H), 2.43 (s, 6H). 13C NMR (125 MHz, CDCl3): δ = 161.6 (d, 
1JC–F = 245.2 Hz, Cq), 161.6 (d, 
1JC–F = 245.2 Hz, Cq), 157.8 (CH), 143.9 (Cq), 138.6 
(d, 4JC–F = 3.2 Hz, Cq), 138.5 (d, 
4JC–F = 3.2 Hz, Cq), 133.6 (Cq), 132.6 (Cq), 132.0 
(CH), 131.4 (Cq), 130.9 (CH), 130.9 (d, 
3JC–F = 8.1 Hz, CH), 130.9 (d, 
3JC–F = 8.1 Hz, 
CH), 130.5 (CH), 129.8 (CH), 128.6 (CH), 128.0 (CH), 115.4 (d, 2JC–F = 21.3 Hz, 
CH), 115.4 (d, 2JC–F = 21.3 Hz, CH), 76.1 (CH), 54.2 (CH), 18.1 (CH3). 
19F NMR 
(282 MHz, CDCl3): δ = −116.48 (tdd, J = 13.8, 8.2, 5.6 Hz), −151.03 (d, J = 1.5 Hz), 
−151.08 (d, J = 2.7 Hz). IR (ATR): 1602, 1504, 1219, 1158, 1050, 822, 755, 699, 
565 cm–1. MS (ESI) m/z (relative intensity): 807 (100) [M−BF4]
+. HR-MS (ESI) m/z 
calcd for C55H43N2F4 [M−BF4]
+ 807.3357, found 807.3364. [α]D
20: +238.0 (c = 1.08, 
CHCl3). 
 




236 was prepared from methyl p-toluate following reported procedures.[330,334] The 
crude product 236 was used in the next step without further purification. 
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(4R,5R)-1,3-Bis[5-(heptan-4-yl)-2-methylphenyl]-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium Tetrafluoroborate (185) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(150 mg, 0.71 mmol, 1.0 equiv), Pd(OAc)2 (7.9 mg, 35 µmol, 5.0 mol %),                   
(+/–)-BINAP (44 mg, 71 µmol, 10 mol %), NaOtBu (204 mg, 2.12 mmol, 3.0 equiv) 
and crude 2-bromo-4-(heptan-4-yl)-1-methylbenzene (236) (615 mg, 1.49 mmol, 
2.1 equiv, 65% purity) in PhMe (12 mL). Short column chromatography 
(n-hexane/CH2Cl2 = 12/1) yielded the crude diarylated diamine (379 mg, 90%). The 
crude N,N′-diarylated diamine (378 mg, 0.64 mmol, 1.0 equiv) was treated with 
ammonium tetrafluoroborate (81 mg, 0.77 mmol, 1.2 equiv) and triethyl orthoformate 
(4.0 mL). Purification by column chromatography (CH2Cl2/acetone = 19/1→10/1) 
yielded 185 (190 mg, 43%) as an off-white foam. M. p. = 88–90 °C. 1H NMR (500 
MHz, CDCl3): δ = 8.51 (s, 1H), 7.44–7.29 (m, 10H), 7.13 (d, J = 1.7 Hz, 2H), 7.09 (d, 
J = 7.8 Hz, 2H), 6.97 (dd, J = 7.8, 1.8 Hz, 2H), 5.82 (s, 2H), 2.46 (s, 6H), 2.45–2.36 
(m, 2H), 1.50–1.39 (m, 4H), 1.39–1.29 (m, 4H), 1.00–0.87 (m, 4H), 0.87–0.75 (m, 
4H), 0.73 (t, J = 7.2 Hz, 6H), 0.72 (t, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3): 
δ = 156.9 (CH), 146.6 (Cq), 133.6 (Cq), 132.5 (Cq), 131.5 (CH), 130.3 (CH), 130.2 
(Cq), 129.7 (CH), 129.5 (CH), 128.5 (CH), 127.2 (CH), 76.1 (CH), 45.0 (CH), 39.1 
(CH2), 38.8 (CH2), 20.6 (CH2), 20.6 (CH2), 18.1 (CH3), 14.2 (CH3), 14.2 (CH3). 
19F NMR (377 MHz, CDCl3): δ = −151.15, −151.20 (d, J = 2.1 Hz). IR (ATR): 2955, 
2928, 1606, 1456, 1214, 1051, 700 cm–1. MS (ESI) m/z (relative intensity): 599 (100) 
[M−BF4]
+. HR-MS (ESI) m/z calcd for C43H55N2 [M−BF4]
+ 599.4360, found 599.4359. 
[α]D
20: +331.2 (c = 0.51, CHCl3). 
 





The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(100 mg, 0.47 mmol, 1.0 equiv), Pd(OAc)2 (5.3 mg, 24 µmol, 5.0 mol %),               
(+/–)-BINAP (29 mg, 47 µmol, 10 mol %), NaOtBu (136 mg, 1.42 mmol, 3.0 equiv) 
and 9-bromophenanthrene (254 mg, 0.99 mmol, 2.1 equiv) in PhMe (8.0 mL). Short 
column chromatography (n-hexane/CH2Cl2 = 16/1→3/1) yielded the crude diarylated 
diamine (284 mg, quantitative) as a yellow foam. The crude N,N′-diarylated diamine 
(280 mg, 0.50 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate 
(62 mg, 0.59 mmol, 1.2 equiv) and triethyl orthoformate (8.0 mL). Purification by 
column chromatography (CH2Cl2/acetone = 15/1→3/1) yielded 186 (275 mg, 83%) 
as a yellow solid. M. p. = 221–223 °C. 1H NMR (300 MHz, CDCl3): δ = 8.59 (dd, 
J = 8.5, 1.1 Hz, 2H), 8.50 (d, J = 8.3 Hz, 2H), 8.31 (s, 2H), 8.13–8.01 (m, 3H), 7.97 
(dd, J = 8.1, 1.3 Hz, 2H), 7.76 (ddd, J = 8.1, 7.0, 1.1 Hz, 2H), 7.61 (ddd, J = 8.4, 7.0, 
1.3 Hz, 4H), 7.57–7.50 (m, 4H), 7.48–7.38 (m, 2H), 7.32–7.18 (m, 6H), 6.26 (s, 2H). 
13C NMR (125 MHz, CDCl3): δ = 158.8 (CH), 132.5 (Cq), 131.3 (Cq), 130.5 (Cq), 
130.4 (CH), 130.3 (Cq), 130.2 (CH), 129.6 (CH), 129.6 (CH), 128.7 (CH), 128.7 (CH), 
128.1 (Cq) 128.0 (CH), 127.8 (CH), 127.7 (CH), 127.1 (Cq), 123.8 (CH), 122.4 (CH), 
121.6 (CH), 77.3 (CH). 19F NMR (282 MHz, CDCl3): δ = −149.68 (m). IR (ATR): 
3065, 1605, 1028, 749, 726, 698 cm–1. MS (ESI) m/z (relative intensity): 575 (100) 
[M−BF4]
+. HR-MS (ESI) m/z calcd for C43H31N2 [M−BF4]
+ 575.2482, found 575.2475. 
[α]D
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(3aR,7aR)-1,3-Bis(5-isopropyl-2-methylphenyl)-3a,4,5,6,7,7a-hexahydro-1H-
benzo[d]imidazol-3-ium Tetrafluoroborate (187) 
 
The general procedure GP4 was followed using (1R,2R)-cyclohexane-1,2-diamine 
(116 mg, 1.02 mmol, 1.0 equiv), Pd(dba)2 (64 mg, 0.11 mmol, 11 mol %), dppf 
(112 mg, 0.20 mmol, 20 mol %), NaOtBu (292 mg, 3.04 mmol, 3.0 equiv) and 
5-isopropyl-2-methylphenyl trifluoromethanesulfonate[329] (600 mg, 2.13 mmol, 
2.1 equiv) in PhMe (10.0 mL). Short column chromatography (n-hexane/CH2Cl2 = 
8/1→4/1) yielded the crude diarylated diamine (90 mg, 23%) as a yellow foam. The 
crude N,N′-diarylated diamine (90 mg, 0.24 mmol, 1.0 equiv) was treated with 
ammonium tetrafluoroborate (30 mg, 0.29 mmol, 1.2 equiv) and triethyl orthoformate 
(1.5 mL). Purification by column chromatography (CH2Cl2/acetone = 9/1→5/1) 
yielded 187 (65.8 mg, 73%) as a pale yellow foam. M. p. = 90–92 °C. 1H NMR 
(500 MHz, CDCl3): δ = 7.97 (s, 1H), 7.49 (s, 2H), 7.24 (app s, 4H), 4.31 (s, 2H), 2.96 
(p, J = 6.8 Hz, 2H), 2.35 (s, 6H), 2.09 (d, J = 10.6 Hz, 2H), 1.96 (d, J = 8.5 Hz, 2H), 
1.86 (app s, 2H), 1.51–1.39 (m, 2H), 1.26 (d, J = 6.7 Hz, 12H). 13C NMR (125 MHz, 
CDCl3): δ = 159.0 (CH), 149.7 (Cq), 132.9 (Cq), 131.6 (CH), 131.0 (Cq), 128.5 (CH), 
125.9 (CH), 71.4 (CH), 33.7 (CH), 27.6 (CH2), 24.0 (CH3), 23.9 (CH3), 23.9 (CH2), 
17.6 (CH3). 
19F NMR (471 MHz, CDCl3): δ = −151.33, −151.39 (d, J = 2.2 Hz). 
IR (ATR): 2900, 2847, 1591, 1449, 1256, 1038, 942, 755 cm–1. MS (ESI) m/z 
(relative intensity): 389 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C27H37N2 
[M−BF4]
+ 389.2951, found 389.2952. [α]D
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(4R,5R)-1,3-Bis(3,5-di-tert-butylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-
ium Tetrafluoroborate (188) 
 
The general procedure GP4 was followed using (R,R)-diphenylethylenediamine 
(200 mg, 0.94 mmol, 1.0 equiv), Pd(OAc)2 (11.0 mg, 49 µmol, 5.0 mol %),             
(+/–)-BINAP (59 mg, 95 µmol, 10 mol %), NaOtBu (272 mg, 2.83 mmol, 3.0 equiv) 
and 1-bromo-3,5-di-tert-butylbenzene (533 mg, 1.98 mmol, 2.1 equiv) in PhMe 
(15 mL). Short column chromatography (n-hexane/CH2Cl2 = 8/1→4/1) yielded the 
crude diarylated diamine (557 mg, quantitative). The crude N,N′-diarylated diamine 
(557 mg, 0.95 mmol, 1.0 equiv) was treated with ammonium tetrafluoroborate 
(119 mg, 1.14 mmol, 1.2 equiv) and triethyl orthoformate (3.0 mL). Purification by 
column chromatography (CH2Cl2/acetone = 20/1→15/1) yielded 188 (545 mg, 87%) 
as a white solid. M. p. = 275–277 °C. 1H NMR (500 MHz, CDCl3): δ = 9.37 (s, 1H), 
7.46–7.37 (m, 10H), 7.31 (t, J = 1.6 Hz, 2H), 7.17 (s, 2H), 7.16 (s, 2H), 5.71 (d, 
J = 0.5 Hz, 2H), 1.22 (s, 36H). 13C NMR (125 MHz, CDCl3): δ = 153.4 (CH), 153.2 
(Cq), 135.0 (Cq), 134.1 (Cq), 130.2 (CH), 130.1 (CH), 127.5 (CH), 122.8 (CH), 116.1 
(CH), 75.4 (CH), 35.3 (Cq), 31.2 (CH3). 
19F NMR (471 MHz, CDCl3): δ = −150.31, 
−150.37 (d, J = 2.2 Hz). IR (ATR): 2902, 1619, 1583, 1054, 756, 700 cm–1. MS (ESI) 
m/z (relative intensity): 599 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C43H55N2 
[M−BF4]
+ 599.4360, found 599.4352. [α]D
20: +190.5 (c = 1.02, CHCl3). 
 
(4S,5S)-1,3-Bis[5-(adamantan-1-yl)-2-methylphenyl]-4,5-di(naphthalen-1-yl)-4,5-
dihydro-1H-imidazol-3-ium Tetrafluoroborate (189) 
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The general procedure GP4 was followed using (1S,2S)-1,2-di(naphthalen-
1-yl)ethane-1,2-diamine[335] (480 mg, 1.54 mmol, 1.0 equiv), Pd(OAc)2 (34.5 mg, 
0.15 mmol, 10 mol %), (+/–)-BINAP (191 mg, 0.31 mmol, 20 mol %), NaOtBu 
(443 mg, 4.61 mmol, 3.0 equiv) and 1-(3-bromo-4-methylphenyl)adamantane 234 
(985 mg, 3.23 mmol, 2.1 equiv) in PhMe (20 mL). Short column chromatography 
(n-hexane/CH2Cl2 = 7/1→1/1) yielded the crude diarylated diamine (737 mg, 63%) 
as an off-white foam. The crude N,N′-diarylated diamine (737 mg, 0.97 mmol, 
1.0 equiv) was treated with ammonium tetrafluoroborate (122 mg, 1.16 mmol, 
1.2 equiv) and triethyl orthoformate (3.0 mL). Purification by column chromatography 
(CH2Cl2/acetone = 25/1→10/1), followed by recrystallization from iPrOH (5.0 mL), 
yielded 189 (656 mg, 79%) as a white solid. M. p. = 292–293 °C. 1H NMR (600 MHz, 
CDCl3): δ = 9.59–8.25 (brm, 2H), 8.24–7.27 (brm, 11H), 7.23–7.03 (brm, 8H), 7.04–
6.08 (brm, 2H), 2.69–2.41 (m, 6H), 2.14–1.84 (m, 6H), 1.83–1.34 (m, 24H). As 
previously reported in a similar situation,[210] peaks were noticeably broadened and 
difficult to integrate, likely due to slow rotation. 13C NMR (125 MHz, CDCl3): 
δ = 157.7 (CH), 151.4 (Cq), 133.7 (Cq), 132.8 (Cq), 132.0 (CH), 131.6 (CH), 131.3 
(Cq), 130.6 (CH), 130.1 (Cq), 129.5 (Cq), 129.1 (CH), 128.2 (CH), 127.3 (CH), 126.3 
(CH), 126.0 (CH), 123.9 (CH), 121.1 (CH), 71.0 (CH), 42.6 (CH2), 36.7 (CH2), 36.1 
(Cq), 28.9 (CH), 18.4 (CH3). 
19F NMR (376 MHz, CDCl3): δ = −151.19, −151.24 (d, 
J = 2.5 Hz). IR (ATR): 2900, 1592, 1260, 1052, 800, 773, 477 cm–1. MS (ESI) m/z 
(relative intensity): 771 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for C57H59N2 
[M−BF4]
+ 771.4673, found 771.4668. [α]D
20: −352.7 (c = 1.0, CHCl3). 
 
(4R,5R)-1-[5-(Adamantan-1-yl)-2-methylphenyl]-3-(4-methyl-[1,1'-biphenyl]-3-
yl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium Tetrafluoroborate (190) 
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190 was prepared following a procedure reported in the literature[242c] from 
(R,R)-diphenylethylenediamine (368 mg, 1.73 mmol, 1.0 equiv), 3-bromo-4-methyl-
1,1'-biphenyl[330] (450 mg, 1.82 mmol, 1.05 equiv) and 1-(3-bromo-4-
methylphenyl)adamantane 234 (1.2 equiv in the 2nd step). After purification by 
column chromatography (CH2Cl2/acetone = 16/1→6/1) and recrystallization from 
iPrOH (3.0 mL) at −30 °C, 190 (556 mg, 46% over 3 steps) was obtained as a white 
solid. M. p. = 154–156 °C. 1H NMR (400 MHz, CDCl3): δ = 8.54 (s, 1H), 7.62 (d, 
J = 1.8 Hz, 1H), 7.54–7.45 (m, 4H), 7.45–7.34 (m, 11H), 7.33–7.27 (m, 2H), 7.24 (d, 
J = 4.0 Hz, 1H), 7.22 (dd, J = 8.1, 2.0 Hz, 1H), 7.14 (d, J = 8.1 Hz, 1H), 5.93 (d, 
J = 10.4 Hz, 1H), 5.74 (d, J = 10.4 Hz, 1H), 2.49 (s, 3H), 2.46 (s, 3H), 2.09–2.00 (m, 
3H), 1.78–1.66 (m, 12H). 13C NMR (100 MHz, CDCl3): δ = 157.5 (CH), 151.6 (Cq), 
141.0 (Cq), 139.0 (Cq), 133.7 (Cq), 133.6 (Cq), 133.3 (Cq), 132.4 (Cq), 132.3 (CH), 
132.1 (Cq), 131.4 (CH), 130.5 (CH), 130.4 (CH), 130.0 (Cq), 129.9 (CH), 129.8 (CH), 
129.0 (CH), 128.7 (CH), 128.6 (CH), 128.3 (CH), 127.9 (CH), 127.2 (CH), 126.8 
(CH), 125.6 (CH), 125.2 (CH), 76.4 (CH), 76.1 (CH), 42.7 (CH2), 36.7 (CH2), 36.2 
(Cq), 28.9 (CH), 18.2 (CH3), 18.0 (CH3). 
19F NMR (376 MHz, CDCl3): δ = −150.81, 
−150.86 (d, J = 2.4 Hz). IR (ATR): 2901, 2847, 1604, 1213, 1052, 760, 698 cm–1. 
MS (ESI) m/z (relative intensity): 613 (100) [M−BF4]
+. HR-MS (ESI) m/z calcd for 
C45H45N2 [M−BF4]
+ 613.3578, found 613.3571. [α]D
20: +340.4 (c = 1.0, CHCl3). 
 
5.4.2. Experimental Procedures and Analytical Data of Novel Chiral HASPOs 
 
(4R,5R)-1,3-Bis[5-(adamantan-1-yl)-2-methylphenyl]-4,5-diphenyl-1,3,2-
diazaphospholidine 2-Oxide (213) 
 
Following a modified procedure,[239b] PCl3 (45 µL, 0.51 mmol, 1.0 equiv) was added 
dropwise at 0 °C to a solution of the N,N′-diarylated diamine (see the synthesis of 
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pre-ligand 180) (340 mg, 0.51 mmol, 1.0 equiv) and Et3N (0.54 mL, 3.85 mmol, 
7.5 equiv) in CH2Cl2 (2.1 mL). After stirring at ambient temperature for 1 h, H2O 
(9.3 µL, 0.51 mmol, 1.0 equiv) was added at 0 °C. The resulting mixture was stirred 
for 20 h at 23 °C, filtered through Celite® and concentrated under reduced pressure. 
The residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc = 19/1→9/1) to yield 213 (211 mg, 58%) as a yellow foam. 
M. p. = 147–149 °C. 1H NMR (300 MHz, CDCl3): δ = 8.07 (d, JH–P = 603.3 Hz, 1H), 
7.44 (dd, J = 7.9, 1.7 Hz, 2H), 7.34–7.17 (m, 9H), 7.05–6.94 (m, 5H), 5.12 (ddd, 
J = 6.1, 3.1, 1.0 Hz, 1H), 4.90 (t, J = 6.0 Hz, 1H), 2.46 (s, 3H), 2.41 (s, 3H), 2.12–
1.93 (m, 6H), 1.84–1.62 (m, 24H). 13C NMR (125 MHz, CDCl3): δ = 150.1 (Cq), 149.8 
(Cq), 139.4 (Cq), 139.4 (Cq), 138.6 (Cq), 138.5 (Cq), 136.7 (Cq), 136.6 (Cq), 136.0 
(Cq), 135.9 (Cq), 134.3 (Cq), 134.2 (Cq), 132.4 (Cq), 132.4 (Cq), 130.9 (CH), 128.6 
(CH), 128.5 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 127.7 (CH), 126.2 (CH), 
124.5 (CH), 123.7 (CH), 123.0 (CH), 72.6 (d, J = 9.0 Hz, CH), 72.5 (d, J = 10.2 Hz, 
CH), 43.2 (CH2), 43.2 (CH2), 37.0 (CH2), 37.0 (CH2), 36.0 (Cq), 36.0 (Cq), 29.1 (CH), 
19.1 (CH3), 18.7 (CH3). 
31P NMR (162 MHz, CDCl3): δ = 9.94. IR (ATR): 2899, 2846, 
1450, 1240, 1137, 1005, 751, 698 cm–1. MS (ESI) m/z (relative intensity): 2143 (100) 
[3M+Na]+, 1437 (37) [2M+Na]+, 729 (35) [M+Na]+. HR-MS (ESI) m/z calcd for 
C48H55N2OPNa [M+Na]
+ 729.3944, found 729.3943. [α]D
20: +82.3 (c = 0.74, CHCl3). 
 
(3aR,8aR)-2,2-Dimethyl-4,4,8,8-tetra(2-methyl-5-adamant-1-ylphenyl)tetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 6-Oxide (218) 
 
The corresponding (R,R)-TADDOL was prepared in 2 steps from L-(+)-diethyl 
tartrate and 234 following reported procedures.[336] 
Following a modified procedure,[207] PCl3 (158 µL, 1.81 mmol, 1.2 equiv) was added 
dropwise at 0 °C to a solution of the diol (1.60 g, 1.51 mmol, 1.0 equiv) and Et3N 
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(0.63 mL, 4.53 mmol, 3.0 equiv) in THF (9.0 mL). After stirring at ambient 
temperature for 16 h, Et3N (0.21 mL, 1.51 mmol, 1.0 equiv) and H2O (27 µL, 
1.51 mmol, 1.0 equiv) were added at 0 °C. The resulting mixture was stirred for 8 h 
at 23 °C, filtered through Celite® and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel (n-hexane/EtOAc = 
25/1→6/1) to yield 218 (835 mg, 50%) as a colorless solid. M. p. = 229–231 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.54–7.35 (brm, 4H), 7.26–6.78 (brm, 9H), 6.39–
5.48 (brm, 2H), 2.31–1.32 (m, 72H), 1.18–0.17 (m, 6H). As previously reported in a 
similar situation,[207] peaks were noticeably broadened and difficult to integrate, likely 
due to slow rotation. 13C NMR (100 MHz, CDCl3): δ = 148.9 (Cq), 147.9 (Cq), 147.5 
(Cq), 140.1 (Cq), 136.4 (Cq), 136.1 (Cq), 135.8 (Cq), 134.8 (Cq), 132.9 (CH), 132.5 
(CH), 132.5 (CH), 132.3 (CH), 126.1 (CH), 125.1 (CH), 124.6 (CH), 124.4 (CH), 
113.4 (Cq), 91.3 (Cq), 90.5 (Cq), 81.3 (CH), 80.7 (CH), 77.4 (CH), 43.3 (CH2), 43.3 
(CH2), 37.0 (CH2), 36.9 (CH2), 36.8 (CH2), 36.8 (CH2), 36.3 (CH), 36.1 (Cq), 36.0 
(Cq), 29.1 (CH), 29.1 (CH), 29.0 (CH), 29.0 (CH), 27.1 (CH3), 25.9 (CH3), 23.0 (CH3), 
22.5 (CH3), 21.2 (CH3), 21.0 (CH3). 
31P NMR (162 MHz, CDCl3): δ = −7.14. 
IR (ATR): 2900, 2847, 1449, 1084, 975, 941, 806, 755 cm–1. MS (ESI) m/z (relative 
intensity): 1128 (100) [M+Na]+. HR-MS (ESI) m/z calcd for C75H93O5PNa [M+Na]
+ 
1127.6653, found 1127.6659. [α]D
20: −123.9 (c = 1.10, CHCl3).  
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5.5. Iron-Catalyzed Enantioselective C–H Alkylation with Alkenes 
 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→6/1) yielded 62cc (88.0 mg, 
95%) as a yellow solid. M. p. = 58–59 °C. 1H NMR (400 MHz, CDCl3): δ = 10.22 (s, 
1H), 8.43 (ddd, J = 7.9, 1.3, 0.7 Hz, 1H), 7.31 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 7.29–
7.20 (m, 4H), 7.14 (dt, J = 8.1, 0.9 Hz, 1H), 7.11 (dd, J = 8.9, 0.9 Hz, 2H), 6.90 
(dddd, J = 6.7, 2.7, 2.0, 1.1 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 5.25 (d, J = 17.1 Hz, 
1H), 5.21 (d, J = 17.1 Hz, 1H), 4.99 (q, J = 7.4 Hz, 1H), 3.77 (s, 3H), 1.72 (d, 
J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 185.4 (CH), 158.5 (Cq), 154.2 (Cq), 
137.0 (Cq), 136.0 (Cq), 133.2 (Cq), 128.9 (CH), 128.0 (CH), 127.6 (CH), 126.0 (Cq), 
125.8 (CH), 123.7 (CH), 123.1 (CH), 121.7 (CH), 114.8 (Cq), 114.2 (CH), 110.1 (CH), 
55.3 (CH3), 47.5 (CH2), 34.3 (CH), 20.0 (CH3). IR (ATR): 2929, 1643, 1510, 1246, 
1179, 1029, 744 cm–1. MS (EI) m/z (relative intensity): 369 (79) [M]+, 261 (30), 197 
(84), 91 (100). HR-MS (EI) m/z calcd for C25H23NO2 [M]
+ 369.1729, found 369.1735. 
[α]D
23: –54.9 (c = 1.74, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 









The general procedure GP6 was followed using indole 59d (93 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→5.5/1) yielded 62dc (79.4 mg, 
80%) as a yellow solid. M. p. = 56–57 °C. 1H NMR (500 MHz, CDCl3): δ = 10.20 (s, 
1H), 8.42 (dt, J = 7.9, 1.0 Hz, 1H), 7.30 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.23 (ddd, 
J = 8.3, 7.1, 1.3 Hz, 1H), 7.16 (dt, J = 8.2, 1.0 Hz, 1H), 7.11 (d, J = 8.4 Hz, 2H), 
6.86–6.74 (m, 6H), 5.19 (d, J = 17.1 Hz, 1H), 5.15 (d, J = 17.1 Hz, 1H), 4.99 (q, 
J = 7.4 Hz, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 1.72 (d, J = 7.4 Hz, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 185.2 (CH), 158.9 (Cq), 158.3 (Cq), 154.1 (Cq), 137.0 (Cq), 
133.3 (Cq), 128.0 (CH), 127.9 (Cq), 127.0 (CH), 126.0 (Cq), 123.5 (CH), 123.0 (CH), 
121.7 (CH), 114.7 (Cq), 114.2 (CH), 114.1 (CH), 110.2 (CH), 55.3 (CH3), 55.3 (CH3), 
47.1 (CH2), 34.5 (CH), 20.2 (CH3). IR (ATR): 2929, 1643, 1509, 1244, 1175, 1030, 
739 cm–1. MS (EI) m/z (relative intensity): 399 (31) [M]+, 278 (40), 263 (10), 250 (13), 
227 (24), 121 (100). HR-MS (EI) m/z calcd for C26H25NO3 [M]
+ 399.1834, found 
399.1826. [α]D
23: –52.4 (c = 1.17, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 10.4 min, 










The general procedure GP6 was followed using indole 59e (90 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→5.5/1) yielded 62ec (90.9 mg, 
94%) as a yellow solid. M. p. = 60–61 °C. 1H NMR (500 MHz, CDCl3): δ = 10.24 (s, 
1H), 8.43 (ddd, J = 7.8, 1.2, 0.7 Hz, 1H), 7.32 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.23 
(ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.14–7.08 (m, 3H), 6.94 (t, J = 8.6 Hz, 2H), 6.84 (dd, 
J = 8.9, 5.1 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 5.19 (s, 2H), 5.02 (q, J = 7.4 Hz, 1H), 
3.77 (s, 3H), 1.72 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.3 (CH), 
162.0 (d, 1JC–F = 246.5 Hz, Cq), 158.4 (Cq), 154.0 (Cq), 136.9 (Cq), 132.9 (Cq), 131.6 
(d, 4JC–F = 3.1 Hz, Cq), 128.0 (CH), 127.4 (d, 
3JC–F = 8.2 Hz, CH), 125.9 (Cq), 123.7 
(CH), 123.2 (CH), 121.7 (CH), 115.7 (d, 2JC–F = 21.7 Hz, CH), 114.8 (Cq), 114.1 
(CH), 110.0 (CH), 55.2 (CH3), 46.9 (CH2), 34.2 (CH), 19.9 (CH3). 
19F NMR 
(471 MHz, CDCl3): δ = –114.54 (tt, J = 8.5, 5.2 Hz). IR (ATR): 2932, 1644, 1508, 
1247, 823, 743 cm–1. MS (ESI) m/z (relative intensity): 797 (28) [2M+Na]+, 410 (42) 
[M+Na]+, 388 (100) [M+H]+, 280 (9). HR-MS (ESI) m/z calcd for C25H23NO2F [M+H]
+ 
388.1707, found 388.1696. [α]D
23: –58.1 (c = 1.47, CHCl3). HPLC separation 
(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): 









The general procedure GP6 was followed using indole 59f (89 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 9/1→7/1) yielded 62fc (83.4 mg, 
87%) as a yellow solid. Using 177: 67.5 mg (70%), 89:11 e.r. M. p. = 48–49 °C. 
1H NMR (300 MHz, CDCl3): δ = 10.22 (s, 1H), 8.49–8.37 (m, 1H), 7.44–7.22 (m, 6H), 
7.18 (dd, J = 8.9, 0.9 Hz, 2H), 7.02 (dd, J = 7.9, 1.6 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 
4.95 (q, J = 7.4 Hz, 1H), 4.22 (ddd, J = 8.9, 6.9, 1.4 Hz, 2H), 3.80 (s, 3H), 2.94 (ddd, 
J = 13.3, 8.8, 6.7 Hz, 1H), 2.64–2.51 (m, 1H), 1.79 (d, J = 7.4 Hz, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 185.0 (CH), 158.4 (Cq), 153.4 (Cq), 137.4 (Cq), 136.1 (Cq), 
133.4 (Cq), 128.7 (CH), 128.5 (CH), 128.1 (CH), 126.9 (CH), 126.2 (Cq), 123.4 (CH), 
122.9 (CH), 121.8 (CH), 114.4 (Cq), 114.2 (CH), 109.7 (CH), 55.3 (CH3), 46.1 (CH2), 
35.3 (CH2), 34.4 (CH), 20.0 (CH3). IR (ATR): 2931, 1643, 1510, 1246, 745,                
699 cm–1. MS (ESI) m/z (relative intensity): 789 (16) [2M+Na]+, 767 (5) [2M+H]+, 398 
(22), 384 (100) [M+H]+, 117 (12). HR-MS (ESI) m/z calcd for C26H26NO2 [M+H]
+ 
384.1958, found 384.1969. [α]D
20: –19.6 (c = 1.20, CHCl3). HPLC separation 
(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): 
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The general procedure GP6 was followed using indole 59g (74 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→6/1) yielded 62gc (64.9 mg, 
80%) as a yellow oil. Using 177: 68.0 mg (84%), 87:13 e.r. 1H NMR (500 MHz, 
CDCl3): δ = 10.20 (s, 1H), 8.41–8.34 (m, 1H), 7.48–7.42 (m, 1H), 7.31 (ddd, J = 8.0, 
7.2, 0.9 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.35 (d, 
J = 11.0 Hz, 1H), 5.31 (d, J = 11.0 Hz, 1H), 5.07 (q, J = 7.3 Hz, 1H), 3.79 (s, 3H), 
3.21 (s, 3H), 1.89 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.8 (CH), 
158.5 (Cq), 154.6 (Cq), 137.1 (Cq), 133.5 (Cq), 128.1 (CH), 125.8 (Cq), 123.8 (CH), 
123.3 (CH), 121.8 (CH), 115.3 (Cq), 114.1 (CH), 109.9 (CH), 74.4 (CH2), 56.1 (CH3), 
55.3 (CH3), 34.2 (CH), 20.5 (CH3). IR (ATR): 2932, 2836, 1647, 1510, 1247, 1029, 
748 cm–1. MS (EI) m/z (relative intensity): 323 (100) [M]+, 276 (40), 263 (27), 215 
(29), 151 (44), 121 (50). HR-MS (EI) m/z calcd for C20H21NO3 [M]
+ 323.1521, found 
323.1530. [α]D
20: –51.0 (c = 1.01, CHCl3). HPLC separation (Chiralpak
® IB-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): tr (major) = 9.6 min, 





The general procedure GP6 was followed using indole 59h (79 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→6/1) yielded 62hc (82.4 mg, 
96%) as a yellow solid. M. p. = 49–50 °C. 1H NMR (500 MHz, CDCl3): δ = 10.22 (s, 
1H), 8.39 (dt, J = 5.4, 2.1 Hz, 1H), 7.38–7.29 (m, 3H), 7.20 (dd, J = 8.9, 0.9 Hz, 2H), 
6.88 (d, J = 8.8 Hz, 2H), 5.44 (tt, J = 55.2, 4.2 Hz, 1H), 5.05 (q, J = 7.4 Hz, 1H), 
4.47–4.33 (m, 2H), 3.80 (s, 3H), 1.88 (d, J = 7.5 Hz, 3H). 13C NMR (125 MHz, 
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CDCl3): δ = 185.5 (CH), 158.7 (Cq), 153.9 (Cq), 136.9 (Cq), 133.0 (Cq), 128.1 (CH), 
125.9 (Cq), 124.0 (CH), 123.5 (CH), 121.8 (CH), 115.3 (Cq), 114.4 (CH), 113.2 (t, 
1JC–F = 245.3 Hz, CH), 109.7 (CH), 55.3 (CH3), 46.4 (t, 
2JC–F = 28.9 Hz, CH2), 34.2 
(CH), 20.2 (CH3). 
19F NMR (471 MHz, CDCl3): δ = –119.04 (dt, J = 55.3, 13.2 Hz). 
IR (ATR): 2960, 2838, 1644, 1511, 1248, 1057, 747 cm–1. MS (EI) m/z (relative 
intensity): 343 (100) [M]+, 328 (44), 326 (33), 311 (25), 235 (56), 121 (30). HR-MS 
(EI) m/z calcd for C20H19F2NO2 [M]
+ 343.1384, found 343.1386. [α]D
23: –77.5 
(c = 1.50, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 80:20, 





The general procedure GP6 was followed using indole 59i (84 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 6/1→3/1) yielded 62ic (75.2 mg, 
82%) as a yellow solid. M. p. = 129–132 °C. 1H NMR (300 MHz, CDCl3): δ = 10.01 
(s, 1H), 8.40–8.33 (m, 1H), 7.50–7.43 (m, 1H), 7.33–7.26 (m, 2H), 7.20 (dd, J = 8.9, 
0.9 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 5.13 (t, J = 3.4 Hz, 1H), 4.93 (q, J = 7.3 Hz, 
1H), 4.34 (dd, J = 3.4, 1.0 Hz, 2H), 3.86–3.81 (m, 4H), 3.79 (s, 3H), 1.88 (d, 
J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.9 (CH), 158.3 (Cq), 155.2 (Cq), 
137.0 (Cq), 134.2 (Cq), 128.1 (CH), 125.9 (Cq), 123.3 (CH), 123.0 (CH), 121.8 (CH), 
114.6 (Cq), 114.1 (CH), 110.5 (CH), 101.9 (CH), 65.3 (CH2), 65.3 (CH2), 55.3 (CH3), 
46.7 (CH2), 34.9 (CH), 21.3 (CH3). IR (ATR): 2925, 1633, 1511, 1247, 1030,    
745 cm–1. MS (ESI) m/z (relative intensity): 753 (16) [2M+Na]+, 471 (36), 388 (16) 
[M+Na]+, 366 (100) [M+H]+, 216 (22), 124 (16). HR-MS (ESI) m/z calcd for 
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C22H24NO4 [M+H]
+ 366.1700, found 366.1708. [α]D
23: –36.4 (c = 1.33, CHCl3). HPLC 
separation (Chiralpak® IF-3, n-hexane/iPrOH 80:20, 0.75 mL/min, detection at 




The general procedure GP6 was followed using indole 59b (66 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→5/1) yielded 62bc (68.2 mg, 
93%) as a yellow oil. Using 177: 55.7 mg (76%), 85:15 e.r. 1H NMR (500 MHz, 
CDCl3): δ = 10.26 (s, 1H), 8.38 (ddd, J = 7.6, 3.1, 1.5 Hz, 1H), 7.34–7.26 (m, 3H), 
7.17 (dd, J = 8.9, 1.0 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 5.16 (q, J = 7.4 Hz, 1H), 3.80 
(s, 3H), 3.47 (s, 3H), 1.86 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 184.8 
(CH), 158.4 (Cq), 153.8 (Cq), 137.3 (Cq), 132.9 (Cq), 128.0 (CH), 125.7 (Cq), 123.4 
(CH), 123.0 (CH), 121.4 (CH), 114.4 (Cq), 114.2 (CH), 109.2 (CH), 55.3 (CH3), 33.7 
(CH), 31.1 (CH3), 18.8 (CH3). IR (ATR): 2933, 1643, 1510, 1468, 1246, 750 cm
–1. 
MS (ESI) m/z (relative intensity): 609 (20) [2M+Na]+, 316 (26) [M+Na]+, 294 (100) 
[M+H]+, 186 (22). HR-MS (ESI) m/z calcd for C19H20NO2 [M+H]
+ 294.1489, found 
294.1489. [α]D
20: –70.6 (c = 0.94, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 10.6 min, 
tr (minor) = 11.5 min, 84:16 e.r. 
The analytical data are in accordance with those previously reported in the literature 
for the racemic compound.[148] 
 
 





The general procedure GP6 was followed using indole 59j (93 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 7/1→5/1) yielded 62jc (97.9 mg, 
98%) as a yellow solid. M. p. = 59–60 °C. 1H NMR (300 MHz, CDCl3): δ = 10.16 (s, 
1H), 7.94 (d, J = 2.5 Hz, 1H), 7.33–7.17 (m, 3H), 7.11 (dd, J = 9.0, 0.9 Hz, 2H), 7.02 
(dd, J = 8.9, 0.5 Hz, 1H), 6.94–6.87 (m, 2H), 6.85 (dd, J = 8.9, 2.6 Hz, 1H), 6.80 (d, 
J = 8.8 Hz, 2H), 5.26–5.13 (m, 2H), 4.91 (q, J = 7.3 Hz, 1H), 3.90 (s, 3H), 3.77 (s, 
3H), 1.71 (d, J =7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.2 (CH), 158.3 
(Cq), 156.8 (Cq), 154.2 (Cq), 135.9 (Cq), 133.2 (Cq), 131.7 (Cq), 128.8 (CH), 127.9 
(CH), 127.6 (CH), 126.6 (Cq), 125.7 (CH), 114.7 (Cq), 114.1 (CH), 113.8 (CH), 110.9 
(CH), 103.4 (CH), 55.9 (CH3), 55.3 (CH3), 47.7 (CH2), 34.5 (CH), 20.2 (CH3). 
IR (ATR): 2933, 1642, 1510, 1453, 1246, 1031, 696 cm–1. MS (EI) m/z (relative 
intensity): 399 (76) [M]+, 308 (42), 291 (26), 278 (23), 200 (22), 197 (74), 91 (100). 
HR-MS (EI) m/z calcd for C26H25NO3 [M]
+ 399.1834, found 399.1826. [α]D
23: –60.0 
(c = 1.68, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 80:20, 
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The general procedure GP6 was followed using indole 59k (90 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→6/1) yielded 62kc (92.0 mg, 
95%) as a yellow solid. M. p. = 54–56 °C. 1H NMR (400 MHz, CDCl3): δ = 10.16 (s, 
1H), 8.11 (dd, J = 9.4, 2.6 Hz, 1H), 7.33–7.21 (m, 3H), 7.11 (d, J = 8.1 Hz, 2H), 7.05 
(dd, J = 8.9, 4.2 Hz, 1H), 6.94 (ddd, J = 8.9, 2.6, 2.6 Hz, 1H), 6.92–6.85 (m, 2H), 
6.81 (d, J = 8.8 Hz, 2H), 5.25 (d, J = 17.3 Hz, 1H), 5.19 (d, J = 17.2 Hz, 1H), 4.94 (q, 
J = 7.3 Hz, 1H), 3.77 (s, 3H), 1.72 (d, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): 
δ = 185.1 (CH), 160.0 (d, 1JC–F = 238.8 Hz, Cq), 158.5 (Cq), 155.3 (Cq), 135.7 (Cq), 
133.4 (Cq), 132.9 (Cq), 128.9 (CH), 128.0 (CH), 127.8 (CH), 126.6 (d,                     
3JC–F = 11.0 Hz, Cq), 125.7 (CH), 114.8 (d, 
4JC–F = 4.3 Hz, Cq), 114.2 (CH), 111.8 (d, 
2JC–F = 26.2 Hz, CH), 111.0 (d, 
3JC–F = 9.6 Hz, CH), 107.4 (d, 
2JC–F = 24.9 Hz, CH), 
55.3 (CH3), 47.7 (CH2), 34.5 (CH), 20.0 (CH3). 
19F NMR (376 MHz, CDCl3):             
δ = –120.24 (ddd, J = 9.3, 4.3, 4.3 Hz). IR (ATR): 2928, 1646, 1510, 1454, 1247, 
1026 cm–1. MS (ESI) m/z (relative intensity): 410 (24) [M+Na]+, 388 (100) [M+H]+, 
372 (30), 289 (27), 280 (9). HR-MS (ESI) m/z calcd for C25H23NO2F [M+H]
+ 
388.1707, found 388.1701. [α]D
23: –54.9 (c = 1.53, CHCl3). HPLC separation 
(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): 





The general procedure GP6 was followed using indole 59l (92 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 9/1→7/1) yielded 62lc (89.5 mg, 
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90%) as a yellow solid. M. p. = 56–58 °C. 1H NMR (300 MHz, CDCl3): δ = 10.22 (s, 
1H), 8.43 (ddd, J = 7.8, 1.3, 0.8 Hz, 1H), 7.31 (ddd, J = 7.9, 6.9, 1.3 Hz, 1H), 7.23 
(ddd, J = 8.2, 6.9, 1.4 Hz, 1H), 7.17 (ddd, J = 8.1, 1.4, 0.8 Hz, 1H), 7.13 (dd, J = 9.0, 
0.9 Hz, 2H), 6.87 (ddd, J = 1.6, 0.9, 0.9 Hz, 1H), 6.81 (d, J = 8.8 Hz, 2H), 6.55–6.47 
(m, 2H), 5.18 (s, 2H), 4.97 (q, J = 7.4 Hz, 1H), 3.78 (s, 3H), 2.21 (s, 3H), 2.21 (s, 
3H), 1.75 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.3 (CH), 158.3 
(Cq), 154.2 (Cq), 138.4 (Cq), 137.0 (Cq), 135.8 (Cq), 133.3 (Cq), 129.2 (CH), 128.0 
(CH), 125.9 (Cq), 123.5 (CH), 123.5 (CH), 123.0 (CH), 121.6 (CH), 114.7 (Cq), 114.0 
(CH), 110.2 (CH), 55.3 (CH3), 47.6 (CH2), 34.5 (CH), 21.3 (CH3), 20.3 (CH3). 
IR (ATR): 2922, 1644, 1510, 1458, 1247, 1179, 745 cm–1. MS (EI) m/z (relative 
intensity): 397 (77) [M]+, 289 (26), 278 (30), 263 (22), 225 (100), 119 (77), 91 (24). 
HR-MS (EI) m/z calcd for C27H27NO2 [M]
+ 397.2042, found 397.2042. [α]D
23: –43.4 
(c = 1.62, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 80:20, 





The general procedure GP6 was followed using indole 59m (100 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 10/1→6/1) yielded 62mc 
(102.6 mg, 96%) as a yellow solid. M. p. = 57–58 °C. 1H NMR (300 MHz, CDCl3): 
δ = 10.16 (s, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 7.04 (d, 
J = 8.9 Hz, 1H), 6.87 (s, 1H), 6.85 (dd, J = 8.9, 2.5 Hz, 1H), 6.80 (d, J = 8.8 Hz, 2H), 
6.54–6.46 (m, 2H), 5.14 (s, 2H), 4.88 (q, J = 7.3 Hz, 1H), 3.91 (s, 3H), 3.77 (s, 3H), 
2.21 (s, 6H), 1.74 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.2 (CH), 
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158.3 (Cq), 156.7 (Cq), 154.2 (Cq), 138.4 (Cq), 135.8 (Cq), 133.4 (Cq), 131.8 (Cq), 
129.2 (CH), 128.0 (CH), 126.6 (Cq), 123.5 (CH), 114.5 (Cq), 114.0 (CH), 113.7 (CH), 
111.0 (CH), 103.3 (CH), 55.9 (CH3), 55.3 (CH3), 47.7 (CH2), 34.6 (CH), 21.3 (CH3), 
20.4 (CH3). IR (ATR): 2932, 1643, 1510, 1457, 1246, 1034, 831 cm
–1. MS (ESI) m/z 
(relative intensity): 855 (39) [2M+H]+, 428 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C28H30NO3 [M+H]
+ 428.2220, found 428.2220. [α]D
23: –46.4 (c = 1.96, CHCl3). HPLC 
separation (Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 





The general procedure GP6 was followed using azaindole 59n (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60c (50 mg, 0.38 mmol, 1.5 equiv). The reaction mixture was 
diluted with sat. aqueous NaHCO3 (10 mL) and extracted with EtOAc (3 × 10 mL). 
The combined organic layers were washed with brine (10 mL), dried over Na2SO4, 
and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (n-hexane/EtOAc = 8/1→6/1) to yield 152nc (100.2 mg, 84%, 
24:76 e.r.) as an off-white solid. The product was recrystallized from iPrOH (5 mL) to 
provide further enantioenriched 152nc (60.6 mg, 51%, 10:90 e.r.) as a colorless 
crystalline solid. M. p. = 170–171 °C. 1H NMR (600 MHz, CDCl3): δ = 8.91 (dd, 
J = 7.8, 1.7 Hz, 1H), 8.50 (s, 1H), 8.37 (dd, J = 4.7, 1.6 Hz, 1H), 7.28–7.19 (m, 4H), 
7.07 (dd, J = 8.9, 0.8 Hz, 2H), 7.02–6.98 (m, 4H), 6.86 (d, J = 8.9 Hz, 2H), 6.81 (d, 
J = 8.8 Hz, 2H), 5.62 (d, J = 16.5 Hz, 1H), 5.50 (d, J = 16.5 Hz, 1H), 4.70 (q, 
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J = 7.3 Hz, 1H), 3.80 (s, 3H), 3.77 (s, 3H), 1.60 (d, J = 7.4 Hz, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 158.3 (Cq), 157.4 (Cq), 153.0 (CH), 149.5 (Cq), 148.5 (Cq), 
146.4 (Cq), 143.9 (CH), 137.5 (Cq), 134.0 (Cq), 131.1 (CH), 128.7 (CH), 128.2 (CH), 
127.4 (CH), 126.3 (CH), 121.8 (CH), 118.8 (Cq), 118.1 (CH), 114.2 (CH), 114.0 (CH), 
110.4 (Cq), 55.5 (CH3), 55.3 (CH3), 45.3 (CH2), 35.0 (CH), 20.4 (CH3). IR (ATR): 
2934, 2834, 1497, 1427, 1242, 1031, 826, 728 cm–1. MS (ESI) m/z (relative 
intensity): 476 (100) [M+H]+. HR-MS (ESI) m/z calcd for C31H30N3O2 [M+H]
+ 
476.2333, found 476.2332. [α]D
23: +192.7 (c = 1.11, CHCl3). HPLC separation 
(Chiralpak® IF-3, n-hexane/iPrOH 90:10, 1.0 mL/min, detection at 273 nm): 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60d (44 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 11/1) yielded 62cd (72.7 mg, 82%) 
as a yellow solid. M. p. = 69–71 °C. 1H NMR (400 MHz, CDCl3): δ = 10.23 (s, 1H), 
8.44 (ddd, J = 7.9, 1.3, 0.8 Hz, 1H), 7.31 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.29–7.23 
(m, 3H), 7.22 (dd, J = 7.1, 1.2 Hz, 1H), 7.15 (dt, J = 8.2, 1.0 Hz, 1H), 7.09 (app s, 
4H), 6.91 (dd, J = 7.1, 2.6 Hz, 2H), 5.26 (d, J = 17.2 Hz, 1H), 5.21 (d, J = 17.2 Hz, 
1H), 5.00 (q, J = 7.4 Hz, 1H), 2.31 (s, 3H), 1.73 (d, J = 7.4 Hz, 3H). 13C NMR 
(100 MHz, CDCl3): δ = 185.4 (CH), 154.2 (Cq), 138.2 (Cq), 137.0 (Cq), 136.6 (Cq), 
136.0 (Cq), 129.4 (CH), 128.8 (CH), 127.6 (CH), 126.9 (CH), 126.0 (Cq), 125.8 (CH), 
123.6 (CH), 123.1 (CH), 121.7 (CH), 114.8 (Cq), 110.1 (CH), 47.5 (CH2), 34.7 (CH), 
20.9 (CH3), 19.9 (CH3). IR (ATR): 2912, 1644, 1421, 1395, 1039, 806, 729 cm
–1. 
MS (EI) m/z (relative intensity): 353 (75) [M]+, 261 (22), 218 (35), 181 (75), 91 (100). 
HR-MS (EI) m/z calcd for C25H23NO [M]
+ 353.1780, found 353.1775. [α]D
23: –51.3 
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(c = 1.33, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 80:20, 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60e (60 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 15/1→11/1) yielded 62ce (72.2 mg, 
73%) as a yellow oil. 1H NMR (300 MHz, CDCl3): δ = 10.24 (s, 1H), 8.44 (ddd, 
J = 7.9, 1.4, 0.8 Hz, 1H), 7.35–7.19 (m, 7H), 7.18–7.09 (m, 3H), 6.96–6.83 (m, 2H), 
5.27 (s, 2H), 5.00 (q, J = 7.4 Hz, 1H), 1.75 (d, J = 7.4 Hz, 3H), 1.28 (s, 9H). 13C NMR 
(125 MHz, CDCl3): δ = 185.3 (CH), 154.1 (Cq), 149.8 (Cq), 138.0 (Cq), 136.9 (Cq), 
135.8 (Cq), 128.7 (CH), 127.5 (CH), 126.6 (CH), 125.9 (Cq), 125.7 (CH), 125.6 (CH), 
123.6 (CH), 123.1 (CH), 121.7 (CH), 114.8 (Cq), 110.1 (CH), 47.6 (CH2), 34.8 (CH), 
34.4 (Cq), 31.3 (CH3), 20.0 (CH3). IR (ATR): 2961, 1645, 1454, 1421, 1395,   
745 cm–1. MS (EI) m/z (relative intensity): 395 (57) [M]+, 338 (25), 261 (19), 248 (23), 
223 (67), 91 (100). HR-MS (EI) m/z calcd for C28H29NO [M]
+ 395.2249, found 
395.2239. [α]D
23: –34.8 (c = 1.34, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (minor) = 5.6 min, 









The general procedure GP5 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60f (68 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 15/1→10/1) yielded 62cf (66.9 mg, 
64%) as a yellow solid. M. p. = 84–85 °C. 1H NMR (300 MHz, CDCl3): δ = 10.29 (s, 
1H), 8.44 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.58–7.39 (m, 6H), 7.38–7.20 (m, 8H), 7.17 
(dt, J = 8.1, 1.1 Hz, 1H), 6.97–6.86 (m, 2H), 5.27 (s, 2H), 5.10 (q, J = 7.4 Hz, 1H), 
1.79 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.1 (CH), 153.6 (Cq), 
140.3 (Cq), 140.2 (Cq), 139.8 (Cq), 137.0 (Cq), 135.8 (Cq), 128.8 (CH), 128.7 (CH), 
127.6 (CH), 127.4 (CH), 127.4 (CH), 127.3 (CH), 126.9 (CH), 126.0 (Cq), 125.7 (CH), 
123.7 (CH), 123.2 (CH), 121.6 (CH), 114.8 (Cq), 110.2 (CH), 47.7 (CH2), 34.9 (CH), 
20.0 (CH3). IR (ATR): 2927, 1644, 1453, 1395, 1039, 746, 694 cm
–1. MS (EI) m/z 
(relative intensity): 415 (92) [M]+, 280 (42), 261 (39), 243 (96), 91 (100). HR-MS (EI) 
m/z calcd for C30H25NO [M]
+ 415.1936, found 415.1934. [α]D
23: –49.0 (c = 1.18, 
CHCl3). HPLC separation (Chiralpak
® IB-3, n-hexane/iPrOH 70:30, 1.0 mL/min, 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60g (46 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 12/1→9/1) yielded 62cg (54.2 mg, 
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61%) as a yellow solid. M. p. = 56–57 °C. 1H NMR (500 MHz, CDCl3): δ = 10.22 (s, 
1H), 8.41 (dt, J = 7.9, 1.0 Hz, 1H), 7.32 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 7.30–7.21 (m, 
4H), 7.17 (ddd, J = 6.6, 1.6, 0.9 Hz, 2H), 7.15 (dd, J = 5.3, 1.0 Hz, 1H), 6.95 (t, 
J = 8.6 Hz, 2H), 6.89 (ddt, J = 6.2, 1.8, 0.8 Hz, 2H), 5.23 (s, 2H), 5.03 (q, J = 7.4 Hz, 
1H), 1.74 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.2 (CH), 161.6 (d, 
1JC–F = 246.4 Hz, Cq), 153.3 (Cq), 137.0 (Cq), 137.0 (d, 
4JC–F = 3.2 Hz, Cq), 135.7 
(Cq), 128.9 (CH), 128.5 (d, 
3JC–F = 7.8 Hz, CH), 127.7 (CH), 126.0 (Cq), 125.7 (CH), 
123.8 (CH), 123.2 (CH), 121.6 (CH), 115.6 (d, 2JC–F = 21.3 Hz, CH), 114.7 (Cq), 
110.2 (CH), 47.5 (CH2), 34.4 (CH), 20.0 (CH3). 
19F NMR (471 MHz, CDCl3):        
δ = –115.64 (ttd, J = 8.5, 5.3, 1.5 Hz). IR (ATR): 2926, 1644, 1507, 1396, 743, 
695 cm–1. MS (ESI) m/z (relative intensity): 1092 (26), 913 (16), 737 (67) [2M+Na]+, 
380 (38) [M+Na]+, 358 (100) [M+H]+, 214 (9). HR-MS (ESI) m/z calcd for C24H21NOF 
[M+H]+ 358.1602, found 358.1608. [α]D
23: –61.9 (c = 0.99, CHCl3). HPLC 
separation (Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 





The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60h (55 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 9/1→6/1) yielded 62ch (72.4 mg, 
76%) as a yellow solid. M. p. = 55–57 °C. 1H NMR (300 MHz, CDCl3): δ = 10.23 (s, 
1H), 8.44 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.35–7.17 (m, 5H), 7.13 (dt, J = 8.1, 1.0 Hz, 
1H), 7.06 (dd, J = 9.0, 0.9 Hz, 2H), 6.98–6.85 (m, 2H), 6.64 (d, J = 8.8 Hz, 2H), 5.27 
(d, J = 17.3 Hz, 1H), 5.21 (d, J = 17.3 Hz, 1H), 4.95 (q, J = 7.4 Hz, 1H), 2.92 (s, 6H), 
1.70 (d, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 185.6 (CH), 155.0 (Cq), 
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149.4 (Cq), 137.1 (Cq), 136.2 (Cq), 128.8 (CH), 128.7 (Cq), 127.6 (CH), 127.5 (CH), 
126.0 (Cq), 125.8 (CH), 123.5 (CH), 123.0 (CH), 121.8 (CH), 114.8 (Cq), 112.8 (CH), 
110.1 (CH), 47.5 (CH2), 40.5 (CH3), 34.2 (CH), 20.0 (CH3). IR (ATR): 2924, 1643, 
1519, 1453, 1395, 746 cm–1. MS (EI) m/z (relative intensity): 382 (100) [M]+, 365 
(48), 291 (34), 261 (73), 247 (36), 210 (48), 91 (69). HR-MS (EI) m/z calcd for 
C26H26N2O [M]
+ 382.2045, found 382.2041. [α]D
23: –55.2 (c = 1.31, CHCl3). HPLC 
separation (Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 





The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60i (56 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→5/1) yielded 62ci (75.4 mg, 
79%) as a yellow solid. M. p. = 62–63 °C. 1H NMR (300 MHz, CDCl3): δ = 10.24 (s, 
1H), 8.42 (ddd, J = 7.8, 1.4, 0.7 Hz, 1H), 7.35–7.29 (m, 1H), 7.29–7.19 (m, 4H), 7.15 
(dt, J = 7.6, 0.7 Hz, 1H), 6.94–6.85 (m, 2H), 6.74–6.60 (m, 3H), 5.90 (ddd, J = 7.2, 
1.4, 0.5 Hz, 2H), 5.26 (s, 2H), 4.97 (q, J = 7.4 Hz, 1H), 1.70 (d, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 185.1 (CH), 153.6 (Cq), 148.0 (Cq), 146.4 (Cq), 
137.0 (Cq), 135.8 (Cq), 135.0 (Cq), 128.8 (CH), 127.5 (CH), 125.9 (Cq), 125.7 (CH), 
123.7 (CH), 123.1 (CH), 121.6 (CH), 119.8 (CH), 114.7 (Cq), 110.1 (CH), 108.2 (CH), 
107.9 (CH), 101.1 (CH2), 47.6 (CH2), 34.8 (CH), 20.1 (CH3). IR (ATR): 2926, 1644, 
1486, 1233, 1035, 745 cm–1. MS (ESI) m/z (relative intensity): 767 (11) [2M+H]+, 489 
(9), 384 (100) [M+H]+, 269 (6). HR-MS (ESI) m/z calcd for C25H22NO3 [M+H]
+ 
384.1594, found 384.1593. [α]D
23: –45.7 (c = 1.49, CHCl3). HPLC separation 
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(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60j (62 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 8/1→5/1) yielded 62cj (55.9 mg, 
56%) as a yellow solid. M. p. = 57–58 °C. 1H NMR (300 MHz, CDCl3): δ = 10.23 (s, 
1H), 8.43 (ddd, J = 7.8, 1.4, 0.8 Hz, 1H), 7.32 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 7.28–
7.20 (m, 4H), 7.16 (d, J = 7.9 Hz, 1H), 6.90 (ddt, J = 5.9, 2.5, 0.8 Hz, 2H), 6.80 (ddd, 
J = 8.3, 1.9, 0.8 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.60 (d, J = 1.8 Hz, 1H), 5.26 (s, 
2H), 5.00 (q, J = 7.3 Hz, 1H), 3.84 (s, 3H), 3.70 (s, 3H), 1.73 (d, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 185.2 (CH), 153.9 (Cq), 149.1 (Cq), 148.0 (Cq), 
137.0 (Cq), 135.9 (Cq), 133.6 (Cq), 128.7 (CH), 127.6 (CH), 125.9 (Cq), 125.7 (CH), 
123.6 (CH), 123.1 (CH), 121.7 (CH), 118.8 (CH), 114.7 (Cq), 111.2 (CH), 110.8 (CH), 
110.1 (CH), 55.9 (CH3), 55.9 (CH3), 47.5 (CH2), 34.8 (CH), 20.2 (CH3). IR (ATR): 
2930, 1644, 1513, 1453, 1237, 1144, 1024, 745 cm–1. MS (ESI) m/z (relative 
intensity): 1220 (8) [3M+Na]+, 821 (20) [2M+Na]+, 799 (16) [2M+H]+, 422 (20) 
[M+Na]+, 400 (100) [M+H]+, 293 (10). HR-MS (ESI) m/z calcd for C26H26NO3 [M+H]
+ 
400.1907, found 400.1903. [α]D
23: –63.5 (c = 0.94, CHCl3). HPLC separation 
(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): 
tr (major) = 10.4 min, tr (minor) = 12.3 min, 90:10 e.r. 
 
 




The general procedure GP6 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and styrene 60k (50 mg, 0.38 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 17/1→12/1) yielded 62ck (37.7 mg, 
41%) as a light yellow oil. 1H NMR (500 MHz, CDCl3): δ = 10.20 (s, 1H), 8.41 (dt, 
J = 7.9, 1.0 Hz, 1H), 7.31 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.25 (d, J = 7.9 Hz, 1H), 
7.24–7.20 (m, 4H), 7.18 (dt, J = 8.2, 1.0 Hz, 1H), 6.99 (dd, J = 7.9, 1.9 Hz, 1H), 
6.88–6.76 (m, 3H), 5.25 (s, 2H), 4.94 (q, J = 7.3 Hz, 1H), 2.25 (s, 3H), 1.95 (s, 3H), 
1.70 (d, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.7 (CH), 153.3 (Cq), 
137.0 (Cq), 136.9 (Cq), 136.4 (Cq), 136.2 (Cq), 135.7 (Cq), 131.9 (CH), 128.7 (CH), 
127.5 (CH), 127.0 (CH), 126.3 (CH), 126.1 (Cq), 125.8 (CH), 123.6 (CH), 123.1 (CH), 
121.6 (CH), 114.8 (Cq), 110.0 (CH), 47.2 (CH2), 34.2 (CH), 20.9 (CH3), 20.8 (CH3), 
19.7 (CH3). IR (ATR): 2921, 1643, 1453, 1395, 1039, 743 cm
–1. MS (ESI) m/z 
(relative intensity): 757 (31) [2M+Na]+, 473 (19), 390 (24) [M+Na]+, 368 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C26H26NO [M+H]
+ 368.2009, found 368.2006. 
[α]D
23: –66.8 (c = 0.52, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 
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The general procedure GP5 was followed using indole 59c (85 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 12/1→9/1) yielded 192ca 
(76.9 mg, 69%) as an orange solid. M. p. = 61–63 °C. 1H NMR (300 MHz, CDCl3): 
δ = 10.17 (s, 1H), 8.37 (d, J = 7.6 Hz, 1H), 7.38–7.27 (m, 4H), 7.26–7.18 (m, 1H), 
7.16 (d, J = 8.0 Hz, 1H), 7.02–6.92 (m, 2H), 5.39 (d, J = 17.3 Hz, 1H), 5.29 (d, 
J = 17.1 Hz, 1H), 4.93 (brs, 1H), 4.36 (dt, J = 2.7, 1.4, Hz, 1H), 4.27–4.10 (m, 1H), 
4.09–4.04 (m, 6H), 3.84 (s, 1H), 1.68 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 185.3 (CH), 154.8 (Cq), 136.8 (Cq), 136.3 (Cq), 128.9 (CH), 127.8 (CH), 
125.9 (CH), 125.9 (Cq), 123.5 (CH), 123.1 (CH), 121.7 (CH), 113.7 (Cq), 109.9 (CH), 
90.0 (Cq), 69.0 (CH), 68.7 (CH), 68.7 (CH), 67.0 (CH), 66.6 (CH), 47.4 (CH2), 31.5 
(CH), 20.1 (CH3). IR (ATR): 2926, 1643, 1422, 1398, 813, 744, 480 cm
–1. MS (EI) 
m/z (relative intensity): 447 (100) [M]+, 382 (64), 381 (75), 290 (50), 262 (45). 
HR-MS (EI) m/z calcd for C28H25FeNO [M]
+ 447.1286, found 447.1263. [α]D
23: 
+220.0 (c = 1.19, CHCl3). HPLC separation (Chiralpak
® IF-3, n-hexane/iPrOH 
80:20, 0.75 mL/min, detection at 250 nm): tr (minor) = 18.3 min, tr (major) = 21.6 min, 
4:96 e.r. 
192ca (190 mg, 0.42 mmol, 96:4 e.r.) was recrystallized from n-hexane/CH2Cl2 to 
furnish the optically pure product (116 mg, 0.26 mmol, 61%) as a dark yellow solid. 
[α]D
23: +347.8 (c = 1.17, CHCl3). HPLC separation (Chiralpak
® IF-3, 
n-hexane/iPrOH 80:20, 0.75 mL/min, detection at 273 nm): tr (minor) = 18.7 min, 
tr (major) = 22.1 min, 0.3:99.7 e.r. Crystals suitable for X-ray crystallography were 










The general procedure GP5 was followed using indole 59d (93 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 10/1→7.5/1) yielded 192da 
(75.8 mg, 64%) as an orange solid. M. p. = 67–69 °C. 1H NMR (400 MHz, CDCl3): 
δ = 10.17 (s, 1H), 8.36 (dt, J = 7.9, 1.1 Hz, 1H), 7.32–7.21 (m, 1H), 7.24–7.18 (m, 
1H), 7.16 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 5.32 
(d, J = 16.8 Hz, 1H), 5.24 (d, J = 16.8 Hz, 1H), 4.94 (brs, 1H), 4.36 (dt, J = 2.6, 
1.3 Hz, 1H), 4.11–4.04 (m, 7H), 3.86 (s, 1H), 3.79 (s, 3H), 1.67 (d, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ = 185.2 (CH), 159.1 (Cq), 154.8 (Cq), 136.8 (Cq), 
128.2 (Cq), 127.1 (CH), 125.9 (Cq), 123.4 (CH), 123.0 (CH), 121.7 (CH), 114.3 (CH), 
113.6 (Cq), 110.0 (CH), 90.2 (Cq), 69.0 (CH), 68.7 (CH), 68.7 (CH), 67.1 (CH), 66.7 
(CH), 55.3 (CH3), 47.0 (CH2), 31.5 (CH), 20.1 (CH3). IR (ATR): 2961, 2929, 1642, 
1510, 1245, 1026, 814, 742 cm–1. MS (ESI) m/z (relative intensity): 577 (60), 572 
(62), 535 (45), 500 (94) [M+Na]+, 478 (100) [M+H]+, 460 (32). HR-MS (ESI) m/z 
calcd for C29H28FeNO2 [M+H]
+ 478.1464, found 478.1444. [α]D
23: +152.1 (c = 1.33, 
CHCl3). HPLC separation (Chiralpak
® IF-3, n-hexane/iPrOH 80:20, 0.75 mL/min, 









The general procedure GP5 was followed using indole 59e (90 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 13/1→7.5/1) yielded 192ea 
(83.2 mg, 72%) as an orange solid. M. p. = 64–66 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.22 (s, 1H), 8.36 (dt, J = 7.9, 1.0 Hz, 1H), 7.28 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 
7.21 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 6.98 (t, J = 8.6 Hz, 2H), 
6.91–6.86 (m, 2H), 5.33 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 16.9 Hz, 1H), 4.99 (brs, 
1H), 4.35 (dt, J = 2.6, 1.4 Hz, 1H), 4.09 (s, 5H), 4.08 (ddd, J = 2.5, 1.3, 1.3 Hz, 1H), 
4.06 (ddd, J = 2.5, 1.3, 1.3 Hz, 1H), 3.87 (s, 1H), 1.66 (d, J = 7.4 Hz, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 185.1 (CH), 162.1 (d, 
1JC–F = 246.8 Hz, Cq), 154.4 (Cq), 136.7 
(Cq), 131.9 (d, 
4JC–F = 3.1 Hz, Cq), 127.5 (d, 
3JC–F = 8.2 Hz, CH), 125.9 (Cq), 123.6 
(CH), 123.1 (CH), 121.7 (CH), 115.8 (d, 2JC–F = 21.6 Hz, CH), 113.7 (Cq), 109.9 
(CH), 89.8 (Cq), 69.0 (CH), 68.8 (CH), 68.7 (CH), 67.1 (CH), 66.6 (CH), 46.9 (CH2), 
31.4 (CH), 19.9 (CH3). 
19F NMR (471 MHz, CDCl3): δ = –114.36 (s). IR (ATR): 2904, 
1643, 1509, 1222, 1039, 819, 743 cm–1. MS (EI) m/z (relative intensity): 465 (100) 
[M]+, 400 (61), 399 (86), 290 (38), 109 (50). HR-MS (ESI) m/z calcd for 
C28H25FFeNO [M+H]
+ 466.1264, found 466.1257. [α]D
23: +175.8 (c = 1.45, CHCl3). 
HPLC separation (Chiralpak® IF-3, n-hexane/iPrOH 80:20, 0.75 mL/min, detection 








The general procedure GP5 was followed using indole 59f (89 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 15/1→10/1) yielded 192fa 
(64.6 mg, 56%) as an orange solid. Using 177: 65.4 mg (57%), 7:93 e.r. M. p. = 62–
63 °C. 1H NMR (300 MHz, CDCl3): δ = 10.20 (s, 1H), 8.40–8.32 (m, 1H), 7.38–7.27 
(m, 6H), 7.13 (d, J = 6.3 Hz, 2H), 5.03 (brs, 1H), 4.46 (dt, J = 2.6, 1.3 Hz, 1H), 4.41–
4.18 (m, 8H), 4.17 (ddd, J = 2.4, 1.2, 1.2 Hz, 1H), 4.10–4.05 (m, 1H), 2.95 (td, 
J = 12.0, 10.3, 5.3 Hz, 1H), 2.58 (brs, 1H), 1.73 (d, J = 7.4 Hz, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 184.6 (CH), 153.6 (Cq), 137.6 (Cq), 136.0 (Cq), 128.7 (CH), 
128.6 (CH), 126.9 (CH), 126.1 (Cq), 123.3 (CH), 122.9 (CH), 121.6 (CH), 113.2 (Cq), 
109.7 (CH), 90.0 (Cq), 69.1 (CH), 69.1 (CH), 68.9 (CH), 67.3 (CH), 66.9 (CH), 46.1 
(CH2), 35.3 (CH2), 31.2 (CH), 19.5 (CH3). IR (ATR): 2932, 1636, 1423, 1038, 809, 
740, 695 cm–1. MS (ESI) m/z (relative intensity): 484 (94) [M+Na]+, 462 (100) 
[M+H]+, 444 (72). HR-MS (ESI) m/z calcd for C29H28FeNO [M+H]
+ 462.1515, found 
462.1507. [α]D
23: +185.3 (c = 1.16, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (minor) = 8.0 min, 
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The general procedure GP5 was followed using indole 59g (74 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 9/1→7/1) yielded 192ga 
(52.2 mg, 52%) as an orange oil. 1H NMR (300 MHz, CDCl3): δ = 10.25 (s, 1H), 
8.37–8.27 (m, 1H), 7.48–7.36 (m, 1H), 7.34–7.23 (m, 2H), 5.40 (s, 2H), 5.06 (q, 
J = 7.3 Hz, 1H), 4.47 (dt, J = 2.7, 1.3 Hz, 1H), 4.25–4.17 (m, 5H), 4.16 (td, J = 2.4, 
1.2 Hz, 1H), 4.13 (td, J = 2.4, 1.3 Hz, 1H), 4.07 (dt, J = 2.6, 1.3 Hz, 1H), 3.23 (s, 3H), 
1.82 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.3 (CH), 154.7 (Cq), 
136.8 (Cq), 125.7 (Cq), 123.6 (CH), 123.1 (CH), 121.6 (CH), 114.3 (Cq), 109.8 (CH), 
90.2 (Cq), 74.3 (CH2), 69.1 (CH), 68.8 (CH), 68.8 (CH), 67.1 (CH), 66.8 (CH), 56.1 
(CH3), 31.4 (CH), 20.5 (CH3). IR (ATR): 2902, 1647, 1386, 1038, 817, 749 cm
–1. 
MS (ESI) m/z (relative intensity): 825 (44) [2M+Na]+, 424 (75) [M+Na]+, 402 (24) 
[M+H]+, 384 (14), 213 (100). HR-MS (ESI) m/z calcd for C23H24FeNO2 [M+H]
+ 
402.1151, found 402.1162. [α]D
23: +206.3 (c = 0.79, CHCl3). HPLC separation 
(Chiralpak® ID-3, n-hexane/iPrOH 70:30, 1.0 mL/min, detection at 273 nm): 




The general procedure GP5 was followed using indole 59h (79 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 10/1) yielded 192ha 
(53.7 mg, 51%) as an orange solid. M. p. = 62–64 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.26 (s, 1H), 8.34–8.29 (m, 1H), 7.35–7.27 (m, 3H), 5.40 (t, J = 53.2 Hz, 1H), 
5.13 (s, 1H), 4.53–4.35 (m, 3H), 4.25–4.19 (m, 6H), 4.18 (td, J = 2.5, 1.3 Hz, 1H), 
4.11 (dt, J = 2.6, 1.4 Hz, 1H), 1.80 (d, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3): 
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δ = 185.1 (CH), 154.0 (Cq), 136.8 (Cq), 125.8 (Cq), 123.8 (CH), 123.4 (CH), 121.4 
(CH), 114.1 (Cq), 113.5 (t, 
1JC–F = 245.2 Hz, CH), 109.8 (CH), 89.7 (Cq), 69.2 (CH), 
69.2 (CH), 68.9 (CH), 67.5 (CH), 66.8 (CH), 46.4 (t, 2JC–F = 29.0 Hz, CH2), 31.0 
(CH), 19.7 (CH3). 
19F NMR (471 MHz, CDCl3): δ = –119.18 (d, J = 55.3 Hz). 
IR (ATR): 2903, 1653, 1396, 1042, 1019, 812, 747 cm–1. MS (EI) m/z (relative 
intensity): 421 (100) [M]+, 356 (42), 355 (93), 230 (31), 138 (30), 121 (45). HR-MS 
(ESI) m/z calcd for C23H22F2FeNO [M+H]
+ 422.1014, found 422.1011. [α]D
23: +230.1 
(c = 0.63, CHCl3). HPLC separation (Chiralpak
® IA-3, n-hexane/iPrOH 80:20, 





The general procedure GP5 was followed using indole 59i (84 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 6/1→4/1) yielded 192ia 
(43.2 mg, 39%) as an orange solid. M. p. = 75–77 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.08 (s, 1H), 8.33–8.28 (m, 1H), 7.47–7.39 (m, 1H), 7.29–7.23 (m, 2H), 5.13 (s, 
1H), 4.92 (brs, 1H), 4.44 (dt, J = 2.5, 1.4 Hz, 1H), 4.40 (dd, J = 15.3, 2.9 Hz, 1H), 
4.35 (dd, J = 15.3, 3.9 Hz, 1H), 4.17 (s, 5H), 4.15 (td, J = 2.5, 1.3 Hz, 1H), 4.12 (td, 
J = 2.5, 1.2 Hz, 1H), 4.09 (dt, J = 2.5, 1.3 Hz, 1H), 3.93–3.84 (m, 4H), 1.80 (d, 
J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.9 (CH), 155.8 (Cq), 136.8 (Cq), 
125.8 (Cq), 123.2 (CH), 123.0 (CH), 121.7 (CH), 113.7 (Cq), 110.5 (CH), 102.1 (CH), 
91.0 (Cq), 68.9 (CH), 68.8 (CH), 68.8 (CH), 67.1 (CH), 66.9 (CH), 65.3 (CH2), 65.2 
(CH2), 46.6 (CH2), 31.6 (CH), 20.8 (CH3). IR (ATR): 2917, 1642, 1460, 1041, 817, 
745 cm–1. MS (ESI) m/z (relative intensity): 909 (47) [2M+Na]+, 466 (100) [M+Na]+, 
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444 (39) [M+H]+. HR-MS (ESI) m/z calcd for C25H26FeNO3 [M+H]
+ 444.1257, found 
444.1255. [α]D
23: +176.1 (c = 0.67, CHCl3). HPLC separation (Chiralpak
® IF-3, 
n-hexane/iPrOH 70:30, 1.0 mL/min, detection at 250 nm): tr (minor) = 10.5 min, 




The general procedure GP5 was followed using indole 59b (66 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 11/1→8.5/1) yielded 192ba 
(49.3 mg, 53%) as an orange oil. 1H NMR (300 MHz, CDCl3): δ = 10.25 (s, 1H), 
8.39–8.26 (m, 1H), 7.36–7.18 (m, 3H), 5.17 (q, J = 7.3 Hz, 1H), 4.44 (dtd, J = 2.7, 
1.3, 0.7 Hz, 1H), 4.25–4.17 (m, 5H), 4.18–4.14 (m, 1H), 4.13 (ddd, J = 2.5, 1.3, 
1.3 Hz, 1H), 4.03 (dtd, J = 2.6, 1.4, 0.3 Hz, 1H), 3.56 (s, 3H), 1.77 (d, J = 7.4 Hz, 
3H). 13C NMR (125 MHz, CDCl3): δ = 184.3 (CH), 153.8 (Cq), 137.1 (Cq), 125.7 (Cq), 
123.2 (CH), 122.8 (CH), 121.1 (CH), 113.2 (Cq), 109.1 (CH), 89.6 (Cq), 69.1 (CH), 
68.7 (CH), 68.6 (CH), 67.1 (CH), 66.8 (CH), 31.2 (CH), 31.0 (CH3), 19.0 (CH3). 
IR (ATR): 2903, 1642, 1391, 1039, 815, 746, 479 cm–1. MS (EI) m/z (relative 
intensity): 371 (100) [M]+, 306 (53), 305 (94), 278 (73). HR-MS (EI) m/z calcd for 
C22H21FeNO [M]
+ 371.0973, found 371.0962. [α]D
23: +217.3 (c = 0.85, CHCl3). HPLC 
separation (Chiralpak® IF-3, n-hexane/iPrOH 80:20, 0.75 mL/min, detection at 
250 nm): tr (minor) = 19.0 min, tr (major) = 21.7 min, 6:94 e.r. 
 
 




The general procedure GP5 was followed using indole 59j (93 mg, 0.25mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 10/1→7/1) yielded 192ja 
(91.9 mg, 77%) as an orange solid. M. p. = 77–79 °C. 1H NMR (400 MHz, CDCl3): 
δ = 10.13 (s, 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.37–7.26 (m, 3H), 7.04 (d, J = 8.8 Hz, 
1H), 6.97 (d, J = 6.5 Hz, 2H), 6.84 (dd, J = 8.9, 2.5 Hz, 1H), 5.35 (d, J = 17.2 Hz, 
1H), 5.26 (d, J = 17.1 Hz, 1H), 4.85 (brs, 1H), 4.35 (dt, J = 2.6, 1.3 Hz, 1H), 4.08 (td, 
J = 2.5, 1.3 Hz, 1H), 4.07–4.02 (m, 6H), 3.88 (s, 3H), 3.83 (s, 1H), 1.66 (d, 
J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 185.2 (CH), 156.8 (Cq), 154.8 (Cq), 
136.3 (Cq), 131.6 (Cq), 128.9 (CH), 127.8 (CH), 126.5 (Cq), 125.9 (CH), 113.7 (CH), 
113.6 (Cq), 110.8 (CH), 103.3 (CH), 90.1 (Cq), 68.9 (CH), 68.7 (CH), 68.7 (CH), 67.0 
(CH), 66.6 (CH), 55.8 (CH3), 47.6 (CH2), 31.6 (CH), 20.2 (CH3). IR (ATR): 2930, 
1640, 1453, 1041, 799, 750, 697 cm–1. MS (ESI) m/z (relative intensity): 1932 (17) 
[4M+Na]+, 1454 (51) [3M+Na]+, 977 (100) [2M+Na]+, 500 (97) [M+Na]+, 478 (57) 
[M+H]+. HR-MS (ESI) m/z calcd for C29H28FeNO2 [M+H]
+ 478.1464, found 478.1452. 
[α]D
23: +259.9 (c = 1.75, CHCl3). HPLC separation (Chiralpak
® ID-3, 
n-hexane/iPrOH 70:30, 1.0 mL/min, detection at 273 nm): tr (major) = 19.1 min, 









The general procedure GP5 was followed using indole 59k (90 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 12/1→9.5/1) yielded 192ka 
(48.9 mg, 42%) as an orange solid. M. p. = 62–64 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.11 (s, 1H), 8.04 (dd, J = 9.4, 2.6 Hz, 1H), 7.38–7.27 (m, 3H), 7.09–7.03 (m, 
1H), 6.98–6.89 (m, 3H), 5.36 (d, J = 17.3 Hz, 1H), 5.29 (d, J = 17.0 Hz, 1H), 4.87 
(brs, 1H), 4.35 (dt, J = 2.7, 1.3 Hz, 1H), 4.16-4.02 (m, 7H), 3.85–3.81 (m, 1H), 1.67 
(d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.0 (CH), 160.0 (d,             
1JC–F = 238.6 Hz, Cq), 155.8 (Cq), 136.0 (Cq), 133.2 (Cq), 129.0 (CH), 127.9 (CH), 
126.5 (d, 3JC–F = 11.0 Hz, Cq), 125.8 (CH), 113.7 (d, 
4JC–F = 4.4 Hz, Cq), 111.7 (d, 
2JC–F = 26.2 Hz, CH), 110.8 (d, 
3JC–F = 9.5 Hz, CH), 107.4 (d, 
2JC–F = 25.2 Hz, CH), 
89.8 (Cq), 69.0 (CH), 68.8 (CH), 68.7 (CH), 67.1 (CH), 66.6 (CH), 47.7 (CH2), 31.7 
(CH), 20.1 (CH3). 
19F NMR (471 MHz, CDCl3): δ = –120.36 (td, J = 9.2, 4.2 Hz). 
IR (ATR): 2903, 1645, 1104, 1024, 1001, 797 cm–1. MS (ESI) m/z (relative intensity): 
953 (10) [2M+Na]+, 488 (47) [M+Na]+, 466 (8) [M+H]+, 253 (18), 213 (100). HR-MS 
(ESI) m/z calcd for C28H25FFeNO [M+H]
+ 466.1264, found 466.1257. [α]D
23: +159.4 
(c = 0.45, CHCl3). HPLC separation (Chiralpak
® ID-3, n-hexane/iPrOH 70:30, 










The general procedure GP5 was followed using indole 59l (92 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 12.5/1) yielded 192la 
(57.9 mg, 49%) as an orange solid. M. p. = 54–56 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.14 (s, 1H), 8.36 (dt, J = 7.9, 1.0 Hz, 1H), 7.28 (ddd, J = 7.9, 6.6, 1.5 Hz, 1H), 
7.22 (td, J = 7.4, 6.6, 1.3 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 6.93 (s, 1H), 6.60 (s, 2H), 
5.34 (d, J = 17.2 Hz, 1H), 5.21 (d, J = 16.9 Hz, 1H), 4.88 (brs, 1H), 4.36 (dt, J = 2.6, 
1.4 Hz, 1H), 4.08 (td, J = 2.5, 1.3 Hz, 1H), 4.07–4.01 (m, 6H), 3.84 (s, 1H), 2.26 (s, 
6H), 1.69 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.4 (CH), 155.0 
(Cq), 138.6 (Cq), 136.9 (Cq), 136.3 (Cq), 129.4 (CH), 125.9 (Cq), 123.7 (CH), 123.5 
(CH), 123.0 (CH), 121.7 (CH), 113.6 (Cq), 110.0 (CH), 90.3 (Cq), 68.9 (CH), 68.7 
(CH), 68.7 (CH), 67.0 (CH), 66.7 (CH), 47.4 (CH2), 31.5 (CH), 21.3 (CH3), 20.3 
(CH3). IR (ATR): 2920, 1643, 1459, 1040, 815, 746, 479 cm
–1. MS (ESI) m/z (relative 
intensity): 973 (51) [2M+Na]+, 498 (100) [M+Na]+, 476 (67) [M+H]+, 335 (25), 213 
(80). HR-MS (ESI) m/z calcd for C30H30FeNO [M+H]
+ 476.1672, found 476.1666. 
[α]D
23: +180.7 (c = 1.06, CHCl3). HPLC separation (Chiralpak
® IF-3, 
n-hexane/iPrOH 80:20, 0.75 mL/min, detection at 250 nm): tr (minor) = 17.5 min, 
tr (major) = 22.2 min, 5:95 e.r. 
 
 





The general procedure GP5 was followed using indole 59m (100 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (80 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 12/1→7/1) yielded 192ma 
(87.2 mg, 69%) as an orange solid. M. p. = 79–81 °C. 1H NMR (300 MHz, CDCl3): 
δ = 10.10 (s, 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.07 (d, J = 8.9 Hz, 1H), 6.93 (s, 1H), 
6.84 (dd, J = 8.9, 2.6 Hz, 1H), 6.59 (s, 2H), 5.30 (d, J = 17.0 Hz, 1H), 5.18 (d, 
J = 17.0 Hz, 1H), 4.81 (brs, 1H), 4.37–4.34 (m, 1H), 4.08 (td, J = 2.5, 1.3 Hz, 1H), 
4.24–3.91 (m, 6H), 3.89 (s, 3H), 3.86–3.83 (m, 1H), 2.26 (s, 6H), 1.68 (d, J = 7.4 Hz, 
3H). 13C NMR (125 MHz, CDCl3): δ = 185.1 (CH), 156.7 (Cq), 154.9 (Cq), 138.5 (Cq), 
136.2 (Cq), 131.6 (Cq), 129.3 (CH), 126.5 (Cq), 123.6 (CH), 113.6 (CH), 113.5 (Cq), 
110.8 (CH), 103.3 (CH), 90.3 (Cq), 68.9 (CH), 68.7 (CH), 68.7 (CH), 67.0 (CH), 66.7 
(CH), 55.9 (CH3), 47.6 (CH2), 31.7 (CH), 21.4 (CH3), 20.3 (CH3). IR (ATR): 2914, 
1641, 1457, 1424, 1042, 798, 751 cm–1. MS (ESI) m/z (relative intensity): 661 (13), 
528 (100) [M+Na]+, 506 (58) [M+H]+, 289 (15), 213 (59). HR-MS (ESI) m/z calcd for 
C31H32FeNO2 [M+H]
+ 506.1777, found 506.1775. [α]D
23: +238.9 (c = 1.48, CHCl3). 
HPLC separation (Chiralpak® ID-3, n-hexane/iPrOH 70:30, 1.0 mL/min, detection at 









The general procedure GP5 was followed using azaindole 59n (85 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene (191a) (50 mg, 0.38 mmol, 1.5 equiv). The reaction 
mixture was diluted with sat. aqueous NaHCO3 (10 mL) and extracted with EtOAc 
(3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried 
over Na2SO4, and concentrated under reduced pressure. The residue was purified 
by silica gel chromatography (n-hexane/EtOAc = 10/1 + 0.5% Et3N) to yield 192na 
(72.7 mg, 53%) as an orange solid. M. p. = 63–64 °C. 1H NMR (600 MHz, CDCl3): 
δ = 8.85 (dd, J = 7.8, 1.6 Hz, 1H), 8.48 (s, 1H), 8.35 (dd, J = 4.7, 1.7 Hz, 1H), 7.40–
7.30 (m, 3H), 7.21 (dd, J = 7.8, 4.7 Hz, 1H), 7.11 (d, J = 7.2 Hz, 2H), 6.98 (d, 
J = 8.8 Hz, 2H), 6.85 (d, J = 8.9 Hz, 2H), 6.07 (d, J = 16.3 Hz, 1H), 5.28 (d, 
J = 16.3 Hz, 1H), 4.58 (q, J = 7.3 Hz, 1H), 4.38 (dt, J = 2.6, 1.3 Hz, 1H), 4.12 (td, 
J = 2.5, 1.3 Hz, 1H), 4.06 (td, J = 2.5, 1.3 Hz, 1H), 3.98 (s, 5H), 3.81 (s, 3H), 3.64 
(dd, J = 2.5, 1.3 Hz, 1H), 1.60 (d, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): 
δ = 157.2 (Cq), 153.0 (CH), 150.1 (Cq), 148.2 (Cq), 146.4 (Cq), 143.6 (CH), 137.9 
(Cq), 131.1 (CH), 128.8 (CH), 127.6 (CH), 126.4 (CH), 121.9 (CH), 118.8 (Cq), 118.0 
(CH), 114.1 (CH), 109.5 (Cq), 90.8 (Cq), 68.9 (CH), 68.9 (CH), 68.9 (CH), 66.8 (CH), 
66.7 (CH), 55.5 (CH3), 45.2 (CH2), 32.2 (CH), 20.3 (CH3). IR (ATR): 2934, 1613, 
1498, 1428, 1242, 728 cm–1. MS (ESI) m/z (relative intensity): 554 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C34H32N3OFe [M+H]
+ 554.1890, found 554.1884. 
[α]D
23: +309.1 (c = 1.16, CHCl3). HPLC separation (Chiralpak
® IF-3, 
n-hexane/iPrOH 90:10, 1.0 mL/min, detection at 273 nm): tr (minor) = 11.3 min, 
tr (major) = 11.8 min, 10:90 e.r. 




The general procedure GP5 was followed using indole 59c (93 mg, 0.25 mmol, 
1.0 equiv) and vinylruthenocene (191b) (96 mg, 0.38 mmol, 1.5 equiv). Purification 
by column chromatography on silica gel (n-hexane/EtOAc = 13/1→7.5/1) yielded 
192cb (59.1 mg, 48%) as a dark yellow solid. M. p. = 52–54 °C. 1H NMR (500 MHz, 
CDCl3): δ = 10.28 (s, 1H), 8.39 (dt, J = 7.9, 1.0 Hz, 1H), 7.34–7.25 (m, 4H), 7.22 (td, 
J = 7.6, 1.3 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 6.97 (dd, J = 7.9, 1.7 Hz, 2H), 5.43 (d, 
J = 17.2 Hz, 1H), 5.39 (d, J = 17.1 Hz, 1H), 4.74 (dt, J = 2.4, 1.1 Hz, 1H), 4.61 (brs, 
1H), 4.48 (s, 5H), 4.44 (td, J = 2.3, 1.1 Hz, 1H), 4.42 (td, J = 2.3, 1.1 Hz, 1H), 4.33 
(brs, 1H), 1.56 (d, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.3 (CH), 
154.6 (Cq), 136.8 (Cq), 136.2 (Cq), 128.9 (CH), 127.8 (CH), 125.9 (Cq), 125.8 (CH), 
123.6 (CH), 123.1 (CH), 121.9 (CH), 113.9 (Cq), 110.0 (CH), 94.0 (Cq), 71.2 (CH), 
71.0 (CH), 70.7 (CH), 69.6 (CH), 69.5 (CH), 47.5 (CH2), 31.5 (CH), 20.9 (CH3). 
IR (ATR): 2904, 1643, 1453, 1022, 805, 744 cm–1. MS (EI) m/z (relative intensity): 
493 (39) [M]+ (102Ru), 384 (28), 317 (40), 300 (28), 259 (24), 91 (100). HR-MS (ESI) 
m/z calcd for C28H26NO
102Ru [M+H]+ 494.1060, found 494.1038. [α]D
23: +103.2 
(c = 0.95, CHCl3). HPLC separation (Chiralpak
® IF-3, n-hexane/iPrOH 80:20, 











The general procedure GP6 was followed using indole 59c (93 mg, 0.25 mmol, 
1.0 equiv) and vinylferrocene 191c (106 mg, 0.38 mmol, 1.5 equiv). Purification by 
column chromatography on silica gel (n-hexane/EtOAc = 20/1) yielded 192cc 
(75.0 mg, 58%) as an orange solid. M. p. = 91–94 °C. 1H NMR (500 MHz, CDCl3): 
δ = 10.25 (brs, 1H), 8.37 (d, J = 7.9 Hz, 1H), 7.34–7.21 (m, 4H), 7.18 (t, J = 7.6 Hz, 
1H), 7.14–6.99 (m, 1H), 6.99–6.70 (m, 2H), 5.25 (brs, 3H), 3.81 (s, 1H), 3.63 (td, 
J = 2.4, 1.1 Hz, 1H), 3.59 (td, J = 2.4, 1.1 Hz, 1H), 3.36 (s, 1H), 1.83 (s, 15H), 1.55 
(d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 185.1 (CH), 155.5 (Cq), 136.9 
(Cq), 136.2 (Cq), 128.8 (CH), 127.5 (CH), 125.8 (Cq), 125.6 (CH), 123.4 (CH), 123.0 
(CH), 121.6 (CH), 113.7 (Cq), 110.0 (CH), 88.9 (Cq), 80.0 (Cq), 73.4 (CH), 71.4 (CH), 
71.3 (CH), 68.6 (CH), 47.2 (CH2), 28.8 (CH), 19.4 (CH3), 11.0 (CH3). IR (ATR): 2898, 
1638, 1423, 1028, 819, 729 cm–1. MS (EI) m/z (relative intensity): 517 (100) [M]+, 
382 (32), 381 (39), 290 (23), 262 (19). HR-MS (EI) m/z calcd for C33H35FeNO [M]
+ 
517.2069, found 517.2051. [α]D
23: +287.0 (c = 1.20, CHCl3). HPLC separation 
(Chiralpak® IF-3, n-hexane/iPrOH 90:10, 1.0 mL/min, detection at 250 nm): 
tr (major) = 12.7 min, tr (minor) = 13.5 min, 95:5 e.r. 
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62cc (90 mg, 0.24 mmol, 1.0 equiv, 92:8 e.r.), 4-bromoaniline (46 mg, 0.27 mmol, 
1.1 equiv) and activated 4Å molecular sieves (1.0 g) were suspended in PhMe 
(5.0 mL) and stirred at 50 °C for 16 h. The suspension was allowed to cool to 
ambient temperature, filtered and concentrated under reduced pressure. The 
residue was recrystallized from n-hexane/isopropanol to provide the optically pure 
imine 197 as a white crystalline solid (67 mg, 53%). M. p. = 179−181 °C. 1H NMR 
(300 MHz, CDCl3): δ = 8.66 (ddd, J = 7.8, 1.4, 0.7 Hz, 1H), 8.61 (s, 1H), 7.43 (d, 
J = 8.7 Hz, 2H), 7.29 (ddd, J = 7.8, 6.8, 1.5 Hz, 1H), 7.26–7.19 (m, 4H), 7.17 (ddd, 
J = 8.0, 1.5, 0.8 Hz, 1H), 7.12 (d, J = 8.2 Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 6.94–6.88 
(m, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.27 (s, 2H), 4.85 (q, J = 7.3 Hz, 1H), 3.78 (s, 3H), 
1.67 (d, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 158.3 (Cq), 155.0 (CH), 
152.8 (Cq), 149.8 (Cq), 137.3 (Cq), 136.6 (Cq), 133.9 (Cq), 131.8 (CH), 128.7 (CH), 
128.1 (CH), 127.4 (CH), 126.0 (Cq), 125.8 (CH), 123.2 (CH), 122.6 (CH), 122.5 (CH), 
122.1 (CH), 117.7 (Cq), 114.0 (CH), 111.9 (Cq), 109.8 (CH), 55.4 (CH3), 47.4 (CH2), 
34.5 (CH), 20.0 (CH3). IR (ATR): 2923, 2827, 1604, 1570, 1421, 752, 725 cm
−1. 
MS (ESI) m/z (relative intensity): 525 (100) [M+H]+ (81Br), 523 (100) [M+H]+ (79Br), 
475 (8). HR-MS (ESI) m/z calcd for C31H28N2O
81Br [M+H]+ 525.1361, found 
525.1360. [α]D
23: +60.1 (c = 0.84, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): tr (major) = 5.9 min, 
tr (minor) = 6.7 min, 99.5:0.5 e.r. 
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Crystals suitable for X-ray crystallography were grown by slow evaporation of a 




Following a modified procedure,[337] a 20 mL oven-dried screw cap reaction tube was 
charged with 4Å molecular sieves (60 mg), 62cc (50 mg, 0.135 mmol, 1.0 equiv, 
90:10 e.r.), Pd(OAc)2 (2.5 mg, 11 µmol, 8.0 mol %) and cyclohexane (0.75 mL). The 
tube was tightly closed by screw cap and placed in a pre-heated oil bath at 140 °C. 
The reaction mixture was vigorously stirred for 24 h. The reaction mixture was 
allowed to cool to ambient temperature and filtered through a short plug of Celite®. 
The Celite® was washed with EtOAc. The filtrate was concentrated under reduced 
pressure. Purification of the residue by column chromatography on silica gel 
(n-hexane/EtOAc = 25/1) yielded deformylated product 198 (30.5 mg, 66%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3): δ = 7.68 (ddd, J = 5.9, 3.1, 0.8 Hz, 1H), 
7.26–7.20 (m, 3H), 7.20–7.15 (m, 1H), 7.13 (dd, J = 6.1, 3.1 Hz, 2H), 7.04 (d, 
J = 8.6 Hz, 2H), 6.85 (ddd, J = 6.9, 1.8, 0.8 Hz, 2H), 6.79 (d, J = 8.7 Hz, 2H), 6.62 (t, 
J = 0.9 Hz, 1H), 5.20 (d, J = 17.2 Hz, 1H), 4.96 (d, J = 17.2 Hz, 1H), 4.04 (q, 
J = 7.3 Hz, 1H), 3.78 (s, 3H), 1.64 (d, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): 
δ = 158.1 (Cq), 144.1 (Cq), 138.0 (Cq), 137.6 (Cq), 136.9 (Cq), 128.6 (CH), 128.2 
(CH), 127.8 (Cq), 127.0 (CH), 125.8 (CH), 121.2 (CH), 120.1 (CH), 119.5 (CH), 114.0 
(CH), 109.3 (CH), 99.8 (CH), 55.2 (CH3), 46.3 (CH2), 37.1 (CH), 22.9 (CH3). 
IR (ATR): 2928, 1509, 1452, 1241, 1031, 830, 727 cm–1. MS (EI) m/z (relative 
intensity): 341 (94) [M]+, 326 (100), 91 (70). HR-MS (ESI) m/z calcd for C24H24NO 
[M+H]+ 342.1852, found 342.1851. [α]D
23: +58.3 (c = 0.62, CHCl3). HPLC 
separation (Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 
273 nm): tr (major) = 4.2 min, tr (minor) = 4.8 min, 88:12 e.r. 





Following a modified procedure,[254] a 5 mL round-bottom flask was charged under 
air with 62cc (74 mg, 0.20 mmol, 1.0 equiv, 90:10 e.r.), [RuCl2(p-cymene)]2 (6.1 mg, 
10 µmol, 5.0 mol %), AgSbF6 (13.7 mg, 40 µmol, 20 mol %), Cu(OAc)2·H2O 
(20.0 mg, 0.10 mmol, 0.50 equiv) and 1,2-dichloroethane (2.0 mL). Methyl acrylate 
(0.15 mL, 1.60 mmol, 8.0 equiv) was then added in a single portion. The flask was 
equipped with a condenser and placed in a pre-heated oil bath at 120 °C. The 
reaction mixture was stirred at 120 °C for 16 h. The suspension was allowed to cool 
down to ambient temperature, diluted with n-hexane/EtOAc 1/1 (5 mL), filtered 
through a short plug of silica gel, and eluted with n-hexane/EtOAc 1/1 (3 × 20 mL). 
The filtrate was concentrated under reduced pressure and purified by column 
chromatography on silica gel (n-hexane/EtOAc = 7/1→3/1) to yield 199a (67.3 mg, 
74%) as a yellow foam. M. p. = 65–67 °C. 1H NMR (400 MHz, CDCl3): δ = 10.37 (s, 
1H), 8.99 (d, J = 15.8 Hz, 1H), 7.49 (dt, J = 7.5, 0.9 Hz, 1H), 7.28–7.20 (m, 3H), 7.20 
(ddd, J = 8.1, 7.4, 0.6 Hz, 1H), 7.12 (dd, J = 8.2, 1.0 Hz, 1H), 7.09 (dd, J = 9.0, 
1.0 Hz, 2H), 6.86–6.81 (m, 2H), 6.79 (d, J = 8.8 Hz, 2H), 6.40 (d, J = 15.8 Hz, 1H), 
5.45 (q, J = 7.4 Hz, 1H), 5.24 (d, J = 17.3 Hz, 1H), 5.17 (d, J = 17.3 Hz, 1H), 3.86 (s, 
3H), 3.76 (s, 3H), 1.67 (d, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 185.3 
(CH), 167.4 (Cq), 158.4 (Cq), 155.5 (Cq), 145.6 (CH), 137.9 (Cq), 135.6 (Cq), 132.8 
(Cq), 129.3 (Cq), 128.8 (CH), 127.9 (CH), 127.6 (CH), 125.6 (CH), 124.7 (Cq), 123.5 
(CH), 122.0 (CH), 119.3 (CH), 115.5 (Cq), 114.1 (CH), 112.0 (CH), 55.3 (CH3), 51.7 
(CH3), 47.7 (CH2), 33.7 (CH), 18.7 (CH3). IR (ATR): 2948, 1712, 1654, 1510, 1247, 
1163, 1031, 725 cm–1. MS (EI) m/z (relative intensity): 453 (44) [M]+, 394 (35), 393 
(57), 392 (44), 302 (42), 197 (88), 91 (100). HR-MS (EI) m/z calcd for C29H27NO4 
[M]+ 453.1940, found 453.1931. [α]D
23: –93.8 (c = 0.53, CHCl3). HPLC separation 
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(Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): 





Following a modified procedure,[254] a 5 mL round-bottom flask was charged under 
air with recrystallized 192ca (89 mg, 0.20 mmol, 1.0 equiv, 99.7:0.3 e.r.), 
[RuCl2(p-cymene)]2 (6.1 mg, 10 µmol, 5.0 mol %), AgSbF6 (13.7 mg, 40 µmol, 
20 mol %), Cu(OAc)2·H2O (20 mg, 0.10 mmol, 0.50 equiv) and 1,2-dichloroethane 
(2.0 mL). Methyl acrylate (0.15 mL, 1.60 mmol, 8.0 equiv) was then added in a 
single portion. The flask was equipped with a condenser and placed in a pre-heated 
oil bath at 120 °C. The reaction mixture was stirred at 120 °C for 16 h. The 
suspension was allowed to cool down to ambient temperature, diluted with 
n-hexane/EtOAc 1/1 (5 mL), filtered through a short plug of silica gel, and eluted with 
n-hexane/EtOAc 1/1 (3 × 20 mL). The filtrate was concentrated under reduced 
pressure and purified by column chromatography on silica gel (n-hexane/EtOAc = 
7/1→4.5/1) to yield 199b (67.9 mg, 64%) as an orange solid. M. p. = 79–80 °C. 
1H NMR (300 MHz, CDCl3): δ = 10.36 (s, 1H), 8.98 (d, J = 15.8 Hz, 1H), 7.47 (d, 
J = 7.1 Hz, 1H), 7.36–7.03 (m, 5H), 6.95–6.79 (m, 2H), 6.38 (d, J = 15.8 Hz, 1H), 
5.52–5.19 (m, 3H), 4.33 (dt, J = 2.6, 1.3 Hz, 1H), 4.10 (brs, 5H), 4.06 (td, J = 2.4, 
1.3 Hz, 1H), 4.04 (td, J = 2.4, 1.2 Hz, 1H), 3.93–3.86 (m, 1H), 3.86 (s, 3H), 1.63 (d, 
J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 184.9 (CH), 167.3 (Cq), 145.6 (CH), 
137.7 (Cq), 135.8 (Cq), 129.2 (Cq), 128.8 (CH), 127.6 (CH), 125.7 (CH), 124.6 (Cq), 
123.4 (CH), 121.8 (CH), 119.1 (CH), 114.6 (Cq), 111.8 (CH), 89.8 (Cq), 69.1 (CH), 
68.8 (CH), 68.7 (CH), 67.0 (CH), 66.6 (CH), 51.7 (CH3), 47.7 (CH2), 31.3 (CH), 19.1 
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(CH3). One Cq could not be observed. IR (ATR): 2925, 1712, 1655, 1259, 1164, 
1018, 794, 727 cm–1. MS (ESI) m/z (relative intensity): 1085 (33) [2M+Na]+, 554 
(100) [M+Na]+, 532 (20) [M+H]+, 281 (23), 213 (22). HR-MS (ESI) m/z calcd for 
C32H30FeNO3 [M+H]
+ 532.1570, found 532.1565. [α]D
23: +292.9 (c = 0.59, CHCl3). 
HPLC separation (Chiralpak® IF-3, n-hexane/iPrOH 70:30, 1.0 mL/min, detection at 




A 100 mL two-necked flask was charged with 62cc (50 mg, 0.135 mmol, 1.0 equiv, 
90:10 e.r.), Pd/C 10 wt. % (15 mg, 0.014 mmol, 10 mol %) and EtOH (15 mL). The 
flask was rapidly evacuated and backfilled with H2 3 times. The suspension was then 
vigorously stirred under H2 atmosphere for 16 h at ambient temperature. The 
suspension was diluted with n-hexane (50 mL) and filtered through a short plug of 
Celite®. The Celite® was washed with n-hexane/EtOAc (1/1).The filtrate was 
concentrated under reduced pressure, and the residue purified by column 
chromatography on silica gel (n-hexane/EtOAc = 15/1) to yield 200 (29.3 mg, 61%) 
as a colorless solid. M. p. = 91–93 °C. 1H NMR (300 MHz, CDCl3): δ = 7.66–7.53 (m, 
1H), 7.27–7.16 (m, 3H), 7.15–7.10 (m, 3H), 7.07 (dd, J = 8.9, 0.8 Hz, 2H), 6.90 (ddd, 
J = 6.8, 1.9, 0.9 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 5.20 (d, J = 17.5 Hz, 1H), 5.12 (d, 
J = 17.5 Hz, 1H), 4.44 (q, J = 7.3 Hz, 1H), 3.78 (s, 3H), 2.30 (s, 3H), 1.62 (d, 
J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.8 (Cq), 139.2 (Cq), 138.3 (Cq), 
136.5 (Cq), 135.5 (Cq), 128.9 (Cq), 128.5 (CH), 128.0 (CH), 126.9 (CH), 125.8 (CH), 
121.2 (CH), 118.9 (CH), 118.1 (CH), 113.7 (CH), 109.2 (CH), 107.6 (Cq), 55.3 (CH3), 
46.9 (CH2), 34.9 (CH), 19.9 (CH3), 9.5 (CH3). IR (ATR): 2924, 1508, 1466, 1241, 
1173, 1034, 736 cm–1. MS (EI) m/z (relative intensity): 355 (100) [M]+, 340 (75), 234 
(22), 91 (55). HR-MS (EI) m/z calcd for C25H25NO [M]
+ 355.1936, found 355.1940. 
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[α]D
23: –22.8 (c = 0.532, CHCl3). HPLC separation (Chiralpak
® IA-3, 
n-hexane/iPrOH 99:1, 1.0 mL/min, detection at 273 nm): tr (major) = 6.3 min, 





A solution of 62cc (75 mg, 0.20 mmol, 1.0 equiv, 90:10 e.r.), morpholine (35 mg, 
0.41 mmol, 2.0 equiv), NaBH(OAc)3 (172 mg, 0.81 mmol, 4.0 equiv) and AcOH 
(1 drop) in DCE (2.0 mL) was stirred at ambient temperature for 18 h. The reaction 
mixture was diluted with CH2Cl2 (10 mL), washed with sat. aqueous NaHCO3 
(10 mL), and dried over Na2SO4. After removal of volatiles under reduced pressure, 
the residue was purified by column chromatography on silica gel (n-hexane/EtOAc = 
7.5/1→5.5/1) to yield 201 (73.3 mg, 82%) as a colorless oil. 1H NMR (300 MHz, 
CDCl3): δ = 7.79–7.72 (m, 1H), 7.25–7.17 (m, 3H), 7.17–7.02 (m, 5H), 6.84 (ddt, 
J = 6.2, 2.5, 0.9 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 5.13 (s, 2H), 4.63 (q, J = 7.3 Hz, 
1H), 3.77 (s, 3H), 3.72–3.50 (m, 6H), 2.52–2.40 (m, 4H), 1.63 (d, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 157.9 (Cq), 142.1 (Cq), 137.9 (Cq), 136.4 (Cq), 134.9 
(Cq), 128.9 (Cq), 128.5 (CH), 128.2 (CH), 126.9 (CH), 125.7 (CH), 121.2 (CH), 119.3 
(CH), 118.7 (CH), 113.6 (CH), 109.4 (CH), 108.5 (Cq), 67.3 (CH2), 55.3 (CH3), 53.6 
(CH2), 52.8 (CH2), 47.1 (CH2), 34.6 (CH), 19.1 (CH3). IR (ATR): 2928, 1510, 1453, 
1246, 1114, 1031, 736 cm–1. MS (ESI) m/z (relative intensity): 441 (6) [M+H]+, 392 
(6), 354 (100). HR-MS (ESI) m/z calcd for C29H33N2O2 [M+H]
+ 441.2537, found 
441.2538. [α]D
23: –41.1 (c = 0.50, CHCl3). HPLC separation (Chiralpak
® IF-3, 
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n-hexane/iPrOH 90:10, 1.0 mL/min, detection at 273 nm): tr (minor) = 6.8 min, 





Following a modified procedure,[338] 62cc (75 mg, 0.20 mmol, 1.0 equiv, 90:10 e.r.) 
and methyl (triphenylphosphoranylidene)acetate (204 mg, 0.61 mmol, 3.0 equiv) 
were suspended in PhMe (5.0 mL). The resulting mixture was stirred under reflux 
(130 °C) for 16 h. The reaction mixture was allowed to cool down to ambient 
temperature, and diluted with EtOAc (15 mL). The solution was washed with H2O 
(15 mL) and brine (15 mL), dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc = 12/1) to provide 202 (70.0 mg, 81%) as an off-white solid. 
M. p. = 63–64 °C. 1H NMR (400 MHz, CDCl3): δ = 8.09 (d, J = 15.8 Hz, 1H), 7.99 
(ddd, J = 7.7, 1.3, 0.7 Hz, 1H), 7.30–7.17 (m, 5H), 7.17 (ddd, J = 8.2, 7.1, 1.2 Hz, 
1H), 7.13–7.04 (m, 3H), 6.88–6.81 (m, 2H), 6.79 (d, J = 8.8 Hz, 2H), 6.54 (d, 
J = 15.8 Hz, 1H), 5.16 (d, J = 17.4 Hz, 1H), 5.10 (d, J = 17.4 Hz, 1H), 4.82 (q, 
J = 7.4 Hz, 1H), 3.80 (s, 3H), 3.77 (s, 3H), 1.64 (d, J = 7.4 Hz, 3H). 13C NMR 
(100 MHz, CDCl3): δ = 168.8 (Cq), 158.2 (Cq), 147.9 (Cq), 137.9 (CH), 137.8 (Cq), 
136.7 (Cq), 133.5 (Cq), 128.7 (CH), 128.0 (CH), 127.3 (CH), 125.9 (Cq), 125.7 (CH), 
122.8 (CH), 121.6 (CH), 120.5 (CH), 114.0 (CH), 113.0 (CH), 110.4 (CH), 109.8 (Cq), 
55.3 (CH3), 51.3 (CH3), 47.5 (CH2), 34.0 (CH), 19.2 (CH3). IR (ATR): 2963, 1705, 
1611, 1245, 1163, 1028, 726 cm–1. MS (ESI) m/z (relative intensity): 873 (60) 
[2M+Na]+, 448 (100) [M+Na]+, 426 (74) [M+H]+, 117 (91). HR-MS (ESI) m/z calcd for 
C28H28NO3 [M+H]
+ 426.2064, found 426.2077. [α]D
23: –65.5 (c = 0.67, CHCl3). HPLC 
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separation (Chiralpak® IA-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 




A 5 mL round-bottom flask was loaded with 62cc (80 mg, 0.22 mmol, 1.0 equiv, 
90:10 e.r.), ammonium acetate (33 mg, 0.43 mmol, 2.0 equiv) and nitromethane 
(1.5 mL). The resulting solution was stirred at 90 °C for 16 h. The reaction mixture 
was concentrated under reduced pressure, and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc = 12/1) to provide 237 (74.8 mg, 
84%) as a bright yellow solid. M. p. = 45–47 °C. 1H NMR (400 MHz, CDCl3): δ = 8.43 
(d, J = 13.3 Hz, 1H), 7.85 (d, J = 13.2 Hz, 1H), 7.81 (dt, J = 8.0, 1.1 Hz, 1H), 7.33 
(ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.29–7.22 (m, 4H), 7.18 (dt, J = 8.0, 1.0 Hz, 1H), 7.07 
(dd, J = 9.0, 0.9 Hz, 2H), 6.91–6.86 (m, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.25 (d, 
J = 17.4 Hz, 1H), 5.20 (d, J = 17.4 Hz, 1H), 4.80 (q, J = 7.4 Hz, 1H), 3.78 (s, 3H), 
1.68 (d, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 158.5 (Cq), 152.2 (Cq), 
138.0 (Cq), 135.9 (Cq), 132.8 (CH), 132.6 (Cq), 132.2 (CH), 128.9 (CH), 128.0 (CH), 
127.7 (CH), 125.7 (CH), 125.3 (Cq), 123.7 (CH), 122.8 (CH), 120.6 (CH), 114.3 (CH), 
111.0 (CH), 106.2 (Cq), 55.3 (CH3), 47.8 (CH2), 34.3 (CH), 19.4 (CH3). IR (ATR): 
2965, 1606, 1510, 1245, 1176, 961, 733 cm–1. MS (ESI) m/z (relative intensity): 847 
(31) [2M+Na]+, 435 (88) [M+Na]+, 413 (53) [M+H]+, 177 (32), 117 (100). HR-MS 
(ESI) m/z calcd for C26H25N2O3 [M+H]
+ 413.1860, found 413.1873. [α]D
23: –77.6 
(c = 0.63, CHCl3). HPLC separation (Chiralpak
® IF-3, n-hexane/iPrOH 90:10, 
1.0 mL/min, detection at 273 nm): tr (minor) = 12.4 min, tr (major) = 13.2 min, 
11:89 e.r. 




A 5 mL round-bottom flask was charged with 237 (40 mg, 0.097 mmol, 1.0 equiv, 
89:11 e.r.). THF (3.0 mL) was then added, followed by LiAlH4 (11 mg, 0.29 mmol, 
3.0 equiv). The resulting suspension was refluxed at 85 °C for 2.5 h. The reaction 
mixture was cooled to 0 °C with an ice bath, and methanol was carefully added 
dropwise. The mixture was then poured into sat. aqueous NaHCO3 (10 mL) and 
extracted with EtOAc (3 × 10 mL). The combined organic layer was washed with 
brine (15 mL), dried over Na2SO4, and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel 
(CH2Cl2/MeOH = 10/1 + 0.5% Et3N) to yield tryptamine 238 (28.3 mg, 76%) as a 
colorless solid. M. p. = 71–72 °C. 1H NMR (400 MHz, CDCl3): δ = 7.72–7.65 (m, 1H), 
7.25–7.15 (m, 3H), 7.11–7.06 (m, 3H), 7.03 (d, J = 8.6 Hz, 2H), 6.87 (dd, J = 7.8, 
1.5 Hz, 2H), 6.76 (d, J = 8.7 Hz, 2H), 6.02 (brs, 2H), 5.13 (s, 2H), 4.51 (q, J = 7.3 Hz, 
1H), 3.71 (s, 3H), 3.18–3.09 (m, 2H), 3.08–3.00 (m, 1H), 2.90 (dt, J = 12.2, 7.7 Hz, 
1H), 1.59 (d, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 158.0 (Cq), 140.9 
(Cq), 137.9 (Cq), 136.8 (Cq), 134.7 (Cq), 128.6 (CH), 128.1 (CH), 128.0 (Cq), 127.0 
(CH), 125.8 (CH), 121.6 (CH), 119.6 (CH), 118.3 (CH), 113.9 (CH), 109.6 (CH), 
107.7 (Cq), 55.2 (CH3), 47.2 (CH2), 41.4 (CH2), 34.2 (CH), 25.3 (CH2), 19.6 (CH3). 
IR (ATR): 2927, 1510, 1466, 1244, 1177, 1030, 736 cm–1. MS (ESI) m/z (relative 
intensity): 769 (6) [2M+H]+, 385 (100) [M+H]+, 368 (20), 251 (16), 135 (37). HR-MS 
(ESI) m/z calcd for C26H29N2O [M+H]
+ 385.2274, found 385.2288. 
The two enantiomers could at this stage not be separated by chiral HPLC (vide 
infra). 
 





To a solution of tryptamine 238 (21.0 mg, 0.055 mmol, 1.0 equiv) in 1,4-dioxane 
(1.0 mL) were added Et3N (17 mg, 0.16 mmol, 3.0 equiv) and Boc2O (18 mg, 
0.080 mmol, 1.5 equiv). The resulting solution was stirred at ambient temperature for 
16 h. The reaction mixture was then concentrated under reduced pressure and the 
residue purified by column chromatography on silica gel (n-hexane/EtOAc = 8/1) to 
provide 203 (24.9 mg, 94%) as a colorless solid. M. p. = 57–59 °C. 1H NMR 
(500 MHz, CDCl3): δ = 7.63 (dd, J = 6.2, 2.8 Hz, 1H), 7.25–7.15 (m, 3H), 7.15–7.05 
(m, 3H), 7.05 (dd, J = 8.9, 0.8 Hz, 2H), 6.85 (dd, J = 7.7, 1.5 Hz, 2H), 6.77 (d, 
J = 8.7 Hz, 2H), 5.11 (s, 2H), 4.61–4.54 (m, 1H), 4.51 (q, J = 7.3 Hz, 1H), 3.77 (s, 
3H), 3.41–3.23 (m, 2H), 2.95 (t, J = 7.0 Hz, 2H), 1.59 (d, J = 7.4 Hz, 3H), 1.41 (s, 
9H). 13C NMR (125 MHz, CDCl3): δ = 158.0 (Cq), 155.8 (Cq), 140.6 (Cq), 138.0 (Cq), 
136.8 (Cq), 134.9 (Cq), 128.5 (CH), 128.2 (Cq), 128.0 (CH), 127.0 (CH), 125.8 (CH), 
121.4 (CH), 119.3 (CH), 118.5 (CH), 113.8 (CH), 109.6 (CH), 109.3 (Cq), 78.9 (Cq), 
55.2 (CH3), 47.2 (CH2), 41.3 (CH2), 34.1 (CH), 28.4 (CH3), 25.3 (CH2), 19.6 (CH3). 
IR (ATR): 2927, 1698, 1509, 1466, 1245, 1172, 734 cm–1. MS (EI) m/z (relative 
intensity): 354 (100) [M]+, 248 (19), 91 (89). HR-MS (EI) m/z calcd for C31H36N2O3 
[M]+ 484.2726, found 484.2730. [α]D
23: –53.5 (c = 0.23, CHCl3). HPLC separation 
(Chiralpak® IB-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): 
tr (minor) = 6.2 min, tr (major) = 6.7 min, 12:88 e.r. 
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5.5.3. Mechanistic Studies 
 
Deuterium-Labeling Experiments 
With 4-methoxystyrene (60c): 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate [D]1-59b 
(66 mg, 0.25 mmol, 1.0 equiv), [Fe(acac)3] (8.8 mg, 0.025 mmol, 10 mol %) and 180 
(38 mg, 0.050 mmol, 20 mol %). The Schlenk tube was closed with a rubber septum, 
then evacuated and backfilled with N2 3 times. THF (0.50 mL), TMEDA (58 mg, 
0.50 mmol, 2.0 equiv) and 4-methoxystyrene (60c) (50 mg, 0.38 mmol, 1.5 equiv) 
were added via syringe. CyMgCl (0.22 mL, 0.275 mmol, 1.1 equiv, 1.23 M in THF) 
was then added dropwise at ambient temperature. The resulting mixture was stirred 
at 45 °C for 16 h. The reaction mixture was allowed to cool to ambient temperature 
and diluted with THF (1.5 mL). HCl (3.0 M, 2.0 mL) was added in a single portion, 
and the resulting mixture was stirred at ambient temperature for 2 h. The mixture 
was poured into sat. aqueous NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). 
The combined organic layers were washed with brine (10 mL), dried over Na2SO4, 
and concentrated under reduced pressure. The yields of recovered starting materials 
and hydroarylation product were determined by 1H NMR analysis of the crude 
mixture using 1,1,2,2-tetrachloroethane as an internal standard. The crude mixture 
was purified by silica gel chromatography (n-hexane/EtOAc 10/1→2/1) to afford the 
product and hydrolyzed starting material. Deuterium contents were determined by 
1H NMR spectroscopic analysis. 
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In contrast to the work of Yoshikai,[148] no deuterium incorporation was observed at 
the methine position. 
 




The same procedure as described above was followed, conducting the reaction for 
5.0 min. 
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With Vinylferrocene (191a): 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate [D]1-59b 
(66 mg, 0.25 mmol, 1.0 equiv), [Fe(acac)3] (8.8 mg, 0.025 mmol, 10 mol %), 180 
(38 mg, 0.050 mmol, 20 mol %) and vinylferrocene (191a) (80 mg, 0.38 mmol, 
1.5 equiv). The Schlenk tube was closed with a rubber septum, then evacuated and 
backfilled with N2 3 times. THF (0.50 mL) and TMEDA (58 mg, 0.50 mmol, 2.0 equiv) 
were added via syringe. CyMgCl (0.28 mL, 0.275 mmol, 1.1 equiv, 1.0 M in THF) 
was then added dropwise at ambient temperature. The resulting mixture was stirred 
at 45 °C for 16 h. The reaction mixture was allowed to cool to ambient temperature 
and diluted with THF (1.5 mL). HCl (3.0 M, 2.0 mL) was added in a single portion, 
and the resulting mixture was stirred at ambient temperature for 2 h. The mixture 
was poured into sat. aqueous NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). 
The combined organic layers were washed with brine (10 mL), dried over Na2SO4, 
and concentrated under reduced pressure. The yields of recovered starting materials 
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and hydroarylation product were determined by 1H NMR analysis of the crude 
mixture using 1,1,2,2-tetrachloroethane as an internal standard. The crude mixture 
was purified by silica gel chromatography (n-hexane/EtOAc 25/1→2/1) to afford the 
product and hydrolyzed starting material. Deuterium contents were determined by 














In an oven-dried 25 mL Schlenk tube were placed indole substrates [D]1-59b 
(66 mg, 0.25 mmol, 0.50 equiv) and 59f (89 mg, 0.25 mmol, 0.50 equiv), Fe(acac)3 
(17.6 mg, 0.050 mmol, 10 mol %) and 180 (76 mg, 0.10 mmol, 20 mol %). The 
Schlenk tube was closed with a rubber septum, then evacuated and backfilled with 
nitrogen 3 times. THF (1.0 mL), TMEDA (116 mg, 1.0 mmol, 2.0 equiv) and styrene 
60c (100 mg, 0.75 mmol, 1.5 equiv) were added via syringe. CyMgCl (0.59 mL, 
0.55 mmol, 1.1 equiv, 0.93 M in THF) was then added dropwise at ambient 
temperature. The resulting mixture was stirred at 45 °C for 16 h. The reaction 
mixture was allowed to cool to ambient temperature and diluted with THF (3.0 mL). 
HCl (3.0 M, 4.0 mL) was added in a single portion, and the resulting mixture was 
stirred at ambient temperature for 2 h. The mixture was poured into sat. aqueous 
NH4Cl (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers 
were washed with brine (20 mL), dried over Na2SO4, and concentrated under 
reduced pressure. The residue was purified by silica gel chromatography 
(n-hexane/EtOAc = 9/1 5/1) to afford [D]n-62bc (67.5 mg, 92%) and [D]n-62fc 
(75.2 mg, 78%). Deuterium contents were determined by 1H NMR spectroscopic 
analysis. 
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The kinetic isotope effect (KIE) was examined by applying the initial rate method. In 
an oven-dried 25 mL Schlenk tube were placed the indole substrates 59b or 
[D]1-59b (198 or 199 mg, 0.75 mmol, 1.0 equiv), Fe(acac)3 (26.4 mg, 0.075 mmol, 
10 mol %) and 180 (114 mg, 0.15 mmol, 20 mol %). The Schlenk tubes were closed 
with a rubber septum, then evacuated and backfilled with nitrogen 3 times. 
THF (1.50 mL), TMEDA (174 mg, 1.50 mmol, 2.0 equiv) and 4-methoxystyrene 60c 
(150 mg, 1.125 mmol, 1.5 equiv) were added via syringe. CyMgCl (0.67 mL, 
0.825 mmol, 1.1 equiv, 1.23 M in THF) was then added dropwise at ambient 
temperature. The Schlenk tubes were placed in a pre-heated oil bath at 45 °C 
(t = 0 min). Aliquots (100 µL) were removed periodically every 5 min via syringe, 
diluted with EtOH (0.50 mL), then with CH2Cl2 (2.5 mL) and filtered through a short 
plug of silica gel. The plug was washed with EtOAc. The combined filtrates were 
concentrated in vacuo. Conversion was determined by 1H NMR using 1,1,2,2-
tetrachloroethane as an internal standard. 
Table 5.2. Kinetic Isotope Effect. 
t/min 152bc / % [D]1-152bc / % 
5 4 6 
10 7 8 
15 9 8 
20 12 10 
25 15 15 
30 17 19 
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Figure 5.1. Kinetic Isotope Effect. 
 
Additionally, KIE studies of the reaction with 4-fluorostyrene (60g) were conducted 
by Dr. D. Zell.[151] 
 
Mercury Drop Test 
In an oven-dried 25 mL Schlenk tube were placed indole 59c (85 mg, 0.25 mmol, 
1.0 equiv), Fe(acac)3 (8.8 mg, 0.025 mmol, 10 mol %) and 180 (38 mg, 0.050 mmol, 
20 mol %). The Schlenk tube was closed with a rubber septum, then evacuated and 
backfilled with nitrogen 3 times. THF (0.50 mL), TMEDA (58 mg, 0.50 mmol, 
2.0 equiv) and vinylarene 60c (0.38 mmol, 1.5 equiv) were added via syringe. 
CyMgCl (0.27 mL, 0.28 mmol, 1.1 equiv, 1.03 M) was then added dropwise at 
ambient temperature. The resulting mixture was stirred at ambient temperature for 
1.0 min. Hg (100 mg, 0.50 mmol, 2.0 equiv) was added via syringe. The reaction 
mixture was then stirred at 45 °C for 16 h. The reaction mixture was allowed to cool 
to ambient temperature and diluted with THF (1.5 mL). HCl (3.0 M, 2.0 mL) was 
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added in a single portion, and the resulting mixture was stirred at ambient 
temperature for 2 h. The mixture was poured into sat. aqueous NH4Cl (10 mL) and 
extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with 
brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The 
residue was purified by silica gel chromatography (n-hexane/EtOAc = 8/1→6/1) to 
afford 62cc (85.7 mg, 93%, 93:7 e.r.). 
 
Non-Linear Effect Studies 
In an oven-dried 25 mL Schlenk tube were placed the indole substrate 59c 
(0.25 mmol, 1.0 equiv), Fe(acac)3 (8.8 mg, 0.025 mmol, 10 mol %) and a mixture of 
180 and ent-180 (total amount: 38 mg, 0.050 mmol, 20 mol %). The Schlenk tube 
was closed with a rubber septum, then evacuated and backfilled with nitrogen 3 
times. THF (0.50 mL), TMEDA (58 mg, 0.50 mmol, 2.0 equiv) and vinylarene 60c 
(0.38 mmol, 1.5 equiv) were added via syringe. CyMgCl (0.28 mmol, 1.1 equiv, 
typically 1.0 M) was then added dropwise at ambient temperature. The resulting 
mixture was stirred at 45 °C for 16 h. The reaction mixture was allowed to cool to 
ambient temperature and diluted with THF (1.5 mL). HCl (3.0 M, 2.0 mL) was added 
in a single portion, and the resulting mixture was stirred at ambient temperature for 
2 h. The mixture was poured into sat. aqueous NH4Cl (10 mL) and extracted with 
EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), 
dried over Na2SO4, and concentrated under reduced pressure. The conversion was 
determined by 1H NMR using 1,1,2,2-tetrachloroethane as an internal standard. 
Enantiomeric excesses were measured by chiral HPLC analysis of the crude product 
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Table 5.3. NLE studies. 
 
Entry ee(180) ee(62cc)[a] Yield[b] 
1 0% 4.2% 88% 
2 20% 20.0% 90% 
3 40% 37.6% 91% 
4 60% 52.8% 88% 
5 80% 71.5% 89% 
6 100% 84.0% 90% 
[a]
 Determined by chiral HPLC analysis of the crude reaction mixture. 
[b]
 Determined by crude 
1




Figure 5.2. Absence of a non-linear effect. 
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Mössbauer Spectroscopy 
Mössbauer sample solutions were prepared by the addition of the Grignard reagent 
(8.0 equiv) to solutions of 57FeCl2 (5.0 mM, 1.0 equiv) and TMEDA (4.0 equiv) in 
THF in a N2-filled glovebox (unless specified otherwise: at –20 °C for CyMgCl, and 
at 23 °C for PhMgCl) and directly transferred into the Mössbauer sample cell before 
immediately freezing in liquid nitrogen (outside of the glovebox). 180 and 59b were 
added before the Grignard reagent.  
After preparation, the spectra were recorded and interpreted by Dr. S. Demeshko 
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Table 5.4. Mössbauer parameters of reactions with CyMgCl. 
Reaction Figure δ [mm s
–1
] ΔEQ [mm s
–1
] Rel. int. [%] Color Assignment 
57
FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) + 

















FeCl2 (5.0 mM) + 



















FeCl2 (5.0 mM) + 























FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) + 
180 (1.0 equiv) + 


































FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) + 




























FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) + 
180 (1.0 equiv) +  
59b (1.0 equiv) + 





























Recorded at 7 K. 
[b]
 Prepared at 23 °C. NHC = C49H54N2. 
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Table 5.5. Mössbauer parameters of reactions with PhMgCl. 
Reaction Figure δ [mm s
–1
] ΔEQ [mm s
–1
] Rel. int. [%] Color Assignment 
57
FeCl2 (5.0 mM) + 
























FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) 
+ 180 (1.0 equiv) + 






























FeCl2 (5.0 mM) + 
TMEDA (4.0 equiv) 
+ 180 (1.0 equiv) +   
59b (1.0 equiv) + 
































Standard sample solutions were prepared by the addition of the Grignard reagent 
(8.0 equiv) to a solution of Fe(acac)3 (1.0 equiv), TMEDA (4.0 equiv) in THF at          
–78 °C, and dilution to 10 mM. 180 and 59b were added before the Grignard 
reagent. 
Samples were prepared and analyzed by Dr. T. Parchomyk and S. Lülf (Koszinowski 
research group). 
 





The amino-tagged NHC precursor 206[278] (3.0 g, 6.65 mmol, 1.0 equiv) was 
dissolved in acetone (25 mL) and NaI (6.0 g, 40 mmol, 6.0 equiv) was added. The 
reaction mixture was stirred at 23 °C for 14 h and then evaporated under reduced 
pressure. The residue was suspended in CH2Cl2, filtered through a short plug of 
Celite® and concentrated to yield the crude imidazolinium iodide quantitatively. 
The imidazolinium iodide (400 mg, 0.81 mmol, 1.0 equiv) was suspended in MeI 
(5.1 mL, 81 mmol, 100 equiv) and stirred at 23 °C for 14 h. Et2O (5.0 mL) was added 
to the reaction mixture. The precipitate was collected by filtration, washed with Et2O 
(10 mL) and dried in vacuo to provide 207 (452 mg, 88%) as a colorless solid. 
M. p. = 308 °C (decomposition). 1H NMR (300 MHz, DMSO-d6): δ = 9.13 (s, 1H), 
7.20–7.13 (m, 2H), 7.12 (app s, 2H), 5.60 (q, J = 10.5 Hz, 1H), 4.92 (t, J = 11.7 Hz, 
1H), 4.56 (t, J = 11.1 Hz, 1H), 4.41 (dd, J = 13.1, 10.1 Hz, 1H), 3.39 (d, J = 13.1 Hz, 
1H), 3.11 (s, 9H), 2.40 (app s, 9H), 2.35–2.24 (m, 9H). 13C NMR (125 MHz, 
DMSO-d6): δ = 161.0 (CH), 140.2 (Cq), 140.2 (Cq), 136.6 (Cq), 135.8 (Cq), 135.7 (Cq), 
135.0 (Cq), 130.3 (CH), 130.2 (Cq), 130.1 (CH), 129.6 (CH), 129.5 (CH), 127.9 (Cq), 
63.7 (CH2), 57.8 (CH), 56.7 (CH2), 52.8 (CH3), 20.7 (CH3), 20.6 (CH3), 18.3 (CH3), 
18.0 (CH3), 17.5 (CH3), 17.4 (CH3). IR (ATR): 2995, 1628, 1482, 1461, 1262, 1021, 
871, 815 cm–1. MS (ESI) m/z (relative intensity): 190 (100) [2M-2I]2+. HR-MS (ESI) 
m/z calcd for C25H37N3 [2M-2I]
2+ 189.6488, found 189.6491. 
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5.6. Asymmetric Nickel-Catalyzed Hydroarylations by C–H Activation 
 
5.6.1. Experimental Procedures and Analytical Data for the Intermolecular 




The general procedure GP9 was followed using 180 (38 mg, 50 µmol, 10 mol %). 
Purification by column chromatography on silica gel (n-hexane/EtOAc = 4.5/1→3/1) 
yielded 106bc (91.5 mg, 53%) as a thick colorless oil. 1H NMR (400 MHz, CDCl3): 
δ = 7.89 (dt, J = 8.1, 0.9 Hz, 1H), 7.29–7.22 (m, 4H), 7.20 (td, J = 8.0, 1.2 Hz, 1H), 
7.17–7.14 (m, 1H), 7.10 (d, J = 8.7 Hz, 2H), 6.93–6.85 (m, 2H), 6.78 (d, J = 8.7 Hz, 
2H), 5.19 (d, J = 16.8 Hz, 1H), 5.03 (d, J = 16.9 Hz, 1H), 4.16 (q, J = 7.0 Hz, 1H), 
3.76 (s, 3H), 1.79 (d, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 158.5 (Cq), 
157.2 (Cq), 142.6 (Cq), 136.1 (Cq), 135.9 (Cq), 135.1 (Cq), 128.9 (CH), 128.4 (CH), 
127.7 (CH), 126.2 (CH), 122.6 (CH), 122.0 (CH), 119.8 (CH), 114.4 (CH), 109.6 
(CH), 55.4 (CH3), 46.9 (CH2), 38.3 (CH), 22.3 (CH3). IR (ATR): 2929, 1509, 1453, 
1241, 1176, 1030, 831, 727 cm–1. MS (ESI) m/z (relative intensity): 365 (33) 
[M+Na]+, 343 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H23N2O [M+H]
+ 343.1805, 
found 343.1798. [α]D
20: −60.9 (c = 1.0, CHCl3). HPLC separation (Chiralpak
® IB-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 6.6 min, 
tr (minor) = 9.2 min, 20:80 e.r. 
 
5.6.2. Mechanistic Studies for the Intermolecular Nickel-Catalyzed 
Hydroarylation of Alkenes 
 
[D]1-99b was prepared by treating 99b with oxalyl chloride/D2O, following a 
procedure previously reported in the literature.[339] 
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The general procedure GP9 was followed using [D]1-99b (105 mg, 0.50 mmol, 
1.0 equiv) and 180 (38 mg, 50 µmol, 10 mol %). Purification by column 
chromatography on silica gel (n-hexane/EtOAc = 4.5/1→0/1) yielded [D]n-106bc 
(74.8 mg, 44%) as a thick colorless oil and re-isolated [D]n-99b (55.7 mg, 53%) as a 








5.6.3 Experimental Procedures and Analytical Data for the Asymmetric 




The general procedure GP11 was followed using 144a (93 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
1/2→0/1) yielded 145a (89.5 mg, 96%) as a white solid. M. p. = 135–136 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.80–7.70 (m, 1H), 7.38–7.21 (m, 3H), 4.24 (ddd, 
J = 12.1, 5.9, 3.0 Hz, 1H), 3.98 (td, J = 11.7, 11.3, 4.9 Hz, 1H), 3.25 (ddd, J = 17.1, 
4.8, 1.9 Hz, 1H), 2.67 (dd, J = 17.1, 10.7 Hz, 1H), 2.29–2.07 (m, 2H), 1.82 (dtd, 
J = 14.0, 10.7, 5.7 Hz, 1H), 1.24 (d, J = 6.5 Hz, 3H). 13C NMR (75 MHz, CDCl3): 
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δ = 151.8 (Cq), 143.1 (Cq), 134.6 (Cq), 122.0 (CH), 121.7 (CH), 118.9 (CH), 108.8 
(CH), 41.6 (CH2), 33.5 (CH2), 30.5 (CH2), 27.7 (CH), 21.1 (CH3). IR (ATR): 3050, 
2948, 2921, 2864, 1458, 1417, 1285, 739, 437 cm–1. MS (ESI) m/z (relative 
intensity): 187 (100) [M+H]+. HR-MS (ESI) m/z calcd for C12H15N2 [M+H]
+ 187.1230, 
found 187.1230. [α]D
20: +63.6 (c = 1.00, CHCl3). HPLC separation (Chiralpak
® IC-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): tr (major) = 16.8 min, 





The general procedure GP11 was followed using 144b (97 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 1.5/1→1/2) yielded 145b (64.1 mg, 66%) as a white solid. 
M. p. = 74–76 °C. 1H NMR (300 MHz, CDCl3): δ = 7.66 (s, 1H), 4.54 (ddd, J = 13.9, 
5.8, 3.0 Hz, 1H), 4.01 (ddd, J = 14.4, 11.0, 4.9 Hz, 1H), 3.81 (s, 3H), 3.04 (ddd, 
J = 17.2, 4.9, 1.8 Hz, 1H), 2.44 (dd, J = 17.2, 10.3 Hz, 1H), 2.13–1.91 (m, 2H), 1.63 
(dtd, J = 14.1, 11.2, 5.6 Hz, 1H), 1.12 (d, J = 6.5 Hz, 3H). 13C NMR (75 MHz, CDCl3): 
δ = 161.1 (Cq), 150.3 (Cq), 137.0 (CH), 121.9 (Cq), 51.3 (CH3), 44.6 (CH2), 33.3 
(CH2), 30.7 (CH2), 26.8 (CH), 21.1 (CH3). IR (ATR): 2957, 1704, 1443, 1224, 1176, 
1141, 1072, 766 cm–1. MS (ESI) m/z (relative intensity): 209 (21), 195 (100) [M+H]+, 
127 (25). HR-MS (ESI) m/z calcd for C10H15N2O2 [M+H]
+ 195.1128, found 195.1123. 
[α]D
20: +72.8 (c = 0.29, CHCl3). HPLC separation (Chiralpak
® ID-3, n-hexane/iPrOH 
60:40, 1.0 mL/min, detection at 250 nm): tr (major) = 7.6 min, tr (minor) = 8.2 min, 
99:1 e.r. 
 




The general procedure GP11 was followed using 144c (149 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
3/1→1.5/1) yielded 145c (131.0 mg, 88%) as a white solid. M. p. = 85–86 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.72–7.64 (m, 1H), 7.33–7.16 (m, 3H), 4.22 (ddd, 
J = 12.0, 5.7, 3.2 Hz, 1H), 3.95 (ddd, J = 12.0, 10.7, 5.0 Hz, 1H), 3.24 (ddd, J = 17.1, 
4.8, 1.7 Hz, 1H), 2.64 (dd, J = 17.1, 10.4 Hz, 1H), 2.27–2.17 (m, 1H), 2.07–1.93 (m, 
1H), 1.78 (dtd, J = 13.4, 10.8, 5.7 Hz, 1H), 1.57–1.15 (m, 16H), 0.89 (t, J = 6.8 Hz, 
3H). 13C NMR (125 MHz, CDCl3): δ = 152.0 (Cq), 143.2 (Cq), 134.6 (Cq), 122.1 (CH), 
121.7 (CH), 119.0 (CH), 108.8 (CH), 41.8 (CH2), 35.7 (CH2), 32.8 (CH), 32.1 (CH2), 
32.0 (CH2), 29.9 (CH2), 29.8 (CH2), 29.8 (CH2), 29.5 (CH2), 29.0 (CH2), 27.0 (CH2), 
22.9 (CH2), 14.3 (CH3). IR (ATR): 2920, 2851, 1513, 1459, 1421, 1287, 740 cm
–1. 
MS (ESI) m/z (relative intensity): 299 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C20H31N2 [M+H]
+ 299.2482, found 299.2480. [α]D
20: +37.2 (c = 1.01, CHCl3). HPLC 
separation (Chiralpak® IC-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 





The general procedure GP11 was followed using 144d (141 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
4/1→2/1) yielded 145d (119.3 mg, 85%) as a white solid. M. p. = 134–135 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.72–7.64 (m, 1H), 7.34–7.15 (m, 3H), 4.22 (ddd, 
J = 11.9, 5.7, 3.2 Hz, 1H), 3.94 (ddd, J = 11.9, 10.6, 5.0 Hz, 1H), 3.24 (ddd, J = 17.1, 
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4.8, 1.7 Hz, 1H), 2.64 (dd, J = 17.1, 10.3 Hz, 1H), 2.28–2.15 (m, 1H), 2.04–1.86 (m, 
1H), 1.86–1.58 (m, 6H), 1.54–1.42 (m, 2H), 1.37–1.07 (m, 6H), 1.01–0.79 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 152.0 (Cq), 143.2 (Cq), 134.6 (Cq), 122.1 (CH), 
121.7 (CH), 119.0 (CH), 108.8 (CH), 41.8 (CH2), 37.9 (CH), 34.7 (CH2), 33.6 (CH2), 
33.6 (CH2), 33.1 (CH), 32.9 (CH2), 32.0 (CH2), 28.9 (CH2), 26.6 (CH2). IR (ATR): 
2916, 2847, 1514, 1455, 1417, 1284, 737 cm–1. MS (ESI) m/z (relative intensity): 
283 (100) [M+H]+. HR-MS (ESI) m/z calcd for C19H27N2 [M+H]
+ 283.2169, found 
283.2161. [α]D
20: +45.0 (c = 1.03, CHCl3). HPLC separation (Chiralpak
® IC-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 14.5 min, 





The general procedure GP11 was followed using 144e (145 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
3/1→1/1) yielded 145e (116.9 mg, 81%) as a white solid. M. p. = 80–83 °C. 1H NMR 
(300 MHz, CDCl3): δ = 7.77–7.66 (m, 1H), 7.40–7.13 (m, 8H), 4.22 (ddd, J = 12.1, 
5.7, 3.2 Hz, 1H), 3.93 (td, J = 11.4, 5.0 Hz, 1H), 3.27 (ddd, J = 17.0, 4.8, 1.7 Hz, 1H), 
2.76–2.57 (m, 3H), 2.29–2.15 (m, 1H), 2.11–1.94 (m, 1H), 1.88–1.68 (m, 3H), 1.61–
1.47 (m, 2H). 13C NMR (125 MHz, CDCl3): δ = 151.7 (Cq), 143.1 (Cq), 142.1 (Cq), 
134.5 (Cq), 128.4 (CH), 128.4 (CH), 125.9 (CH), 122.1 (CH), 121.7 (CH), 119.0 (CH), 
108.8 (CH), 41.7 (CH2), 36.0 (CH2), 35.1 (CH2), 32.7 (CH), 31.9 (CH2), 28.8 (CH2), 
28.8 (CH2). IR (ATR): 3026, 2919, 2856, 1510, 1483, 1455, 1284, 742, 691 cm
–1. 
MS (ESI) m/z (relative intensity): 291 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C20H23N2 [M+H]
+ 291.1856, found 291.1855. [α]D
20: +39.3 (c = 1.01, CHCl3). HPLC 
separation (Chiralpak® IC-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 
273 nm): tr (major) = 20.6 min, tr (minor) = 25.5 min, 97:3 e.r. 





The general procedure GP11 was followed using 144f (143 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
1/1→0/1) yielded 145f (118.5 mg, 83%) as a white solid. M. p. = 99–100 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.75–7.61 (m, 1H), 7.35–7.15 (m, 3H), 4.89 (t, 
J = 4.6 Hz, 1H), 4.23 (ddd, J = 12.0, 5.7, 3.2 Hz, 1H), 4.04–3.81 (m, 5H), 3.25 (ddd, 
J = 17.1, 4.8, 1.7 Hz, 1H), 2.66 (dd, J = 17.1, 10.4 Hz, 1H), 2.32–2.17 (m, 1H), 2.12–
1.91 (m, 1H), 1.87–1.65 (m, 3H), 1.65–1.47 (m, 4H). 13C NMR (125 MHz, CDCl3): 
δ = 151.8 (Cq), 143.2 (Cq), 134.6 (Cq), 122.1 (CH), 121.7 (CH), 119.0 (CH), 108.8 
(CH), 104.4 (CH), 65.1 (CH2), 41.8 (CH2), 35.5 (CH2), 34.0 (CH2), 32.9 (CH), 32.0 
(CH2), 28.8 (CH2), 21.5 (CH2). IR (ATR): 2922, 2893, 1457, 1415, 1106, 1053, 1021, 
741 cm–1. MS (ESI) m/z (relative intensity): 287 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C17H23N2O2 [M+H]
+ 287.1754, found 287.1753. [α]D
20: +39.1 (c = 0.42, 
CHCl3). HPLC separation (Chiralpak
® IC-3, n-hexane/iPrOH 30:70, 1.0 mL/min, 





The general procedure GP11 was followed using 144g (172 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 3/1→1/1.5) yielded 145g (149.3 mg, 87%) as a white solid. 
M. p. = 134–135 °C. 1H NMR (500 MHz, CDCl3): δ = 7.73–7.64 (m, 1H), 7.33–7.26 
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(m, 1H), 7.26–7.18 (m, 2H), 4.24 (ddd, J = 12.0, 5.7, 3.1 Hz, 1H), 3.95 (td, J = 11.4, 
5.0 Hz, 1H), 3.66 (td, J = 6.3, 2.3 Hz, 2H), 3.25 (ddd, J = 17.1, 4.8, 1.7 Hz, 1H), 2.65 
(dd, J = 17.1, 10.6 Hz, 1H), 2.23 (dtd, J = 12.9, 4.9, 2.6 Hz, 1H), 2.08–1.95 (m, 1H), 
1.84–1.75 (m, 1H), 1.72–1.61 (m, 2H), 1.61–1.46 (m, 2H), 0.90 (s, 9H), 0.06 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ = 151.9 (Cq), 143.2 (Cq), 134.6 (Cq), 122.2 (CH), 
121.8 (CH), 119.1 (CH), 108.9 (CH), 63.1 (CH2), 41.8 (CH2), 32.6 (CH), 31.9 (CH2), 
31.9 (CH2), 30.1 (CH2), 28.9 (CH2), 26.1 (CH3), 18.5 (Cq), -5.1 (CH3). IR (ATR): 
2933, 2854, 1457, 1251, 1094, 832, 771, 739 cm–1. MS (ESI) m/z (relative intensity): 
345 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H33N2OSi [M+H]
+ 345.2357, found 
345.2358. [α]D
20: +37.6 (c = 0.59, CHCl3). HPLC separation (Chiralpak
® IB-3, 
n-hexane/THF 80:20, 1.5 mL/min, detection at 280 nm): tr (major) = 8.4 min, 





The general procedure GP11 was followed using 144h (127 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
3/1→1.5/1) yielded 145h (106.4 mg, 84%) as a white solid. M. p. = 98–99 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.73–7.64 (m, 1H), 7.33–7.18 (m, 3H), 5.17–5.08 
(m, 1H), 4.24 (ddd, J = 12.1, 5.7, 3.2 Hz, 1H), 3.96 (td, J = 11.4, 5.0 Hz, 1H), 3.26 
(ddd, J = 17.1, 4.8, 1.7 Hz, 1H), 2.66 (dd, J = 17.1, 10.4 Hz, 1H), 2.28–2.18 (m, 1H), 
2.20–2.07 (m, 2H), 2.08–1.93 (m, 1H), 1.80 (dtd, J = 13.4, 10.9, 5.8 Hz, 1H), 1.70 (s, 
3H), 1.64 (s, 3H), 1.57–1.48 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 151.9 (Cq), 
143.2 (Cq), 134.6 (Cq), 132.3 (Cq), 123.8 (CH), 122.1 (CH), 121.7 (CH), 119.0 (CH), 
108.8 (CH), 41.7 (CH2), 35.6 (CH2), 32.1 (CH), 31.7 (CH2), 28.8 (CH2), 25.8 (CH3), 
25.2 (CH2), 17.9 (CH3). IR (ATR): 2957, 2924, 2852, 1486, 1450, 1286, 1228, 
742 cm–1. MS (ESI) m/z (relative intensity): 255 (100) [M+H]+. HR-MS (ESI) m/z 
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calcd for C17H23N2 [M+H]
+ 255.1856, found 255.1853. [α]D
20: +45.4 (c = 1.01, 
CHCl3). HPLC separation (Chiralpak
® IC-3, n-hexane/iPrOH 80:20, 1.0 mL/min, 





The general procedure GP11 was followed using 144i (161 mg, 0.50 mmol, 
1.0 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc = 
3.5/1→2/1) yielded 145i (134.6 mg, 84%) as a white solid. M. p. = 79–80 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.73–7.64 (m, 1H), 7.33–7.17 (m, 3H), 5.18–5.04 
(m, 2H), 4.23 (ddd, J = 11.9, 5.7, 3.2 Hz, 1H), 3.95 (ddd, J = 11.9, 10.7, 5.0 Hz, 1H), 
3.25 (ddd, J = 17.1, 4.8, 1.7 Hz, 1H), 2.66 (dd, J = 17.1, 10.4 Hz, 1H), 2.28–2.19 (m, 
1H), 2.21–2.09 (m, 2H), 2.10–1.94 (m, 5H), 1.87–1.67 (m, 1H), 1.65 (s, 3H), 1.63 (s, 
3H), 1.59 (s, 3H), 1.58–1.49 (m, 2H). 13C NMR (125 MHz, CDCl3): δ = 151.9 (Cq), 
143.2 (Cq), 135.9 (Cq), 134.6 (Cq), 131.5 (Cq), 124.3 (CH), 123.6 (CH), 122.1 (CH), 
121.7 (CH), 119.0 (CH), 108.8 (CH), 41.8 (CH2), 39.9 (CH2), 35.7 (CH2), 32.3 (CH), 
31.9 (CH2), 29.0 (CH2), 26.9 (CH2), 25.9 (CH3), 25.3 (CH2), 17.9 (CH3), 16.3 (CH3). 
IR (ATR): 2962, 2911, 2851, 1510, 1451, 1322, 1107, 742 cm–1. MS (ESI) m/z 
(relative intensity): 323 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H31N2 [M+H]
+ 
323.2482, found 323.2478. [α]D
20: +34.2 (c = 1.22, CHCl3). HPLC separation 
(Chiralpak® IC-3, n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 273 nm): 








The general procedure GP11 was followed using 144j (120 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 3/1→1.5/1) yielded 145j (64.3 mg, 54%) as a white solid. 
M. p. = 110–111 °C. 1H NMR (600 MHz, CDCl3): δ = 7.71–7.65 (m, 1H), 7.31–7.27 
(m, 1H), 7.26–7.20 (m, 2H), 5.82 (ddt, J = 17.1, 10.2, 6.7 Hz, 1H), 5.03 (ddt, 
J = 17.1, 1.8, 1.6 Hz, 1H), 4.98 (ddt, J = 10.2, 2.3, 1.3 Hz, 1H), 4.23 (ddd, J = 11.9, 
5.7, 3.2 Hz, 1H), 3.95 (ddd, J = 11.7, 10.9, 5.0 Hz, 1H), 3.25 (ddd, J = 17.0, 4.8, 
1.7 Hz, 1H), 2.65 (dd, J = 17.0, 10.5 Hz, 1H), 2.26–2.19 (m, 1H), 2.11 (q, J = 6.9 Hz, 
2H), 2.05–1.96 (m, 1H), 1.79 (dtd, J = 13.5, 10.9, 5.8 Hz, 1H), 1.59–1.45 (m, 4H). 
13C NMR (125 MHz, CDCl3): δ = 151.8 (Cq), 143.2 (Cq), 138.5 (CH), 134.6 (Cq), 
122.1 (CH), 121.7 (CH), 119.0 (CH), 114.9 (CH2), 108.8 (CH), 41.8 (CH2), 35.1 
(CH2), 33.9 (CH2), 32.8 (CH), 32.0 (CH2), 28.9 (CH2), 26.3 (CH2). IR (ATR): 2927, 
2856, 1511, 1456, 1414, 1284, 907, 742 cm–1. MS (ESI) m/z (relative intensity): 259 
(35), 241 (100) [M+H]+. HR-MS (ESI) m/z calcd for C16H21N2 [M+H]
+ 241.1699, found 
241.1697. [α]D
20: +54.9 (c = 0.42, CHCl3). HPLC separation (Chiralpak
® IC-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 15.4 min, 




The general procedure GP11 was followed using 144q (93 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
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(n-hexane/EtOAc = 1/1→1/3) yielded 145q (37.9 mg, 41%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3): δ = 7.78–7.69 (m, 1H), 7.33–7.17 (m, 3H), 4.12 (ddd, 
J = 10.2, 8.7, 4.2 Hz, 1H), 4.00 (ddd, J = 10.2, 8.1, 7.0 Hz, 1H), 3.28–3.16 (m, 1H), 
2.86 (dtd, J = 12.6, 8.3, 4.2 Hz, 1H), 2.35 (ddt, J = 13.0, 8.8, 7.0 Hz, 1H), 2.16–1.92 
(m, 1H), 1.72 (dp, J = 13.6, 7.5 Hz, 1H), 1.12 (t, J = 7.4 Hz, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 163.6 (Cq), 148.6 (Cq), 132.2 (Cq), 121.8 (CH), 121.6 (CH), 119.7 (CH), 
109.5 (CH), 42.1 (CH2), 37.7 (CH), 32.9 (CH2), 26.3 (CH2), 11.9 (CH3). IR (ATR): 
2962, 2931, 1524, 1451, 1415, 1277, 908, 730 cm–1. MS (ESI) m/z (relative 
intensity): 187 (100) [M+H]+. HR-MS (ESI) m/z calcd for C12H15N2 [M+H]
+ 187.1230, 
found 187.1231. [α]D
20: –1.1 (c = 0.60, CHCl3). HPLC separation (Chiralpak
® IC-3, 
n-hexane/iPrOH 80:20, 1.0 mL/min, detection at 250 nm): tr (major) = 10.7 min, 




The general procedure GP11 was followed using 144r (100 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 2/1→1/1.5) yielded 145r (16.4 mg, 16%) as a white solid. 
M. p. = 63–65 °C. 1H NMR (300 MHz, CDCl3): δ = 7.77–7.67 (m, 1H), 7.34–7.24 (m, 
1H), 7.24–7.16 (m, 2H), 4.13 (ddd, J = 10.2, 8.7, 4.2 Hz, 1H), 4.00 (ddd, J = 10.1, 
8.0, 7.0 Hz, 1H), 3.27 (tdd, J = 8.1, 7.1, 5.8 Hz, 1H), 2.86 (dtd, J = 12.6, 8.2, 4.2 Hz, 
1H), 2.34 (ddt, J = 12.9, 8.7, 7.0 Hz, 1H), 2.10–1.91 (m, 1H), 1.71–1.42 (m, 3H), 
0.99 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 164.0 (Cq), 148.8 (Cq), 
132.3 (Cq), 121.8 (CH), 121.7 (CH), 119.8 (CH), 109.5 (CH), 42.1 (CH2), 36.1 (CH), 
35.5 (CH2), 33.3 (CH2), 20.7 (CH2), 14.1 (CH3). IR (ATR): 2955, 2929, 1522, 1451, 
1411, 1275, 1217, 740 cm–1. MS (ESI) m/z (relative intensity): 201 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C13H17N2 [M+H]
+ 201.1386, found 201.1386. [α]D
20: –0.4 
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(c = 0.38, CHCl3). HPLC separation (Chiralpak
® IC-3, n-hexane/iPrOH 80:20, 
1.0 mL/min, detection at 250 nm): tr (major) = 9.7 min, tr (minor) = 13.1 min, 96:4 e.r. 





The general procedure GP11 was followed using 144x (86 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 1.5/1→1/3) yielded 223 (63.8 mg, 74%) as a pale yellow oil. The 




1H NMR (600 MHz, CDCl3): δ = 7.88 (s, 1H), 7.82–7.78 (m, 1H), 7.39–7.35 (m, 1H), 
7.31–7.24 (m, 2H), 5.86–5.79 (m, 0.16H, Z-isomer), 5.77–5.69 (m, 0.84H, E-isomer), 
5.67–5.57 (m, 1H), 4.78 (ddd, J = 6.8, 1.7, 0.9 Hz, 0.34H, Z-isomer), 4.70–4.66 (m, 
1.70H, E-isomer), 1.84 (ddt, J = 7.0, 1.9, 0.9 Hz, 0.50H, Z-isomer), 1.72 (dq, J = 6.2, 
1.3 Hz, 2.51H, E-isomer). 13C NMR (75 MHz, CDCl3): δ = 144.1 (Cq, both isomers), 
142.9 (CH, both isomers), 142.7 (Cq, both isomers), 134.0 (CH, Z-isomer), 130.7 
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(CH, E-isomer), 129.7 (CH, Z-isomer), 124.9 (CH, E-isomer), 124.0 (CH, Z-isomer), 
122.9 (CH, E-isomer), 122.2 (CH, Z-isomer), 122.1 (CH, E-isomer), 120.5 (CH, 
Z-isomer), 120.5 (CH, E-isomer), 110.0 (CH, E-isomer), 109.8 (CH, Z-isomer), 47.0 
(CH2, E-isomer), 41.8 (CH2, Z-isomer), 17.7 (CH3, E-isomer), 13.3 (CH3, Z-isomer). 
IR (ATR): 2917, 1493, 1458, 1285, 1260, 1198, 963, 743 cm–1. MS (ESI) m/z 
(relative intensity): 195 (3) [M+Na]+, 173 (100) [M+H]+, 119 (18). HR-MS (ESI) m/z 
calcd for C11H13N2 [M+H]
+ 173.1073, found 173.1072. 
The analytical data for the major E-isomer are in accordance with those previously 
reported in the literature.[340] 
 
Alkene Isomerization with D-Labeling 
The general procedure GP11 was followed using [D]1-144x (86 mg, 0.50 mmol, 
1.0 equiv), Ni(cod)2 (13.8 mg, 50.0 µmol, 10.0 mol %) and 220 (12.6 mg, 25.0 µmol, 
5.00 mol %) in PhMe (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc = 1.5/1→1/3) yielded [D]n-223 (66.1 mg, 76%) as a pale yellow oil. 
The E/Z ratio was determined by 1H NMR analysis of the crude product. Deuterium 
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5.6.4. Mechanistic Studies for the Asymmetric Intramolecular Nickel-Catalyzed 
Hydroarylation of Alkenes 
 
Non-Linear Effect Studies 
 
Inside a nitrogen-filled glovebox, an oven-dried 25 mL Schlenk tube was charged 
with a mixture of stock solutions of 220 and ent-220 in PhMe (both c = 6.90 mg/mL) 
for a total volume of 1.0 mL. Ni(cod)2 (6.9 mg, 25 µmol, 5.0 mol %), and substrate 
144a (93 mg, 0.50 mmol, 1.0 equiv) were then added. The Schlenk tube was closed 
with a rubber septum, taken out of the glovebox, and placed in a pre-heated oil bath 
at 95 °C. The reaction mixture was stirred at 95 °C for 16 h, then cooled to 23 °C 
and diluted with EtOAc (5.0 mL). The mixture was filtered through a short plug of 
silica gel, rinsed with EtOAc (4 × 10 mL) and concentrated in vacuo. The conversion 
was determined by 1H NMR using 1,1,2,2-tetrachloroethane as an internal standard. 
Enantiomeric excesses were measured by chiral HPLC analysis of the crude product 
(Chiralpak® IC-3, n-hexane/iPrOH 80:20, 1.0 mL/min). 
 
Table 5.6. Non-Linear Effect Studies. 
Entry ee(220)[a] ee(144a)[b] Yield[c] 
1 0% −0.6 >98% 
2 10% 9.8 >98% 
3 20% 19.8 >98% 
4 30% 29.0 >98% 
5 40% 38.6 >98% 
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6 50% 49.2 >98% 
7 60% 58.4 >98% 
8 70% 67.2 >98% 
9 80% 77.2 >98% 
10 90% 88.0 >98% 
11 100% 95.0 >98% 
[a]
 Prepared by mixing two stock solutions of each enantiomer of pre-ligand 220. 
[b]
 Determined by chiral HPLC analysis of the crude reaction mixture. 
[c]
 Determined by crude 
1




Figure 5.3. Absence of a non-linear effect. 
  
y = 0.9629x + 0.1818 
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Following a modified procedure,[341] 145a (75 mg, 0.40 mmol, 1.0 equiv, >99:1 e.r.) 
was dissolved in methyl iodide (1.5 mL) and the resulting mixture was stirred for 
16 h. The resulting suspension was diluted with Et2O (15 mL). The precipitate was 
collected by filtration, washed with Et2O (3 × 5 mL) and dried in vacuo to provide 
benzimidazolium iodide 230 (123.5 mg, 93%) as a white powder. M. p. = 151 °C 
(decomposition). 1H NMR (300 MHz, CDCl3): δ = 7.72–7.61 (m, 2H), 7.62–7.48 (m, 
2H), 4.47 (ddd, J = 12.7, 5.7, 2.5 Hz, 1H), 4.28 (td, J = 11.9, 4.8 Hz, 1H), 4.02 (s, 
3H), 3.73 (ddd, J = 18.1, 5.4, 1.0 Hz, 1H), 3.04 (dd, J = 18.2, 10.3 Hz, 1H), 2.67–
2.49 (m, 1H), 2.36–2.25 (m, 1H), 2.02 (dtd, J = 14.0, 11.4, 5.6 Hz, 1H), 1.27 (d, 
J = 6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 151.0 (Cq), 131.9 (Cq), 131.0 (Cq), 
126.8 (CH), 126.4 (CH), 112.5 (CH), 112.3 (CH), 43.8 (CH2), 32.7 (CH), 30.8 (CH2), 
28.9 (CH2), 25.7 (CH3), 21.0 (CH3). IR (ATR): 3017, 2955, 2909, 1537, 1470, 760, 
427 cm–1. MS (ESI) m/z (relative intensity): 201 (100) [M–I]+. HR-MS (ESI) m/z calcd 
for C13H17N2 [M–I]
+ 201.1386, found 201.1386. [α]D
20: +50.7 (c = 0.60, CHCl3). 
Crystals suitable for X-ray crystallography were grown by vapor diffusion from Et2O 
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Following a modified procedure,[307a] benzimidazolium iodide 230 (200 mg, 
0.61 mmol, 1.0 equiv, >99:1 e.r.), potassium hydride (29.3 mg, 0.73 mmol, 
1.2 equiv), and potassium tert-butoxide (1.4 mg, 12 µmol, 2.0 mol %) were combined 
with THF (3.5 mL) inside a nitrogen-filled glovebox. The suspension was stirred at 
23 °C for 20 h, and then filtered through a short plug of Celite®. The filter cake was 
washed with THF (3 × 5.0 mL). The filtrate was cooled to 0 °C, and phenyl 
isocyanate (109 mg, 0.91 mmol, 1.5 equiv) was added dropwise under inert 
atmosphere. The resulting solution was stirred for 1 h at 0 °C; then at 23 °C for 16 h. 
The reaction mixture was concentrated under reduced pressure, and the residue 
was recrystallized from Et2O/MeOH = 25/1 at −30 °C to provide 231 (140 mg, 72%) 
as a pale yellow solid. M. p. = 168 °C (decomposition). 1H NMR (300 MHz, C6D6): 
δ = 7.81 (d, J = 7.9 Hz, 2H), 7.24 (dd, J = 8.5, 7.3 Hz, 2H), 6.97–6.81 (m, 3H), 6.74 
(brs, 1H), 6.52–6.40 (m, 2H), 3.18 (s, 3H), 3.15–3.05 (m, 1H), 2.95–2.78 (m, 2H), 
1.43 (tt, J = 12.7, 5.1 Hz, 1H), 1.30–1.18 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H). 13C NMR 
(75 MHz, CDCl3): δ = 165.7 (Cq), 150.7 (Cq), 140.2 (Cq), 135.9 (Cq), 133.0 (Cq), 
129.1 (CH), 122.2 (CH), 121.5 (CH), 121.1 (CH), 119.1 (CH), 108.0 (CH), 105.9 
(CH), 79.2 (Cq), 37.6 (CH2), 35.9 (CH3), 28.7 (CH), 28.5 (CH2), 21.8 (CH3). IR (ATR): 
3341, 2953, 1539, 1495, 1428, 1307, 1188, 1147, 731 cm–1. MS (ESI) m/z (relative 
intensity): 320 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H22N3O [M+H]
+ 
320.1757, found 320.1758. HPLC separation (Chiralpak® IA-3, n-hexane/iPrOH 






Following a modified procedure,[308] methyl 2-chloro-2-oxoacetate (122 µL, 
1.34 mmol, 1.50 equiv) was added dropwise to an ice-cold solution of 145a (166 mg, 
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0.89 mmol, 1.0 equiv, >99:1 e.r.) and Et3N (621 µL, 4.46 mmol, 5.00 equiv) in 
acetonitrile (9.0 mL). The resulting suspension was stirred at 0 °C for 2 h, then at 
23 °C for 18 h. The mixture was diluted with EtOAc (20 mL) and filtered through a 
short plug of Celite®, which was rinsed with EtOAc (3 × 20 mL). The volatiles were 
removed under reduced pressure, and the residue was purified by column 
chromatography (n-hexane/EtOAc = 5/1→2/1) to provide 232 (126 mg, 52%) as a 
yellow solid. M. p. = 137–139 °C. 1H NMR (500 MHz, CDCl3): δ = 13.93 (brs, 1H), 
7.66–7.60 (m, 1H), 7.36–7.32 (m, 1H), 7.32–7.28 (m, 2H), 4.21 (ddd, J = 12.3, 5.6, 
1.7 Hz, 1H), 4.09 (td, J = 12.6, 4.2 Hz, 1H), 3.90 (s, 3H), 3.86 (tdd, J = 7.1, 5.2, 
3.3 Hz, 1H), 2.14 (tdd, J = 13.0, 5.6, 4.1 Hz, 1H), 2.05 (dddd, J = 13.7, 4.5, 2.9, 
1.7 Hz, 1H), 1.27 (d, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 
152.6 (Cq), 150.3 (Cq), 137.9 (Cq), 132.9 (Cq), 123.4 (CH), 123.3 (CH), 117.0 (CH), 
109.1 (CH), 106.4 (Cq), 52.3 (CH3), 37.9 (CH2), 28.5 (CH2), 26.0 (CH), 19.8 (CH3). 
IR (ATR): 2951, 1720, 1536, 1292, 1253, 1211, 1153, 748 cm–1. MS (ESI) m/z 
(relative intensity): 567 (17) [2M+Na]+, 295 (48) [M+Na]+, 273 (100) [M+H]+, 213 (7) 
[M-CO2Me]
+. HR-MS (ESI) m/z calcd for C15H17N2O3 [M+H]
+ 273.1234, found 
273.1236. [α]D
20: –0.76 (c = 1.00, CHCl3). HPLC separation (Chiralpak
® IC-3, 
n-hexane/iPrOH 25:75, 0.50 mL/min, detection at 290 nm): tr (major) = 31.2 min, 
tr (minor) = 41.5 min, >99:1 e.r. 
Crystals suitable for X-ray crystallography were grown by slow evaporation from a 
solution of rac-232 in iPrOH/CH2Cl2 = 25/1. 
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5.7. Crystallographic Data 
 
The crystal structures of 192ca and 197 were measured and solved by H. Keil 
(Stalke research group). 
The data were collected from a shock-cooled crystal at 100(2) K on a 'BRUKER D8' 
three circle diffractometer equipped with an INCOATEC Mo Microsource with mirror 
optics (MoKα radiation, λ = 0.71073 Å). The data were integrated with SAINT.
[342] A 
multi-scan absorption correction and a 3λ correction[343] was applied using 
SADABS.[344] The structures were solved by SHELXT[345] and refined on F2 using 
SHELXL[346] in the graphical user interface SHELXLE.[347] 
 
Table 5.7. Crystal data and structure refinement of 192ca and 197. 
Compound 192ca 197 
CCDC number 1559085 1559086 
Empirical formula C28H25FeNO C31H27BrN2O 
Formula weight 447.34 523.45 
Temperature [K] 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 
Crystal system Orthorhombic Orthorhombic 
Space group P212121 P212121 
a[Å] 11.061(2) 9.643(2) 
b[Å] 11.652(2) 10.147(2) 
c[Å] 16.748(3) 25.036(3) 
a[°] 90 90 
b[°] 90 90 
g[°] 90 90 
Volume [Å3] 2158.5(7) 2449.7(8) 
Z 4 4 
Absorption coefficient [mm-1] 0.719 1.706 
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F(000) 936 1080 
Crystal size [mm3] 0.3 x 0.2 x 0.2 0.2 x 0.2 x 0.1 
Theta range for data collection 2.129 to 26.382° 1.627 to 26.376° 
Reflections collected 25569 54351 
Independent reflections 4407 5006 
Rint 0.0366 0.0419 
Max. and min. transmission 0.7454 and 0.6670 0.7454 and 0.6485 
Data / restraints / parameters 4407 / 0 / 281 5006 / 0 / 318 
Goodness-of-fit on F2 1.032 1.051 
Final R indices [I>2sigma(I)] 
R1 = 0.0237 
wR2 = 0.0552 
R1 = 0.0195 
wR2 = 0.0452 
R indices (all data) 
R1 = 0.0272 
wR2 = 0.0567 
R1 = 0.0213 
wR2 = 0.0457 
Absolute structure parameter 0.013(6) 0.010(3) 
Largest diff. peak and hole 
[e Å-3] 
0.242 and -0.212 0.222 and -0.152 
 
 
Figure 5.4. Molecular structure of 192ca with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
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Table 5.8. Bond lengths [Å] and angles [°] for 192ca. 
Fe(1)-C(23)  2.032(2) 
Fe(1)-C(27)  2.038(2) 
Fe(1)-C(19)  2.042(2) 
Fe(1)-C(28)  2.043(2) 
Fe(1)-C(22)  2.047(3) 
Fe(1)-C(24)  2.047(2) 
Fe(1)-C(26)  2.048(2) 
Fe(1)-C(20)  2.048(2) 
Fe(1)-C(25)  2.051(2) 
Fe(1)-C(21)  2.052(2) 
C(1)-N(1)  1.365(3) 
C(1)-C(2)  1.392(3) 
C(1)-C(17)  1.513(3) 
O(1)-C(9)  1.227(3) 
N(1)-C(8)  1.396(3) 
N(1)-C(10)  1.464(3) 
C(10)-C(11)  1.514(3) 
C(11)-C(16)  1.389(3) 
C(11)-C(12)  1.395(3) 
C(2)-C(9)  1.431(3) 
C(2)-C(3)  1.444(3) 
C(16)-C(15)  1.388(3) 
C(3)-C(8)  1.404(3) 
C(3)-C(4)  1.407(3) 
C(15)-C(14)  1.387(4) 
C(4)-C(5)  1.383(3) 
C(14)-C(13)  1.384(4) 
C(5)-C(6)  1.391(4) 
C(13)-C(12)  1.383(3) 
C(6)-C(7)  1.384(3) 
C(7)-C(8)  1.397(3) 
C(17)-C(19)  1.520(3) 
C(17)-C(18)  1.533(3) 
C(19)-C(23)  1.426(3) 























C(1)-C(2)-C(9)  126.2(2) 
C(1)-C(2)-C(3) 107.2(2) 
C(9)-C(2)-C(3)  126.7(2) 
C(15)-C(16)-C(11) 120.6(2) 
C(8)-C(3)-C(4)  119.2(2) 
C(8)-C(3)-C(2)  106.6(2) 
C(4)-C(3)-C(2) 134.2(2) 
C(14)-C(15)-C(16) 120.1(2) 




C(7)-C(6)-C(5)  121.5(2) 
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C(20)-C(21)  1.426(4) 
C(21)-C(22)  1.415(4) 
C(22)-C(23)  1.424(3) 
C(24)-C(28)  1.423(3) 
C(24)-C(25)  1.424(3) 
C(25)-C(26)  1.416(3) 
C(26)-C(27)  1.420(4) 



















































































Figure 5.5. Molecular structure of 197 with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Table 5.9. Bond lengths [Å] and angles [°] for 197. 
Br(1)-C(20)  1.906(2) 
O(1)-C(28)  1.368(3) 
O(1)-C(31)  1.428(3) 
N(1)-C(1)  1.375(3) 
N(1)-C(4)  1.388(3) 
N(1)-C(9)  1.456(3) 
C(1)-C(2)  1.391(3) 
C(1)-C(23)  1.517(3) 
N(2)-C(16)  1.287(3) 
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C(2)-C(16)  1.439(3) 
C(2)-C(3)  1.447(3) 
C(23)-C(25)  1.528(3) 
C(23)-C(24)  1.534(3) 
C(25)-C(30)  1.386(3) 
C(25)-C(26)  1.403(3) 
C(26)-C(27)  1.378(3) 
C(27)-C(28)  1.401(3) 
C(28)-C(29)  1.381(3) 
C(29)-C(30)  1.391(3) 
C(3)-C(8)  1.403(3) 
C(3)-C(4)  1.406(3) 
C(4)-C(5)  1.393(3) 
C(5)-C(6)  1.384(3) 
C(7)-C(8)  1.382(3) 
C(7)-C(6)  1.398(3) 
C(17)-C(22)  1.396(3) 
C(17)-C(18)  1.398(3) 
C(18)-C(19)  1.391(3) 
C(9)-C(10)  1.520(3) 
C(22)-C(21)  1.386(3) 
C(10)-C(11)  1.389(3) 
C(10)-C(15)  1.390(3) 
C(19)-C(20)  1.381(3) 
C(11)-C(12)  1.392(3) 
C(20)-C(21)  1.381(3) 
C(12)-C(13)  1.379(4) 
C(13)-C(14)  1.377(4) 


















C(4)-C(3)-C(2)  106.66(18) 
N(1)-C(4)-C(5)  129.2(2) 
N(1)-C(4)-C(3) 108.12(19) 
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The crystal structures of 230 and rac-232 were measured and solved by Dr. C. Golz. 
A suitable crystal was selected and mounted on a 'Bruker APEX-II CCD' 
diffractometer. The crystal was kept at 100 K during data collection. Using Olex2,[348] 
the structure was solved with the XT[345] structure solution program using intrinsic 
phasing and refined with the XL[349] refinement package using least squares 
minimization. 
 
X-Ray Crystallographic Data of 230 
 
Figure 5.6. Molecular structure of 230 with thermal ellipsoids at 50% probability level. 
 
Table 5.10. Crystal data and structure refinement for 230.  
Compound 230 
CCDC number 1871584 
Empirical formula  C13H17IN2  
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Formula weight  328.18  
Temperature/K  100.0  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  6.4848(3)  
b/Å  12.6132(6)  
c/Å  15.9161(8)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  1301.84(11)  
Z  4  
ρcalc/g·cm
-3  1.674  
μ/mm-1  2.436  
F(000)  648.0  
Crystal size/mm3  0.237 × 0.166 × 0.138  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.118 to 65.194  
Index ranges  -9 ≤ h ≤ 9, -19 ≤ k ≤ 15, -24 ≤ l ≤ 23  
Reflections collected  19301  
Independent reflections  4738 [Rint = 0.0180, Rsigma = 0.0153]  
Data/restraints/parameters  4738/0/147  
Goodness-of-fit on F2  1.104  
Final R indexes [I>=2σ (I)]  R1 = 0.0144, wR2 = 0.0389  
Final R indexes [all data]  R1 = 0.0146, wR2 = 0.0391  
Largest diff. peak/hole / e Å-3  0.46/-0.46  
Flack parameter -0.009(6) 
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Table 5.11. Bond lengths for 230. 
Atom Atom Length/Å   Atom Atom Length/Å 
N1 C1 1.3398(17)   C3 C6 1.525(3) 
N1 C5 1.4742(19)   C4 C5 1.526(3) 
N1 C7 1.3886(18)   C7 C8 1.3973(19) 
N2 C1 1.3389(18)   C7 C12 1.3887(19) 
N2 C8 1.3897(17)   C8 C9 1.394(2) 
N2 C13 1.4643(18)   C9 C10 1.386(2) 
C1 C2 1.484(2)   C10 C11 1.404(2) 
C2 C3 1.541(3)   C11 C12 1.385(2) 
C3 C4 1.523(3)        
 
Table 5.12. Bond angles for 230. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C1 N1 C5 125.02(12)   C3 C4 C5 112.16(16) 
C1 N1 C7 108.58(12)   N1 C5 C4 109.25(13) 
C7 N1 C5 126.39(12)   N1 C7 C8 106.56(11) 
C1 N2 C8 108.52(11)   N1 C7 C12 131.02(13) 
C1 N2 C13 124.57(12)   C12 C7 C8 122.41(13) 
C8 N2 C13 126.92(12)   N2 C8 C7 106.61(12) 
N1 C1 C2 124.23(13)   N2 C8 C9 131.80(13) 
N2 C1 N1 109.72(12)   C9 C8 C7 121.58(12) 
N2 C1 C2 126.06(13)   C10 C9 C8 116.04(13) 
C1 C2 C3 110.14(13)   C9 C10 C11 122.10(13) 
C4 C3 C2 109.30(16)   C12 C11 C10 121.86(13) 
C4 C3 C6 112.71(17)   C11 C12 C7 116.00(13) 
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X-Ray Crystallographic Data of rac-232 
 
Figure 5.7. Molecular structure of rac-232 with thermal ellipsoids at 50% probability level. 
 
Table 5.13. Crystal data and structure refinement for rac-232. 
Compound rac-232 
CCDC number 1871585 
Empirical formula  C15H16N2O3  
Formula weight  272.30  
Temperature/K  99.98  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  7.3560(4)  
b/Å  15.9260(7)  
c/Å  11.3561(5)  
α/°  90  
β/°  107.168(2)  
γ/°  90  
Volume/Å3  1271.11(11)  
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Z  4  
ρcalc/g·cm
-3 1.423  
μ/mm-1  0.100  
F(000)  576.0  
Crystal size/mm3  0.273 × 0.2 × 0.11  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.116 to 59.474  
Index ranges  -10 ≤ h ≤ 10, -22 ≤ k ≤ 22, -15 ≤ l ≤ 15  
Reflections collected  20336  
Independent reflections  3597 [Rint = 0.0287, Rsigma = 0.0209]  
Data/restraints/parameters  3597/0/187  
Goodness-of-fit on F2  1.072  
Final R indexes [I>=2σ (I)]  R1 = 0.0418, wR2 = 0.1038  
Final R indexes [all data]  R1 = 0.0484, wR2 = 0.1084  
Largest diff. peak/hole / e Å-3  0.38/-0.25  
 
Table 5.14. Bond Lengths for rac-232. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C3 1.3502(13)   C4 C5 1.4492(16) 
O2 C1 1.4460(14)   C4 C6 1.5200(15) 
O2 C2 1.3393(13)   C6 C7 1.5367(16) 
O3 C2 1.2086(14)   C6 C9 1.5277(17) 
N1 C5 1.3367(14)   C7 C8 1.5259(17) 
N1 C10 1.3886(15)   C10 C11 1.4081(16) 
N2 C5 1.3676(14)   C10 C15 1.3967(16) 
N2 C8 1.4674(14)   C11 C12 1.3938(16) 
N2 C11 1.3806(14)   C12 C13 1.3857(18) 
C2 C3 1.4936(16)   C13 C14 1.4055(19) 
C3 C4 1.3608(15)   C14 C15 1.3896(18) 
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Table 5.15. Bond Angles for rac-232. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 O2 C1 114.79(9)   N2 C5 C4 121.96(10) 
C5 N1 C10 105.11(9)   C4 C6 C7 109.72(9) 
C5 N2 C8 124.93(10)   C4 C6 C9 110.71(10) 
C5 N2 C11 107.07(9)   C9 C6 C7 112.00(10) 
C11 N2 C8 127.88(10)   C8 C7 C6 112.45(10) 
O2 C2 C3 111.44(9)   N2 C8 C7 108.96(9) 
O3 C2 O2 123.31(11)   N1 C10 C11 109.62(10) 
O3 C2 C3 125.24(10)   N1 C10 C15 130.27(11) 
O1 C3 C2 113.33(9)   C15 C10 C11 120.10(11) 
O1 C3 C4 123.98(10)   N2 C11 C10 105.71(10) 
C4 C3 C2 122.69(10)   N2 C11 C12 131.55(11) 
C3 C4 C5 117.81(10)   C12 C11 C10 122.72(11) 
C3 C4 C6 126.20(10)   C13 C12 C11 116.38(11) 
C5 C4 C6 115.97(9)   C12 C13 C14 121.70(12) 
N1 C5 N2 112.48(10)   C15 C14 C13 121.61(11) 
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(using pre-ligand 177) 














(using pre-ligand 177) 













































(using pre-ligand 177) 




























































































































































































































































(using pre-ligand 177) 


















































































































































































































































































































(using pre-ligand 176) 
(The peak shoulders are an artefact of 
the chiral column. The product was 
determined to be >95% pure by 
1
H NMR analysis.) 




































































































































































































Chiral HPLC of 232: 
 
 
 
 
 
 
 
